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This dissertation examines the production and management of genetic risk for breast and 
ovarian cancer in the United States in the new era of multi-gene panel testing. Drawing on three 
years of ethnographic fieldwork and in-depth interviews with genetics health professionals and 
women with mutations, this project is the first social science study to examine how breast and 
ovarian cancer genetic risk is constructed and managed among women with variants of uncertain 
significance or moderate-risk mutations. Moving beyond an individual-level focus on women’s 
risk management decisions, this project instead explores how the structures, practices, and 
organization of genetic medicine constrain and enable those decisions. 
There are four key findings from this study. First, the adoption of panel testing has 
shifted the boundaries of risk, disease, and patienthood and contributed to a spectrum of 
medicalization of breast and ovarian cancer risk. Women with high-risk breast and ovarian 
cancer mutations are now typically viewed and treated like full patients with a "disease," while 
women with moderate-risk mutations occupy a liminal space of qualified patienthood. Second, 
the structures and organization of genetic medicine in the United States point women with breast 
and ovarian cancer mutations toward risk-reducing mastectomy and breast reconstruction and 
encourage choosing those surgical responses over breast surveillance or staying flat. Mastectomy 
has become the standard “treatment” for the “disease” of genetic risk for breast cancer, 
regardless of whether women have high- or moderate-risk mutations and despite more 
conservative recommendations in clinical guidelines.  
 
 Third, the structures of genetic medicine and the contemporary gender order in the United 
States are mutually constituted and co-produced. Breast reconstruction and gynecologic surgery 
practices both emerge from and reinforce gendered social and cultural norms that prioritize 
women's appearance and their reproductive capacity over their embodied experiences and daily 
quality of life. Finally, the discourses and practices of genetic medicine leave many women un- 
or under-prepared for the duration and severity of the side effects and consequences associated 
with breast reconstruction and risk-reducing salpingo-oophorectomy. By closely examining the 
social and structural dimensions of how cancer genetic risk is produced and managed in the 
United States, this project illuminates how clinical practices that magnify and focus on reducing 
certain risks simultaneously obscure and generate exposure to others.
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 1 
Introduction: “The Wild, Wild West:” The New Era of Multi-Gene Panel Testing 
“So here it is. It's the Wild, Wild West, right?… Many of the panels include genes where if 
we found a true mutation in one of those genes it would be fair to ask, ‘Well, what does that 
mean for my cancer risk?’ And there are genes that we could find mutations in where all I 
would do is wiggle around uncomfortably in my chair and shrug and go, ‘I don't know. 
Higher than other people?’ You know? That's how much we know about some of the genes 
that are being tested." (Linda, Genetic Counselor) 
In May 2013, the New York Times published “My Medical Choice,” an Op-Ed by the 
famous actress Angelina Jolie about her decision to have risk-reducing mastectomy (RRM)1 and 
implant reconstruction after learning she had a mutation on the BRCA1 gene (Jolie, 2013). While 
there had been coverage of genetic risk for cancer in the media prior to Jolie’s Op-Ed, her story 
launched hereditary risk for breast and ovarian cancer (BOC) into the spotlight and made 
“BRCA” a household term. Jolie’s Op-Ed had such a broad impact that following its publication 
there were significant increases in internet searches about BRCA mutations and requests for 
genetic testing and RRM (Bhatti & Redelmeier, 2015; Borzekowski, Guan, Smith, Erby, & 
Roter, 2014; Desai & Jena, 2016; D. G. Evans et al., 2015; Noar, Althouse, Ayers, Francis, & 
Ribisl, 2014). 
One month after Jolie’s Op-Ed made waves through the media, the Supreme Court of the 
United States issued a unanimous ruling that revoked the patents on the BRCA genes that the 
laboratory Myriad Genetics had held since their discovery nearly two decades earlier 
("Association for Molecular Pathology v. Myriad Genetics," 2013; Azvolinsky, 2013; E. 
Marshall, 2013).2 In combination with concurrent increases in the speed and power of genetic 
                                                             
1 Appendix A provides an alphabetized reference of acronyms used in this study. 
2 Prior to the ruling, other genetics laboratories had been limited to researching and providing tests for 
mutations on genes besides BRCA1 and BRCA2 that were linked to breast and ovarian cancer. 
 2 
sequencing methods, that Supreme Court decision transformed the landscape of genetic testing in 
the United States. Other laboratories quickly entered the BRCA testing market and competed by 
bundling tests for BRCA mutations with tests for mutations on 20 - 30 other genes associated 
with low to moderate BOC risk. Compared to the earlier targeted tests of the well-known, high-
risk BRCA1/2 genes, these multi-gene panels generated considerably more genetic information 
for experts to interpret and explain, much of which was not medically actionable. Hence, the 
rapid shift to panel testing for genetic risk ushered in a new era in genetic medicine rife with 
scientific and clinical uncertainties just at the moment that public concern about genetic risk 
rapidly escalated. 
 As science and technology studies (STS) scholars have argued, processes of scientific 
classification and medical technologies like panel testing are neither objective nor value neutral. 
Rather, they take shape in particular social and cultural locations, are influenced by a range of 
actors, and can be enlisted in achieving particular agendas (Hess, 1997; Latour, 1987, 2005; 
Montoya, 2011; Rapp, 2000). Now that multi-gene panel tests have become the standard of care, 
this study explores how certain ideas about BOC genetic risk and approaches to risk management 
have gained credibility over others and how the discourses and practices of US genetic medicine 
have shifted in the era of panel testing. Drawing on data collected during three years of 
ethnographic fieldwork and through in-depth interviews with women with mutations and 
genetics health professionals, the project moves beyond an individual-level focus on women’s 
psychological and behavioral responses to learning they have cancer genetic mutations. Instead, 
this study examines how social structures and the organization and practices of BOC genetic 
medicine in the United States both constrain and enable women’s medical decisions. 
The central research question of this study is: How is BOC genetic risk produced and 
 3 
managed in the United States in the era of multi-gene testing? Throughout the analysis, I explore 
similarities and differences between the experiences of women with high-risk BRCA mutations, 
moderate-risk mutations (MRMs), and variants of uncertain significance (VUSs), which are 
genetic variants that scientists have not yet classified as harmful or benign (S. Domchek & 
Weber, 2008). I also pay specific attention to how structures of gender and genetic medicine 
intersect and to how the practices of BOC genetic medicine and broader social and cultural 
contexts in the United States magnify certain risks while obscuring others. By closely examining 
the social and structural dimensions of the production and management of cancer genetic risk, 
this project illuminates how the dominant practices of BOC genetic medicine and the 
contemporary gender order in the United States work to mutually sustain and justify each other. 
Research Context 
Discovering the BOC Genes 
BRCA1 and BRCA2 (BRCA1/2) are tumor suppressor genes that were discovered in the 
mid 1990s (Miki et al., 1994; Wooster et al., 1995), and individuals who inherit a mutation3 on 
these genes face significantly elevated risks of developing breast and ovarian cancer in their 
lifetimes. The risk of female breast cancer among women with BRCA mutations is between 3-6 
times the normal lifetime risk of 12%, and their risk of ovarian cancer is 5-35 times the normal 
lifetime risk of 1.5% (Antoniou et al., 2003; Begg et al., 2008; Ford et al., 1998; M. C. King, 
Marks, & Mandell, 2003; Kuchenbaecker et al., 2017; A. W. Kurian, Sigal, & Plevritis, 2010; 
National Cancer Institute, 2018d, 2018e; Thorlacius et al., 1997). Mutations on the BRCA genes 
                                                             
3 The term “variant” refers to a change in the typical code of a gene, but it does not signal the effect of the 
change on gene function, which may be benign, pathogenic, or uncertain. The term “mutation” refers to a 
genetic variant that has been interpreted as pathogenic and affects typical gene function. 
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are also associated with elevated risks of developing melanoma, pancreatic, testicular, male 
breast, and early-onset prostate cancers, but the cancers they are most commonly associated with 
are breast and ovarian (PDQ® Cancer Genetics Editorial Board, 2019). Importantly, neither 
BRCA1 nor BRCA2 has 100% penetrance;4 not everyone who carries a BRCA mutation will 
develop cancer. Moreover, while BRCA mutations are considered “high-risk” mutations and 
have a higher population prevalence than most other cancer-associated mutations (Couch et al., 
2017; Kuchenbaecker et al., 2017; PDQ® Cancer Genetics Editorial Board, 2019), genetic 
mutations, overall, seem to account for only 5% - 15% of all female breast cancers (PDQ® 
Cancer Genetics Editorial Board, 2019) and approximately 20% of ovarian cancers (National 
Library of Medicine, 2019; Toss et al., 2015). Hence, while extensive media attention and 
scientific resources have been devoted to the BRCA genes, they account for a relatively small 
proportion of all breast and ovarian cancers.5 
The discovery of the BRCA genes were major breakthroughs in hereditary cancer 
research. Yet because mutations on BRCA1 and BRCA2 do not account for all of the 
concentrated familial patterns of breast and ovarian cancers that suggest a hereditary component, 
scientists have continued searching for and found other genes involved in tumor suppression 
pathways that also increase BOC risk. Mutations on other genes that have been discovered 
mostly pose a moderate-risk for breast or ovarian cancer that is higher than the risk among 
                                                             
4 Penetrance refers to the proportion of individuals carrying a mutation who will manifest the disease. 
5 Most breast and ovarian cancers are a result of environmental exposures, and even genetically-linked 
cancers have environmental components. Individuals with BRCA mutations typically have one damaged 
copy of either the BRCA1 or BRCA2 gene. However, people contain two copies of every gene in their 
bodies—one inherited from their mother and the other from their father. For the tumor suppression 
function of the BRCA1 or BRCA2 genes to be disrupted, both copies of one of the genes must become 
damaged (Begg et al., 2008; Ford et al., 1998; PDQ® Cancer Genetics Editorial Board, 2019; Thorlacius 
et al., 1997). 
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women in the general population but lower than the risk of BRCA mutation carriers (Couch et 
al., 2017; PDQ® Cancer Genetics Editorial Board, 2019). The most prevalent of these MRMs 
are on the ATM, CHEK2, and PALB2 genes, which were discovered in 1995, 1998, and 2006, 
respectively. ATM, CHEK2, and PALB2 mutations are associated with a higher-than-average 
risk of developing breast cancer (Couch et al., 2017; Matsuoka, Huang, & Elledge, 1998; N. 
Rahman et al., 2007; Savitsky et al., 1995; Uziel et al., 1996; Xia et al., 2006), and some studies 
suggest they are also associated with a higher risk of developing ovarian cancer (Minion et al., 
2015; Toss et al., 2015). Even though some of the moderate-risk genes were discovered in the 
1990s, very few women were tested for MRMs prior to the early 2010s because of legal and 
regulatory restrictions on testing and limitations in genetic sequencing technologies. 
The Birth of Panel Testing 
The lawsuit against Myriad, Association for Molecular Pathology v. Myriad Genetics, 
Inc. (AMP v. Myriad), had been making its way through the US federal court system since 2009, 
when lawyers from the American Civil Liberties Union filed a suit on behalf of a group of 
scientists, genetic counselors, clinicians, and patients. The plaintiffs argued that the patents held 
on the BRCA1/2 genes by Myriad Genetics since their discovery were hampering scientific and 
medical research. Previously, Myriad had successfully persuaded the US Patent and Trade Office 
that the forms of the BRCA1 and BRCA2 genes that they worked with in their labs, which were 
isolated from their respective locations on chromosomes 17 and 13, did not exist “in nature” and 
therefore could be patented. But Myriad’s interpretations, which had long been challenged by 
other scientists, were upended in the late 2000s by the discovery that the genomes of fetuses 
could be recreated from fragments of fetal deoxyribonucleic acid (DNA) found in the blood of 
pregnant women. Those naturally existing fetal DNA fragments included the BRCA1 and 
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BRCA2 genes that Myriad had theretofore claimed were “produced” in their labs ("Association 
for Molecular Pathology v. Myriad Genetics," 2013; Azvolinsky, 2013; E. Marshall, 2013). In 
AMP v. Myriad, the Supreme Court ruled against Myriad, which invalidated their patents and 
enabled other genetics laboratories to begin testing for BRCA mutations ("Association for 
Molecular Pathology v. Myriad Genetics," 2013). 
 The AMP v. Myriad decision coincided with technological transformations in the tools and 
methods used to perform DNA sequencing. Since the 1970s, genetic testing laboratories had 
used a slow and costly sequencing method (i.e., capillary or Sanger sequencing) that could only 
sequence one DNA fragment at a time (Shendure & Ji, 2008; van Dijk, Auger, Jaszczyszyn, & 
Thermes, 2014). As a result, most genetic tests searched for specific, known mutations on one or 
two genes. In the early 2010s, however, genetic testing laboratories adopted new sequencing 
technologies developed a few years earlier that could simultaneously sequence millions of DNA 
fragments (Pareek, Smoczynski, & Tretyn, 2011; Shendure & Ji, 2008; van Dijk et al., 2014). 
The dramatic increase in sequencing speed and volume made possible by these “next generation 
sequencing” (NGS) technologies allowed laboratories to shift from conducting targeted gene 
tests to offering panel tests that could examine dozens of genes for both known and unknown 
variants at little to no additional cost.  
 While NGS technologies existed before 2013, until the AMP v. Myriad ruling, multi-gene 
panels were not commonly utilized in BOC genetic testing. Because BRCA mutations are the 
most prevalent and highest risk BOC mutations, BRCA testing is always recommended among 
individuals without known mutations in their families. However, since only Myriad could legally 
test for and conduct research on the BRCA genes prior to the AMP v. Myriad decision, other 
laboratories lacked sizable markets for their panels that only tested for MRMs or low-risk 
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mutations. Immediately after the AMP v. Myriad ruling, however, laboratories and clinics began 
offering and advertising hereditary cancer panel tests that screened for BRCA1/2 mutations and 
for variants on moderate- and low-risk genes that had known or possible associations with cancer 
risk (Figure 1). As Laura, a medical geneticist, explained:   
The impact on the field was almost instantaneous… laboratories were watching this very 
carefully. And many of them knew that the opportunity was that if the patents got taken 
down that they would have the opportunity to now start bundling together—number one, 
be able to offer BRCA1 and 2. But more importantly than that, start bundling together 
additional genes beyond just BRCA1 and 2. And I think that was for us in hereditary 




Figure 1: Flyer from Ambry Genetics Distributed in the Fall of 2013 (Front Image)6 
 
                                                             




Figure 2: Flyer from Ambry Genetics Distributed in the Fall of 2013 (Back Image) 
 
 This study examines the consequences of this pivot to panel testing that occurred in the 
wake of the AMP v. Myriad decision and the adoption of NGS technologies. One of the 
immediate effects of the shift was to increase the accessibility and affordability of cancer genetic 
testing. When Myriad had a monopoly on the market, it charged approximately $3,000 for a 
BRCA1/2 test, which made testing inaccessible to most people when it was not covered by 
insurance. But after the AMP v. Myriad decision, market competition between labs, coupled with 
the ability to bundle services in panel tests, brought prices down dramatically. For example, 
Color Genomics, a consumer-oriented laboratory that began operating in 2014, offered their 
hereditary cancer panel for $249. While that price point was still prohibitive for some 
individuals, at less than 10% of the price Myriad had been charging, testing became more 
accessible to people forced to pay out of pocket because they lacked or were denied insurance 
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coverage. Over time, the consumer price for testing has come down even further. Color now 
charges $199 for their hereditary cancer panel, and another major US laboratory, Invitae, offers a 
“patient pay” price of $250 (Color Genomics, 2019; Invitae, 2019). 
 While the AMP v. Myriad ruling and adoption of panel testing helped to reduce prices, a 
provision of the Affordable Care Act (ACA) that went into effect in 2013 expanded insurance-
covered access to BOC genetic testing. The ACA requires that all preventative services graded A 
or B by the U.S. Preventative Services Task Force (USPSTF) be covered without patient cost-
sharing (111th Congress, 2010; Johns & Bayer, 2016). BRCA testing has a B grade for women 
whose personal or familial cancer history suggests the cancers might be hereditary. Therefore, 
women who meet specific high-risk criteria7 are entitled to BRCA testing without copays or 
coinsurance and regardless of any unmet deductibles (US Preventative Services Task Force, 
2018). Insurers are not required to cover panel tests and could demand targeted-gene testing for 
BRCA mutations; however, in practice they rarely do. Hence, by bundling BRCA tests in panels 
that screen for mutations on other genes linked to hereditary cancer, women considered high-risk 
gained insurance-covered access to the new panel tests without out-of-pocket costs.  
 Most cancer panel tests examine 25 - 35 genes for variants, but some screen over 80 genes. 
However, more information is not necessarily better. Rather, it is an empirical question whether 
and how the genetic information panels provide is having a positive impact on people’s lives and 
health. With 30 or more genes included in panel tests rather than one or two, panels generate 
considerably more genetic information for experts to interpret, classify, and explain and for 
                                                             
7 According to the National Cancer Institute, factors that would suggest a hereditary pattern and indicate 
BRCA testing include being diagnosed with breast cancer prior to age 50, cancer in both breasts in the 
same woman, both breast and ovarian cancers in either the same woman or in the same family, multiple 
breast cancers in the family, cases of male breast cancer in the family, and Ashkenazi Jewish ethnicity 
(National Cancer Institute, 2018a). 
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patients to understand and manage. Moreover, since many of the genes included in panel tests 
are associated with only low or moderate cancer risk, much of the genetic information panels 
provide is not medically actionable. As women’s stories in the following chapters reveal, it can 
be frustrating and anxiety producing, not empowering, to learn one has an MRM that is 
associated with an increased risk of breast and other cancers but lacks clear recommendations for 
additional screenings or services. In addition, the widespread adoption of panel tests has led to an 
increase in the number of people learning they have VUSs. Scientists classify variants as VUSs 
when there is not enough data to determine whether they pose any risk. Most VUSs are likely to 
be harmless; over 90% of VUSs that get reclassified are downgraded to benign (Lincoln et al., 
2017; Mersch et al., 2018). Genetics experts agree that until VUSs are reclassified, they should 
be treated like “negative” findings and should not affect medical management. Yet clinical 
studies indicate that some women with VUSs are having prophylactic mastectomies (Culver et 
al., 2013; M. L. Murray, Cerrato, Bennett, & Jarvik, 2011; Ready et al., 2011). Thus, panel tests 
may be contributing to the mismanagement or overtreatment of mutations or variants with risk-
reducing surgical procedures that have their own risks and potential harms.  
   The adoption of panel testing spawned a new era in genetic medicine. Linda, a cancer 
genetic counselor who has been practicing since the 1990s, referred to panel testing as the “wild, 
wild west” because in this era scientific knowledge and best clinical practices are unclear and 
constantly evolving. This study, which began as the pivot to panel testing occurred and spanned 
the initial years of clinical adoption of the technology, sheds light on the landscape and 




This project involved over three years of qualitative research that included participant 
observation, in-depth interviews, and document analysis. As is common in qualitative research, I 
conducted data collection and analysis concurrently, transcribing and coding interviews and field 
notes soon after they were completed. Preliminary findings from the earlier years of the study 
informed subsequent data collection, and triangulating data through these three methods enabled 
me to iteratively test and refine my working hypotheses on how BOC genetic risk is produced 
and managed in the United States in the era of panel testing. Below is a brief overview of the 
research methods used in this study. A detailed description of the research methods and 
approach, including tables of summary characteristics for the 75 women who participated in the 
study and an account of the challenges I encountered during the research process, are included in 
Appendix B. 
Participant Observation and Document Analysis 
Between the fall of 2013 and spring of 2017, I engaged in participant observation at more 
than 40 professional and patient-centered events. These included national scientific conferences, 
webinars, and research seminars for genetic scientists, clinicians, and counselors and advocacy 
conferences, symposia, and webinars on cancer genetic risk for people with BOC mutations and 
the broader public. The events for scientists and health professionals illuminated how experts 
communicated with one another about genetic risk, clinical and scientific developments in cancer 
genetics, and the topics and issues of importance to genetics professionals. The patient-centered 
and public events were sources of data on the issues of importance to women with mutations, 
whether and how mutation carriers were forming biosocial identities and communities, and the 
ways in which experts communicate and translate complex genetic risk information to people 
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with mutations and lay audiences. During fieldwork, I gathered and systematically analyzed 
publications, brochures, webpages, and reports produced by the five major US laboratories that 
perform most BOC genetic testing in the United States: Ambry Genetics, Color Genomics, 
GeneDx, Invitae, and Myriad Genetics. I also examined materials published by key advocacy 
groups for BOC mutation carriers, professional societies involved in genetic medicine, and 
federal institutes or agencies that provide information and data on cancer and genetics. 
Interviews and Recruitment 
Concurrent with fieldwork and document analysis, I conducted a total of 85 in-depth, 
semi-structured interviews: 75 with women with BOC mutations or variants and 10 with health 
professionals working in cancer genetics. The conversations with women with mutations and/or 
variants provided opportunities to elicit detailed narratives about their experiences navigating 
genetic medicine, their knowledge and beliefs about BOC genetic risk, and their risk 
management decisions. The interviews with genetic counselors and clinicians provided insights 
into the processes involved in producing genetic risk and facilitated an analysis of agreements 
and disjunctures between professionals’ and patients’ descriptions of the practices of BOC 
genetic medicine. Interviews lasted, on average, one hour and 15 minutes, and all interviews 
were conducted via telephone or video-chat and were digitally audio-recorded in order to capture 
participants’ exact responses. I developed semi-structured guides for the interviews that drew on 
topics and themes I had identified through preliminary fieldwork and existing literature on BOC 
genetic medicine. 
The health professionals were recruited during fieldwork at scientific and professional 
meetings and through relationships I built at those meetings with key informants. Women with 
mutations or VUSs were primarily recruited through cancer genetic counselors located 
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throughout the United States whom I met at national conferences and through the cancer special 
interest group (SIG) of a professional association for genetic counselors.8 Genetic counselors 
shared the study’s IRB-approved recruitment flyers with their clients, and then women who were 
interested in participating contacted me directly. I also recruited women through a modified 
snowball approach to sampling. At the end of each interview, I asked participants if they would 
be willing to share information about the study with other women they knew with BOC 
mutations or VUSs, and if they agreed, I provided them with the same IRB-approved flyers. 
Finally, I recruited patient participants through national education and advocacy groups that 
serve people with BOC mutations. All names used in the following chapters are pseudonyms, 
and quotations or descriptions that contained potential identifying information, such as unique 
elements of their life stories, have been altered to protect the confidentiality and privacy of 
participants.    
Theoretical Foundations and Contributions 
One of the major contributions of this study is that it sheds light on the experiences of an 
emerging and rapidly growing population in BOC genetic medicine that has barely been studied 
in either the medical or social sciences literatures: women with genetic variants that pose 
moderate, low, or unknown risk for breast or ovarian cancer. Research on the patienthood 
experiences of women with MRMs and VUSs has been limited, in part because prior to the shift 
to panel testing, few women were tested for MRMs and only 5% - 15% of BRCA analyses 
                                                             
8 This organization has a membership category for professionals who are not genetic counselors but do 
work related to genetic counseling. In all communications in this group, I was transparent about being a 
researcher studying the consequences of panel testing and the production and management of BOC 
genetic risk. 
 14 
uncover a VUS (Dagan & Goldblatt, 2009; Gibbon, 2007; Hesse-Biber, 2014). In fact, to date, 
all of the major sociological and anthropological studies conducted on the experiences of women 
with BOC mutations have included only women with BRCA mutations; there are currently no 
published social science analyses that focus on women with MRMs or VUSs. Yet, as multi-gene 
panels have become the standard of care, the proportion of women with BOC variants who have 
MRMs and VUSs is rapidly increasing, and these women encounter unique issues as they 
navigate the terrain of genetic medicine.  
Another contribution of this project is that it brings sociological, science and technology 
studies (STS), and gender studies frameworks to the study of BOC genetic risk. Medical 
researchers have conducted a majority of the studies on BRCA medicine. These analyses tend to 
assume the objectivity and neutrality of genetic tests and focus on assessing barriers to genetic 
testing, patients’ comprehension of genetic information, and the individual and familial factors 
that are associated with women’s testing and risk management decisions. Instead, this study 
examines how genetic risk is constructed and made visible and how certain ideas about and 
responses to genetic risk gain credibility over others. The project also explores how gendered 
social and cultural norms are both embedded in and reproduced by genetic risk technologies, risk 
management guidelines, and surgical practices. The study engages with and makes contributions 
to scholarship on genetic medicine in four overlapping bodies of literature in medical sociology 
and STS: risk, (bio)medicalization, (pre)patienthood, and gender and embodiment. In the 
following sections, I broadly describe these literatures and situate this analysis in their respective 





In contrast to medical studies that present health risks and numeric risk estimates as 
preexisting “facts” that are uncovered through scientific inquiry, this study explores how risk is 
actively produced, not discovered. It builds on sociological, anthropological, and STS 
scholarship that views risk as always constructed because it is an estimated measurement 
generated by experts who draw on social and cultural assumptions, discourses, and knowledges 
(d'Agincourt-Canning, 2001; Nina Hallowell, 1999; Klawiter, 2002; Lupton, 1993, 1999; 
Mozersky & Joseph, 2010; Rapp, 2000; Scott, Prior, Wood, & Gray, 2005; Simpson, 2000). 
Specifically, this project is in conversation with two broad domains of social sciences 
scholarship on risk: literature on genetic risk and on breast cancer risk.  
Several social scientists have explored the social implications of using genetic 
technologies in medicine. Early scholars of genetic diagnostic technologies examined how they 
could be used to define norms, create social categories, and exert social control (Lippman, 1992; 
Nelkin, 1992; Nelkin & Tancredi, 1994). Other researchers have focused on the social and 
political effects of the rapid integration of genetic technologies into standard medical care and 
reproductive health care (Ettorre, 2002; Rapp, 2000; Rothman, 1986). More recently, scholars 
have examined the ways in which the social constructs of race, ethnicity, and populations have 
become entangled with research and practices in the field of genetic medicine (Bridges, 2011; 
Montoya, 2011; Mozersky & Joseph, 2010; Wailoo & Pemberton, 2006). 
Other scholars have examined the constructed nature of the risk estimates and 
classifications generated by computerized tools used in medicine to assess women’s current and 
lifetime risks for breast cancer. Anthropologist Margaret Lock highlights how the risk estimates 
for breast cancer produced by these tools are not “facts,” but rather are statistical abstractions 
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from population data that require significant translation and interpretation (Lock, 1998). In 
Jennifer Fosket’s study of the Gail Model, one of those tools, she argues that they are “black 
boxes” (Latour, 1987) that obscure the constructed nature of the statistical abstractions they 
generate. Fosket’s study reveals that the numeric threshold for “high-risk” of breast cancer that 
continues to be used to classify women without genetic mutations was arbitrarily established in a 
clinical trial (Fosket, 2004).  
This project integrates and builds on these literatures on genetic risk and breast cancer 
risk by using STS tools to explore how multiple actors and actants—genetics laboratories, 
researchers, screening tools, laboratory tests, counselors, clinicians, advocacy groups, and 
patients—work together to produce BOC genetic risk and make it visible and tangible to 
patients. In Chapter One, I illustrate that the classification systems for genetic variants are also 
black boxes, as the processes scientists use to determine whether genetic variants are benign, 
harmful, or pose uncertain risk are largely obscured. In addition, I highlight inconsistencies in 
and disagreement about the risk profiles and classifications of certain mutations, including 
variations in whether and how laboratories report VUSs to patients. Hence, this study contributes 
to the social science risk literature by illuminating the processes of genetic interpretation, 
classification, and reporting that actively, but often invisibly, construct BOC genetic risk.  
(Bio)medicalization and (Pre)patienthood 
 This study contributes to sociological theory on medicalization and biomedicalization by 
exploring if and how BOC genetic risk is being defined and treated as an illness and whether 
patienthood experiences are being transformed through developments in biomedicine. 
Sociologist Peter Conrad defines medicalization as a social process by which normal human 
conditions are defined and described in medical language, understood through medical 
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frameworks, or treated with medical interventions (Conrad, 2007). Building on the concept of 
medicalization, STS scholar Adele Clarke and her colleagues have argued that technoscientific 
advances in the 21st century have been transforming the structures of both social life and 
medicine, producing “increasingly complex, multisited, multidirectional processes of 
medicalization” that they term “biomedicalization” (Clarke, Shim, Mamo, Fosket, & Fishman, 
2003, p. 162). 
 There is an ongoing conversation among scholars about which concept—medicalization 
or biomedicalization—has more utility in capturing how science and medicine are operating as 
forces of social control and change in the 21st century. Rather than enter this debate, I engage 
with both frameworks in this project, as they raise unique questions about, and illuminate distinct 
aspects of, how genetic risk is produced and managed in the era of panel testing. For example, 
the practices of BOC genetic medicine exemplify several of the recent transformations to 
biomedicine and patienthood identified by Clarke and her colleagues and by sociologist Nikolas 
Rose, whose theory of vital politics (Rose, 2007) dovetails with the biomedicalization thesis. 
Scientific and social interest in identifying the genetic mutations linked to cancers illustrate 
processes of molecularization, and the effort that women devote to identifying and managing 
BOC genetic risk reflects the processes they term optimization and subjectification (Clarke et al., 
2003; Rose, 2007). But in addition, being “at risk” is a normal, human condition—we all face 
varying types and degrees of risk through unavoidable, everyday aspects of life—and this study 
reveals that being “at risk” is increasingly defined and regarded as an illness that requires 
“treatment.”  
 Most STS scholars and medical sociologists who have explored the medicalization of the 
“at-risk” health status have argued that risk is a liminal state between sickness and health in 
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which patients’ roles and obligations are less clearly defined than in illness (Dagan & Goldblatt, 
2009; Gibbon, 2007; Kenen, 1996; Lock, 1998; Rose, 2007; Scott et al., 2005; S. Timmermans & 
Buchbinder, 2010). Researchers have coined various terms to describe individuals occupying this 
in-between social location in which they deemed neither healthy nor sick: “pre-patients” (Rose, 
2007), “pre-symptomatic ill” (Lock, 1998), “anticipatory patients” (Gibbon, 2007), “beings-at-
risk” (Scott et al., 2005), and “patients-in-waiting” (S. Timmermans & Buchbinder, 2010). Some 
scholars have specifically explored the complexities of pre-patienthood among women with 
BRCA mutations (Dagan & Goldblatt, 2009; Gibbon, 2007; Hesse-Biber, 2014), but no 
published social science analyses have focused on women with MRMs or VUSs. By comparing 
the experiences of women with BRCA mutations with those of the growing numbers of women 
with VUSs and MRMs, this study illuminates shared and distinct dimensions of (pre)patienthood 
for women across the spectrum of BOC genetic risk and if and how panel testing has altered the 
boundaries of health, risk, and illness. 
Gender and Embodiment 
 Both professionals within and scholars of genetic medicine have paid little attention to 
how surgical risk management and breast reconstruction practices affect and are affected by 
gendered constructs of femininity (A. Finch & Narod, 2011; Nina Hallowell, 2000; Press et al., 
2005). While genetic counselors, clinicians, and researchers have emphasized how risk-reducing 
surgeries affect women’s reproductive capacities, their attention to gender and embodiment has 
been limited to the domains of reproduction and motherhood and tends to overlook other 
dimensions of women’s embodied experiences, such as sexuality. Two scholars of BRCA 
medicine in the United Kingdom stand out as exceptions. Nina Hallowell’s research on 
mastectomy and reconstruction among women at high risk for breast cancer examines how 
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women’s conceptions of femininity and womanhood shape their surgical decisions (Nina 
Hallowell, 2000, pp. 166-167). In addition, Sahra Gibbon’s analysis of the dimensions of BRCA 
patienthood explores how the demands of genetic responsibility are gendered (Gibbon, 2007).     
 Expanding on these analyses of the gendered dimensions of BRCA medicine and 
patienthood in the United Kingdom, this study explores how structures of gender and BOC 
genetic medicine in the United States are co-produced, as they simultaneously shape and are 
shaped by one another. In addition, this study uniquely examines the experiences of women with 
BOC mutations who refuse or challenge gendered expectations that they actively manage their 
risk through prophylactic surgeries and maintain feminine bodies through breast reconstruction. 
In her research on amniocentesis, anthropologist Rayna Rapp describes the women making 
complex decisions to use or refuse the prenatal testing technology as “moral pioneers”: 
In considering whether or not to accept prenatal testing, all were participating in an 
impromptu and large-scale social experiment: Whether as willing conscripts or draft 
resisters to biomedicine’s technicist promise of more control over pregnancy outcomes, 
all made conscious a set of values, ethics, and choices which were located in the realm of 
the private but were shaped and in turn helped to shape a more social terrain. (Rapp, 
2000, p. 309) 
Women with BOC mutations considering whether or not to have prophylactic surgeries or 
reconstruct their breasts face similarly complex, private, and yet socially embedded choices that 
are linked to their values and ethics. They are also responding to “biomedicine’s technicist 
promise[s] of more control,” only the promises issued to them are about control over cancer 
outcomes and feminine appearances. Hence, women with BOC mutations can also can be seen as 
pioneers, and this project contributes to the literature on genetic medicine by exploring the 
experiences of women who are “willing conscripts” and those who are “draft resisters.” 
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Conceptual Frameworks 
There are three concepts that I use throughout the following chapters that have variable 
meanings across disciplines: structures, practices, and architecture. In this section, I identify the 
specific definitions of these terms that I am referencing by briefly describing the theoretical 
frameworks they are derived from and how I use them in my analysis. 
Structures and Practices 
 Most of the clinical and social science literature on the management of cancer genetic 
risk explores women’s beliefs and feelings about their risk management decisions, the individual 
or familial factors that shape those decisions, and the outcomes of their surgeries. This study 
takes a different approach to investigating women’s experiences navigating cancer genetic 
medicine by focusing instead on how social systems and structures constrain and enable what 
choices are made available to women. For this structural analysis, it is useful to draw on 
sociologist Raewyn Connell’s framework on the mutually constitutive relationship between 
structures and practices. Connell argues, “Structure is always emergent from practice and is 
constituted by it. Neither is conceivable without the other… ‘structure’ specifies the way practice 
(over time) constrains practice” (Connell, 1987, pp. 94-95). Yet Connell also asserts that 
structure, which she defines as “the intractability of the social world” (Connell, 1987, p. 92), is 
not simply a static, restraining force, but rather “is vulnerable to major changes of 
practice”(Connell, 1987, p. 93). In other words, structures limit social practices, but also are both 
formed and transformed through practices. 
Genetic Medicine Fields of Practices: Risk Production and Risk Management 
Utilizing Connell’s theoretical framework, the structures of BOC genetic medicine can be 
divided into two overlapping fields of practices: the field that constructs genetic risk and makes 
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it visible, and the field that responds to genetic risk and attempts to make it manageable. The 
“risk production” field of practices that constructs BOC genetic risk encompasses the 
technologies, methods, materials, people, procedures, policies, and places involved in the 
collection, sequencing, interpretation, classification, reporting, communication, and translation of 
people’s genetic data. The “risk management” field of practices that responds to BOC genetic 
risk includes the technologies, methods, materials, people, procedures, policies, and places 
involved in defining, informing, guiding, constraining, and enabling how people in bodies 
respond to their genetic data. Figure 2 below provides examples of key components in each field 
of practices, including the primary actors and locations through which the fields overlap.   
 
Figure 3: Fields of Practices in BOC Genetic Medicine in the United States 
 
As Figure 2 highlights, the Risk Production and Risk Management fields of practices 
intersect and are mutually constitutive. For example, scientists’ interpretations and classifications 
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of genetic data form evidence that clinical experts use to develop guidelines on the management 
of genetic risk for cancer. These clinical guidelines, in turn, affect what procedures are and are 
not offered to patients and whether those procedures are covered by insurance. Conversely, as it 
has become evident that some women are undergoing prophylactic surgeries for VUSs, 
laboratories and genetic counselors have modified how they report and translate VUS data to 
clients in ways that minimize their visibility and salience. 
Architecture 
The various components that operate within the risk production and risk management 
fields of practices, and the ways in which those components are assembled and organized, are 
diverse and in-flux. In her cross-national comparison of the development of BRCA testing 
systems in the United States and United Kingdom (UK), science studies scholar Shobita 
Parthasarathy coined the term architecture to refer to the distinctive organization of components 
and linkages within each country’s system (Parthasarathy, 2007). Throughout this analysis, I 
borrow Parthasarathy’s concept to distinguish between the structures of genetic medicine in the 
United States—the fields of practices involved in producing and managing genetic risk—and the 
architecture of US genetic medicine, which refers to how the components within these fields are 
configured and connected. 
Parthasarathy’s research reveals notable differences between the structures and 
architectures of BRCA medicine within the US’s market-based health system and the UK’s 
nationalized system. Her findings underscore how social science research on genetic medicine in 
countries with nationalized health care systems are not fully generalizable to the US context. Yet 
the vast majority of social science scholarship on BOC genetic medicine has been conducted 
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outside of the United States,9 in countries such as the United Kingdom (Gibbon, 2007; Nina 
Hallowell, 1999; Nina Hallowell, Foster, Eeles, Ardern-Jones, & Watson, 2004; Mozersky, 
2013); Israel  (Dagan & Goldblatt, 2009); and Canada (d'Agincourt-Canning, 2006). In fact, 
there was no published sociological or anthropological literature on US women with BRCA 
mutations prior to the 2014 publication of Sharlene Hesse-Biber’s research on the testing and 
decision-making experiences of women with BRCA mutations (Hesse-Biber, 2014). Hence, 
through its focus on women and health professionals in the United States, this project contributes 
to the literature on genetic medicine by shedding light on the distinct features of BOC genetic 
patienthood and the transition to panel testing in a market-based system. 
Notes on Writing 
This is a study of BOC genetic medicine in the United States. While I will periodically 
draw attention to that specific context, to avoid repeatedly using the acronyms “BOC” and “US,” 
I will typically use the unmodified phrases “genetic medicine” and “genetic risk.” If at any point 
I intend to signal the inclusion of other national contexts, sub-fields of genetic medicine, or types 
of genetic risk, I will make that explicit. Similarly, I will generally use the term “mastectomy” to 
refer to “risk-reducing mastectomy (RRM)” in the following chapters in order to avoid the 
repeated use of another acronym. When I discuss mastectomy in the context of cancer treatment, 
I will specify that in the analysis. However, even with these adaptations, this is an acronym-
heavy text. As such, I have provided an alphabetized glossary of acronyms in Appendix A, and I 
will reintroduce acronyms the first time they appear in each chapter. In addition, the term 
“mutation” in this text always refers to a genetic variant that has been interpreted as harmful and 
                                                             
9 There is a considerable body of clinical research on women with BRCA mutations in the United States, 
but qualitative social science research on their experiences has been limited. 
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affects typical gene or protein function. However, “variant” is an umbrella term that refers to any 
identified change in the typical code of a gene, and therefore could be a variation that is benign, 
pathogenic, or uncertain.  
Chapter and Themes Roadmap: Revisiting the Jolie Op-Ed 
To provide a roadmap for the issues that I explore in the chapters that follow, it is helpful 
to return to Angelina Jolie’s Op-Ed, as it reflects and condenses many of the key points and 
themes of this project. Published just one month before the AMP v. Myriad ruling, the Op-Ed 
expanded awareness about BRCA mutations, genetic testing, prophylactic mastectomy, and 
breast reconstruction just as NGS technologies, the Supreme Court decision, and the ACA 
combined to generate the shift to panel testing and increase access to testing services. In the 
month after the Op-Ed ran in the New York Times, Jolie’s story was discussed on the morning 
shows of all the major US television networks and featured in over 100 articles in US, UK, and 
Canadian newspapers (Kamenova, Reshef, & Caulfield, 2014). The Op-Ed also spread like 
wildfire on social media platforms like Facebook and Twitter, and it continues to circulate; as of 
2018, it had been shared over 600,000 times. In fact, it caused such a stir that several researchers 
have examined what they have termed the “Angelina Jolie effect”—whether and to what degree 
her Op-Ed was related to a subsequent rise in BOC genetic testing and/or mastectomy (Bhatti & 
Redelmeier, 2015; Borzekowski et al., 2014; Desai & Jena, 2016; D. G. Evans et al., 2015). 
 Since the wide circulation of her story, Jolie has become a symbol for being BRCA-
positive and a starting point for understanding the issues surrounding cancer genetic testing and 
risk. During my research, when I would describe the study to people, they responded with 
comments such as, “Oh, you’re studying people like Angelina Jolie!” Similarly, several of the 
women with BOC mutations who participated in this study said they used Jolie’s Op-Ed as a way 
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to explain their “at-risk” status to their friends. Hence, Jolie’s Op-Ed is important because it has 
functioned as a social anchor for conversations about genetic risk, influenced the social context 
in which panel testing emerged, and increased demand for testing. But in addition, the Op-Ed 
strikingly contextualizes broad themes and specific arguments in the following chapters.  
 Chapter One examines how panel testing has contributed to the geneticization and 
medicalization of risk and shifted the boundaries of patienthood. I explore how genetic risk is 
actively produced and made visible and challenge common discourses that frame cancer genetic 
risk as a firm, quantifiable fact that is discovered through testing. The language and numeric 
estimates that Jolie uses to describe her risk both mirror and reproduce those discourses. She 
opens the Op-Ed by sharing that her mother died from cancer at age 56, after a decade of living 
with the disease, and she describes explaining this to her children:  
We often speak of “Mommy’s mommy,” and I find myself trying to explain the illness 
that took her away from us. They have asked if the same could happen to me. I have 
always told them not to worry, but the truth is I carry a “faulty” gene, BRCA1, which 
sharply increases my risk of developing breast cancer and ovarian cancer. My doctors 
estimated that I had an 87 percent risk of breast cancer and a 50 percent risk of ovarian 
cancer, although the risk is different in the case of each woman. Only a fraction of breast 
cancers result from an inherited gene mutation. Those with a defect in BRCA1 have a 65 
percent risk of getting it, on average. Once I knew that this was my reality, I decided to 
be proactive and to minimize the risk as much as I could. (Jolie, 2013) 
Jolie describes the risk associated with her mutation using precise values, a practice that was also 
common among women in this study because risk was typically presented to them, both in 
conversations with their providers and in their genetic test reports, as a static fact that was 
uncovered through testing. While Jolie notes that “the risk is different in the case of each 
woman,” she uses specific percentages to describe her own risk, implying that firm estimates can 
be generated for other women. Yet, Chapter One reveals how genetic risk is actively interpreted 
and produced, not discovered. Both whether particular genetic variants are classified as “risky” 
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and the specific numeric estimates of the ranges of risk associated with those variants vary 
widely across studies and over time. 
 Chapter Two examines how mastectomy has become the “treatment” for the “disease” of 
BOC genetic risk in the United States. The experiences of women in this study reveal that 
mastectomy is regularly offered even to women with MRMs, for whom it is not recommended, 
and despite it not being significantly more effective than screening at reducing mortality. One of 
the key arguments I make linking Chapters One and Two is that cancer genetic testing and 
mastectomy are practices that co-constitute and generate demand for one another, and Jolie’s Op-
Ed exemplifies that mutually constitutive relationship. Jolie describes learning about her 
mutation and her cancer risk as if they happened simultaneously. She states that once she tested 
positive for a BRCA1 mutation, she then “knew” that her high risk for breast cancer was a 
“reality,” and those test results were what motivated her to “be proactive” and surgically 
minimize her risk. Yet Jolie’s family history alone would have placed her in a higher-than-
average risk category for both breast and ovarian cancer, and thus real knowledge of her risk 
existed prior to testing. In Chapter One, I illustrate how in making cancer risk a tangible, 
quantifiable “fact,” genetic testing makes risk feel more “real,” which in turn motivates women 
to take action and reduce that risk through surgery. Then, in Chapter Two, I reveal how genetic 
tests are frequently used, in practice, to determine whether or not women are candidates for 
prophylactic surgeries, and therefore the availability of mastectomy as a “treatment” for cancer 
genetic risk is often what motivates people to seek out genetic testing in the first place.      
 In Chapter Two, I also examine two discursive slippages I observed during fieldwork and 
in interviews that were exhibited in Jolie’s Op-Ed: a conflation between the risk of developing 
breast cancer and the risk of dying from it, and a parallel conflation between mastectomy’s 
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success at reducing cancer incidence and its success at reducing cancer mortality. While Jolie 
acknowledges that the decision to have breast surgeries was “not easy,” she explains that she is 
glad she made that choice, stating, “My chances of developing breast cancer have dropped from 
87 percent to under 5 percent. I can tell my children that they don’t need to fear they will lose me 
to breast cancer” (Jolie, 2013). Here Jolie jumps from a statement about her risk of developing 
breast cancer to one about her possibility of dying from the disease. Yet, as I illustrate in Chapter 
Two, most women who develop breast cancer will not die from it, and while mastectomy 
significantly reduces women’s lifetime risk of developing the disease, it does not significantly 
reduce women’s risk of dying from breast cancer if they follow the guidelines for high-risk 
screening (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010; Li et al., 2016).  
 One theme I explore across Chapters Two and Three is how the discourses and practices 
of genetic medicine position mastectomy and reconstruction as the “empowered” and “right” 
choices, thereby encouraging women to undergo the procedures. Jolie’s Op-Ed is both infused by 
and perpetuates these rhetorics of “choice” and “empowerment.” She explicitly states that she 
wants to encourage women who “might be living under the shadow of cancer” to not be scared 
by their risk, but instead to “make [their] own informed choices,” “know that they have strong 
options,” and “take on and take control” of their lives. Yet like any piece of writing rooted in 
personal experiences, Jolie’s Op-Ed does not, nor could it, comprehensively reflect the range of 
options available to women. Rather, as a personal story, the piece reflects her individual 
concerns, the options that were available to her, and the decisions she made among those options. 
In fairness to Jolie, no woman should ever be put in the untenable—and impossible—position of 
being asked to speak for or to all women. But the power of Jolie’s celebrity magnified and 
elevated the specific decisions she made in the unique context of her life—to undergo 
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mastectomy and reconstruction—while it minimized other options available to women with BOC 
mutations, such as ongoing surveillance or staying flat. Companies pay celebrities large sums of 
money to promote their products and services precisely because it makes those products and 
services seem more desirable. Hence, while Jolie’s stated intentions in writing the Op-Ed were to 
help inform women, her fame functioned as a de-facto “endorsement” of her specific decisions, 
framing them as the “strong” and best ones. 
 Another issue I explore in Chapter Three is how the architecture and practices of BOC 
genetic medicine in the United States funnel women toward reconstruction by pairing the 
procedure with mastectomy. The title of Jolie’s Op-Ed, "My Medical Choice," implies that she 
made a single decision. However, reconstruction is a separate choice with its own risks. In fact, 
the majority of the risks of breast surgeries are associated with reconstruction, not mastectomy. 
Yet, Jolie does not convey grappling with or actively "choosing" reconstruction, nor does she 
discuss the physical complications and risks posed by reconstructive surgeries. In Chapter Three, 
I reveal how breast reconstruction is typically presented to patients in genetic medicine just as it 
is in Jolie’s Op-Ed—as an assumed, inherent part of the process of a prophylactic mastectomy. 
 Jolie’s Op-Ed also mirrors two additional key themes in Chapter Three: how women are 
often left un- or under-prepared for the side effects and complications of reconstructive surgeries 
and how practices in BOC genetic medicine reflect and reinforce the dominant gender order in 
the United States. Jolie describes reconstruction as a relatively quick process, saying that “nine 
weeks” after mastectomy, the “final surgery of the breasts is completed with the reconstruction of 
the breasts with an implant” (Jolie, 2013). Yet, as the stories from women in this study illustrate, 
reconstructive surgeries often require multiple revisions and have enduring side effects. In 
addition, even if the initial reconstructive surgery has no complications, all breast implants have 
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to be replaced approximately every 15 years (Cordiero, 2008; Eisemann & Spiegel, 2018). 
Therefore, a woman Jolie’s age would require, on average, at least three additional surgeries over 
the course of her lifespan; her “final” surgery would not be just nine weeks after mastectomy. 
Jolie then emphasizes how her reconstructed breasts look rather than describing her internal 
experience of having them, a practice that this study shows is common in US genetic medicine. 
She states, “I do not feel any less of a woman. I feel empowered that I made a strong choice that 
in no way diminishes my femininity,” and she reassures readers that reconstruction “results can 
be beautiful,” noting that her children “see nothing that makes them uncomfortable… small scars 
and that’s it.” (Jolie, 2013). Yet nowhere in the piece does Jolie describe her embodied 
experiences with reconstruction.  
 Chapter Four explores women’s under-preparation and under-treatment for risk-reducing 
salpingo-oophorectomy (RRSO) and how it is linked to tension between the clinical emphasis on 
ovarian cancer risk and prevention and the predominant social and cultural focus on breast 
cancer risk and prevention. There are currently no evidence-based screening tools for ovarian 
cancer, and it often presents with vague symptoms that are mistaken for other common health 
conditions. As a result, ovarian cancer is typically diagnosed at later stages and has a poorer 
prognosis than breast cancer. Ovarian cancer has a five-year survival rate of only 47%, while the 
five-year survival rate for breast cancer is nearly double that, at 90% (National Cancer Institute, 
2018d, 2018e). In addition, unlike mastectomy, RRSO has been robustly associated with an 
increase in survival among women with BRCA mutations and is firmly recommended in clinical 
guidelines (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010; Li et al., 2016; National 
Comprehensive Cancer Network, 2018b). Yet, despite these data and the fact that Jolie’s mother 
died from ovarian cancer, not breast cancer, her initial concern and the focus of her blockbuster 
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Op-Ed was, like most media coverage, on breast cancer risk and prevention. In fact, when the 
New York Times published a second Op-Ed by Ms. Jolie two years later in which she discussed 
her experiences with RRSO, that piece was ignored by the media; I only heard that Op-Ed 
discussed within hereditary breast and ovarian cancer communities. In Chapter Four, I argue that 
the social focus on breast cancer risk and prevention over ovarian cancer risk and prevention that 
was reflected in both the content and media coverage of Jolie’s Op-Eds contributes to women’s 
under-preparation and under-treatment for the side effects of medically induced menopause. 
 In the final chapter, I present policy and practice recommendations that address the key 
findings of the study. Interestingly, just as Jolie’s Op-Ed marked the beginning of this research 
project, another celebrity essay about BOC genetic risk and mastectomy marked its conclusion. 
In February 2019, Nina Garcia, the editor-in-chief of Elle magazine and a long-time judge on the 
television show Project Runway, published a piece in Elle about her decision to schedule a 
prophylactic mastectomy after years of following the high-risk screening protocol and 
experiencing numerous false positive results (N. Garcia, 2019). Titled “A Personal Choice,” 
Garcia’s essay deploys the rhetorics of choice and empowerment that are embedded in Jolie’s 
Op-Ed and circulate throughout genetic medicine. But importantly, Garcia’s essay marks the new 
era of panel testing. Her mutation is on the BARD1 gene, a low-to-moderate-risk gene that is 
included in most BOC panels. Compared to mutations on CHEK2, ATM, and PALB2, which are 
the three moderate-risk genes that I highlight in this study, BARD1 mutations are less prevalent 
and are supported by less robust data on risk (Couch et al., 2017). Garcia acknowledges the 
clinical uncertainty of BARD1 mutations, stating, “Doctors think it increases cancer risk, but 
there isn’t enough data to know by how much” (N. Garcia, 2019). Garcia’s essay underscores the 
importance of several of the recommendations I issue in the conclusion, such as creating a clear 
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system for classifying the risk and risk management recommendations of all genes included in 
panel tests in order to help patients navigate the uncertain risk information the tests often 
generate. Nearly six years into the era of panel testing, it is critical to understand the implications 
of this shift in genetic medicine and to structurally address the challenges it has produced. This 
project aims to makes progress on both fronts.  
 
32 
Chapter 1: “Half a Diagnosis with Half a Recommendation”:  
The Geneticization and Medicalization of Breast and Ovarian Cancer Risk 
 “I think the big issue in the battlefield, if you will, that is going on right now is around 
moderate penetrance genes. Are they going to be slotted into the same mental construct as 
BRCA? Or are we going to somehow carve out a different space for them in terms of 
risk? And I know that we see a reasonable number of people who come for second 
opinion counseling for moderate-penetrance mutations who have been told to be 
managed exactly like a BRCA mutation, you know? Prophylactic mastectomy, 
prophylactic oophorectomy, and—even without necessarily the strong family history.” 
(Steve, Oncologist) 
It seems like they do not quite know how to handle you. There is nobody to coordinate 
the information because CHEK2 is such an emerging area. The information is not all the 
same; it depends on which source you are getting it from. It has been very overwhelming. 
(Josephine, Age 41, CHEK2) 
Introduction 
 The meanings and implications of the “at-risk” health status have been explored at length 
in sociological, anthropological, and science studies literatures. Previous studies have argued that 
people at genetic risk for illnesses occupy a liminal state of “prepatienthood” between sickness 
and health in which patient identity and the course of action is often unclear. (Dagan & 
Goldblatt, 2009; Gibbon, 2007; Kenen, 1996; Lock, 1998; Rose, 2007; Scott et al., 2005; S. 
Timmermans & Buchbinder, 2010). As multi-gene panels have become the testing standard for 
assessing genetic risk for cancer, both the number of people identified as “at-risk” for developing 
breast and/or ovarian cancer (BOC) has increased and the range of affected genes, and therefore 
the extent of people’s risks, has widened. However, social scientists have not examined 
variability in how individuals within this expanding “at-risk” population are viewed, positioned, 
and treated in the US health care system.  
This chapter examines recent shifts in and current practices of BOC genetic medicine in 
the United States, with special attention to the experiences of women with moderate-risk 
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mutations (MRMs) and variants of uncertain significance (VUSs). Drawing on ethnographic data 
from scientific and lay conferences, reports and documents from genetic testing laboratories, and 
interviews with providers and women with genetic variants, I explore how familial cancer risk 
has been geneticized through panel testing and how genetic cancer risk has, in turn, been 
medicalized. I analyze the technologies, documents, and practices that are used to construct BOC 
genetic risk and render it tangible, “factual,” and manageable in order to reveal how panel testing 
has transformed the boundaries of risk, disease, and patienthood.  
I begin by illustrating how panel testing accelerated the geneticization of BOC risk and 
generated a shift from subjective to (dis)embodied sources of risk knowledge. I argue that 
obscuring the scientific interpretation and production of genetic risk contributes to the feeling 
among women with positive test results that breast cancer is inevitable without the use of 
preventative surgical interventions. I then explore how BOC genetic risk has been medicalized, 
arguing that multi-gene panels have contributed to a spectrum of medicalization in which women 
with BRCA1/2 mutations are treated as patients and have fully medicalized experiences, while 
women with MRMs are regarded as “qualified patients” and have only partially medicalized 
experiences. In contrast, I show how VUSs are a contested instance of medicalization in which 
genetics experts typically challenge the attribution of patienthood status while women with 
VUSs may seek patienthood status. In the final section, I examine why and how patients and 
providers attempt to transform the uncertainty of VUSs and MRMs into certainty and seek or 
provide risk management services that are not recommended. By closely examining the tools and 
practices used to assemble genetic risk and render it factual and manageable among women with 
high-risk mutations, MRMs, and VUSs, this chapter sheds light on how the changing landscape 
of US genetic medicine has generated concomitant shifts in the boundaries of patienthood.  
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Geneticization of Cancer Risk 
 In her book Building Genetic Medicine, Shobita Parthasarathy argues that with its patent on 
the BRCA genes, Myriad Genetics constructed a new category of risk: hereditary risk for cancer. 
Myriad distinguished hereditary risk, which was diagnosable through the company’s tests for 
BRCA mutations, from familial risk, which was rooted in a family history of the disease 
(Parthasarathy, 2007). Parthasarathy asserts that Myriad used this rhetorical maneuver to help 
generate a market for their test. But in addition, by creating a sub-type of risk that could be 
defined and identified only through genetic screening, Myriad initiated a process of geneticizing 
BOC risk that this study reveals was hastened and cemented with the shift to panel testing.  
 First coined by social epidemiologist Abby Lippman in the early 1990s, geneticization is a 
broad concept that is both an “ideology and a practice” (Lippman, 1998, p. 64). The term refers 
to how people are, or might be, classified and differentiated according to their genetics, or 
“reduced to their DNA codes,” and to the ways in which “most disorders, behaviors and 
psychological variations [are] defined, at least in part, as genetic in origin” (Lippman, 1991, p. 
19). But in addition, geneticization refers to the increasing tendency for scientists and clinicians 
to use genetic technologies to “diagnose, treat, and categorize conditions previously identified in 
other ways” (Lippman, 1998, p. 64). Using this latter definition, the shift away from using the 
knowledge generated by family histories of cancer and toward using genetic test results to define 
cancer risk and determine appropriate interventions is an example of “geneticization.”  
 Lippman was critical of geneticization because she was concerned about the possibility of 
genetic determinism and its social consequences. She envisioned a potential future in which the 
social, environmental, and structural roots of inequity and disease were ignored, and instead 
people were reduced to their genes (Lippman, 1991, 1992, 1998). Since the completion of the 
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Human Genome Project (HGP), multiple scholars have critically examined the utility of the 
concept of geneticization, noting that the worst of Lippman’s fears about the process never 
became reality (Arribas-Ayllon, 2016; Susan E. Bell & Figert, 2015; Shostak & Moinester, 
2015). Sociologists Susan Bell and Anne Figert highlight how the proliferation of genomics 
research in the 21st century has disrupted rather than reinforced deterministic thinking about 
genetics by revealing multiple factors involved in gene expression and activation and a non-
linear relationship between genes and behavioral or physical outcomes (Susan E. Bell & Figert, 
2015). Similarly, science studies scholars Sara Shostak and Margot Moinester argue that the 
deterministic discourse of geneticization is limited because it is rooted in a nonexistent binary 
between genes and the environment that overlooks complex gene-environment interactions 
(Shostak & Moinester, 2015).   
 I concur with these and other scholars that the social consequences of geneticization have 
not been as bleak as Lippmann imagined and that the original “zero-sum relationship” (Shostak 
& Moinester, 2015) she posited between genes and the environment was flawed. However, with 
the current emphasis on personalized medicine that is reflected in large research initiatives such 
as “All of Us” and the “Cancer Moonshot” (National Cancer Institute, 2018b; National Institutes 
of Health, 2018), an increasing number of “disorders, behaviors and psychological variations” 
are, as Lippmann posited, being studied and defined, “at least in part, as genetic in origin” 
(Lippman, 1991, p. 19). Moreover, clinical practices in genetic medicine lag far behind scientific 
and theoretical understandings of genetics; while scientists know there are epigenetic factors and 
gene-environment and gene-gene interactions that affect gene expression, their mechanisms are 
poorly understood and therefore that knowledge rarely informs clinical applications of genetics. 
In fact, the findings of this study reveal that in the era of panel testing, genetic tests have become 
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essential to the “diagnosis, treatment, and categorization” of being high-risk for breast and 
ovarian cancer, and thus the concept of geneticization is still useful in describing contemporary 
configurations of genetic medicine.  
 In fact, BOC risk has become narrowly defined as genetic risk since the adoption of panel 
testing as the industry standard. Before the discovery of the BRCA genes in the mid-1990s, a 
family history of breast cancer was the primary way in which women were identified as at high-
risk of the disease. Between the discovery of the BRCA genes and the widespread use of multi-
gene panel tests, clinicians often triangulated familial and hereditary sources of information to 
determine women’s lifetime BOC risk, such as detailed family histories of cancer (i.e., cancer 
“pedigrees”), estimates produced by computerized risk-assessment tools that assess lifestyle and 
biological factors,10 and the results of one or more carefully selected single-gene tests. However, 
familial patterns of breast and ovarian cancer are now largely used to determine women’s 
eligibility for genetic testing, and those tests are then used to confirm and validate BOC risk and 
women’s eligibility for additional risk management services. Thus, panel testing accelerated and 
completed the geneticization of cancer risk that Myriad set in motion. 
Moving from Subjective to (Dis)embodied Knowledge 
 The older and broader concept of familial risk for breast cancer that was established 
through women’s family histories of the disease is a form of subjective knowledge, as it is 
gathered through people’s lived experiences and the stories that circulate in families. Here I am 
distinguishing technical knowledge about a specific incidence of cancer in a family member and 
                                                             
10 Computerized risk-estimation tools, such as the Gail Model and Tyrer-Cuzick tool, account for a 
multitude of factors that have been robustly associated with an increased lifetime risk of developing 
breast cancer, including cancer in first degree relatives, age at menarche and menopause, parity, 
breastfeeding, lifestyle factors (i.e., exercise, alcohol consumption, tobacco use), and environmental 
exposures. Some of these tools have been developed or modified to incorporate genetic testing results in 
their models (Centers for Disease Control and Prevention, 2018; Millstine, David, & Pruthi, 2014). 
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what that person’s cancer suggests for other family members about their risk of cancer. While 
specific biological information about a person’s cancer, such as lymph node involvement or 
tumor grade, would initially be gathered through imaging or testing, that technical, biomedical 
information is not required, and in fact is rarely used, to constitute other family members’ 
knowledge of their familial risk. Rather, a family history of cancer is an observable pattern of 
disease across multiple family members. The general knowledge that certain people within a 
particular family had cancer can circulate without mediation or translation by technoscientific 
tools, yet that knowledge still serves to make risk visible. To contextualize this point, it is helpful 
to draw on an example from my own life. My mother learned she had a BRCA1 mutation in 
1997. However, growing up in the 1980s, I did not need a clinician or scientist to run tests on me, 
nor did I need the technoscientific details of her tumor tests, to know that I was considered at 
“high risk” of developing breast and ovarian cancer. With a grandmother who died from ovarian 
cancer at age 57 and a mother who was diagnosed with breast cancer at age 39 and then ovarian 
cancer six years later, the lived experiences of my relatives attuned me to my risk and made it 
visible long before the BRCA genes were even discovered.  
 Some social scientists have theorized and analyzed hereditary genetic risk, not familial 
risk, as a specific form of subjective knowledge: embodied knowledge (Brown et al., 2011; Nina 
Hallowell, 2000; Kavanagh & Broom, 1998; Lorentzen, 2008). This may make sense, as genetic 
risk for cancer obviously involves and implicates bodies. Deoxyribonucleic acid (DNA) encodes 
the protein building blocks that quite literally make up our bodies, and therefore a harmful 
mutation in a portion of our DNA can have significant embodied consequences. In addition, 
patients are the experts on what it means to live with genetic risk, and the potential outcomes of 
and responses to that risk—cancer and surgeries—are unquestionably embodied.  
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 However, while genetic risk is of the body, it is not embodied. People cannot internally feel 
whether they have genetic risk, nor can they independently determine whether or to what degree 
their risk exists. Unlike, for example, activists in environmental breast cancer movements 
(Fosket, 2000; Klawiter, 2008; Ley, 2009) or DES daughters (Susan E.  Bell, 2009), who have 
drawn on embodied knowledge, women at genetic risk for breast and ovarian cancer are not yet 
sick, so they do not share a phenotype or experience similar physical symptoms. In addition, 
because most forms of embodied knowledge originate from patients’ inner experiences or their 
phenotypic characteristics, they are the primary experts on and translators of that knowledge. 
However, in sharp contrast, information about whether or not someone is at genetic risk is 
knowable and verifiable only through clinical testing, genetic sequencing, and numeric or 
statistical abstractions. As a result, knowledge about genetic risk originates with scientists, 
clinicians, and genetic counselors and is always translated by those experts to patients. Hence, 
while genetic risk resides inside patients’ bodies and has serious embodied implications, the 
power to identify and define genetic risk lies outside of those bodies, and as such, it is not 
embodied in the ways that term is most commonly understood.  
 Instead, I argue that BOC genetic risk is (dis)embodied, a concept I use to signal the two 
important dimensions of genetic risk that I have highlighted in this section: first, how it is 
simultaneously located inside and outside of the body, and second, that it is constructed through 
technoscience and can only be abstractly known, not physically felt or seen. Like other forms of 
scientifically produced expert knowledge, the molecularized, (dis)embodied knowledge about 
cancer risk constructed through the various processes of panel testing is deemed more precise, 
objective, and therefore valid than the subjective knowledge of family history. Yet as I will 
illustrate in the following sections, knowledge about genetic risk is not factual information that is 
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discovered through biomedical testing. Rather, cancer genetic risk is a moving target that is 
coproduced through both technoscientific and social processes.  
Making Risk Factual: The Black Boxes of Genetic Testing 
 DNA molecules are often colloquially referred to as “blueprints” because, similar to 
architectural plans, they contain instructions for assembling the building blocks of life. The 
structure of DNA molecules, called a “double helix,” looks like a twisted ladder and is comprised 
of two connected, winding strands made up of four chemical bases that pair specifically with one 
another: adenine (A) with thymine (T), and cytosine (C) with guanine (G). Sequential groupings 
of the base pairs of A, C, T, and G tell the body how to produce and assemble amino acids to 
form proteins, which are vital to cellular structures and functions throughout the body. The 
National Human Genome Research Institute (NHGRI) uses a language analogy to explain how 
DNA encodes for protein production: “The order of the As, Ts, Cs and Gs determines the 
meaning of the information encoded in that part of the DNA molecule just as the order of letters 
determines the meaning of a word” (National Human Genome Research Institute, 2015a).  
 When a person undergoes genetic testing, a sample of either their tissue or blood is sent to 
a genetics laboratory for DNA sequencing, which involves determining the order of base pairs on 
the genes included in their test. The sequence of base pairs on their genes is then compared to the 
sequence of base pairs in what are referred to as “wild types”11 of the genes—the most common 
                                                             
11 In Biocapital, Rajan argues that genetic “wild types” are constructed analytical tools, not examples of 
what is typically found in nature. He states: “A wild-type organism is, however, very much an artificial 
construct. Nature is extremely unlikely to have wild types (indeed, the very concept of a genotype that is 
not mutated is an anachronism, since genotypes themselves have arisen as a consequence of both natural 
selection and mutation), only a range of uncontrolled  and uncharacterized mutants, some with a greater 
selective advantage than others” (Rajan, 2006, p. 160). 
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sequences of that gene that correctly encode for protein production (National Human Genome 
Research Institute, 2015b). There are rarely discrepancies between the major US genetics 
laboratories that conduct cancer genetic testing in their DNA sequencing results.12 
Discordant Variant Classifications 
When testing is done with reputable laboratories, there is usually agreement as to whether 
and where a variant exists in a person’s genetic code;13 however, disagreement between labs on 
the significance of variants is not uncommon because variant interpretation and classification 
practices are neither objective nor standardized (Balmaña et al., 2016; Lincoln et al., 2017; 
Phimister, 2015; Thomas P. Slavin, Blazer, & Weitzel, 2016). Linda, a cancer genetic counselor 
who has been practicing in the field since its inception in the 1990s, explained how machines 
perform DNA sequencing and then scientists have to interpret the meaning of those results: 
So, when you do a genetic test you send in the blood, and if all of our genes are like a big 
library, whatever genes you tell them to test, they go in and find both of your copies of 
that gene and then they proofread them, right? They read through the sequence of 
whatever genes you tell them to. And the first thing they do is they find all the spots 
where yours doesn't match the one on file. And no matter whose blood we send in we all 
have lots of variability in the way our genes are spelled out. So, there's a lot of normal 
variation. And what the labs have to do is kind of tell the signal from the noise. So, the 
machines now find all of the variations. And then people have to look at each one of 
those and figure out, okay, is that just another normal human variation or does that 
interfere with the function of this gene? (Linda, Genetic Counselor) 
As scientists “try to tell the signal from the noise,” they typically use a five-item classification 
                                                             
12 The five US laboratories most commonly used for BOC genetic testing are Myriad, Ambry, Invitae, 
GeneDx, and Color. However, there are other major reputable labs in the United States. 
13 A recent study found significant variation among labs worldwide that conduct BRCA testing along 
specific technical dimensions, such as their minimum read depth, whether they sequenced non-coding 
regions of the genome, and the techniques they used for large rearrangement detection. However, there 
was less variation among US labs, and the differences that did exist would not be likely to contribute to 




scale for genetic variants: pathogenic, likely pathogenic, uncertain significance, likely benign, 
and benign (Richards et al., 2015). 
As Linda noted, genetic variation is normal. Everyone has variants in their DNA, and 
variants are sometimes advantageous—species evolve through a combination of genetic variation 
and natural selection. But the vast majority of genetic variants are harmless “noise,” so when 
those variants are identified through testing, scientists classify them as likely benign or benign. 
Just as the small differences between British and American spellings of certain English words 
(e.g., “colour” and “color”) do not make those words indecipherable or alter their meaning, a 
slight variation in a person’s genetic sequence will often have no effect on gene or protein 
function, and, therefore, on their bodies or health. When existing data suggest that variants are 
likely to affect protein production or genetic function,14 scientists classify them as pathogenic or 
likely pathogenic and refer to them as “mutations.” Using Linda’s framework, mutations are the 
“signals” that the scientists are attempting to weed out and identify. Variants get classified as 
VUSs when their impact on protein production is unclear and/or there is not yet enough data on 
them to determine whether there are statistically valid associations between that genotype and 
the phenotype of interest.  
Classifying variants requires drawing on scientific expertise and judgement, which varies 
across laboratories and scientists. While an increasing number of genetics laboratories are 
sharing their interpretations of variants through online databases like ClinVar (ClinGen, 2018; 
                                                             
14 Scientists consider numerous sources of data to make variant classifications and interpretations. For 
example, they draw on information in population, disease, and sequence databases; existing literature on 
genetic conservation and variation in human and animal studies; predictive algorithms; and data from 
functional studies. In addition, certain types of variants (e.g., nonsense and frameshift) and/or specific 
coding regions within a gene can indicate whether those variants are likely to affect protein production or 
function (Rebbeck et al., 2015; Richards et al., 2015). 
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Landrum et al., 2018) and aligning their variant interpretation practices with industry guidelines 
jointly issued by the American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) (ClinGen, 2018; Richards et al., 2015), some labs 
are not participating in these efforts. For example, Myriad, which has the most extensive data on 
BRCA variants due to its patent on the genes for over 15 years, has actively resisted calls for 
transparency and data-sharing (Guerrini, McGuire, & Majumder, 2017; McGowan, 2018). 
Instead, Myriad maintains its own trademarked classification system and database of results and 
promotes those as scientific strengths that distinguish the company in the BOC genetic testing 
market. Laura, a clinical geneticist, discussed this “unfortunate” corporate decision: 
There are notable exceptions to laboratories that don't participate and don't contribute 
their data to ClinVar. Myriad in this case being the biggest one of those. And so that 
does—I mean it's a black box essentially in terms of how they're interpreting variants, 
whether they're doing it correctly or incorrectly. Of course, they will argue from a 
marketing point of view that they have more data and so therefore they have better 
interpretation of data. It's hard for any of us to know or assess that because they haven't 
been transparent about that process. So, I do think that's unfortunate for patients as a 
whole. I think if people are trying to serve patients in the best way, they should make data 
from patients available and patients should be able to, in the aggregate, help each other 
by this pool of de-identified information. But obviously that's a business decision that 
they've made. And I understand why they've made it, I just think it's unfortunate. (Laura, 
Clinical Geneticist) 
 Moreover, while sharing data and following the ACMG-AMP guidelines are helpful in resolving 
conflicting interpretations, these practices, on their own, are not a panacea. The ACMG-AMP 
guidelines are vague and broad, which means they can be interpreted differently, and there are no 
independent means for assessing actual laboratory practices or adherence to the guidelines 
(Nykamp et al., 2017; Thomas P. Slavin et al., 2016). In addition, as Steve, an oncologist, 
explains, “The idea that if everybody just puts all of the variants we’ve ever seen into the 
database, that somehow magically everything is going to become clear, is a conceit…. What’s 
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helpful is when people put their variant classifications and their reasoning behind their variant 
classifications in to a central database.” Yet, while multiple databases exist for sharing variant 
calls, they are not linked, and many labs do not provide the specific evidence they draw on to 
form their variant interpretations (ClinGen, 2018; Thomas P. Slavin et al., 2016).   
Given this combination of thin data, disagreements in scientific judgement, and obscured, 
siloed interpretation practices and sources of evidence, laboratories sometimes generate 
discordant classifications of variants (Amendola et al., 2016; Balmaña et al., 2016; Lincoln et al., 
2017).15 Alyssa, a genetic counselor who works for a testing laboratory, shared how conflicting 
interpretations of variants has become a bigger issue in recent years. “I think we're all trying, it's 
just that they're called guidelines because they're guidelines. And for some variants, two groups 
of really smart people could look at the exact same evidence and come to different conclusions. 
So, I think that the ACMG guidelines are really great and they provide us all framework, but I 
have heard a lot of chatter recently around discrepant interpretations.” Stacy, a genetic counselor 
who works at an academic medical center, recalled a recent case in her group practice that 
involved conflicting interpretations of the same variant: 
There's one case that comes to mind at our institution, it wasn't even mine, but this has 
also happened to me, where a family member came in with two reports from, like, her 
sister and her mother. And they were both done at separate labs, and it was the same 
variant that was found, but one lab called it a VUS and one lab called it likely pathogenic. 
So basically, the counselor here got to pick which labs she sent it to to figure out how it 
would be called, which is a tough situation. (Stacy, Genetic Counselor)  
                                                             
15 In this analysis of discordant classifications, I am only referring to conflicting interpretations of variants 
that would result in a change in medical management (e.g., between likely pathogenic and uncertain, but 
not between pathogenic and likely pathogenic). Laura, a clinical geneticist, noted that even though 
variants with discordant classifications that would change medical management constitute a small 
proportion of overall variants, they are concerning. “The thing that I get more worried about is the small 
percentage, which is five percent, I believe, where they actually are meaningful differences that impact 
clinical care. But five percent is like not a small number to me. It is something that has to be resolved.” 
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Similarly, Jackie, who also practices at an academic medical center and has been working in 
cancer genetics for over 20 years, stated, “I've had families, we all have here, where you do two 
family members and because of their insurance situation we use different labs. And it’s the same 
finding, again, but it was found in one lab where they called it likely pathogenic, yet the 
relative's lab is going to call it an uncertain variant.”  
There were also striking examples of discordant results among the women who 
participated in this study. For example, Deena, who has a CHEK2 variant with conflicting 
interpretations, was treated at two different clinics for her colon and thyroid cancers. Both clinics 
asked her to do genetic testing, and each one used a different laboratory. Both labs identified the 
same CHEK2 variant, but they classified them differently.  
Now, [the private clinic] told me I have the CHEK2 gene mutation. [The academic clinic] 
told me I have an unknown variant of the CHEK2 mutation. They came up with different 
readings on the CHEK2. They came up with the same variant. But one of them classified 
it as unknown and of them said it is. I went right to my [private clinic] geneticist and 
talked to her, she said it's based on labs, that each lab knows, has different knowledge, 
and she felt their lab knew more than [the academic clinic’s] lab did. I'm thinking [the 
academic clinic] is supposed to be cutting edge of research, so I would think they know 
more, but…. (Deena, Age 45, CHEK2) 
Three other women I interviewed had the same variant as Deena, which is listed in ClinVar as 
having conflicting interpretations. One of the women was told it was a VUS, while the other two 
were issued “positive” results.16 Interestingly, one of the women who was told it was positive 
chose not to have surgery, while the other three all had mastectomies. 
 Penelope, who by age 32 had been diagnosed with both ovarian and kidney cancer, had 
                                                             
16 For any participant who had a variant with conflicting interpretations in ClinVar, I noted the conflict in 
my data. However, I categorized the women as either having a mutation or VUS based on the 
determination of their testing laboratory. Since the women’s decisions and the responses of their medical 
teams were based on the conclusions provided in their genetic testing reports, those conclusions were 
critical context for understanding their medical management. 
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genetic testing done with three different laboratories,17 and like Deena, she received discordant 
results.  
The first time happened when a genetic counselor came to the hospital while I was still 
admitted from the [ovarian] surgery. They submitted the genetic blood work to a 
company called GeneDx. There was a breast and ovarian cancer panel. That came back 
with two different results. I had a CHEK2 gene labeled expected pathogenic and I had a 
BRCA2 gene that they labeled unknown significance…. [Then] I did Myriad because of 
the BRCA2 variant of unknown significance. [The doctors] said that Myriad has the most 
information about BRCA2 and they wanted me to find out what Myriad had to say about 
the BRCA2 mutation…. [Myriad] came back and said that my CHEK2 was of uncertain 
significance instead of expected pathogenic. They said that BRCA mutation was negative 
and there was no clinically significant mutation detected…. So then after I had the kidney 
cancer, my geneticist…sent my information to Ambry Genetics and expanded it to a 49 
gene analysis associated with hereditary cancer, and that came back with three results. 
That was CHEK2 variant likely pathogenic, BRCA2 variant of unknown significance, 
and SDHA variant of unknown significance. (Penelope, Age 32, CHEK2, BRCA2 VUS) 
Similar to Deena’s experiences, the three labs Penelope tested with all identified the same 
variants on BRCA2 and CHEK2, but they had discordant interpretations of them. While only 
Ambry identified the SDHA variant, that was the most expansive panel, and based on the 
information Penelope shared and the constitution of various panels at the time of her original 
tests, it was unlikely that Myriad and GeneDx sequenced that gene.  
When laboratories generate conflicting interpretations of variants on BOC genes, it 
reflects disagreement about whether or not that variant increases a person’s risk for developing 
cancer. But being “at-risk” for cancer is, itself, a state of uncertainty, and therefore discordant 
classifications layer uncertainty on top of uncertainty, a magnification that generates challenges 
for both patients and providers. For patients, the discrepancies are frustrating and confusing. 
                                                             
17 Importantly, for women like Deena and Penelope who have already been diagnosed with cancer, 
genetic tests do more than identify levels of risk. Test results are increasingly used to guide cancer 
treatment decisions and can determine eligibility for certain medications and clinical trials. 
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When I asked Penelope how she felt after receiving so many conflicting interpretations, she said, 
“Pissed!” Then, toward the end of our conversation, Penelope explained that she wished labs 
would share data and try to reach resolution. “It’s a little frustrating. I’d love if they could all 
share their information so if you get genetic testing results, you get results.” 
As Stacy noted, discordant classifications put genetic counselors and clinicians in a 
“tough situation” because they, not the scientists, then have to make judgements about whether to 
counsel patients to treat those variants as harmful or uncertain, which in turn impacts medical 
management. Most often, genetics professionals leaned toward treating those variants as likely 
pathogenic, which were interpretations that they perceived as cautious, but might, in practice, be 
harmful. For example, Stacy recalled a patient whose ATM variant had conflicting 
interpretations.  
It came back as a VUS at the lab that I sent to, and then in ClinVar, two other reputable 
labs that we do send to regularly were calling it pathogenic. One was pathogenic and one 
was likely pathogenic. And then I did ACMG guidelines on it and had our geneticist look 
at it, and she thought that it looked pretty pathogenic, also. So, in that case, we did tell 
her to follow the ATM guidelines, if possible. It's just hard for these people getting 
insurance coverage for it sometimes. (Stacy, Genetic Counselor)  
Jackie also shared that typically she sides with the interpretation of higher risk when there is 
disagreement. “If somebody's leaning towards it being pathogenic, I need to counsel that we 
have to err in that direction, or lean in that direction…. So, we're going to do more frequent 
screenings rather than not enough screening. Put it that way. We'd go in the direction of more 
rather than the routine average screening.” If the guidelines for risk management were regularly 
being followed and additional screening was the only intervention that women with moderate-
risk mutations (MRMs) were receiving, erring on the side of classifying variants with conflicting 
interpretations as pathogenic would be the cautious approach. However, as I will illustrate in 
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Chapter Two, most women with MRMs are being offered risk-reducing mastectomy, and many 
of them are opting for the surgery, which notably alters the risk-benefit calculation of managing 
women according to the “riskiest” interpretations of variants with discordant classifications.  
Inconsistent Risk Information 
 Once variant interpretations are made, laboratories produce a report that they issue to 
clinicians and/or patients, and even when their classifications are concordant, the content of 
those reports varies across labs. The ACMG-AMP guidelines provide some standards for 
reporting, and most laboratories adhere to the technical recommendations, such as using 
consistent variant nomenclature and providing descriptions of sequencing methods and citations 
for risk estimates. All of the five major US laboratories that conduct BOC genetic testing—
Ambry, Color, GeneDx, Invitae, and Myriad—report variants classified as pathogenic and likely 
pathogenic; those are labeled “positive” results. Conversely, none of the five major labs report on 
variants that they have classified as likely benign or benign. When scientists judge a variant to be 
harmless, that variant remains invisible outside of the testing laboratory; the report sent to 
doctors and patients simply communicates that the genetic test was “negative.” Thus “negative” 
does not mean “no variants,” but rather “no variants that have been judged to have clinical 
significance.” In addition, none of the major laboratories provides variant-specific risk estimates, 
despite research showing that risk is mutation-specific and varies by mutation type and location, 
even for pathogenic variants on the same gene (Rebbeck et al., 2015). Instead, all five labs report 
risk estimates at the level of the gene. However, laboratories vary considerably in how they 
organize their reports, what types of risk estimates they use, and what information they highlight, 
including whether and how they report VUSs. Moreover, their reports often contain strikingly 
different cancer risk information, even for pathogenic mutations on the same gene. 
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 I analyzed and compared the content of five genetic test reports—one from each of the five 
major BOC genetic testing laboratories in the United States—that identified pathogenic CHEK2 
mutations. The reports were provided to me by women I interviewed and were issued between 
2015 and 2017. Table 1 provides a summary of the content included in each report, stratified by 
lab, and Table 2 charts the CHEK2-associated cancer risks mentioned in each laboratory’s report. 
Because four of the five laboratories follow the ACMG-AMP guidelines on reporting, they 
mostly included similar content sections, such as descriptions of their sequencing and 
classification methods and a list of scientific references; only Myriad did not include sources or 
methods (Table 1). However, despite those uniform features and the fact that all of the reports 
were for pathogenic CHEK2 mutations and therefore should have contained similar risk 
information, not one of the reports was consistent with another in either the range of potential 
cancer risks it identified (Table 2) or in the specific estimates provided for those risks (Table 1).18 
                                                             
18 As noted earlier, the risk information provided in laboratory reports is gene-level, not mutation-level, 
data. Once a variant is classified as a mutation (i.e., it is considered pathogenic or likely pathogenic), 
people with that variant are cited broad ranges of the risks of having a mutation on that gene. While 
research on BRCA mutations has shown that risks are mutation-specific (Rebbeck et al., 2015), for most 
MRMs, there is not enough data on each specific variant to calculate mutation-specific risks. But even 
when those calculations are possible (e.g., for BRCA founder mutations), mutation-specific risk 
information is not provided on lab reports. This simplification of risk information on laboratory reports is 




Table 1: Content of Pathogenic CHEK2 Test Result Reports, by Laboratory 
 
 
Table 2: Cancers Associated with CHEK2 Mutations in Test Results Reports, by Lab 
  
 Color and Invitae were the most conservative among the five labs in providing information 
on the cancer risks associated with pathogenic CHEK2 mutations. Color only highlighted the two 
types of cancer—breast and colorectal—that have been robustly connected to CHEK2 mutations 
in previous research, and their report explicitly noted no known connection between CHEK2 and 
ovarian cancer. It states, “Testing positive for a likely pathogenic mutation in the CHEK2 gene 
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means your chance of developing breast cancer is greater than that of the average US woman. 
Your chance of ovarian cancer is not known to be affected by this mutation.” Invitae’s report also 
provided a limited range of possible increased cancer risks, but their scope was slightly wider 
than Color’s. Directly under the large “positive” summary result banner that was highlighted in 
beige, Invitae’s report states, “The CHEK2 gene is associated with an increased risk for 
autosomal dominant breast, colon, thyroid and prostate cancers.”  
 While Ambry and Myriad also emphasized the associations between CHEK2 mutations 
and breast and colon cancers, their reports added information about other potential cancer risks 
with far weaker bases of evidence. For example, Ambry stressed the risk of breast and colorectal 
cancers, noting both of them more prominently on the first page of their report. However, on the 
second page, they added, “Studies indicate that mutations in the CHEK2 gene may confer an 
increased risk of developing many types of cancer including breast, prostate, colon, thyroid, 
ovarian, and kidney.” Myriad literally highlighted the connections between CHEK2 mutations 
and increased risk of breast and colorectal cancers in their report, which features a table 
underneath their dark red “positive” result banner that states “HIGH RISK: Female Breast” in a 
bright red cell and “ELEVATED RISK: Colorectal” in a bright orange cell (Figure 3). In 
addition, in the section titled “CHEK2-associated Cancer Risk,” the Myriad report notes a range 
of other cancer risks, stating, “Some studies have described a possible increased risk for a wide 
range of cancers in patients with CHEK2 mutations, including prostate, leukemia, lymphoma, 





Figure 4: Positive Results Banner and Table from Myriad Report 
 
 GeneDx’s report stood out among the five laboratories because it challenged the general 
consensus in the field that CHEK2 mutations confer an increased risk of colorectal cancer. The 
report stated that while a 2003 study had “observed a higher frequency of this pathogenic variant 
among families with Hereditary Breast and Colon Cancer than families with Hereditary Breast 
Cancer alone,” the most common pathogenic CHEK2 variant “does not appear to confer a higher 
risk of sporadic colon cancer.” Instead, GeneDx’s report focused on the association between 
CHEK2 mutations and female breast cancer, and it was the only one to highlight women’s 
increased risk of developing a second primary breast cancer. But like Ambry and Myriad, 
GeneDx also mentioned various other cancers that one or more previous studies had found to be 
associated with CHEK2 mutations, including prostate, endometrial, ovarian, and thyroid cancers.  
 In total, 10 different cancers were mentioned across the five reports as possibly associated 
with CHEK2 mutations, but only an elevated risk of breast cancer was identified in all of them 
(Table 2). Four of the five laboratories stressed the relationship between CHEK2 mutations and 
increased risk of colon cancer, which is consistent with the screening and risk management 
recommendations issued by the National Comprehensive Cancer Network (NCCN), the leading 
professional organization in the United States that develops and regularly updates guidelines for 
cancer prevention and care (National Comprehensive Cancer Network, 2018b). Four out of five 
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of the lab reports also mentioned studies showing elevated risks of thyroid and prostate cancers, 
yet NCCN mentions neither of those cancers in their CHEK2 screening and management 
recommendations (National Comprehensive Cancer Network, 2018b). Two laboratories noted a 
possible increased risk of ovarian cancer, but that information contradicts Color’s report and the 
NCCN guidelines, both of which assert that ovarian cancer is not known to be associated with 
CHEK2 mutations (National Comprehensive Cancer Network, 2018b). The remaining five 
cancers that some studies have suggested may be connected to CHEK2 mutations were each 
noted by only one laboratory. Among the five laboratories, Myriad identified the greatest number 
of potential cancer risks linked to CHEK2 mutations, but they also qualified their long list by 
noting that the studies demonstrating those risks “are not conclusive and there are no medical 
management guidelines to address these possible risks.” It is possible that scientists at Myriad 
chose to err on the side of over-informing patients. However, as I will illustrate later in the 
chapter, the problem with such an approach is that patients often imagine the worst possible 
outcomes even when potential risk information is downplayed.  
 In addition, even though the laboratories were consistent in associating CHEK2 with an 
increased risk of breast cancer, the specific risk estimates for breast cancer that they provided 
varied (Table 1). Both Ambry and GeneDx presented relative risk estimates, but the values were 
incongruent. Ambry indicated that women with a CHEK2 mutation have “up to a 2-fold 
increased risk” (emphasis added), while GeneDx presented odds ratios that suggest women have 
at least a twofold risk and up to a fourfold risk, depending on their family history. In addition, 
neither Ambry nor GeneDx provided data on baseline breast cancer risk among US women. 
Color, Invitae, and Myriad all presented absolute risk estimates that varied slightly but were 
fairly consistent with one another. All three labs also all provided data on breast cancer risk 
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among women in the general US population. However, the data they cited suggest that women 
with CHEK2 mutations are somewhere between three and six times more likely to develop breast 
cancer than average US women, which is higher than the estimates presented by both Ambry and 
GeneDx. Interpreting risk estimates always requires some degree of statistical literacy and 
numeracy skills, but when those estimates have wide ranges, are incongruent, and/or are 
presented without baseline data, they become even more challenging to interpret. 
Inconsistent VUS Reporting 
 Another critical way in which the laboratories’ reports differ is in how they communicate 
VUS results.19 There is an ongoing, lively debate in US cancer genetics communities about the 
ethics of VUS reporting and what should be considered “best practices” for the field. Some 
people believe that VUSs, like benign variants, should not be reported because several previous 
studies show that VUSs increase patients’ fears and are often misinterpreted as positive results, 
which can lead to potentially unnecessary interventions that carry their own risks (Eccles, 
Copson, Maishman, Abraham, & Eccles, 2015; Allison W. Kurian et al., 2017; M. L. Murray et 
al., 2011; Ray, 2017; Ready et al., 2011; Zuppello, 2018). Others feel that patients have a right to 
know and control their personal genetic information and are concerned about withholding VUS 
results because, while it happens infrequently, they are sometimes upgraded and reclassified as 
likely pathogenic or pathogenic. Some advocate for a middle ground—reporting the presence of 
a VUS and the importance of maintaining contact information for follow up, but not providing 
detailed information about the location of the VUS in order to minimize patient anxiety and the 
                                                             
19 Data on VUS reporting were gathered through copies of test results that study participants with VUSs 
shared and through sample reports provided online by the laboratories. No women in the study who 
shared their reports and were tested by GeneDx had a VUS, and GeneDx does not share sample reports 
online. Thus, GeneDx is not included in this part of the analysis. 
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possibility of unnecessary interventions. In addition, some experts advocate for different 
approaches to reporting in different populations, both because the prevalence of VUSs varies 
across populations and because any genetic findings, including VUSs, may affect treatment 
pathways or clinical trial eligibility for women who already have cancer (M. C. King, Levy-
Lahad, & Lahad, 2014; T. P. Slavin et al., 2018). 
 Consistent with their conservative reporting of associations with various cancers, Color 
takes a cautious approach to reporting VUSs that is closest to the middle-ground position. When 
they classify a variant as uncertain, in the “Genes Analyzed” section of their report they include a 
paragraph with the header “Genes with Variants of Uncertain Significance” that states:  
A “Variant of Uncertain Significance” (VUS) was identified. This is a genetic change 
whose impact on breast and ovarian cancer risk is not yet known. This is a common 
finding and does not change screening guidelines. To date, most VUS's [sic] have been 
found to be harmless (benign), and if it is further classified, we will try to contact you at 
[patient’s phone and email.] If you would like to know the technical details of this VUS, 
contact us. 
The text is printed in the same size font as the rest of the main report content and is not bolded or 
highlighted in any way. I interviewed a Color employee at a national meeting where I was doing 
fieldwork,20 and she explained the reasoning behind their VUS reporting strategy:  
If you or your provider would like to have the actual VUS, the gene, the allele, the 
supporting evidence, you can request that by phone or e-mail. And then we send an 
addendum to the report. And providers can actually select, by default, “I just always want 
to see those details on the reports.” And so that way there's a little bit of a gate so that if 
we find a VUS someone can absolutely access it—we totally believe your data is yours. 
But first we put a little bit of a gate there to help explain and prevent the possibility that it 
could be accidentally interpreted as a positive result and someone would act on it. 
                                                             
20 All five of the major BOC genetic testing laboratories in the United States have exhibit booths at the 
national cancer genetics meetings I attended during my fieldwork. 
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The Color employee further explained that they made this decision, in part, because their reports 
are uniquely directed to patients, not providers. As she stated, “the YOU in the report is the 
person being tested,” and they designed their report content considering the question, “What do 
people want to know when they get these results?”  
 Myriad provides more detail on VUSs than Color, as they identify the gene and variant 
sequence. However, these findings are visually and substantively muted compared to any 
positive findings communicated in their reports. Underneath the giant red and green banners 
Myriad uses to communicate whether test results are positive or negative for mutations, there is a 
much thinner gray banner included in all reports that says “Additional Findings: (No) Variant(s) 
of Uncertain Significance (VUS) Identified.” When there are no VUSs, the word “No” is 
included, and when they interpret variants as VUSs, the word “No” is removed and the list of 
genes and reference sequences for the variants follows (Figure 4). By separating VUS 
information from any positive findings and including the green negative banner in the absence of 
other positive results, Myriad communicates that VUSs are not “clinically significant” and 
should not alter medical management. In addition, all of Myriad’s reports, even ones with no 
VUSs, include the following paragraph in the “Additional Findings” section titled “Details About 
Non-Clinically Significant Variants”:     
 All individuals carry DNA changes (i.e., variants), and most variants do not increase an 
individual's risk of cancer or other diseases. When identified, variants of uncertain 
significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and 
benign variants (Polymorphisms) are not reported and available data indicate that these 
variants most likely do not cause increased cancer risk. Present evidence does not suggest 
that non-clinically significant variant findings be used to modify patient medical 
management beyond what is indicated by the personal and family history and any other 
clinically significant findings. 
Finally, Myriad provides no information in their reports about the cancer risks associated with 
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mutations on the genes in which VUSs are located, which further conveys that the VUSs do not 
confer known risks.   
 
 Figure 5: Negative Results Banner with VUSs from Myriad Report 
  
 In contrast to Color and Myriad, Ambry and Invitae both prominently feature VUS results. 
In fact, VUSs in Ambry’s and Invitae’s reports are listed in the same sections and highlighted 
with the same graphic features as pathogenic mutations. Figures 5 and 6 show positive and VUS 
results reports from Ambry and Invitae, respectively, and they illustrate that the genes and variant 
sequences for VUSs are identified in large banners on the front pages of their reports, just like 
pathogenic mutations (Figures 5 & 6). Ambry and Invitae differ, however, in the details they 
provide that are relevant to interpreting VUS results. Ambry’s report highlights that the VUS 
should not affect medical management, stating in bolded text, “No known clinically actionable 
alterations were detected.” The report then clarifies that estimates of risk “should be based on 




Figure 6: Positive and VUS Results from Ambry Reports 
 
 
Figure 7: Positive and VUS Results from Invitae Report 
  
 Invitae stood out among the four laboratories by providing risk information for all genes 
with reported results, including ones with only VUSs. For example, the report that Figure 6 was 
taken from identified a mutation on the CHEK2 gene and a VUS on the MSH2 gene, but listed 
the risks and associations of pathogenic mutations on both CHEK2 and MSH2. Directly beneath 
the bulleted risk estimates for mutations in CHEK2, the report includes a section on MSH2 that 
states, “The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called 
hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and 
autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen 
UID: 78553).” Invitae then qualified that risk information, stating, “The clinical significance of 
this variant is uncertain at this time. Until this uncertainty can be resolved, caution should be 
exercised before using this result to inform clinical management decisions.” Unlike the other 
three laboratories, which communicated that VUSs should not alter clinical care, Invitae only 
urged “caution” in using VUS results to inform medical management.  
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 The images and quotes from reports issued by Color, Myriad, Ambry, and Invitae reveal 
important differences between the laboratories in how they emphasize VUS results. Color and 
Myriad minimize the importance of variants they classify as VUSs and mark them as distinct 
from pathogenic mutations by separating those results into different report sections and clearly 
labeling reports without any pathogenic findings as “negative.” They clearly distinguish between 
the risks posed by pathogenic mutations and the uncertainty of VUSs. In contrast, Ambry, and 
especially Invitae, highlight VUS results and present them with pathogenic mutations in their 
summary results banners, which conveys importance and suggests parity between the pathogenic 
and VUS classifications. Their reports make VUSs appear to be at least in part connected to 
cancer risk, which, in turn, makes those reports more likely confuse or alarm patients.  
 The distinctions between laboratory reports illustrated in this section might not be 
noteworthy if testing results were always interpreted and translated by genetic counselors or 
clinicians with genetics expertise in genetics, as those professionals could minimize patient 
misinterpretations (Culver et al., 2013). However, an increasing number of patients are having 
tests ordered by primary care doctors, OB/GYNs, or breast surgeons, and a recent study shows 
that only half of patients who undergo genetic testing meet with a genetic counselor at any point 
in the testing process (Allison W. Kurian et al., 2017). Given previous literature that documents 
VUS misinterpretation among both patients and providers without genetics training (Eccles et al., 
2015; Allison W. Kurian et al., 2017; M. L. Murray et al., 2011; Ray, 2017; Ready et al., 2011; 
Zuppello, 2018), these differences in framing and presentation of VUSs matter, and as I will 
illustrate later in the chapter, can have a notable impact on patient understandings and care.   
Black Boxes and Cancer Fatalism 
Taken together, stories from patients and providers about discordant results and the 
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variable content in laboratory reports illustrate how genetic testing is what STS scholars refer to 
as a black box (Latour & Woolgar, 1979). From patients’ perspectives, when they undergo 
testing, they provide a blood or saliva sample that gets sent off to a lab. That “input” then passes 
through the black box of testing, and at the end they receive an “output”—a report—that tells 
them whether they are “positive” or “negative” for a mutation. The various components of 
genetic testing described in this chapter—DNA sequencing, variant classification, and results 
reporting—each involve complex scientific and social practices that are obscured from patients 
and other non-scientists. The obfuscation and complexity of the decisions and processes that 
occur between the moments of input and output make the outcomes of genetic tests appear to be 
preexisting, natural “facts” that were discovered rather than interpretations that were produced.  
In highlighting that genetic test results are constructed, I am not arguing that they are not 
real. What science studies scholar Donna Haraway argues about other corporeal entities and 
processes also applies to genetic variants: “Cells, organisms, and genes are not ‘discovered’ in a 
vulgar realist sense, but they are not made up” (Haraway, 1997, p. 142). Whether a variant 
identified during DNA sequencing exists is rarely in question. I never encountered an example of 
discordance in sequencing results between the major labs in over three years of fieldwork. 
However, as Deena’s and Penelope’s stories reveal, how a variant is classified and whether 
scientists believe it is likely to result in the development of an illness is a matter of interpretation, 
and information about the health impact of a variant is typically what people are seeking when 
they decide to do genetic testing. For some variants, such as the three Ashkenazi BRCA founder 
mutations,21 there is a high degree of consensus in the field about the scope and severity of risk 
                                                             
21 Founder mutations are pathogenic variants that are found in higher-than-average frequencies in 
populations that share a small, defined ancestral group. There are three BRCA founder mutations that are 
ten times more prevalent among Ashkenazi Jews than in the general population: BRCA1 185delAG, 
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that they pose. But the analysis in this study of genetic test results reports reveals how patients 
receive curated, filtered information about their variants that is sometimes inconsistent or even 
contradictory. Hence, the binary outcomes of genetic tests (i.e., whether people are told they are 
“positive” or “negative” for mutations) are not preexisting, objective facts that are discovered 
through biomedicine. Rather, knowledge about cancer genetic risk is coproduced through both 
technoscientific and social processes (Jasanoff, 2004; Reardon, 2001), but the black boxes of 
testing make them appear to be natural, firm, and conclusive.  
In his book Biocapital, Anthropologist Kaushik Sunder Rajan refers to this process of 
making scientific knowledge appear natural as “epistemic fetishism.” Rajan argues that epistemic 
fetishism is only possible because the processes involved in the production of genetic knowledge 
are obscured. He states, “The ideological power of epistemic fetishism comes from the fact that 
the mystification that elevates a statement established by rigorous scientific method into that 
natural thing-in-itself, the Scientific Fact, is invisible.” Rajan then explores a critical tension that 
is linked to the black-boxing of the scientific processes involved in genetic and genomic testing: 
that the produced and interpreted outcomes of tests for genetic variants are simultaneously 
portrayed as “facts” and “probability statements.” For example, as I illustrated in the previous 
sections, individual results on genetic tests are communicated in laboratory reports as firm 
“facts” that are discovered. Testing clients are informed through those reports whether they are 
“positive” or “negative” for a mutation, and reports typically include information about the genes 
on which pathogenic or uncertain variants are located and the health implications of variants on 
those genes. However, when test results are “positive,” the “fact” of the mutation is also 
qualified, as it only confers an elevated risk of developing breast or ovarian cancer. Hence, 
                                                             
BRCA1 5382insC, and BRCA2 6174delT (Levy-Lahad et al., 1997). 
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positive BOC genetic test results are oxymoronically communicated as factual probabilities, or 
certain uncertainties. 
Yet, for several women in this study, developing breast cancer felt like their fate rather 
than a possibility. Women were almost always aware that the relationship between their positive 
test result and breast cancer was “stochastic, open and not closed… probabilistic rather than 
deterministic" (Rose, 2007, p. 51), but they still felt destined for cancer. For example, Alicia, 
who is 42 years old and has a BRCA1 mutation, shared, “Just kind of knowing about my family 
history, I kind of approached my 20s as like, ‘Ahhh, probably eventually I’ll get breast cancer.’” 
Josephine, who has a CHEK2 mutation and is also in her early 40s, said, “I definitely felt like 
cancer was in my future. I felt that it was inevitable.” For women who already expected to 
develop breast cancer, receiving a positive result on their genetic test only served to reinforce the 
sense that cancer was inescapable. As Nora, who was 32 years old when she learned about her 
BRCA2 mutation, explained, “When I found out, automatically I was just convinced in my head 
that I had cancer. I was a ticking time bomb.” 
The feeling among women that cancer was inevitable was not simply a result of 
inaccurate information or misunderstandings of risk statistics. There were several women in the 
study who, through their professional training, were knowledgeable about risk estimates, yet they 
also felt destined to develop cancer. For example, Jill, a nurse with a BRCA2 mutation, shared 
that she expected to develop breast cancer, and because she was still in her 40s, she did not want 
to spend decades of her life undergoing surveillance and waiting for it to happen. “It felt like it 
was just a matter of when it was going to come. Like I couldn’t take that stress of like thinking, 
‘Is it going to be this time, is it going to be?’ I wasn’t willing to, mentally, I don’t think I could 
have done that. Not at 45. Maybe if I was 65 or 70, it would be a different choice, but not at this 
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young of age and so much time to just do surveillance.” Marci, a 39-year-old public health 
researcher who also had a BRCA2 mutation, expressed, “Even as someone that understands 
population-based risk, I still feel like most days that I’m suddenly going to get cancer.”  
Previous studies have illustrated that women’s perceptions of their breast cancer risk are 
shaped by various familial, relational, and contextual factors in addition to the numeric risk 
estimates they are provided with, such as whether they have children, how many close relatives 
have been affected, and whether those relatives survived their cancers (Dean, 2016; Nina 
Hallowell, Statham, & Murton, 1998; Hesse-Biber, 2014). When multiple family members have 
been diagnosed with or died from cancer, women often expect a similar future for themselves. As 
I will illustrate in Chapter Two, among the women in this study, being a mother or experiencing 
the death of a mother or sibling unquestionably shaped their feelings about risk. Yet those 
familial-level factors provide only a partial explanation for why women often feel that breast 
cancer is inevitable even if they cognitively understand that BOC mutations only confer a higher 
likelihood of disease. Opening the black box of genetic testing and exposing positive results as 
certain uncertainties sheds new light on structural elements that influence why and how genetic 
mutations are “likely to be treated—by others and by themselves—as if they were, now or in the 
future, certain to be affected in the severest fashion" (Rose, 2007, p. 75).  
Rajan explains how concealing the active construction of the results of genetic tests and 
presenting them as naturalized “facts” helps to transform “probability” into “prophecy”: 
The irony—and power—of epistemic fetishism is that probability statements start 
operating with determinate legitimacy. Probability statements therefore acquire 
performative force. When confronted with the question of what one does when 
confronted with a probability statement, the absence of an obvious response allows the 
probability statement to harden into a reified statement of prophecy. Therefore it is a 
fetishism that is at once an operation of naturalization (the detail of the history of 
construction of a statement) and an operation that, while naturalizing the statement, shifts 
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it from being a statement of association to one of causality. (Rajan, 2006, pp. 167-168) 
What Rajan points to in this passage is how black-boxing the production of genetic risk directs 
attention toward what is made visible and tangible through testing—the “fact” of the positive 
result and information about the likelihood that cancer will develop—rather than what is 
obscured in the process, which is the social, human production of that test result and the potential 
that cancer might not develop. Rajan’s passage also illuminates why positive genetic test results 
make cancer risk feel more “real” to women even when that risk has been visible for many years 
through family history. Positive results on genetic tests transform the subjective knowledge of 
familial risk into (dis)embodied knowledge and “facts,” thereby making risk seem less 
probabilistic and a cancer outcome feel more certain.  
 Moreover, after cancer risk has been transformed and made “factual,” patients and 
providers understandably turn toward how to respond to that risk by either preventing cancer or 
detecting it early. But embedded in questions about how to effectively manage cancer genetic 
risk is an assumption that there is a definite, looming “thing” to respond to and an unavoidable 
cancer outcome to beat or catch. Specific risk percentages become irrelevant because the 
structures of genetic medicine discourage the imagination that one might not get cancer. The 
“fact” of the positive test result makes the probabilistic “maybe” of risk feel instead like a 
deterministic “not yet,” regardless of gene penetrance. In turn, as I will illustrate in subsequent 
chapters, these fatalistic feelings about the inevitability of cancer have contributed to the 
medicalization of genetic risk and medical over-management of VUSs and MRMs.      
Making Risk Manageable: Medicalizing BOC Genetic Risk 
Once BOC risk has been geneticized and made to feel more factual and tangible, women 
are thrust into making decisions about how to manage and respond to their risk. Their situation is 
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unusual, because while people with BOC mutations are not ill, they also are not viewed or 
treated, by themselves or their providers, as fully healthy. In fact, when people at BOC genetic 
risk first began collectively organizing and advocating for research and access to clinical care, 
they created a term—“previvor”—to refer to their unique in-between status and distinguish their 
experiences and identities from those of people managing or surviving cancer. Researchers have 
generated their own terms to describe genetically at-risk individuals: “pre-patients” (Rose, 2007), 
“pre-symptomatic ill” (Lock, 1998), “anticipatory patients” (Gibbon, 2007), “beings-at-risk” 
(Scott et al., 2005), and “patients-in-waiting” (S. Timmermans & Buchbinder, 2010). While the 
precise definition of each scholar’s term varies, their frameworks share several unifying features. 
Each one examines and describes genetic risk as a liminal state of pre-patienthood that is located 
between sickness and health. In addition, social science risk scholars generally agree that genetic 
pre-patienthood is generated through clinical interactions, produces both social and biological 
uncertainty, and focuses attention on individual-level causes of and solutions for risk rather than 
on social or structural ones.  
My findings in this study expand on the important work of these researchers, showing 
how high BOC genetic risk has been transformed from a state of pre-patienthood to one of full 
patienthood since the widespread adoption of panel tests. Unlike women in previous research, 
very few women with BRCA mutations in this study were treated or saw themselves as 
inhabiting an “in-between,” unclear health status. Instead, once genetic testing validated their 
high-risk status by making their breast cancer risk tangible and “factual,” their risk was nearly 
always viewed and managed as if it was an illness that required medical intervention. In other 
words, their cancer risk was first geneticized, and then having a BOC mutation—particularly one 
on a high-risk gene such as BRCA1/2—was medicalized.  
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The concept of medicalization took root in the 1970s, when several sociologists 
examined the increasing expansion of medical jurisdiction and medicine’s role in social control 
(Conrad, 1975, 1979; Freidson, 1970; Illich, 1976; Zola, 1972). Peter Conrad, the sociologist 
often identified as the author of the medicalization thesis, emphasizes that medicalization is a 
definitional process in which “a problem is defined in medical terms, described using medical 
language, understood through the adoption of a medical framework, or ‘treated’ with a medical 
intervention” (Conrad, 2007, p. 5). Conrad notes that medicalization is not inherently a negative 
process that is imposed on patients or problems, despite a heavy focus in the scholarly literature 
on medicalization’s harmful consequences, social control, and overmedicalization. Rather, 
Conrad and other scholars have stressed that the fundamental processes of medicalization—“the 
creation, promotion, and application of medical categories (and treatments or solutions) to 
human problems and events” (Conrad, 2007, p. 13)—are collective efforts that involve 
collaboration between patients and medical professionals (Conrad, 2007; Figert, 2011; Lupton, 
1997).  
Previous studies of the medicalization of cancer risk have explored how the process 
created new categories of disease and brought an increasing number of people under the 
jurisdiction of medical treatment for breast cancer. For example, in her study of the clinical trials 
for the drugs Tamoxifen and Raloxifene, medical sociologist Jennifer Fosket argues that the 
emergence of chemoprevention as an option for reducing women’s risk of breast cancer 
transformed their risk from a state between sickness and health into its own new illness category 
that required pharmaceutical treatment (Fosket, 2010). Building on Fosket’s arguments about 
how classifications of breast cancer risk are constructed, mutable, and contingent, I explore how 
the combined processes of geneticization and medicalization have not created new categories of 
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illness, but rather have reconfigured the boundaries between existing categories of risk, disease, 
and patienthood.  
Other researchers have examined the relationships between medicalization and 
geneticization, illustrating that while the two processes sometimes co-occur, they do not have an 
inherent relationship. Using case studies of depression, homosexuality, and chemical sensitivity, 
science studies scholar Sara Shostak and her colleagues showed that geneticization and 
medicalization do not inevitably lead to one another, nor are they always outcomes of the 
identification of genetic risk factors for conditions (Shostak, Conrad, & Horowitz, 2008). Yet, in 
the domain of BOC risk, this study highlights that the identification of genetic risk factors and 
processes of geneticization and medicalization have had a mutually constitutive relationship. In 
the following sub-sections, I will illustrate how geneticization and medicalization have worked 
together to shift the zones of risk and reshape understandings of and responses to being “at-risk” 
for breast and ovarian cancer.   
Reconfiguring Risk and Patienthood 
Talcott Parsons’ concept of the “sick role” is a theoretical tool that medical sociologists 
use to illuminate the social expectations involved in illnesses and examine the lived experiences 
of having a disease. Parsons viewed illness as a form of deviance, and he argued that two pairs of 
social rights and responsibilities were a means for managing that deviance. According to 
Parsons, sick individuals are not held responsible for their illnesses because they did not choose 
to develop or contract the diseases they have, and while they are ill they are exempt from their 
normal social obligations. However, these two benefits are tied to two expectations of individuals 
occupying the sick role: that they seek out expert assistance for their illnesses and actively try to 
get better (Parsons, 1951).  
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Several of the scholars who have argued that the “at-risk” status is a liminal space 
between illness and health have, in part, supported their arguments by showing how individuals 
at genetic risk are typically not subject to the rights and obligations of the sick role (Dagan & 
Goldblatt, 2009; Kenen, 1996; Scott et al., 2005). However, my findings in this study illustrate 
that individuals with BOC mutations now have the full rights and obligations of the sick role. 
They neither see themselves, nor are viewed by others, as responsible for their condition because 
they cannot control their genes. For example, Katarina described how she felt after learning 
about her CHEK2 mutation. “In some ways I felt vindicated. Like, ok, this wasn't my fault, it's 
you know, it's hereditary.” Similarly, Naomi said about her PALB2 mutation, “It is not my body’s 
fault. It just inherited this mutation.” Even Janet, who had a CHEK2 variant with conflicting 
interpretations, felt absolved of any blame for her risk because of the potential genetic link. “It’s 
like, factors were not necessarily in my control to have this, right?” In addition, like most other 
surgical patients, women are temporarily excused from their normal social obligations during and 
after they have any prophylactic surgeries to manage their risk.  
Moreover, similar to when a person has an illness and occupies the sick role, having 
knowledge about genetic risk generates social demands for action. As I will illustrate in detail in 
Chapters Two and Four, women are expected to take active measures to do “whatever is 
possible” to reduce their risk and to cooperate with medical experts in that “treatment” process. 
While genetic counseling as a field may espouse a non-directive ethos, genetic tests are not 
neutral technologies that simply provide people with knowledge about their DNA. Rather, as 
anthropologist Rayna Rapp argues in her ethnography of prenatal genetic testing in the late 




It is hard to argue for the neutrality of a technology explicitly developed to identify and 
hence eliminate fetuses with problem-causing chromosomes (and increasingly, genes) … 
The very existence and routinization of the technology implies anything but neutrality. It 
assumes that scientific and medical resources should be placed in the service of prenatal 
diagnosis and potential elimination of fetuses bearing chromosome problems. (Rapp, 
2000, p. 59)       
In this passage, Rapp highlights how one cannot separate prenatal genetic screening technologies 
from the potential actions taken in response to them. The likelihood and potential value of 
terminating a pregnancy in which the fetus has a chromosomal abnormality is implied in the 
resources committed to prenatal genetic testing and the decision to do the test. 
 Similarly, the “very existence” of BOC panel testing implies that sizable biomedical 
resources should be devoted to understanding and preventing hereditary breast and ovarian 
cancer. Thus, women who test positive are encouraged to adopt approaches to breast cancer 
prevention that involve high-tech interventions, such as mastectomy and drug therapies, all of 
which carry their own risks. As I will examine in detail in Chapter Two, prophylactic breast 
surgery is typically framed as the “best” medical choice for US women with BOC mutations, and 
women’s desire for the procedure is influenced by these discourses and practices. While women 
in this study actively participated in their decisions to have mastectomies, an important influence 
on their choices was what physician and medical historian Robert Aronowitz refers to as 
“anticipated regret” (Aronowitz, 2009)—the guilt they imagined they would feel if they 
developed cancer but had not acted on their genetic knowledge and done “everything within their 
power” to prevent cancer. As Amy, who has a BRCA1 mutation, expressed, “I’m in control of 
this to an extent…. So, I think that’s my relief, is just I did what I was capable of doing to 
prevent this.” Currently, mastectomy is the only effective means of preventing breast cancer; 
intensive surveillance can catch breast cancer early and improve women’s odds of surviving the 
disease, but it does not prevent breast cancer from developing.  
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 Moreover, another issue I will further examine in Chapter Two is that when women 
choose not to reduce their risk and instead opt for monitoring that risk with surveillance, they 
sometimes face resistance and judgement. While a couple of respondents shared stories of people 
criticizing their decision to have prophylactic surgeries, more expressed the opposite—feeling 
judged and unsupported if they chose screening over surgeries. In addition, there is debate within 
hereditary breast and ovarian cancer (HBOC) communities about whether women can call 
themselves “previvors” if they have not had risk-reducing mastectomy, which reveals how risk 
identity is intertwined with medicalized interventions. Marci, who has a BRCA2 mutation, was 
frustrated by how her providers and other women in HBOC communities treated having a 
mutation like a clearly defined disease rather than a state of uncertainty or possibility:  
I think words like “previvor” make it very, like there’s a thing, this clear thing that we’re 
dealing with and we’re overcoming. And it’s not a clear thing, because we don’t have 
anything. Like, you know, my sister could say, “I have breast cancer. I’m focused on that. 
I’m going to get better.” Mine is like, “I’m focused on this nebulous thing that may or 
may not happen and making decisions based on a complete unknown.” And to me that’s a 
really, that choice is a little harder, and comparing these feels a little awkward, like it’s a 
harder choice than my sister had to make. She got her diagnosis, it was like, “This is what 
I’m going to do.” There’s a clear road. The road for people with BRCA is not clear. It’s 
just not, and it’s complicated and I feel like people are trying to make it, put it in this box: 
“This is what you should do.” And it’s like, what’s right for me may not be right for the 
person next to me or the person down the street. (Marci, Age 39, BRCA2) 
Rather than viewing cancer as a certainty, Marci took seriously the possibility that she would not 
develop cancer. She was one of the few women in this study who actively resisted the 
medicalization of her risk status, but her refusal to view risk as a disease and have mastectomy 
required tremendous effort. Marci felt she had to constantly remind her doctors and other women 
of the uncertainty of BOC mutations, which underscores how genetic medicine treats them like 
diseases and structures responses to BOC mutations around the worst possible outcomes.  
Thus, while previous studies framed genetic risk as a gray zone in which the course of 
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action was unclear, this project reveals that having genetic risk for cancer is now defined, 
viewed, and treated like an illness. Raina, who has a BRCA2 mutation, summed up the current 
state: “People look at it like a disease, not a condition.” Steve, an oncologist who specializes in 
cancer genetics, noted that the medicalization of genetic risk has been nearly complete among 
US women with high-penetrance mutations like BRCA1/2. He explained, “I mean, because of 
BRCA and because of the high-penetrance predispositions, people have kind of thought of 
genetic risk as being similar to a diagnosis of disease, at least in the United States. It’s not 
necessarily that way everywhere, but at least in the US.”  
Steve singled out the BRCA mutations among the BOC mutations because they are the 
most prevalent, have been the most extensively studied, and pose the greatest risk. But his 
comment alludes to how “[m]edicalization need not be total” (Conrad, 2007, p. 6), and much like 
risk itself, instead often occurs in degrees or along a spectrum. In the following sections, I will 
examine that spectrum for BOC genetic risk, revealing how, in contrast to the full medicalization 
of BRCA mutations, MRMs have only been partially medicalized and VUSs are mostly not 
medicalized. Because “treating” BOC mutations with interventions is a key component of the 
medicalization of genetic risk, illuminating these varying degrees of medicalization first requires 
an understanding of the current risk management recommendations for different groups of BOC 
variants. Thus, I begin with a summary and analysis of a document that has played a critical role 
in the medicalization of BOC genetic risk and has become one of the most important tools in 
genetic medicine: the “Genetic/Familial High-Risk Assessment: Breast and Ovarian” Guidelines 
(“NCCN Guidelines”) issued by the National Comprehensive Cancer Network (NCCN). 
NCCN Guidelines 
 NCCN is the leading professional organization in the United States that develops and 
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regularly updates guidelines for cancer prevention and care. In countries with nationalized health 
care systems, there are clear and uniform protocols that specify under what circumstances 
different services will be provided and covered. However, the privatized, fragmented health care 
system in the United States lacks centralized protocols, and therefore medical providers often 
rely on clinical guidelines from professional associations like NCCN to assist them in providing 
up-to-date, evidence-based care. Similarly, insurance companies in the United States often use 
professional society guidelines to help them determine medical necessity and coverage for 
services.  
 The NCCN Guidelines are developed by an expert panel of genetic counselors, surgeons, 
clinical geneticists, and oncologists.22 They provide evidence-based recommendations for both 
BOC genetic risk assessment and risk management. The first version of the NCCN Guidelines 
was released in 2006, and they were subsequently updated in 2010 and 2014. Those earlier 
versions of the NCCN Guidelines only included information on high-risk mutations, such as 
BRCA1/2, TP53, and PTEN, that were robustly associated with well-established cancer 
syndromes (National Comprehensive Cancer Network, 2006, 2010, 2014).23 In 2015, NCCN 
began updating the Guidelines at least once per year, added information on multi-gene panel 
testing, and provided brief, general recommendations for MRM management (Daly et al., 2016). 
By 2018, the NCCN Guidelines contained specific recommendations, supported by extensive 
citations, for mutations on 19 genes that are associated with elevated BOC risk.  
                                                             
22 There is also one patient advocate on the panel.  
23 TP53 mutations are associated with Li-Fraumeni Syndrome, and PTEN mutations are associated with 
Cowden Syndrome. These two cancer syndromes include a high-risk of developing breast cancer, but also 
are associated with a high-risk of developing a wide range of other cancers, including those of the brain, 
colon, and stomach. Because the health implications of TP53 and PTEN mutations are much broader and 
more severe than those of other BOC mutations, individuals with those mutations were not eligible to 
participate in this study. 
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 For breast cancer surveillance in women with BRCA mutations, the current NCCN 
Guidelines recommend annual breast MRI between ages 25 and 75 and annual mammograms 
between ages 30 and 75(National Comprehensive Cancer Network, 2018b). Women are typically 
advised to stagger their appointments for MRIs and mammograms six months apart so that they 
are seen by a clinician and imaged twice per year. For risk-reducing surgeries, the NCCN 
Guidelines instruct providers working with BRCA-positive women to “Discuss [emphasis added] 
the option of risk-reducing mastectomy” with patients, including a “discussion regarding degree 
of protection, reconstruction options, and risks” (National Comprehensive Cancer Network, 
2018b, pp. BRCA-A1). But the NCCN Guidelines provide firmer guidance for reducing the risk 
of ovarian cancer, telling providers to “Recommend [emphasis added] risk-reducing salpingo-
oophorectomy (RRSO), typically between 35 and 40 y[ears] and upon completion of child 
bearing” (National Comprehensive Cancer Network, 2018b, pp. BRCA-A1). The Guidelines 
further clarify that RRSO counseling should include a “discussion of reproductive desires, extent 
of cancer risk, degree of protection for breast and ovarian cancer, management of menopausal 
symptoms, possible short-term hormone replacement therapy, and related medical issues” 
(National Comprehensive Cancer Network, 2018b, pp. BRCA-A1). 
 The recommendations in the NCCN Guidelines for managing MRMs are less intensive 
than those for BRCA mutations but more involved than the breast screening guidelines for 
women at average risk in the general population. The recommendations for PALB2 mutation-
carriers are similar to those for BRCA mutation-carriers but suggest beginning screenings at age 
30 rather than age 25. The Guidelines recommend that women with CHEK2 and ATM mutations 
begin annual mammography screening even later, at age 40, and they are less firm on the 
benefits of adding breast MRI, stating instead that clinicians should “consider” the procedure for 
 
73 
these women. But where the NCCN Guidelines most clearly differ for carriers of MRMs is in 
their recommendations for risk-reducing surgeries. The Guidelines do not indicate that providers 
should either recommend or discuss mastectomy with women with CHEK2, ATM, or PALB2 
mutations. Rather, for women with these mutations they state, “Evidence insufficient, manage 
based on family history” (National Comprehensive Cancer Network, 2018b, pp. GENE-2-4). For 
ovarian cancer risk management among women with MRMs, the NCCN Guidelines do not 
recommend RRSO. Instead, they note that there is “No increased risk of OC [ovarian cancer]” 
for ATM and CHEK2 mutation carriers and “Unknown or insufficient evidence” for PALB2 
mutation carriers (National Comprehensive Cancer Network, 2018b, pp. GENE-2-4). Yet, as I 
will illustrate in Chapter Two, all but one of the 38 women in this study with MRMs reported 
that mastectomy was offered to them, and they often reported that surgery was strongly 
recommended. 
MRMs: Uncertainty about the Extent of and Responses to Risk 
 Because testing for BRCA mutations and research on their cancer associations has been 
ongoing for over two decades, they have clearly established screening and risk management 
recommendations and robustly established risk profiles. In addition, most people, especially 
clinicians, have at least heard of BRCA mutations, both because BRCA1 and BRCA2 were 
among the first cancer risk genes to be identified and because Angelina Jolie generated 
widespread awareness about them. In combination, the public visibility of BRCA mutations and 
broad scientific consensus about the severity of their risks have contributed to their near-
complete medicalization. While there is an inherent uncertainty in any “at-risk” health status 
because no one can predict the future, the other aspects of having BRCA mutations—what they 
mean in relation to people’s health and the interventions available to “treat” them—are nearly 
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indistinguishable from having an illness. Going back to the notion of positive test results as 
certain uncertainties, BRCA mutations are the most certain among the BOC mutations, and 
therefore people who are BRCA-positive are likely to be viewed and treated as if they are 
patients with a disease.  
 Likewise, the partial medicalization of MRMs is connected to their vague risk management 
recommendations, conflicting cancer-risk profiles, and inconsistent risk estimates. Similar to 
BRCA mutations, MRMs are also certain uncertainties—people with MRMs receive positive 
results and are therefore “diagnosed” with the “disease” of genetic risk for breast cancer. 
However, MRMs produce far less certainty than BRCA mutations. Most of the moderate-
penetrance genes were discovered at least a decade after the BRCA genes; hence, the science 
around MRMs is less conclusive, fewer people have been tested for them, and clinicians are less 
likely to have heard of and understand them. As Colette stated, “There is a lot of information out 
there about BRCA1 or BRCA2, but there is not much about CHEK2.” In addition, according to 
the NCCN Guidelines, while women with MRMs may receive additional breast surveillance, 
they should not be considered eligible for “treatments” or surgical interventions because of the 
uncertainty about the scope and severity of their risks. Thus, women with MRMs are sometimes 
treated as “qualified patients” with limited sanctioned access to medical management or 
interventions. The existence of their risk is certain, but the extent of their risk is not, and as a 
result women’s experiences with having MRMs reflect some of the confusion and uncertainty 
that previous studies have argued were characteristic of women with BRCA mutations.  
Range of Cancers Is Unclear 
 I asked every participant in this study to reflect on what, among all of the things we had 
discussed, was the most important thing that they wanted me to understand. The most common 
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answers among women with MRMs centered on the feelings of confusion and frustration they 
experienced because the cancer risk profiles and risk-management recommendations for MRMs 
were unclear. As Fiona lamented, “I don’t know what is CHEK2-related and what isn’t.” Megan, 
who also has a CHEK2 mutation, said, “There's no consistency. There's no straightforward 
answers, and that's been super frustrating.” June shared Megan’s and Fiona’s frustrations with the 
absence of standardized information and care:  
I think for me it’s just the lack of knowing and understanding, really, what CHEK2 
actually does. I mean, DNA's confusing, it's not you know, something simple to 
understand. You know, so when you're told that you've got this—and you know, he did 
show me all the little squiggles and where it could come from and all that, but it doesn't 
really mean very much, to be honest. I think I'd just like to know a concrete, “Yes, 
CHEK2, definitely affects this, this and this. This is what you need to now do.” (June, 
Age 51, CHEK2) 
Josephine also wished there was more clarity on CHEK2 risks and management. “It is pretty 
overwhelming that the doctors cannot just tell you what needs to be done because it is not a super 
high risk. It is an elevated risk and a moderate risk. There are two cancers and then all of these 
other cancers that we do not know.” Holly, who also has a CHEK2 mutation, summarized these 
sentiments: “The thing that stands out the most is the uncertainty, the unknown.”  
 Many women were especially concerned about the inconsistencies in information about the 
cancers for which they were at risk. Several of them shared stories about receiving different 
information from their health care providers, in research articles, and from women in their social 
networks of mutation carriers. For example, Deena, who has a variant with conflicting 
interpretations on CHEK2, shared how the risk information she received from her geneticist, on 
the internet, and in her social media group varied:  
With my first geneticist, I was told that typically breast cancer, colon cancer, and prostate 
were linked for the CHEK2. And then, when I talked to the other geneticist, she said 
 
76 
those were the three that they knew of but she said they were finding more thyroid. That 
there was a lot more thyroid in there, as well. When I've looked it up, I've seen—granted, 
this is on the computer, so I know you can't rely on that very much—I’ve seen where 
even lung is a possibility, kidney is a possibility, and then prostate, colon, and thyroid. 
Couple of the other ladies on the CHEK2 group have talked about even other cancers: 
pancreas, liver, and one of them I know has had lung cancer. So, lung, you know, has all 
been mentioned through them. I was never told that widespread of cancers—I was told 
that primarily it was a breast, colon—because they had said that's what it's even called, 
it's the breast-colon cancer. That typically the woman will get both of those and that's not 
uncommon, that you will get two primaries with it. (Deena, Age 45, CHEK2 VUS) 
Megan’s doctors also emphasized that breast and colon cancer were the risks of CHEK2 
mutations. She described the information sheet she was given after her visit, and how 
overwhelmed she felt when she began learning more about the mutation through her own 
research and in her CHEK2 social media group.  
On that paper, it specifically talked about breast cancer and colon cancer and the need for 
screening, so colonoscopies and the breast screenings. And it didn't speak to any other 
risks associated with it, or increase of risk. But then of course, as I read my own stuff, I'm 
finding out, we're kind of just on the edge of learning about CHEK2 and what it all 
means. And I’m seeing in this group that I very carefully only go to when I definitely feel 
like I can handle it, over and over again, I'm seeing thyroid cancer. Over and over again. 
And you know, my head goes, “This can't be a coincidence!” This is a group of women, 
it's all women in this group who have been diagnosed with CHEK2, and over and over 
again, they were saying “ultrasounds on thyroids.” And my paper didn't say anything 
about thyroid. And then people have talked about lung cancer, the paper didn't say 
anything about lung cancer. (Megan, Age 35, CHEK2) 
Emily, who like Megan has a CHEK2 mutation, also described the “fuzziness” of CHEK2-
associated risks and how they were constantly changing:  
The goalpost is moving all the time with CHEK2 regarding other cancers that are 
involved. So, the main one that she was concerned about was colon. But then, she talked 
about some other stuff that she said may be related and she said it was the—the blood 
cancers, is what she mentioned. Like the lymphoma and the leukemia. She also 
mentioned the skin cancers, and then, well, testicular wouldn’t apply to me. And then, so 
it was the question of, is it, you know, is it ovaries or uterine? And do we do something 
about that? You know, and so that’s where everything gets really fuzzy, because the only 
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thing she really came down and said was, definitely, you have to get the colonoscopy. But 
like, like I’m talking to other women in these groups, and in some of their cases their 
genetic counselors told them and their doctors told them that they needed to get thyroid 
screens, you know, every year. So, it gets really kind of fuzzy as far as what really is 
included in the CHEK2 gene besides the breast cancer and the colon cancer. (Emily, Age 
51, CHEK2) 
Finally, Josephine shared how the variability and uncertainty about the risks posed by MRMs 
was stressful because it created uncertainty about how to most effectively respond. “It seems like 
they do not quite know how to handle you. There is nobody to coordinate the information 
because CHEK2 is such an emerging area. The information is not all the same; it depends on 
which source you are getting it from. It has been very overwhelming.” 
 Not only were women overwhelmed by the steady stream of information about new risks, 
but also, they were frustrated by conflicting information about established risks that left them 
even more bewildered about the best way to manage their health. For example, a few women 
shared stories about other women in their social media groups who had been told by doctors that 
CHEK2 was not linked to breast cancer. For example, Fiona said, “There are things like, ‘My 
doctor said that CHEK2 doesn’t increase the chance of breast cancer.’ Everyone is like, ‘That is 
not true!’ There is that. It is always very surprising to me.” Holly recalled a similar story: 
It’s just confusing. One of them went to their doctor about prophylactic mastectomy, and 
the doctor said there’s no proof that CHEK2 is related to breast cancer and she wouldn’t 
be able to get it done. Which is crazy because that’s what it has the most high chance of 
getting. You get all these mixed things, and of course everybody in the group is saying, 
“That’s not true! You need to go to a different doctor.” (Holly, Age 44, CHEK2)  
Marsha, who has a CHEK2 variant with conflicting interpretations, described her personal 
experience with receiving contradictory information from her doctors. “I’ll tell you what the 
providers provided me with, which was confusing. My surgeon said it was related to colon 
cancer, but my oncologist said it was related of the ovarian cancer. Maybe they're both right, but 
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they were confused, and one said one was wrong.” Marsha then explained how that inconsistent 
information made it challenging for her to figure out how to respond to her risk. “Your first 
inclination is to act. And your next thing is you go through all this information, which is mind-
boggling and hard to make a decision. And as a matter of fact, when you make a decision, the 
next day there's more information that changes the decision from the previous day. So, there's a 
lot of confusion.”  
Marsha’s story also illustrates confusion that several women had about whether MRMs 
increased their risk of ovarian cancer. For example, most of the genetics literature does not link 
PALB2 mutations to ovarian cancer, but Millie firmly believed that her PALB2 mutation 
increased her ovarian cancer risk. She said, “So, pancreatic cancer is a risk for this mutation. 
Obviously, breast and ovarian. Those are the only ones that are clearly identified at this point 
with the percentage referred to in the literature in these reports, but the increase screening for 
pancreatic is not—there is not screening for pancreatic cancer. Ovarian, at this point, is not 
covered by insurance to do anything more than to see your gynecologist every year.” Millie 
believed that she was at increased risk for ovarian cancer because numbers for the relationship 
between PALB2 and ovarian cancer were “clearly identified” in her laboratory report. While 
Millie was unsure who did her testing, it was likely GeneDx because they are the only one of the 
five major laboratories that provides any risk data or statistics for ovarian cancer in their PALB2 
reports. NCCN also does not identify a relationship between PALB2 and ovarian cancer, most 
likely because the data supporting the relationship are thin to non-existent. The 2011 study that 
GeneDx cites found that people with PALB2 mutations were 1.3 times more likely to have a 
relative with ovarian cancer (Casadei et al., 2011). Not only is that a fairly low odds ratio, but 




In contrast to Millie, several women with CHEK2 mutations were at least aware that 
there was a debate about the link between CHEK2 and ovarian cancer. As Katarina, who has a 
CHEK2 mutation, stated, “You know, some people say ovarian. I believe ovarian cause it's in my 
family, but some of the, you know, CHEK2 literature doesn't link it with ovarian. There's—
there's so much that isn't known.” Women without family histories of ovarian cancer found the 
lack of certainty about the relationship frustrating and frightening. For example, Josephine 
shared: 
Then there is this whole discussion in the CHEK2 group about ovarian cancer because 
apparently one of the genetic testing companies lists that as a possible but the other 
companies do not. There doesn’t seem to be a whole lot of science connecting those two, 
but there are several women in this group who have had their ovaries removed because 
they are CHEK2 positive. I don’t even think they had family members. I think family 
history would help lean a little more that way, but it is kind of alarming to hear women 
who have had no family history of ovarian cancer having ovaries removed because of 
CHEK2. Science isn’t there yet but maybe it is coming or maybe it is not. It is kind of 
scary. (Josephine, Age 41, CHEK2) 
Importantly, Josephine’s fears were not just about developing ovarian cancer; she was also afraid 
because she observed other women in their social media group having prophylactic 
oophorectomies they might not need. Among women with BRCA mutations, multiple studies 
have found that RRSO significantly decreases all-cause mortality (S. M. Domchek et al., 2010; 
A. P. Finch et al., 2014; Ingham et al., 2013; A. W. Kurian et al., 2010; Parker et al., 2013). 
However, as I will illustrate in Chapter Four, this study shows that women who have risk-
reducing salpingo-oophorectomies (RRSO) are frequently un- or under-informed about 
potentially enduring and disruptive side effects of the surgery. Moreover, those side-effects often 
are un- or under-treated. Given those findings, Josephine’s concerns are warranted, as women 
with MRMs who have RRSO when it is not clinically indicated are subjecting themselves to 
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risks with minimal or no established benefit.    
 Several women with CHEK2 mutations also felt scared and confused about whether they 
were at increased risk of thyroid cancer. Megan shared how unsettling it was to learn about the 
potential links between CHEK2 and thyroid cancer from the other women in her social media 
group rather than from her health care providers:  
The thyroid thing is kind of terrifying. There's just been a lot of people talking about 
finding these nodules and then having to have things removed and tested and biopsied 
and like... in the beginning of this whole journey, nobody was like, "Hey, also, thyroid 
cancer!” That was never a thing, and so it's like, kind of being thrown one more thing. 
But the thing about that is, I don't feel I have anybody to turn to for that 
information. (Megan, Age 35, CHEK2) 
Marlene had a similar experience to Megan. She explained, “I posted a question about my 
thyroid maybe because I was shocked to learn so many of these women have thyroid cancer. But 
they're all like, ‘Me too!’ We're all super confused and we all don’t—we all need more 
information.” Marlene noted that until she gets more information, she is insisting on annual 
thyroid ultrasounds, a request with which her clinicians have complied. Margaret noted her 
confusion about what exactly she should do to monitor her risks for thyroid and colon cancer. 
She said, “Again, there are no guidelines for the thyroid. The colon cancer screening—I am still 
confused about that. Sometimes I hear three years and sometimes I hear five. And since my 
gastroenterologist knew nothing, I don’t feel like I could ask him.”  
Responses Are Unclear  
Margaret’s comment that she could not turn to her gastroenterologist (GI) for guidance 
illustrated another common frustration among women with MRMs: that many of their doctors—
especially ones who did not specialize in genetics, such as primary care physicians, OB/GYNs, 
and GI specialists—knew little to nothing about their mutations. Fiona shared that women 
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frequently discussed other clinicians’ lack of knowledge in their CHEK2 social media group. “I 
would say that the number one thing I notice gets mentioned is just how few doctors—
particularly outside of an academic setting, so in more clinical realms—have no idea what to 
advise people when it comes to having a CHEK2 diagnosis.” Megan, who learned about her 
CHEK2 mutation after her sister with premenopausal breast cancer tested positive, shared how 
her sister’s OB/GYN had never heard of CHEK2: 
It is very frustrating; the lack of knowledge is intense. My sister actually, she had an OB 
appointment coming up in, it was like, I think four months after she got her positive 
diagnosis. She called her OB and left him a message and said, "Hey, listen, I just want to 
give you a heads up, I just got this back, I'm positive for something called a CHEK2 
mutation. I know it's not very well known, that's why I'm giving you a heads up, cause 
I'm gonna want to talk to you about it." So, then she went and talked to her OB, and her 
OB was like, "Yeah, I've never heard of it.” (Megan, Age 35, CHEK2) 
Heather had a similar experience when she went to see her primary care clinician and OB/GYN. 
She said, “I would actually walk into my doctor's and be like, ‘I have the CHEK2 gene. Do you 
think I should be doing this?’ And they'd say, ‘I don't even know what that is.’ Some of the 
doctors, just had no clue about the gene.” 
Some women even told stories about clinicians in the Risk Management field of practices 
(Figure 2), such as breast and plastic surgeons, who had never heard of their mutations or had 
very limited knowledge about them. For example, Sylvia, who has an ATM mutation, shared a 
comment she overheard her plastic surgeon make to a nurse: “When I went to the plastic 
surgeon, he was talking outside. He said, ‘Oh my god, I cannot keep up with these new genes.’ I 
was like, ‘That is interesting.’ I just thought I’d share that because it is like, god, they really don’t 
know about this.” Megan recalled how multiple clinicians involved in her breast screenings knew 
nothing about CHEK2: 
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I mean even just, after I had my mammogram, the two ultrasound techs and two 
radiologists asked me what that CHEK2 was on my chart. Which is fine, like “Thank you 
for being honest and asking.” But, like, also, how crappy to be cursed with something 
that the people you would have turned to for help go, "What's this?” …. I can't trust my 
healthcare professionals, because they don't—I mean, I trust them, but I can't trust them 
to inform me, cause they don't know about it. (Megan, Age 35, CHEK2) 
Margaret shared that even her genetic counselor had trouble keeping up with new findings about 
MRMs. She stated, “Not even the genetic counselors. I think that they follow the NCCN 
guidelines, but those are ultra-conservative from what I can tell. So, the things like thyroid 
cancer, which seems to be starting to be connected. Or, I had melanoma nine years ago. I went to 
my yearly check-up and I mentioned this to him and he said that he didn’t think it was involved 
with this. And then I go, ‘I find research that says they think it is.’” 
Margaret’s story also reflects how many women with MRMs felt that they had to take 
responsibility for educating their providers. She recalled a conversation with her GI specialist, 
whom she felt should know about CHEK2 mutations since there is general consensus that they 
elevate risk for colorectal cancer:  
I had a screening colonoscopy because it was time, and I mentioned it to the doctor then. 
I told him that I have 1100delC24, and he goes, “Well, gosh that is specific.” And I asked, 
“Do you know that they showed a higher increase?” He responded, “No,” and I’m like, 
“Dude! This is colon cancer!” The same with my family physician. She doesn’t know 
anything about it, so I keep feeding her research papers. I feel like I am educating the 
doctors. (Margaret, Age 60, CHEK2) 
Similar to Margaret and Megan, Marlene also felt that she had to “be on top of” current research 
and screening recommendations because she could not trust her doctors to be informed: 
It's hard. It sucks because you read something online and you see actual women who 
have your mutation that, you know, have thyroid cancer and breast cancer, and so you 
                                                             
24 1100delC is the most common CHEK2 variant and the one on which there is the largest body of 
research (Leedom et al., 2016; Schmidt et al., 2016). 
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know the risk is real and you know it's out there. But then you see these people, these 
providers and they just don't know anything about it. So, I think the biggest, the scariest 
thing for me is I feel like I have to be on top of it in order to demand testing from my 
general practitioner who doesn't know anything about it…. most family doctors don't 
know anything about these mutations unless it's BRCA.  (Marlene, Age 35, CHEK2) 
A couple of women with BRCA mutations also shared stories about having to educate their 
health care providers. For example, Lily, who has a BRCA1 mutation, recalled having to teach 
her new OB/GYN that not only was it safe for her to be on hormonal birth control, but also it 
was recommended as a form of chemoprevention for ovarian cancer. “But mostly, my experience 
has been I am teaching my doctors about BRCA. And I'm like, ‘You are doctors, you should 
know about this!’ But as soon as I got this new doctor who was excellent, she says, ‘Well, you 
can't be on that birth control. Blah, blah, blah, you can't be on this birth control.’ So, I had to go 
online and pull up all these studies.” However, such stories were considerably less frequent 
among women with BRCA mutations. Moreover, the fact that women with BRCA mutations 
sometimes had to inform their clinicians about their risks and appropriate medical management 
only underscores the challenges faced by women with MRMs. For while there has been over two 
decades of research on the BRCA mutations and there is regular media coverage of women who 
have them, there are far fewer studies on MRMs and media stories on women with MRMs are 
almost nonexistent.  
Qualified Patienthood 
 Marlene’s comment that doctors “don’t know anything about these mutations unless it’s 
BRCA” highlights a feeling shared by several of the women with MRMs: that they were second-
class citizens in the world of BOC genetics. For example, Maya, who has a PALB2 mutation, 
stated, “It feels as though the other mutations are just kind of afterthoughts.” Holly, who was 
working as a receptionist at a clinical breast center when she tested positive for a CHEK2 
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mutation, said her colleagues in reception were not empathetic, and instead they reacted like, 
“You don’t have BRCA!” Rose described feeling different and marginalized: “I don't know, 
sometimes I feel with this mutation that I'm like an alien of some sort. It’s not the BRCA gene 
and it's, you know, this weird mutation, this CHEK2. It's like, it's not mainstream at all.” Riki 
explained that she felt BRCA mutations were taken more seriously because of greater awareness 
of them. “I also think that BRCA1 and BRCA2 have a lot more clout because of just the way that 
came out…. I feel that the medical community and the general populace is more aware of what 
BRCA is. It is just out there.” 
In drawing these contrasts between how MRMs and BRCA mutations are regarded, 
women were juxtaposing the partial medicalization of MRMs against the full medicalization of 
high-risk mutations. Like women with BRCA mutations, women with MRMs are told with 
certainty that they are positive for a mutation and have the “disease” of genetic risk for breast 
cancer. But women with MRMs subsequently face uncertainty that women with BRCA 
mutations do not about both the extent of their breast cancer risk and the range of other cancers 
for which they have elevated risk. Moreover, unlike for women with BRCA mutations, there are 
no recommended “treatments” for the “disease” of risk among women with MRMs. While 
current guidelines indicate that women with MRMs should have access to additional screenings, 
such as more frequent mammograms and breast MRIs, evidence currently does not support their 
access to interventions that reduce their risk and/or prevent cancer, such as prophylactic 
surgeries. Bailey, a 30-year-old woman with a CHEK2 mutation, shared her frustration with the 
inability to act on her risk knowledge: 
You know, the thing that was probably the most frustrating about all of this is that they 
have these tests that tell you you're a moderate risk mutation for cancer, but there's just 
still not all that much information out there in terms of what you can do to lower your 
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risk….Or, you know, the studies some places say 25%, some places say 35%, so the 
range of risk even varies in the information that's out there. And I know it's because it's so 
new, but that's a bit frustrating, is that they know this mutation's out there, but they don't 
necessarily know what to do with the information. (Bailey, Age 30, CHEK2) 
The vexation that Bailey conveys in this passage emerges from being a qualified patient—she 
was issued a “diagnosis” and thrust into the sick role, and she sought expert guidance, but they 
could not provide her with sanctioned “treatments” or ways to take action and try to get better.  
 Megan explicitly pinpointed the partial medicalization of MRMs when she referred to 
having one as “half a diagnosis.” She shared Bailey’s frustration but also expressed how the 
uncertainty of qualified patienthood made her feel sad and isolated:   
Giving somebody half a diagnosis with half a recommendation and a big question mark 
can be pretty heavy for a lot of people. So, you know, you're given a diagnosis, without 
really being told exactly what to do. We start screening at 30, or maybe 40, and insurance 
will pay for it, or they might not. And we think that it affects breast and lung—or, breast 
and colon cancer, but apparently there's also some other cancers that are identified. So, 
the big question mark is infuriating and it—you just feel lonely. (Megan, Age 35, 
CHEK2) 
Like many of the women in this study with MRMs, what Megan desired was clarity about the 
extent of her risk and a clear set of steps she could follow in order to manage that risk. “Like, am 
I supposed to get an ultrasound on every organ in my body? Like, what do I do? There's a point 
when this is ridiculous. So, I just wish that there was factual evidence-based information on, 
‘This is what you need to do and these are what your concerns are, and this is the screening that 
you need at this age.’” In other words, what Megan and other women with MRMs often want is 
to move from qualified patienthood to full patienthood. In the final sections of this chapter, I will 
illustrate how women with VUSs share that desire to transform their uncertainty into certainty, 




In contrast to the uncertainty about the extent of risk generated by MRMs, VUSs reflect 
uncertainty about the existence of elevated cancer risk. Women who have VUSs and no other 
pathogenic mutations do not receive a positive result, and therefore they have not been 
“diagnosed” with the “disease” of genetic risk like women with BRCA mutations or MRMs. In 
fact, as I illustrated earlier in the chapter, some of the major laboratories use “negative” results 
banners in their VUS reports to emphasize this distinction. In addition, there is widespread 
agreement among genetics experts that VUSs have not been determined to confer risk and 
therefore should not be treated with interventions. Clinicians without genetics training sometimes 
misinterpret VUS results, but throughout my fieldwork I heard providers with training in 
genetics religiously repeat the phrase “VUSs should not affect medical management.” Hence, 
while BRCA mutations and MRMs are “certain uncertainties”—it is certain that they elevate 
women’s risk of breast cancer, yet they also generate uncertainty because risk is a state of 
probability—there is no certainty in a VUS result. Rather, VUSs are “uncertain uncertainties” 
because whether or not they even pose additional cancer risk is in question. 
As “uncertain uncertainties,” VUSs have mostly not been medicalized by genetics 
experts. Professional society guidelines and laboratory reports do not define VUSs medically, 
describe them with medical language or frameworks, or recommend treating them with medical 
interventions. In addition, most genetic counselors and clinicians with genetics training do not 
view or treat women with VUSs as either full or qualified patients. Women with VUSs share 
some experiences with “patients-in-waiting” (Stefan Timmermans & Buchbinder, 2013), such as 
occupying a liminal state of scientific uncertainty. However, pre-patients usually face clinical 
uncertainty and are treated like patients in their medical encounters, but genetics experts 
 
87 
explicitly advise against the use of surveillance or interventions in response to VUS results. The 
sanctioned standpoint within genetic medicine is that women with VUSs should not be 
considered patients at all because there is no established risk that should be managed or treated.  
Despite that official position, previous studies have illustrated that, in practice, women 
with VUSs sometimes do become patients who access screenings and interventions (Culver et 
al., 2013; M. L. Murray et al., 2011; Ready et al., 2011). Genetics experts refer to this practice of 
regarding VUSs as similar to positive results and “treating” them with surveillance or surgery as 
“VUS mismanagement.” The findings of this study support prior research documenting VUS 
mismanagement in genetic medicine. Genetic counselors and clinicians shared stories with me, 
both in interviews and during fieldwork at conferences, about women with VUSs being 
mismanaged. In addition, three of the four participants in this study with just VUSs or variants 
with conflicting interpretations were offered prophylactic breast surgery, and two of them opted 
to have the procedure. Yet what this study can reveal about the existence of VUS 
mismanagement is limited given how few women with only VUSs participated. However, by 
combining those four women’s experiences with stories from genetics professionals, data from 
fieldwork at cancer genetics conferences, and the experiences of ten women who had both a 
mutation and a VUS, the following sections shed light on how VUS mismanagement happens 
and why it, but not MRM mismanagement, is a focus of concern in genetic medicine. 
Producing Gray Answers 
 Providers who have training in genetics all stress the uncertainty of VUS results, and most 
of them adhere to professional society guidelines that indicate that VUSs should not affect 
clinical management (Richards et al., 2015). For example, Linda, a genetic counselor who has 
been working in cancer genetics since the 1990s, described how she explains VUSs to her testing 
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clients. “So, a VUS is exactly what it says. We don't know whether or not it is connected to 
cancer risk. And it should not be used for medical management decisions.” Similarly, Jackie, a 
genetic counselor who works for a BOC genetic testing laboratory, shared what she says to 
clients about the possibility of VUS results before they are tested. “I say, pre-test, that there is 
this possibility that we're going to find something, one or more somethings that we do not yet 
know how to interpret. And we don't make medical decisions based on if it's a true variant of 
uncertain significance. We don't use that finding to, as I say, to color medical management.” 
Alexandra, a cancer genetic counselor at a community hospital, said that in recent years she had 
changed her explanation to emphasize that VUSs should be treated like negative results since 
most of the time they are reclassified as benign. She conveyed what she says to patients: 
“For practical purposes, you should act as if this test result is totally normal…. You have 
not been shown to have a mutation. You shouldn't say to yourself that you have a 
mutation. You have what's called a quirk in the genes. You have this quirk. What does it 
mean? Probably nothing.” So, I feel like I really try to talk down a patient, just to 
normalize the situation and to do my best to not allow them to act as if they have a 
mutation that they're not known to have. (Alexandra, Genetic Counselor) 
Lisa, a genetic counselor who works at a regional cancer clinic in a mid-sized city, noted that she 
even emphasizes in her clinical notes and letters to other providers, such as breast surgeons, that 
VUSs should not affect medical management. “Our phone notes say, you know, ‘Patient had a 
VUS. This should be treated clinically as negative. This does not indicate any medical 
management changes or surgeries should happen based on that result.’ Our letter will say the 
exact same thing.”  
 Unfortunately, Lisa also shared that despite the “best efforts” of genetic counselors at her 
clinic to minimize VUS mismanagement, she knew of several women with VUSs who ended up 
having mastectomy. She recalled two recent cases in which the breast surgeons either did not 
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understand the uncertainty of VUSs or chose to ignore that uncertainty:  
We are at a cancer center with three certified genetic counselors working with providers 
that are cancer surgeons, and we have had two patients who have had their breasts 
removed because of a VUS. And that's here with experts…. I think part of the issue is 
sometimes the surgeons interpret that as a positive result, despite what we say, despite 
what our phone notes say, despite what our letters say, they think they know better. (Lisa, 
Genetic Counselor) 
Hence, even at a clinic where there were genetics experts and all of the providers met weekly and 
had excellent coordination, surgeons and patients were uneasy with the uncertainty of VUS 
results and sometimes responded to those results as if they were sufficient to justify an 
intervention. Lisa further commented about the detailed letter that she and other genetic 
counselors provide to surgeons and their clients, “Sometimes I think they don't even read it.”  
 However, most women with VUSs whom I spoke with had heard and read the 
recommendations from their genetics providers. The problem was not that they were unaware 
that VUSs are scientifically uncertain results that should not affect medical management, but 
rather that they did not fully believe that explanation. Most women who seek out genetic testing 
do so because they are trying to determine the cause of their personal or family’s history of 
cancer; there is an existing phenotype, either in their own bodies or their family members’ 
bodies, that is in search of an explanation. Thus, several women believed that there “had to be” a 
causal link between their VUS and their own or their relatives’ cancer(s) despite being told by 
genetics experts that their VUS results should be treated as negative until otherwise informed. 
For example, Heather, who was diagnosed with breast cancer at age 34 and subsequently learned 
she had VUSs on the CHEK2 and MUTYH genes, shared her reaction to women’s posts in the 
CHEK2 social media group: 
I was keeping a close eye on the board, and thyroid, breast, cancer, mastectomy, all the 
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words that I know are coming up. And I’m like, “Oh my god! This has to be connected! It 
just has to be!” I know I don’t have the known variant. And then knowing that the 
CHEK2 is related to the BRCA genes? I mean, that just sealed it for me. I mean, I’m not 
a scientist, I have no idea how they’re related, but if they’re connected in any way, that is 
something. That must be something. (Heather, Age 35, CHEK2 VUS, MUTYH VUS) 
Similarly, Marlene who has a CHEK2 mutation and PALB2 VUS, said that her VUS made her 
feel even more certain about her decision to have a mastectomy: 
I went to a surgeon, I think, that's pretty reputable and had other CHEK2 patients. Like 
she has seen—I wasn't her first one. I felt like I was the first one with everyone I saw. 
And she kind of made it, like, a definite yes in my head, especially with the PALB2 
unknown. They tell you, “Oh don’t—we're not going to worry about that one because we 
don't know.” But I'm like, “Even having that unknown significance is still significant, 
right? That's why it's unknown significance!” (Marlene, Age 35, CHEK2, PALB2 VUS) 
Both Heather and Marlene reinterpreted their VUSs, transforming the uncertain results produced 
by the black boxes of genetic testing into certain ones I call “gray answers.” Rather than seeing 
their VUS results as scientific unknowns or questions like their genetics providers did, women 
bestowed those results with explanatory power. 
 Even women with high genetic literacy sometimes felt nervous about VUSs and 
transformed them into gray answers. For example, Jessie, who like Marlene has a CHEK2 
mutation and PALB2 variant, demonstrated sophisticated knowledge about BOC risk, 
particularly for a non-scientist, during our interview. Yet she was still concerned about her 
PALB2 VUS. “The doctor gave me the spiel on variants, and I was fine on the variants until I 
found out I was PALB2 variant.” Jessie was concerned because PALB2 mutations are associated 
with an increased risk of pancreatic cancer, which is extremely difficult to detect and has, by far, 
the lowest five-year survival rate of any type of cancer (National Cancer Institute, 2018f). 
Similarly, Naomi, who has a PALB2 mutation and a CDH1 variant, is a biology professor, and 
her understanding of genetics made her more concerned about her VUS. She said, “It’s an 
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unknown variant, you know, how common is that? To find something, a mutation, some kind of 
nucleotide substitution, it’s probably fairly common. But then I went back in and read the report 
and then I was like, ‘Oh my god! CDH1 is like the worst!’ You know, so like panic set in for a 
little bit.” Mutations on CDH1 are associated with multiple cancers, including an 80% lifetime 
risk of developing stomach cancer, and understanding the science of how a variant could affect 
protein function added to Naomi’s anxiety about having one on the CDH1 gene. Thus, it was not 
only women with less education or lower genetic literacy who were concerned about the 
potential risks of VUSs, and having one on a gene in which pathogenic variants are linked to 
serious cancers heightened women’s anxiety.  
 Much like the “fact” of a positive result encourages women and clinicians to envision the 
“worst possible outcome,” thereby helping to transform the probability of risk into prophecy of 
an inevitable future (Rajan, 2006), these women’s responses to their VUSs illustrate how any 
reported variants, even ones formally labeled “uncertain,” are “things” that people can point to as 
potential causes of their or their family’s history of illnesses. While variants labeled pathogenic 
and highlighted in reports are more factual and have more credibility than variants that are 
classified as uncertain, once variants are identified and information about them is distributed 
outside of the laboratory, scientists cannot control how people respond to them. Anyone, not just 
genetic scientists, can interpret VUSs as harmful and transform them into gray answers. In fact, 
in contrast to positive and negative results, which are presented as firm facts, the uncertainty of 
VUSs highlights how risk classifications are constructed rather than preexisting and discovered. 
By calling attention to the active production of risk classifications that is usually made invisible 
by the black boxes of genetic testing, VUSs and variants with discordant classifications invite 
reinterpretation outside of the laboratory in a manner that the firmer “facts” of positive and 
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negative results do not. By publicly admitting that they do not know how to classify VUSs, 
scientists open the door for people to view that “unknown significance as significant.” 
 Linda, the cancer genetic counselor who has been practicing for over two decades, noted 
how people tended to view and treat VUSs like mutations: “There's a bias toward acting upon a 
VUS as if it's a mutation or a deleterious mutation. There's kind of a bias toward that. So 
somehow people put more weight on that possibility than the fact that, whatever you do, there's a 
50/50 chance you're doing the wrong thing, whichever way you treat it.” What Linda meant by 
this statement was that VUSs treated as benign might end up being reclassified as harmful, and 
conversely, VUSs treated as harmful might be reclassified as benign. But the probability of 
“doing the wrong thing” is, in fact, not “50/50.” Rather, previous studies have demonstrated that 
over 90% of VUSs that get reclassified are downgraded to benign or likely benign (Balmaña et 
al., 2016; Mersch et al., 2018; T. P. Slavin et al., 2018). Thus, the bias toward treating VUSs as if 
they were mutations is more likely to be “wrong” than treating them as harmless. 
 Importantly, while women with VUSs and women with MRMs experience different types 
of uncertainty, their discomfort with their uncertainty often centers on the same problem: not 
knowing how to effectively respond to their uncertain risk and not having access to screenings or 
treatments they may want or need. Many BOC genetic testing clients are what anthropologist 
Sahra Gibbon refers to as “anticipatory patients”—women who have evidence of familial risk 
but are seeking proof of their high-risk status in order to gain insurance-covered access to 
increased surveillance and/or risk-reducing surgeries (Gibbon, 2007). Being issued a genetic 
“finding,” even if that finding is characterized by uncertainty about the existence or extent of 
their cancer risks, only underscores women’s concerns about developing cancer and, in turn, their 
desire to take action to manage those potential risks. Hence, both women with MRMs and those 
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with VUSs sometimes desire further medicalization because they are uneasy with the liminality 
of being a qualified patient or a maybe-in-the-future patient. In response, they challenge, 
negotiate, and reinterpret the significance and meanings of their MRMs and/or VUSs by drawing 
on knowledge shared in their social networks or gathered through their own research. In addition, 
similar to individuals with emergent or contested illnesses, women with MRMs and VUSs also 
develop and share tactics for accessing clinical management services that exceed 
recommendations in current guidelines (Barker, 2008; Dumit, 2006).  
Gaining Access and Coverage 
 As I highlighted earlier in the chapter, there were considerable variations in the risks that 
women with MRMs were informed about and the screenings that were recommended to them. 
That unevenness in information and care is characteristic of the private-profit heath system in the 
United States, in which there are no official protocols for providers of genetic medicine to 
follow. There are clinical guidelines, but those are suggestions, and health care providers are not 
required to adhere to them. The fragmented, insurance-based US system, combined with the lack 
of clinical protocols, produces inconsistency and inequality in BOC genetic medicine, 
particularly in the Risk Management field of practices. While navigating that uneven terrain, 
many women in this study turned to online social media groups for information and support. 
Women shared how finding other women like them helped them feel less isolated and scared. For 
example, Holly said about her CHEK2 group, “It’s like, ‘Wow! All these people have the same 
thing.’ And that’s helpful to me—it’s not just my sister and I. There are all these people across 
the country who have it too.” 
Likely because less is known about MRMs than BRCA mutations, women with MRMs, 
in particular, noted that these groups were not just venues for emotional support, but also vital 
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sources of medical and scientific knowledge. As Jessie stated about the CHEK2 group she helps 
to moderate, “I don’t think the literature has caught up with the patient…. I don’t go there as 
much for emotional support so much as I do looking for the clinical trends of my 200 people in 
my tribe that have the CHEK2 mutation that I have.” Josephine echoed Jessie’s feelings about 
her CHEK2 group helping women “get ahead” of the scientific literature. “These patient groups 
are where a lot of knowledge is. They can talk about things and family history and you have to 
take it with a grain of salt. Sometimes science follows the experiences being shared by the 
patient population. You cannot always wait for the guidelines.” Marsha shared how she thought 
of the women in her CHEK2 group as part of an extended scientific and clinical care “team.” She 
said, “People at the grassroots level who have this knowledge, now, because of the computer, can 
be connected to help figure out the puzzle…. I have all these people on my team now that are 
working to figure out what they can.” What Jessie, Josephine, and Marsha were pointing to with 
these statements is how some women at BOC genetic risk engage with these topics as lay experts 
(Susan E.  Bell, 2009; Epstein, 1996). That lay expertise was also evident in the responses of 
several women in this study who demonstrated sophisticated genetic knowledge and had put 
considerable effort into reading and understanding their results.  
 Several women with MRMs shared how they learned through their social media groups 
about additional screening tests and/or surgeries to request from their doctors. For example, 
Marlene was advised in her CHEK2 group to ask her primary care doctor to scan her thyroid 
even though that screening is not recommended in the current NCCN guidelines (National 
Comprehensive Cancer Network, 2018b). “I am now getting a thyroid ultrasound in a couple 
weeks because I demanded it,” she explained. Jessie also began insisting that her doctors order 
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thyroid screenings, and she requested more frequent colonoscopies25 after learning more about 
her risks from women in her group: 
Everybody will do what I ask. As far as, I told my GI I’m having annual colonoscopies. 
He’s not giving me a hard time. Otherwise it’s either make stuff up or I find a GI that 
would give me annual colonoscopies. My thyroid doctor is going along with my every-
six-month thyroid ultrasound. That is about as benign of a procedure that you can get, 
and now I’m going to beat thyroid cancer to the punch. (Jessie, Age 48, CHEK2) 
Jessie’s comment that she would have either faked symptoms or searched for another doctor if 
her GI specialist had denied her requests highlights two other things women indicated they had 
learned through their social networks and advocacy groups: strategies for accessing screenings 
and/or surgical services that their providers initially denied and how to get those tests and 
procedures covered by insurance.  
 The first tactic women described learning about and using was feigning symptoms. For 
example, Margaret described how women in her CHEK2 group had listed specific symptoms 
they could relay to their doctors in order to get thyroid ultrasounds covered. “Interesting enough, 
women are sharing that on the CHEK2 site—that you are hoarse or that you have pressure 
there.” Margaret then used those symptoms to justify getting an ultrasound, but she let her doctor 
in on the ruse. “I shared with her why I wanted one, and then we figured out how to get around 
the insurance problem. I had some symptoms suddenly.” Jessie also described feigning 
symptoms to get her screenings covered while ensuring that she made what she was doing clear 
to her clinicians:   
Look, the first thing you have to do is lie to a physician. I actually—if I’m going to lie to 
my physician, my Gyn/OB, I kind of make it clear that she kind of knows that I’m about 
                                                             
25 NCCN currently recommends that women with CHEK2 mutations have colonoscopies every five years 
beginning at age 40, which is 10 years earlier and twice as frequent as the  recommendations for women 
in the general population (National Comprehensive Cancer Network, 2018c). 
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to lie to her. So, we’re still kind of on the same page, she’s still doing her due diligence of 
whatever she needs to do for her medical stuff. But if I had insurance that did not cover 
my colonoscopy unless I was having rectal bleeding, I’m telling you right now my butt is 
bleeding. (Jessie, Age 48, CHEK2, VUS-PALB2) 
Margaret was angry that she and other women with CHEK2 mutations had to pretend to have 
symptoms in order to get insurance companies to cover the costs of screenings for cancers for 
which they were told they had higher-than-average risk. “Also, it is frustrating sometimes. Like, 
the thyroid thing. In the CHEK2 support group, there are a lot of women popping up on there 
that have thyroid cancer and they are finding it because they demanded that somebody pay 
attention. And so that makes me angry. It’s like, a thyroid screen is an ultrasound. It is very low 
cost and has no side effects. Why don’t they give it to everybody who has a CHEK2 mutation? 
How hard is that?” 
 The second tactic women shared with one another in their social networks was “doctor 
shopping”—the practice of seeing multiple clinicians until finding one who agrees to perform a 
desired test or procedure. For example, the first two surgeons Penelope saw refused to perform 
mastectomy to manage her CHEK2 variant, one that has conflicting interpretations, because they 
said that it was not clinically indicated. However, she had other doctors who had recommended 
the procedure to her. Buoyed by women in her CHEK2 group, she continued to seek out a doctor 
who would perform the surgery:  
The first doctor was like nope. Two times [the risk] is not enough. Have a good day. My 
gynecologist, oncologist, and urologist recommended that I get a mastectomy, and in my 
CHEK2 support group there is another person who has my exact mutation—there is only 
300 of us in there—and she had stage four metastatic breast cancer. So, I was like, 
“Nahhh! I do not care what your paper says.” Once I found out that—originally, I think I 
just wanted some information. But the more I looked into it, the more I wanted the 
surgery. I do not care if I have a 2% risk. It is a low-risk surgery and it reduces my risk. I 
am not removing my colon and living with a bag. It is a low-risk surgery. Let us get it 
done so I do not have to worry about it…. The third doctor that I met with agreed to do 
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the surgery. It is relatively—especially given my age, and aside from cancer, I am pretty 
healthy—a low-risk surgery. I would ten times rather have a low-risk unnecessary surgery 
than wait and have to have the surgery because I have breast cancer down the road. 
(Penelope, Age 32, CHEK2, conflicting interpretations) 
Penelope acknowledged that she might be having an “unnecessary surgery” but felt strongly that 
surgery was a better option than potentially developing cancer. Deena, who has a CHEK2 VUS, 
also did not want to risk getting cancer, so she met with multiple surgeons until she found one 
who was willing to perform mastectomy. She explained, “I do know that supposedly my CHEK2 
is linked less—more likely colon and less likely breast, but I figured I didn't want to take the 
risk.”  Likewise, Heather, who has VUSs on the CHEK2 and MUTYH genes, shared how her 
first surgeon advised against contralateral prophylactic mastectomy (CPM) of her healthy breast, 
but she subsequently found a doctor who would perform the procedure. “I looked into it, and I 
asked the breast surgeon, and they didn't know. No one could give me information. They said, 
‘We don't know. It's not connected. You shouldn't take the other breast because of it. It's not a big 
deal.’ So, I thought, ‘I gotta take the other breast.’ It was my first instinct. So, I did a double 
mastectomy.”  
 Jessie combined feigning symptoms with doctor shopping in order to gain access to 
services she desired. She wanted to have a hysterectomy because, based on her own research and 
what she had learned through her CHEK2 social media group, she was concerned about a 
possible link between CHEK2 mutations and ovarian cancer. Because there is general consensus 
around CHEK2’s associations with female breast and colon cancer but not ovarian cancer, the 
first couple of doctors Jessie met with adhered to the NCCN guidelines and refused to perform 
the procedure because it was not recommended. But she was persistent and continued to seek 




I said, “I need to let you know that I’m going to have a hysterectomy. I want you to be 
my surgeon. So, I guess what I need to know is, if I walk out the door today and go home 
and have extreme heavy uterine bleeding that doesn’t go away after a day or two, can I 
call you for my hysterectomy?” And she looked at me like, “Seriously?” And she said, 
“Yeah, if you call me and tell me you’re having really heavy, abnormal bleeding, we’ll do 
your surgery.” So, I waited until the end of December, and called and said, “Hey! I’m 
having really heavy bleeding, it won’t stop after two days, I want a hysterectomy.”  
(Jessie, Age 48, CHEK2, VUS-PALB2) 
Jessie also went to see five different breast surgeons in order to have CPM. She explained why 
she was tenacious and continued searching for a doctor who would perform the surgery: 
The first four surgeons that I got opinions from, all four said they would only do a single 
mastectomy, and they would not take off the healthy breast. And I said, well I’m not 
keeping the healthy breast, it’s going. I mean, I saw pictures of reconstruction. Two 
things: 1. I’m not going to be a unicorn. So, if I don’t get reconstruction I’m not going to 
have one breast. And 2. I saw reconstruction of one new breast and one healthy breast, 
and my new breast was going to be happy and my old breast was going to be a normal 
48-year-old breast, and I’m not going to do that either. The fifth surgeon that I saw, I said, 
look—same story with the GYN-Oncs: “Look, you’re going to be my surgeon. I already 
know this, and I’m having a bilateral mastectomy. And I understand that you have a 
dissertation to give me on why I don’t need my right healthy breast removed. But I want 
to confirm you are comfortable with taking it anyway.” She said, “Yup. You’re the 
patient. Let’s do it.” 
Together, these stories highlight how in the fragmented, fee-for-service US health system, 
women who are persistent and either have financial resources or insurance coverage that allows 
them to see a broad network of providers can usually find doctors who will surgically manage 
their risk regardless of the penetrance or pathogenicity of their variants.  
 However, women’s stories also reveal that there are a variety of complex reasons why 
they advocate for themselves and seek services that are not formally recommended. Some 
women and their clinicians without genetics training were unaware of the current guidelines for 
managing MRMs and VUSs. However, many women in this study were fully aware of those 
recommendations but actively challenged them because they felt that getting certain screenings 
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or surgeries was what was best for their bodies and lives. When women with MRMs and VUSs 
engage in practices like feigning symptoms and doctor shopping, they are seeking what 
sociologist Kristen Barker refers to as “physician compliance” in her study of women with 
contested illnesses —the willingness of doctors to concur with their assessments of their risks 
and the best ways to monitor those risks (Barker, 2008, p. 31).  
 The response Jessie’s breast surgeon provided—“You’re the patient”—sheds light on why 
some providers are willing to “comply” and respond to symptoms they know are feigned or 
perform surgeries they know are not clinically indicated. The clinicians in genetic medicine 
whom I interviewed and encountered over more than three years of fieldwork were largely 
motivated by a desire to help their patients. Many of them were actively striving to provide 
patient-centered care and to employ a model of shared decision-making—to listen to their 
patients wants and needs and factor them into the decision-making process. In addition, health 
professionals, like patients, are human beings with their own feelings and life experiences. Some 
clinicians I met who worked in genetic medicine had chosen to pursue their medical specialties 
because of their own family’s experiences with hereditary BOC cancers. Given that many health 
professionals both care about their patients and witness the unevenness of care in the insurance-
based US health system, it is not surprising that some are willing to, as Jessie said, “be creative” 
in order to help their patients navigate those varying insurance restrictions and obtain coverage 
for their care. 
 I observed one provider, during a breakout session at an advocacy conference, openly 
encourage a woman to deploy creative tactics in order gain insurance coverage for a desired 
screening. The session was devoted to cancers other than breast and ovarian that are associated 
with BOC mutations, and the conversation had turned toward pancreatic cancer. One patient 
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shared her frustration that she had been unable to get her insurance company to cover the cost of 
endoscopic ultrasounds (EUSs) even though she had a BRCA mutation and a brother who had 
died of pancreatic cancer. The current screening guidelines state that EUS is indicated when two 
first degree relatives have had pancreatic cancer, not one (Canto et al., 2013). A genetic 
counselor in the room responded to her, “They don’t check. All I’m saying is, when you give a 
family history, they don’t verify it.” While subtler than Jessie’s explicit directive to lie, this 
genetic counselor was suggesting that the woman say she had two relatives with pancreatic 
cancer rather than one so she could gain access to insurance-covered screenings. And her 
strategy would, indeed, be effective for women whose insurance companies base their coverage 
for services on current guidelines because clinicians and insurance companies cannot legally 
demand proof of family history due to patient privacy protections. 
Boundary Work 
 The previous section illustrated how women employ various tactics to manage the 
uncertainty of MRMs and VUSs, and in the uneven and unequal terrain of the US health system, 
some health care providers are willing to partner with them in that process. However, whether 
these practices are interrogated and critiqued by genetics experts or are largely overlooked and 
sanctioned by the field varies both by the type of service provided and who is seeking that 
service. For example, providing women with additional screenings that are not recommended 
among women in the general population, such as MRIs and ultrasounds, is barely discussed 
among professionals in genetic medicine, either at scientific conferences or in the literature. 
Given that most types of surveillance are low-risk, the absence of critique or examination of 
screening mismanagement in the field, whether it occurs among women with MRMs or VUSs, is 
unsurprising. While screening procedures can generate false positives that lead to more invasive 
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follow-ups, and they occasionally have risks of their own, such as reactions to MRI contrast dye, 
most surveillance is fairly benign.  
 In contrast, surgical mismanagement is widely examined and critiqued by genetics experts, 
but, importantly, only when it occurs among women with VUSs. Several studies have investigated 
surgical mismanagement of VUSs, and commentaries and reviews that grapple with the issue 
have also been published in the medical literature (Culver et al., 2013; S. Domchek & Weber, 
2008; Miller-Samuel et al., 2011; M. L. Murray et al., 2011; Ready et al., 2011; Vos et al., 2012). 
In addition, sessions that focused on minimizing VUS misinterpretation and mismanagement 
were regularly offered at medical genetics conferences during the three years I conducted 
fieldwork, and discussions in other sessions sometimes veered toward the topic. Yet “MRM 
mismanagement”—providing mastectomy or RRSO to women with MRMs, which is not 
supported by current evidence-based recommendations—remains largely invisible in the 
discourses of genetic medicine, despite, as I will illustrate in Chapter Two, the practice being 
exceedingly common. Other than a few individual conversations with health professionals, in 
over three years of research, I never encountered articles or conference sessions focused on 
MRM mismanagement. 
 In her study of prenatal genetic screenings, medical anthropologist Rayna Rapp highlights 
how the US medical system tends to classify women as “good” or “bad” based on their health 
behaviors. “In the United States, multiple iterations of our sex/gender system index our medico-
legal system: We have normative and deviant reproducers, just as there are justified and selfish 
aborters, or good women and bad women” (Rapp, 2000, p. 307). While Rapp was examining 
reproductive medicine, the same patterns are evident in BOC genetic medicine. Some women are 
considered “good,” adherent patients, while others are “bad,” noncompliant ones, and there is 
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“appropriate” and “inappropriate” medical management of BOC genetic risk. Given that 
mastectomy is not clinically indicated for either women with VUSs or MRMs, why are experts 
within genetic medicine concerned about the former but not the latter? Both women with VUSs 
and women with MRMs who have surgeries are being subjected to the risks of procedures that 
may provide them with limited to no benefit to their physical health; yet, managing VUSs with 
surgery is criticized, while managing MRMs with surgery is not only ignored, but often 
encouraged. 
 The disparity between the responses to surgical mismanagement of VUSs and MRMs is, in 
part, a reflection of boundary work performed by the scientists and health professionals in BOC 
genetic medicine who are considered genetics experts. Sociologist Thomas Gieryn first used the 
phrase “boundary work” to describe how scientists demarcate their work from non-scientists in 
order to protect their credibility and authority in their professional domains (Gieryn, 1983). As I 
have highlighted throughout the chapter, VUSs reflect uncertainty about the existence of risk, 
and that uncertainty is identified within the Risk Production field of practices (Figure 2). The 
professionals in that field who are most directly involved in the interpretation of variants and the 
production of VUS results are genetics experts: clinical geneticists, laboratory scientists, and 
genetic counselors. Among those experts, there is widespread consensus that since VUSs have 
not yet been classified as “risky” they should not affect medical management. When there is 
uncertainty in the field of practices that produces genetic risk, the individuals with the expert 
knowledge on variant classification have not issued a “positive result” and declared that any risk 
exists. Therefore, those experts agree that there should be no change in actions in the Risk 
Management field of practices because there is no risk that warrants a response. As I illustrated 
earlier in the chapter, genetics laboratories and genetic counselors often engage in discursive 
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practices that minimize the visibility of VUSs in order to prevent testing clients and non-genetics 
providers from “treating” VUSs as risk.  
 When women and providers without training in genetics disregard the cautions of those 
experts and seek or provide surgery in response to VUSs, they are reinterpreting the meaning of 
those variants and thereby challenging the expertise of the scientists and practitioners involved in 
the initial interpretations. Whether or not that challenge is intended, having or performing 
mastectomy for a VUS indicates that the patient, surgeon, or both believe that the VUS is not 
uncertain and poses some risk. Lisa, a genetic counselor, discussed surgical VUS 
mismanagement that she had witnessed at her cancer clinic, and she framed the issue as a 
struggle over authority between the genetics experts on the clinical team, most of whom were not 
physicians, and the members without expertise in genetics, who mostly were physicians:  
Part of the issue is if I tell a patient that they don't need a surgery, and I'm not a doctor, 
and then they go see a breast surgeon who says they are a perfect candidate for a surgery, 
and they're an MD and they're a breast surgeon, who is the patient going to listen to? The 
doctor. So, I don't think that the patient is getting all of the info that they should be 
getting, and the balanced discussion that they should be getting, from some of our breast 
surgeons. Despite our best efforts. (Lisa, Genetic Counselor) 
By noting that patients were not receiving the “balanced discussion that they should be getting” 
from breast surgeons about VUSs, despite the “best efforts” of the genetics team, Lisa’s 
statement highlights how individuals with expert genetic knowledge, such as genetic counselors 
and laboratory scientists, are sometimes perceived as having less credibility and authority on 
variant interpretation and management than non-experts because they are not medical doctors. In 
response, genetics experts engage in boundary work—they attempt to reassert their jurisdiction 
over variant interpretation and (mis)management and to protect their domains of expertise by 
conducting studies, writing articles, and actively discussing VUS mismanagement during 
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scientific meetings (Abbott, 1988; Gieryn, 1983).  
 But these discourses in genetic medicine that are critical of VUS mismanagement are not 
solely about the risks to patients; if they were, experts would also critique MRM 
mismanagement. Rather, as science studies scholar Steven Epstein stated in his study of the 
politics of AIDS activism and knowledge, “debates within science are simultaneously debates 
about science and how it should be done—or who should be doing it” (Epstein, 1996, p. 3). 
Hence, the ongoing debate over VUS reporting, misinterpretation, and mismanagement in 
genetic medicine is both a debate about patient care and a debate about scientific expertise. 
Genetic experts are contesting the reinterpretations of and challenges to expert knowledge that 
are required for VUSs to be conceptually reclassified as “risky” and thus become medically 
mismanaged in the first place.  
In contrast to VUSs, there is no uncertainty about whether MRMs are classified as risky 
in the Risk Production field of practices (Figure 2). The scientific and clinical experts who 
produce genetic risk have firmly interpreted MRMs as harmful and made them clearly visible to 
patients as “positive” findings. The degree to which MRMs elevate breast cancer risk and the 
other cancers with which they are associated may be in question, but whether MRMs increase 
women’s risk of breast cancer is not. Once variants are classified as pathogenic or likely 
pathogenic and labeled mutations by experts, women have been “diagnosed” with genetic risk 
for breast cancer. That risk may be either moderate or high, but the risk “exists;” it is a “fact” 
according to scientists, and therefore a clinical response in the Risk Management field of 
practices is not only sanctioned, it is often expected. Since no reinterpretation of risk is required 
to “treat” MRMs, neither the women who seek surgical responses to them nor their surgeons are 
encroaching on the authority of genetics experts. In fact, determining optimal courses of 
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treatment for patients with clear diagnoses falls squarely within clinicians’ and surgeons’ 
domains of expertise, not genetic scientists’ or counselors’. Hence, women and breast surgeons 
may be exceeding the recommendations in current guidelines for managing MRMs, but that 
mismanagement is only a matter of degree and does not challenge the jurisdiction of the genetics 
scientists and providers who make risk factual. In turn, there is no need for genetics experts to 
perform boundary work around MRM mismanagement, which helps to explain the absence of a 
collective discourse or professional response to the issue, despite it being, as I will illustrate in 
the following chapter, a pervasive phenomenon with potentially serious health implications for 
women. 
Conclusion: How Risky? Which Responses? 
This chapter examined how, in the wake of the transition to multi-gene panel testing, risk 
for breast and ovarian cancer was geneticized, genetic risk was medicalized, and in turn, these 
shifts have reconfigured the boundaries of risk, illness, and patienthood. Drawing on stories from 
women and providers and test results reports from the five major BOC genetic testing 
laboratories in the United States, I argued three main points. First, that the geneticization of 
cancer risk and practices that black-box the active production of genetic risk make cancer seem 
inevitable because testing directs attention toward the seemingly certain “facts” of mutations 
rather than the uncertain probability of developing cancer that those mutations signal. Second, in 
contrast to literature that has theorized genetic susceptibility as a liminal space between sickness 
and health, I argued that panel tests have contributed to a spectrum of medicalization of BOC 
genetic risk. Women with high-risk mutations have patienthood experiences that are almost 
indistinguishable from those of people with diseases, while women with MRMs are “qualified 
patients” who have also been “diagnosed” with the “disease” of genetic risk but lack formally 
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sanctioned access to “treatments” like surgical interventions. VUSs, however, are contested sites 
of medicalization; some women with VUSs actively seek medical management and patienthood 
status, while genetics professionals actively work to prevent the clinical management of VUSs.  
Finally, I argued that professional boundary work accounts for the discourses in genetic medicine 
that critique surgical VUS mismanagement but mostly overlook surgical MRM mismanagement, 
despite the pervasiveness of the latter.  
 Collectively, the stories and examples shared in this chapter reveal that there is no static, 
preexisting, objective “truth” about people’s cancer risk that gets discovered by panel tests. 
Rather, BOC genetic risk is a moving target. Not only are the results of genetic tests actively 
coproduced through social and technological processes, but also the scientific and clinical 
relevance of mutations are constantly in flux, and patients and providers are agents who 
reinterpret those results and negotiate their responses to them. Clinicians and genetic counselors 
may provide women with specific numeric risk estimates, as Angelina Jolie’s doctors did when 
they informed her that she had an “87 percent risk of  breast cancer and a 50 percent risk of 
ovarian cancer” (Jolie, 2013). However, even those seemingly firm risk numbers are 
constructions, as they are statistical abstractions of data from populations in previous studies that 
have ascertainment bias.26  
 Yet even if accurate individual-level risk estimates could be generated, the experiences of 
women with MRMs and VUSs shared in this chapter illustrate how people’s responses to genetic 
                                                             
26 Ascertainment bias is bias generated by the selection criteria or data collection methods for a study. 
Risk estimates in cancer genetics are broadly acknowledged to suffer from ascertainment bias because 
they are mostly generated from studies of women who either already had cancer or came from extremely 
high-risk families. Since the proportions of people in those populations with mutations are likely to be 
higher than in the general population, the selection criteria of the populations in the studies distorts the 
estimates (Obeid, Hall, & Daly, 2017; Sorscher, 2018). 
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test results are not rational or calibrated according to the specific numeric percentages of risk that 
get communicated to them. Whether they are told they are 23% likely to develop cancer or 87% 
likely, once any findings are made tangible and reported—sometimes even if those findings are 
uncertain—people often envision the worst outcome and want to take action to prevent that 
outcome from occurring. The “facts” of “positive” results make risk seem more real even among 
women whose risk was visible through their family histories prior to testing. Moreover, as 
genetic risk is increasingly medicalized, one of the consequences is that medicalization generates 
a desire among patients to “treat” that risk. As Nikolas Rose stated, risk thinking “denotes a 
family of ways of thinking and acting that involve calculations about probable futures in the 
present followed by interventions into the present in order to control that potential future” (Rose, 
2007, p. 70). In the following chapter, I will examine how the structures and architecture of US 
genetic medicine encourage women to seek one of those “interventions into the present” that can 
“treat” their risk: prophylactic risk-reducing mastectomy.   
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Chapter 2: “Risk Is Continuous, and yet Responses Are Dichotomous":  
Risk-Reducing Mastectomy in US Genetic Medicine 
“There seems to be a huge movement in the country to do this prophylactic surgery.” 
(Ingrid, Age 62, PALB2)  
“It’s the when you’re going to have it, not if you’re going to have it.” (Marci, Age 39, 
BRCA2) 
“So, it’s only kind of more recently with next-gen panel testing and also a more broad 
acceptability, if you will, of genetics that we have had to wrestle with this idea that the 
risk is continuous, and yet responses are dichotomous. So, you have to pick a point at 
which somebody stops doing the average and starts doing something more than 
average…. And how you determine where that point is, is, I think, a societal question.” 
(Steve, Oncologist) 
Introduction 
 The factors that shape whether and why women with BRCA mutations undergo risk-
reducing mastectomy (RRM), along with the outcomes of their surgical experiences, have been 
widely examined in the fields of genetic counseling and clinical genetics (D. G. Evans et al., 
2009; Gilbert et al., 2017; Glassey, Ives, Saunders, & Musiello, 2016; Howard, Balneaves, & 
Bottorff, 2009). However, few social scientists have explored women’s experiences with 
prophylactic breast surgeries, and those who have typically have focused on psychological, 
familial, or interpersonal dimensions of women’s decisions (Dagan & Goldblatt, 2009; Nina 
Hallowell, 2000; Hamilton, Williams, Bowers, & Calzone, 2009; Hesse-Biber, 2014). This 
chapter, instead, examines the social and structural factors that constrain and enable women’s 
medical management options and facilitate the selection of certain choices over others. Drawing 
on three years of fieldwork at cancer genetics conferences and interviews with 75 women with 
breast and ovarian cancer (BOC) mutations and/or variants, I analyze how and why uptake of 
prophylactic breast surgery is high in the United States. I illustrate widespread departures from 
the risk management guidelines for women with moderate-risk mutations (MRMs), revealing 
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how US genetic medicine financially and socially incentivizes mastectomy and frames it as the 
bravest and best medical choice, regardless of the penetrance of women’s mutations.  
 I argue that the practices of cancer panel testing and risk-reducing mastectomy mutually 
justify, sustain, and define one another. Pathogenic findings on genetic tests legitimize breast 
cancer risk and have become required for insurance-covered access to prophylactic breast 
surgery—without genetic knowledge, mastectomy would be considered drastic, not brave. At the 
same time, prophylactic breast surgery validates the utility of cancer genetic testing by providing 
a mechanism for transforming its abstract, molecular knowledge into action and power—without 
the treatment of surgery, genetic knowledge would not be power, it would merely generate 
anxiety. Through a close examination of the mastectomy experiences of women in the United 
States with both high- and moderate-penetrance mutations, this chapter sheds light on how and 
why risk-reducing mastectomy has become the standard and preferred treatment for the “disease” 
of BOC genetic risk.  
Departing from the NCCN Guidelines 
 As I explained in the previous chapter, the NCCN Guidelines recommend discussing the 
option of mastectomy with BRCA1/2 mutation carriers but not with women with MRMs. Most 
of the health professionals I interviewed indicated that they followed the NCCN Guidelines when 
counseling and treating patients. For example, Linda, a genetic counselor, said, “I find myself 
reviewing the medical literature often. But also the NCCN guidelines. Those are a really nice 
summary of what do we know right now, and they get updated at least once a year. And they 
have some guidance in there.” Similarly, Steve, an oncologist, stated, “NCCN in particular has 
become a bit of an arbiter.” Jackie, a genetic counselor at an academic medical center who began 
working in cancer genetics at the field’s inception, explained how she utilizes the specific 
 
110 
language in the NCCN Guidelines when discussing risk management.  
I explain what the current guidelines are. For example, if we're talking BRCA, I will 
explain bilateral mastectomy as an option. It's one of the options. Whereas removal of the 
ovaries and tubes is a recommendation. I explain there's a difference in the wording there, 
and there's a reason there's a difference in that wording. So, we fall back on what the 
current guidelines are. And NCCN is constantly tweaking even BRCA guidelines and 
then coming up with more information for some of these other genes as well. (Jackie, 
Genetic Counselor) 
However, the guidance patients reported receiving and risk-management options presented to 
them rarely aligned with the nuanced recommendations in the guidelines. As I will illustrate in 
Chapters 3 and 4, very few women reported being counseled about the full range of surgery-
related issues that the NCCN guidelines recommend discussing; instead, many conveyed that 
they were un- or under-prepared for the side-effects of RRSO and breast reconstructive surgeries.  
 In addition, the nuanced distinctions between “no risk” and “insufficient evidence” and 
what clinicians should “recommend,” “discuss,” or “consider” are murky in practice and rarely 
had an impact on women’s understandings of the guidance they received. For example, Marci 
recalled her initial conversation with her genetic counselor after discovering she was BRCA2-
positive.  
So, I said, “Well, what’s the recommendation?” And she said, “Well, you know, we 
recommend that you have a double mastectomy and we recommend that—” either 
recommend or consider. I think they were—they couldn’t recommend it. She’s not a 
doctor; she’s a genetic counselor. So, she was very clear on the boundary. What I heard 
was a little different. What I heard was, “Cut off your breasts and cut out your ovaries” 
was what I heard. (Marci, Age 39, BRCA2) 
Like Marci, nearly all the women I interviewed, whether they had high- or moderate-risk 
mutations, indicated that mastectomy had been presented not only as a possible option, but also 
often as the recommended and desired option. 
 In fact, of the 38 women I interviewed who had MRMs, all but one were offered the 
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option to have either contralateral prophylactic mastectomy (CPM) or bilateral prophylactic 
mastectomy (BPM).27 Among the 37 women offered mastectomy, nearly two-thirds of them had 
already had the surgery or were planning to have it in the near future (Table 3). In addition, all 
three28 women who learned they had VUSs prior to undergoing any interventions were offered 
mastectomy, and two of them chose to have surgery (Table 3). The high prevalence of RRM 
among carriers of genetic mutations is unique to the United States. Other countries have much 
lower prevalence of BPM among unaffected29 women with high- and moderate-risk mutations 
and CPM among mutation carriers with breast cancer (Laitman et al., 2014; Mamtani & Morrow, 
2017; K. A. Metcalfe et al., 2008; K. A. Metcalfe, Goel, Lickley, Semple, & Narod, 2002; Nash 
et al., 2017). So why is mastectomy a consistent practice in the otherwise uneven landscape of 
US genetic medicine?  
 
                                                             
27 CPM and BPM are both forms of risk-reducing mastectomy. CPM is the removal of an unaffected 
breast in a woman with cancer and BPM is the removal of both healthy breasts. Some women who have 
breast cancer have genetic testing to help them determine whether they should have CPM, as a higher risk 
of a second primary breast cancer is associated with some mutations. However, genetic testing is only 
recommended in a limited subset of breast cancer patients since most breast cancers are not genetically 
linked. In addition, some women who have mastectomy and CPM are candidates for lumpectomy, and 
therefore they are choosing both treatment mastectomy and a risk-reducing surgery. 
28 There were four women who participated in this study who had no pathogenic variant and only a VUS 
in a gene associated with breast cancer risk. However, in 1982, over a decade before the discovery of any 
mutations associated with breast cancer, one of those women, Marsha, had a prophylactic mastectomy 
based on her family history. Because her VUS was not known at the time of her RRM, I do not include 
her in the group of women with VUSs who were offered mastectomy. 
29 I use the phrase “unaffected women” as a concise way to refer to women who have never experienced 
cancer in their own bodies. I recognize that many, if not most, of the women whom I describe with this 
phrase have loved ones who have experienced cancer and therefore have lives that have been deeply 




Table 3: Number of Women Offered Breast Surgeries, by Decision and Variant Type  
Desiring Mastectomy 
Previous social science scholarship has examined a complex array of individual and 
relational factors that affect the risk management decisions of women at high risk for breast and 
ovarian cancer. For example, studies have shown that the breast cancer experiences of women’s 
mothers—in particular, whether their mothers survived—and being a mother both notably 
influence women’s feelings and decisions about risk-reducing surgeries (Dagan & Goldblatt, 
2009; Gibbon, 2007; Nina Hallowell, 2000; Hamilton et al., 2009; Hesse-Biber, 2014). In this 
study, I move beyond an individual-level analysis of women’s decisions and instead explore the 
social and structural dimensions of US genetic medicine that shape those decisions and 
encourage certain choices over others. Analyzing the system-level factors that encourage high 
uptake of prophylactic breast surgery in the United States requires an understanding of both why 
women at BOC genetic risk desire mastectomy and how the procedure has become widely 
accessible to women, even when many of them do not meet the criteria specified in clinical 
guidelines. In this section, I illustrate, through women’s voices and stories, the four most 
common reasons they shared for wanting prophylactic breast surgery: to prevent chemotherapy 
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and other difficult treatments, to reduce their stress and anxiety about developing cancer, to “be 
there” for their children, and to save their lives.  
Preventing Breast Cancer and Intensive Treatments 
 Mastectomy is extremely effective at reducing women’s risk of developing breast cancer. 
Women who have the procedure reduce their lifetime risk of developing breast cancer to 
approximately 5%, which is less than half of the 12% lifetime risk of women in the general 
population (S. M. Domchek et al., 2010; Kuchenbaecker et al., 2017; A. W. Kurian et al., 2010; 
Li et al., 2016; Razzaboni et al., 2012). In addition, mastectomy is relatively quick and safe when 
compared to many other major surgeries. The procedure takes, on average, two hours, and the 
most common risks and side effects are ones associated with any major surgery, such as pain, 
infection, swelling, numbness, and/or scar tissue formation (Breastcancer.org, 2013; Eisemann & 
Spiegel, 2018). Mastectomy is also a relatively straightforward decision, as there are limited 
options to weigh. Women who desire reconstruction are sometimes offered the option of nipple-
sparing surgery, which removes the glandular breast tissue but leaves the breast skin and areola 
intact in order to create a more “natural” reconstructed look. Current estimates for women’s 
lifetime risk of breast cancer when they have nipple-sparing mastectomy is 8%, so slightly 
higher than that of women who have RRM without nipple-sparing surgery but still below the 
lifetime risk of women in the general population (Galimberti et al., 2017; Jakub et al., 2018). A 
similar option that is sometimes offered is skin-sparing mastectomy, which preserves all of the 
skin around the breast except for the nipple and areola, which are more connected than other skin 
to the underlying glandular tissue and therefore are the most likely areas to contain some cancer 
cells (Galimberti et al., 2017).  
 The alternative to mastectomy for women at high risk of breast cancer is to undergo semi-
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annual breast screenings that typically include clinical manual breast exams and alternate 
between breast MRI and mammography. The goal of breast surveillance is early detection. By 
examining and imaging women’s breasts every six months, if breast cancer develops, it is usually 
caught in its earliest stages of growth, when it most likely to be curable. However, curing breast 
cancer, even when it is detected early, at minimum involves surgery (either mastectomy or 
lumpectomy) and may also require other intensive treatments, such as radiation, chemotherapy, 
immunotherapy, or other drug therapies. For example, women who have low-stage, low-grade30, 
hormone-receptor-positive cancers are often candidates for lumpectomy, which removes only the 
area directly affected by cancer, thereby conserving a majority of the breast. But the standard of 
care for women who have lumpectomies also includes several weeks of localized radiation 
treatments in order to ensure that any dormant cancer cells that were missed during surgery are 
killed. In addition, women with early-stage, hormone-receptor positive breast cancers are 
typically prescribed anti-estrogenic drugs (either a selective estrogen receptor modulator or an 
aromatase inhibitor) for 5 - 10 years post-surgery. These drugs have a range of side effects, 
including increased risks of blood clots, bone loss, joint pain, hot flashes, vaginal dryness, and 
endometrial cancer (National Comprehensive Cancer Network, 2018a). Hence, women who have 
mastectomy undergo a more invasive surgical procedure than they would require if they 
developed a low-grade, low-stage, hormone-receptor-positive cancer, but they avoid radiation 
treatments and ongoing drug therapies.  
 In addition, there are circumstances in which clinicians will recommend chemotherapy 
                                                             
30 The grade of a cancer indicates how abnormal the cells appear and behave at a molecular level. It is 
distinct from the stage of a cancer, which refers to how extensively the cancer has penetrated tissues in 
the body (i.e., the tumor size and how far the cancer cells have spread). At any stage, low-grade cancers 
appear similar to normal cells and are slower-growing; high-grade cancers look atypical and are faster-
growing and harder to treat (National Cancer Institute, 2018c). 
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and/or immunotherapy even when a breast cancer is caught early and localized. For example, 
approximately 25% of breast cancers test positive for HER2 protein31 overexpression. HER2-
positive cancers tend to be more aggressive—they grow quickly and are more likely to 
metastasize and recur than HER2-negative cancers (Onitilo, Engel, Greenlee, & Mukesh, 2009; 
Parise, Bauer, Brown, & Caggiano, 2009). However, certain immunotherapy drugs are extremely 
effective at targeting the HER2 growth pathway and killing those cells. As a result, women with 
early-stage HER2-positive cancers are usually treated with immunotherapies in order to reduce 
the likelihood of recurrence or spread. Similarly, breast cancers that are negative for HER2 
overexpression and for estrogen and progesterone receptors, which are called “triple-negative” 
breast cancers, are also aggressive and more likely to metastasize and recur. But they are even 
harder to treat than HER2-positive cancers because they do not respond to immunotherapies or 
hormone-blocking drugs. Therefore, regardless of stage, oncologists almost always recommend 
that women with triple-negative breast cancers be treated with chemotherapy.  
 Women with BRCA1 mutations are disproportionately likely to develop triple negative 
breast cancer. Approximately 70% of BRCA1-associated cancers are triple-negative, compared 
to only 12-14% of total breast cancers(K. N. Maxwell, 2015). In addition, a recent study found 
that the absolute risk of developing triple-negative breast cancer was 18% for carriers of BRCA1 
mutations, 10% for women with PALB2 mutations, and 6% for women with BRCA2 mutations, 
which range from five to 16 times greater than the absolute risk in the general population 
(Shimelis et al., 2018). As a result, even when surveillance is effective at detecting breast cancer 
early, a majority of women with BRCA1 mutations and a sizable proportion of those with 
mutations on PALB2 and BRCA2 will likely require chemotherapy treatments if they develop 
                                                             
31 HER2 proteins are receptors on breast cells that control cell growth, division, and repair. 
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cancer. Nina’s story provides an example of such a case.  
 Nina discovered her BRCA1 mutation relatively young, at age 26. Despite being 
encouraged to have mastectomy by clinicians, family members, and other women with 
mutations, she elected to continue with surveillance. Surveillance was effective for Nina—when 
she developed breast cancer nine years later, it was caught at an early stage. However, she 
explained that no one had ever informed her that as a BRCA1 mutation carrier she was at high 
risk of developing a triple negative cancer and therefore of needing chemotherapy.  
I knew the goal was early detection. But the only thing I guess I was frustrated about was 
that no one said triple negative is a thing, and if you get triple negative, no matter if it’s 
Stage 1, you’re still gonna do chemo. Like, I didn’t have any concept of that part. That 
part I was like, “Well wait. So early detection, you know, wouldn’t have changed a 
thing?” Well yeah, I mean, I guess it changes the risk of it metastasizing, but other than 
that, the treatment would still have been the same. So, it would have been helpful to 
know that information in advance. (Nina, Age 35, BRCA1)  
Nina clarified that she was not upset that chose surveillance over mastectomy. “I don’t regret 
doing surveillance anyway. I got to keep my healthy breast tissue for quite a while.” But she 
wished she had been informed about her disproportionate likelihood for needing chemotherapy 
treatment even when surveillance achieved its “goal” and detected cancer early.  
 Nina’s story reveals an important, but often under-emphasized, benefit of mastectomy—
that by reducing women’s risk of developing breast cancer, it also reduces women’s risk of 
needing toxic treatments. Beverly, a woman with a BRCA1 mutation whom I met a conference, 
explained that avoiding the painful and difficult treatments she had witnessed family members 
endure was one of the many reasons she chose mastectomy. “The way I saw it was, I can either 
have a mastectomy, or I can have a mastectomy with a side of chemo. I’ll take mine without the 
chemo, thanks.” Similarly, Eleanor, an ATM mutation carrier who had a unilateral mastectomy to 
treat her breast cancer, expressed that her desire to avoid a second round of chemotherapy was 
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why she was strongly considering prophylactically removing her remaining breast.  
I think the thing informing most of my personal decisions is that I don’t want to go 
through chemo again. I’m not a vain or even very feminine person, but I do like having 
hair on my head. I’ve read that people who’ve done chemo multiple times reach a point 
where their hair doesn’t come back. And I can live without my chest; that doesn’t bother 
me even remotely. But it is nice to be able to pass as a healthy person by having hair on 
your head and having eyebrows and all that silly stuff. (Eleanor, Age 42, ATM) 
Eleanor’s, Beverly’s, and Nina’s stories illustrate that, for some women, the risks and recovery 
from mastectomy are preferable to potentially needing ongoing, uncomfortable treatments or 
therapies that could severely impact their daily quality of life.  
Reducing Stress and Anxiety 
 Many of the women I interviewed and spoke with at conferences discussed the beneficial 
effects that risk-reducing surgeries had on their mental health. They expressed how the stress and 
anxiety of ongoing surveillance, which is sometimes referred to as “scanxiety,” was difficult for 
them to manage. Once women undergo mastectomy, they no longer have annual MRIs or 
mammograms because their lifetime risk of breast cancer is even lower than among women in 
the general population. The possibility of eliminating the cyclical stress of breast screenings 
motivated some women to consider and eventually have surgery. For example, Joan, who was 24 
when she discovered her BRCA2 mutation, explained how her anxiety about her surveillance 
appointments was what led her to pursue surgery.  
Once I found I was positive, and I started doing the every six months mammograms and 
breast MRIs—I just hated it. I hated it! I mean, I was so young, I had such dense breast 
tissue, they always saw stuff, had to come back for ultrasounds and, "Oh, we think that 
might be something, we're not sure, that could be something." And I just couldn't deal 
with it. It was just making me so anxious and worried, I dreaded these appointments and I 
just was terrified they were gonna find something, so I was like, “I just want to do it. I 
want to do it now!” (Joan, Age 34, BRCA2) 
Similarly, Colette, a 34-year-old woman with a CHEK2 mutation, shared that the stress from 
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repeated screenings was why she had scheduled her mastectomy. “All of this surveillance—this 
is on my mind. If I have to have another MRI and then a follow-up biopsy every six months, that 
is a lot of emotional, physical, and financial stress every six months.”  
 Like Joan, several women mentioned that their regular screenings often required follow 
up visits or additional imaging, which compounded their stress. Mindy, who has a CHEK2 
mutation, chose to have a lumpectomy after being diagnosed with early-stage breast cancer. She 
recalled the intense stress of waiting for the results after one of her mammograms when her 
doctor thought she saw something suspicious. 
Every six months I have to think about having these tests, which involve radiation, and 
think about the fact that I may have to go back and have the mastectomy later on. The 
fear that you have that the test might include the results. I just had my six-month 
mammogram after completing radiation, and the way it works at the center, you have 
your mammogram, and if they don't need more pictures and everything is fine, they tell 
you to get dressed and you go home. If the radiologist has to look at your pictures, they 
escort you into this lovely room where they have soft lute music playing, and bottled 
water, and a blanket warmer where you sit down on this very comfortable chair and wait 
for the radiologist to come out and talk to you. You know that if you're going to this 
lovely room, you're screwed. After they had the mammogram and escorted me into that 
room, it took the radiologist a good half-hour to go over my films. And in that half-hour, I 
had myself dead, buried, my children in mourning, my house sold, and me just trying to 
imagine how I am going to handle hospice. It only took half an hour to go through this 
grief process. (Mindy, Age 59, CHEK2) 
Mindy did not have cancer—the suspicious spot the radiologist saw was a calcification. But she 
was shaken when she shared her story and was clearly still feeling the reverberations of the 
anxiety she experienced in that visit.  
 Summer also shared a story about suspicious results that ultimately were found to be 
benign. After waiting months for a conclusive finding on those images and biopsies, she felt she 
did not want to endure that stress on a regular basis. 
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I went in for my very first mammogram and of course they found something. So, I went 
through an MRI guided biopsy and they found flat epithelial atypia [FEA]. My 
understanding is that can occur in close proximity to an actual cancer. They were 
concerned that maybe they hit the FEA and not the cancer. So, I had a lumpectomy. The 
lumpectomy did not find any cancer. After three months of thinking, “Oh my god, I 
already have cancer, it is too late for me!” and the stress of going through the procedures 
and waiting, I decided that going through that every six months was not for me. It seemed 
almost inevitable anyway because of my risk, so why not get it over with when I have 
decent insurance and I am young? (Summer, Age 35, ATM) 
Summer’s experience with suspicious imaging and follow-up procedures made breast cancer feel 
like less of a risk and more of a certainty, which propelled her toward surgery. Similarly, Fiona, 
who was 33 when she discovered her CHEK2 mutation, decided to have CPM rather than a 
unilateral mastectomy or lumpectomy to treat her early stage breast cancer because she did not 
want to feel perpetually anxious about developing it in her other breast. “It came down to the 
peace of mind mentally. I am very much a worrier and Type-A. I knew that I would be paranoid 
even more so than I already am.”  
 Eliminating constant worry was also a major reason that Hannah and Amber, the two 
youngest women to participate in the study, chose to have mastectomy at age 23. Amber, who 
has a BRCA1 mutation, explained, “I feel like I would stress too much about when I’m going to 
get breast cancer by not having it done. So, by going ahead and getting it done, then I can stop 
worrying about it all the time.” Like Joan, Hannah, who has a BRCA2 mutation, did not want to 
live a majority of her life worried about when she might develop cancer. “Honestly, by the time I 
had seen the genetic counselor I had already had my surgery scheduled and I met with 
surgeons…. I just realized that they were ticking time bombs sitting on my chest. I have my 
whole life ahead of me, and I don’t want to wait every year to think, ‘Is this my year?’ I was like, 
‘No. That is not for me.’”  
 Women were often aware that having a mastectomy would not eliminate 100% of their 
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risk, but they still noted how relieved they would feel once they had their surgeries. For example, 
Adele had already been diagnosed with early-stage endometrial cancer and kidney cancer by age 
40. She was eagerly awaiting breast surgery in order to avoid developing a third cancer: 
I will feel much better. I feel like I’m walking—I feel like I did when I had cancer.32 I 
feel like I’m walking around with cancer in my body and I just want to get it out. And I 
understand that if I have the mastectomy, that that doesn’t mean that I’m never going to 
get cancer, that they can’t get all the breast tissue out and it can go elsewhere. And even 
the ovarian cancer, there could be ovarian cells right now inside me that have turned 
cancerous. I get all that. But I’m going to feel much better when the bulk of it is gone. 
(Adele, Age 42, BRCA2) 
Megan, a pregnant CHEK2 mutation carrier who was delaying mastectomy until she was done 
breastfeeding, was also eager to have her surgery. She explained how the mental health benefits 
of RRM mattered more to her than the risks of the surgery to her physical health:  
I want to understand the risks associated with surgery, but I have to weigh the mental 
health part of it. Every six months, with the screening and the question mark… I guess if 
I went a few years and everything was fine, I would almost feel different. But I've read a 
lot of stories where things have been missed, and to me, you know, if my boob's gonna 
kill me, take my boob off! My mental health is very important to me, and if I can take 
away 97% of the anxiety of the breast cancer part, then, heck! Take it away. And it 
sounds terrifying, like I know it's a major surgery and you know, it can have its own 
complications. But that's the whole kind of cost-benefit analysis that I want to speak to a 
surgeon about. (Megan, Age 35, CHEK2) 
While Megan was aware of potential surgical complications from mastectomy, she felt that on 
balance, removing her anxiety about developing breast cancer was worth the physical toll of the 
surgery and the risk of additional complications.  
 Women who had already had mastectomies confirmed that the procedure had reduced 
                                                             
32 Adele had genetic testing because she was diagnosed with endometrial and kidney cancer by age 40. 
She did not discover any mutations that are significantly or robustly associated with endometrial or 




their stress and anxiety, just as Adele and Megan anticipated. For example, Veronica, who had no 
family history of breast cancer and discovered her BRCA1 mutation through a genetic ancestry 
test, explained how prophylactic breast surgery helped her regain a feeling of “control” in her 
life: 
When I first got diagnosed or tested positive, I felt like I had no control over my life. 
Like, this had been determined from conception. From the moment I was conceived, I 
was mutated. Just, you know, I felt like I had no control. And now I feel like I have more 
control than ever, in that I feel like I, in some ways, have more control than people in the 
general population, because I took this step to reduce my risk, and now the risk is so 
low…. And I feel like, you know, there's always gonna be some kind of risk out there, but 
I am personally doing everything that I can. And it feels very empowering. (Veronica, 
Age 32, BRCA1)  
Amy also shared how mastectomy removed her constant stress and worry about developing 
cancer. Like Veronica, she felt reassured by taking action and doing “everything possible” to 
manage the factors that she felt were within her “control”:  
I’ve done what I’m in control of. So, I don’t have that stress of, “Oh, I’m not going to do 
this and then I’m going to have to wait, and then they’re going to have to do a breast MRI 
every other year, and I’m going to have to have mammograms, and I’m going to be 
nervous about that every time.” Like every time my mom had one we all held our breath, 
you know? … And if anything else happens, I mean I’ll deal with it, but I didn’t want to 
sit and wonder, “Like okay, I could have done this and I didn’t! I could have minimized 
my chances down to the same risk as everyone else has.” Or I’m going to sit and worry, 
“Great, I have this and now I’m just going to wait for it to develop into something.” I 
didn’t want to do that. So, I think that’s my relief, is just I did what I was capable of 
doing to prevent this. (Amy, Age 41, BRCA1) 
Veronica and Amy both knew that having a mastectomy did not completely eliminate their risk 
of developing breast cancer, but they were glad they had the procedure because it reduced their 
anxiety and helped them feel more in control of their bodies and lives. 
 Marsha was the only woman in the study who could reflect back on decades of living 
with a reduced risk of breast cancer after having a prophylactic mastectomy. She was 74 when 
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she learned about her CHEK2 variant, but based on her strong family history, she had a 
prophylactic mastectomy over 30 years earlier—in 1982, long before the discovery of the BRCA 
genes. Marsha acknowledged that it was impossible to know, with certainty, whether her 
mastectomy was the primary reason that at age 75 she had not yet developed breast cancer, 
which had affected many of her female relatives much earlier in life. “So, the thing is, you know, 
did I forestall the inevitable? Would I have gotten premenopausal breast cancer like everybody 
else and did this help me live a longer life? Or maybe it wouldn't have mattered.” Yet even with 
her uncertainty about how surgery had affected her outcomes, Marsha expressed that she was 
glad she had prophylactic surgery. “For me, I think it was the right decision because it helped me 
live all those years without that—I was able to tolerate the uncertainty much better than if I 
would have had my breasts and would have kept bringing my breasts to doctors who would 
wring their hands and say, ‘Well, we don't know about the changes.’” For Marsha, an important 
benefit of mastectomy was that it helped her cope with the “uncertainty” of risk.  
 Together, women’s stories illustrate that breast screening and surveillance often focuses 
and intensifies their anxiety about developing cancer, while mastectomy relieves their fears. This 
difference in women’s feelings about their risk management options helps to explain, in part, 
why they seek out prophylactic surgeries regardless of the penetrance of their mutations. As the 
previous chapter illustrated, by making risk tangible and “factual,” positive results on genetic 
tests can make their cancer risk feel more "real" even when the specific probabilistic risk 
estimates women are provided suggest otherwise. In turn, what women often seek to reduce 
through mastectomy is not their overall risk of developing cancer, but rather their anxiety about 
developing breast cancer. Mastectomy removes them from the perpetual state of uncertainty and 
fear generated by being “at-risk” and “waiting for cancer to come” (Hesse-Biber, 2014). Nina 
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Garcia, the Editor-in-Chief of Elle and Project Runway judge, shared this perspective with the 
public in her recent essay in Elle about her decision to have a prophylactic mastectomy:  
[F]or three-plus years, I’ve been closely monitored, getting regular mammograms and 
breast checks. Throughout this time, I’ve had numerous biopsies, two lumpectomies, and 
countless follow-ups…. I was living in a loop of testing, every day waking up thinking: Is 
today the day I will get cancer? I no longer wanted to have these scary thoughts, and I 
knew the only way they would stop was to schedule the surgery. The answer was clear. 
(N. Garcia, 2019) 
Garcia had been following the high-risk screening protocol for her BARD1 mutation, but the 
continuous screenings and false alarms heightened her anxiety, as they did for many women in 
this study. Hence, while clinicians may divide women at genetic risk according to their lifetime 
risk estimates, from the perspective of patients, what prophylactic mastectomy responds to and 
reduces is not that abstract numeric risk. Instead, mastectomy ameliorates women’s lived 
experiences of stress and fear that are generated by their genetic risk for cancer, and those 
feelings are not directly proportional to the penetrance or pathogenicity of their specific variants. 
 The scientific literature on RRM rarely emphasizes the mental health benefits of 
removing the stress and anxiety that women experience from breast screenings and being at 
elevated genetic risk for breast cancer. In contrast, among women in the general population, the 
stress caused by suspicious breast imaging results and the follow up exams they require is often 
emphasized as a negative outcome of over-screening. For example, scientific literature on the 
anxiety and invasive biopsies associated with false positives on mammograms was among the 
evidence that led to recent controversial changes in the US Preventative Services Task Force 
(USPSTF) mammography guidelines. These revisions included raising the age threshold for 
mammography screenings for women in the general population from 40 to 50 and reducing the 
recommended frequency of screenings for women between the ages of 50 and 75 from annual to 
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biannual (Pitman et al., 2017; Squiers et al., 2011; Witten & Parker, 2018). If the stress from 
false positives on breast screening tests are cited as reasons to limit the use of those tests in the 
general population, then avoiding the stress of those screening tests should also be cited as a 
benefit of risk-reducing surgeries among women at moderate-risk or high-risk.  
Being There for Your Kids 
This study supports previous research that has documented the influence of motherhood 
on the risk-management decisions of women with BOC mutations. One of the earliest themes 
that emerged from women’s stories about choosing prophylactic mastectomy was the impetus of 
“doing it for your kids.” Several women shared how becoming a mother and forming a family 
altered their perspectives on risk, making them less tolerant of uncertainty and therefore more 
inclined to choose surgery. For example, Alicia, who has a BRCA1 mutation, explained:  
I want to do everything that I possibly can to be around for my kids. And I think having 
children made that decision a lot easier to make. I think it would be a totally different 
decision, like if I were single, or if I didn’t have kids. Like, you know, once you become 
a mother, you’re like, your kids become the focus of everything. And it’s like I don’t 
want to leave my children without a mother. And, you know, I may still get cancer. But at 
least everybody knows I did every damn thing I possibly could to not get it. (Alicia, Age 
42, BRCA1) 
Anita, a BRCA2 mutation carrier who was nursing her infant during our interview, was planning 
to have a mastectomy once she was done breastfeeding. She shared a similar sentiment: “Now 
that I have a family it’s just like, I don’t want to take that risk and leave them behind…. You 
don’t want to leave your spouse behind. And then also your baby, it’s like I can’t imagine not 
being able to be there for him, and raising him.” Similarly, Veronica, a BRCA1 mutation carrier, 
had recently adopted her foster daughters and explained how becoming a mother was the catalyst 
for her decision to have surgery: 
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Once I started meeting with them and knew that we were going to adopt them, I said, “I 
just wanna have the surgeries!” I don't want to die young or have cancer and put them 
through more loss and more sadness and trauma in their lives. And prophylactic surgery 
kind of sucks and I was really nervous about the surgery, but for me, as soon as I was 
matched to the kids, and as soon as I met them, my risk tolerance plummeted to like, 
zero. (Veronica, Age 32, BRCA1) 
The stories shared by Alicia, Anita, and Veronica illustrate how the process of becoming a 
mother can transform women’s feelings and decisions about prophylactic breast surgery and alter 
their timelines for the procedure.  
Being a mother also made women less tolerant of the prospect of chemotherapy, 
radiation, and the stress generated by ongoing screenings. For example, Megan, who has a 
CHEK2 mutation, was in her third trimester of pregnancy during our interview. She had suffered 
a previous pregnancy loss, and she felt that becoming a mother and wanting to be there for her 
daughter had changed what felt acceptable to her going forward: 
We've tried really hard to have a healthy baby, and I want to be around. And so, I don't 
want any part of me—my breasts, my colon, my anything—to take away that experience, 
or make it more difficult. I don't ever want to in my life be having to go through chemo 
and radiation and have a young child. So, like, it's very frustrating, and I think it's 
because it has changed the way that I get to look at the future. Because my future now is, 
every six months, I need to look at these tests and be ok with it kind of thing. And I think 
with... with having a child on the way, it just makes it bigger for me. (Megan, Age 35, 
CHEK2) 
Joan, who inherited her BRCA2 mutation from her mother, explained how difficult it had been 
for her as a child to witness both of her parents going through chemotherapy. She explained that 
she, in part, chose mastectomy to protect her children from that pain:  
My kids. And... not wanting to be sick, not, you know. You watch a parent go through--
my dad also had cancer when I was in high school, both of my parents were sick, at the 
same time. Both going through chemo, nobody could work. It's horrible, and I never want 




Colette, a CHEK2 mutation carrier, also remembered how scared she was as a teenager watching 
her mother endure chemotherapy. She also chose surgery because she wanted to try to prevent 
her children from going through the same experience. “It was really hard to see her go through 
chemo and radiation and being scared. Even though I was a 17 year old, I was scared that I was 
going to lose my mom. It was hard. If I can keep that experience from my kids, I want to.”  
 Like Megan and Joan, other women shared how their desire to undergo mastectomy was 
linked to wanting “to live” so that they could “be around” to support their children and watch 
them grow up. For example, Jessie, who has a CHEK2 mutation and PALB2 VUS, shared, “My 
favorite question is—my husband’s name is Jim—when they say, ‘Well what did your husband 
say? What does Jim think?’ And I say ‘Jim who? I don’t give a shit about what Jim thinks. I want 
to be here to watch my children grow up. It’s about longevity.’” Elena also said that being a 
mother was a major factor in her decision to have CPM. “When [the test] came back CHEK2 
positive and they knew I had this increased likelihood of having breast cancer or getting it again, 
I just decided with three young kids and a lot of life still left to live, I decided on the bilateral 
mastectomy.” Similarly, Deena, who has a CHEK2 VUS, explained that she sought out breast 
surgery experts who would perform risk-reducing mastectomy because she wanted to be there for 
her son. “I just kind of felt like, if I have this, I want to live as long as I can for my four year old, 
so I'm going to go to the people who know what they're doing…. I figured you can remove every 
body part I have, as long as I'm here for him.” Colette, a CHEK2 mutation carrier, conveyed that 
her certainty about mastectomy was rooted in being a mother. She stated, “I know this is the right 
decision for my family. It gives me more time with my kids, and as a mom that is all that I want.” 
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The impact of motherhood on women’s decision to have prophylactic breast surgery was 
also illustrated by the sizable overlap between the small fraction of women who did not have 
children and the relative few who declined or were undecided about mastectomy. Women 
without children constituted 25% (19/75) of the participants in this study, yet they accounted for 
45% (10/22) of the women who had declined or were undecided about surgery (Table 4). Viewed 
another way, among the women with children, 77% (43/56) had or were planning a mastectomy, 
while that was true of only 47% (9/19) of women without children (Table 4). These proportions 
need to be interpreted cautiously because samples in qualitative research are not designed to be 
representative or to generate statistical estimates or rates, and qualitative analyses do not control 
for other variables that might help explain these differences.33 However, the disproportionate 
desire to have mastectomy among women with children and their corresponding 
underrepresentation among the women who were avoiding or unsure about surgery was striking, 
and when these numbers are triangulated with women’s stories, it further reveals the importance 
of motherhood to women’s decisions. 
Table 4: Women's Mastectomy Decisions (Ns), by Motherhood 
 
                                                             
33 For example, an obvious potential confounder of these uneven distributions is age. In the general 
population, a greater proportion of younger women would be childless, and given the relative uncertainty 
of employment and relationship contexts at that stage in the life course, younger women might also be 
more likely to be undecided about surgery. However, while the median ages of women with and without 
children were slightly different (43.5 vs. 37, respectively), the median ages of women who were 
undecided about or had declined surgery and those who had chosen or planned on having RRM were 





An important assumption embedded in women’s desire to “be there for their kids” and 
“watch them grow up” was the belief that having mastectomy would increase their longevity. 
Similarly, the improvements in mental and emotional health that women reported after 
mastectomy were not independent of their belief that the procedure could help them avoid dying 
young. Women, in part, felt less stressed about getting cancer after having mastectomy because 
they believed it would “save their life.” For example, Lily, a 27-year-old BRCA1 mutation 
carrier who was undecided about having a prophylactic mastectomy but leaning toward having 
the procedure, said that saving her life was her top priority. “I hate ‘Save the TaTas!’ That’s one 
of the things that I really can’t stand. I’m like, ‘No, save me!’ We don’t say that about any other 
cancer. We don’t say, ‘Save the skin!’ or ‘Save the pancreas!’ And I think if I had cancer, I 
wouldn’t be worried about losing my breasts, I’d be worried about my life.” Similar to Megan, 
Lily was explicit about her willingness to remove a part of her body if it meant that she would 
not die prematurely. Tara, whose sister died of breast cancer, also explained that she was much 
more concerned about not dying than she was about keeping her breasts. “At the time my sister 
was dying. There was just nothing that would ever—I mean I can't even imagine saying, ‘Oh, 
you know, I'm not going to do this because I like my boobs or that seems scary.’ Nothing was 
scarier than watching her do that, you know?”  
Many women explicitly noted how learning about their mutation had “saved their life.” 
For example, Alicia, a BRCA1 mutation-carrier, expressed the gratitude she and her mother felt 
toward her doctors.  
My mom always says that my doctors saved my life. I mean, every time, when my mom 
came for my surgeries, she gave my OB/GYN a huge hug. She didn’t have to come, but 
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she came and saw me before my surgeries and visited me in the hospital. You know, my 
mom was like, “You saved my daughter’s life.” I mean, it’s a huge thing, and I hopefully 
am going to see my kids grow up. (Alicia, Age 42, BRCA1) 
Veronica also felt saved by testing and surgery. She had no family history of breast cancer and 
discovered her BRCA1 mutation through a direct-to-consumer ancestry test that had been given 
to her as a gift. “I always joke around that it was the worst gift that anyone ever got, but it was 
also kind of great in a way, because it probably saved my life. You know, my dad is in his 60s, 
and for men, it's not the same type of risk. But for me and my sister, I mean, we would never 
have suspected. And so, knowing that, that stupid little gift probably saved our lives.”  
Like Veronica, Hannah had no family history of breast or ovarian cancer, so her BRCA2 
mutation was also a surprise finding. She was a pre-med student working in an OB-GYN’s office 
where women were frequently tested, and she tested herself on a whim one day because she 
wanted to better understand the process for her patients. When the representative from the testing 
company emailed Hannah the results, she did not know they were for Hannah herself and said, 
“Look, this 23-year-old just saved her life!” Even one of the speakers at a major professional 
conference on cancer genetics repeatedly referred to mastectomy as lifesaving. She was both a 
physician and BRCA mutation-carrier, and she told audience members that by learning their risk-
status and having surgery, “You can save your life or your family’s life.” 
While women often felt that by learning their risk status and having a mastectomy they 
had, as Jill said, “dodged a bullet,” data do not support those feelings. High-risk women who 
have mastectomies reduce their lifetime risk of developing breast cancer to approximately 5%, 
which is a highly significant reduction and even lower than lifetime risk among women in the 
general population, which is 12% (Li et al., 2016; National Cancer Institute, 2018d). However, 
multiple studies have illustrated that prophylactic mastectomy is not associated with a 
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statistically significant reduction in mortality when compared to the typical protocol for high-risk 
breast surveillance (i.e., alternating semi-annual MRIs and mammograms), even for women with 
high-penetrance mutations (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010; Li et al., 
2016). The increase in survival is only significant when compared to no screening (A. W. Kurian 
et al., 2010), and women who have the social and financial capital to access and use genetic 
testing services are very unlikely to do nothing in response to a positive result. If anything, as I 
will highlight later in this chapter, the selection bias among women who get tested for genetic 
mutations is toward individuals who espouse a more interventionist model of care. 
Of course, most patients do not read scientific literature or medical guidelines, which 
helps to explain why many are unaware that mastectomy does not significantly reduce all-cause 
mortality. However, for researchers and health professionals, the data on prophylactic 
mastectomy and survival are hiding in plain sight. The meta-analyses and comprehensive 
reviews that illustrate the lack of a survival benefit from mastectomy are widely cited and are 
referenced multiple times in the NCCN Guidelines. In fact, the subtle language distinctions in the 
guidelines reflect these findings—clinicians are guided to “recommend” risk-reducing salpingo-
oophorectomy (RRSO) because it is associated with a reduction in all-cause mortality among 
women at genetic risk. But the guidelines only suggest providers “discuss” the option of RRM 
with patients because the evidence supporting the procedure is far less robust. Similarly, 
countries that have universal health care systems34 typically encourage and cover RRSO because 
it improves survival, but often limit covered access to mastectomy to only women at the highest 
risk. In contrast, women’s accounts in this study illustrate that US women at BOC genetic risk, 
                                                             
34 The United States stands alone among its peer nations as the only large developed country that does not 
provide some form of universal health care coverage (Fisher, 2012). 
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even those with moderate-penetrance mutations, are usually offered mastectomy and often elect 
to have the procedure.  
Given that prophylactic mastectomy is not significantly associated with reduced mortality 
rates, why is the procedure frequently offered and performed among women at genetic risk in the 
United States? Most health care providers genuinely want to help their patients, and breast health 
specialists bear daily witness to the stress and complications associated with breast cancer 
screenings and treatments. Thus, surgeons might offer mastectomy to patients despite being 
aware that it likely will not extend their lives because it can improve the quality of their lives. As 
I illustrated earlier in this section, many women expressed feeling less stressed and anxious 
about developing cancer after RRM or shared feeling relieved that they would likely avoid toxic 
treatments. However, the potential for improvements in women’s mental health and quality of 
life from mastectomy is not unique to US women, so it does not fully explain how and why the 
procedure is widely offered in the United States. Similarly, both this study and previous research 
illustrate that motherhood and women’s desire to “be there” for their children are among the 
individual-level factors that motivate them to have risk-reducing surgeries. But a strong desire to 
live to see your children grow up is also not limited to women in the United States, and therefore 
“being there for your kids” does not explain why US women disproportionately choose 
mastectomy.  
People’s health care practices and the services they desire are not solely driven by 
scientific data. The recent controversy that ensued in response to the evidence-based changes in 
the USPSTF mammography screening guidelines illustrated the potential for disconnect between 
women’s feelings about breast health practices and scientific evidence. A careful, comprehensive 
review of the scientific evidence of the benefits and risks of mammography had revealed that the 
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potential harms of annual mammography between the ages of 40 and 50 (and of annual rather 
than biannual mammography after age 50), outweighed the potential benefits among women at 
average risk for breast cancer (Gotzsche & Jorgensen, 2013). Yet when the screening 
mammography guidelines were altered to reflect these findings, women across the United States 
were furious that their access to mammography might be delayed and or reduced (Pitman et al., 
2017; Squiers et al., 2011; Witten & Parker, 2018).  
Because health-related beliefs and practices always emerge within and often reinforce 
broader social, economic, and cultural contexts, understanding the high uptake of mastectomy in 
the United States requires an exploration of not just women’s beliefs, but also of the practices 
that shape those beliefs and facilitate certain decisions. In the following section of the chapter, I 
will examine how and why social discourses and the structures and architecture of genetic 
medicine in the United States encourage women to have mastectomy regardless of the 
penetrance of their mutations and despite current data and clinical guidelines that suggest 
otherwise. I will illustrate the financial and social incentives women encounter that encourage 
them to choose RRM and how prophylactic breast surgery is framed as the best medical choice 
for all women with BOC mutations. I argue that the discourses and practices that encourage 
mastectomy are both rooted in and reinforce the medicalization of breast cancer risk.  
Encouraging Mastectomy Regardless of Penetrance 
In the previous section, I illustrated why women at genetic risk, regardless of the 
recommendations in clinical guidelines, often desire mastectomy. However, women in other 
countries also want to avoid chemotherapy, reduce their anxiety about developing cancer, 
increase their longevity, and be alive to see their children grow up, yet their rates of mastectomy 
are much lower. Moreover, whether or not women want prophylactic surgery, without clinicians 
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who recommend and perform surgery and health insurance coverage for the costs, they would be 
unable to have it. Hence, in this section, I shed light on how social norms and discourses in the 
United States and the unique structures and architecture of the health care system encourage 
women, both implicitly and explicitly, to make the “strong” choice to have RRM. 
Incentivizing Mastectomy 
Both the privatized structures and fragmented architecture of the US health care system 
encourage mastectomy and contribute to the relatively high US rates of prophylactic breast 
surgeries among women at genetic risk, regardless of the penetrance of their mutations. In the 
United Kingdom, the National Health Service (NHS) strives to optimize public health 
expenditures because the costs of procedures are distributed across UK citizens. Hence, BOC 
genetic medicine in the United Kingdom limits access to procedures that have minimal evidence 
of a survival benefit or a low benefit-to-risk ratio, such as mastectomy for carriers of moderate-
risk mutations. However, the fragmented, insurance-based, fee-for-service organization of health 
care in the United States serves to maximize profits for corporations and private medical 
practices,35 not to control public or individual patients’ risks or costs. In the US system, there is 
no consistency or transparency in billing charges, negotiated rates, or actual prices for the 
isolated insurance pools or individual patients who shoulder those costs.  
With less public accountability and oversight and more industry control, it is not 
surprising that the privatized, insurance-based US healthcare system provides greater flexibility 
in accessing procedures with limited evidence of medical benefit. While some US doctors and 
clinics adhere to professional society guidelines, they are recommendations, not binding 
                                                             
35 Maximizing profits for private medical practices is sometimes in tension with maximizing profits for 
corporations, particularly insurers. But in both cases, minimizing costs for and impact on patients is not 
the goal or priority. 
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protocols. Therefore, some health professionals might be more tentative in their guidance, 
particularly in a field like medical genetics where the science is changing at an accelerated pace. 
In turn, if patients are persistent and have the resources, they often can, as Jessie did with her 
hysterectomy, find ways to access the services they desire. But in addition, the financial 
structures and fragmented architecture of the US healthcare system sometimes actively 
encourage women to have mastectomy.  
Diagnostic Loophole 
As I illustrated earlier in the chapter, once women get tested and discover they have a 
genetic mutation that places them at elevated risk of developing breast cancer, most genetics 
providers recommend following the NCCN Guidelines. For breast screening in women with 
BRCA mutations, the guidelines indicate that women ages 25-29 should have annual breast MRI 
with contrast and women ages 30-75 should have both annual MRI with contrast and annual 
mammograms, with consideration of tomosynthesis (i.e., 3D mammography) (National 
Comprehensive Cancer Network, 2018b, pp. BRCA-A1). The guidance in the NCCN Guidelines 
for women with moderate risk mutations are similar—for women with PALB2 mutations, they 
eliminate the recommendation for MRI screening between ages 25 and 29, and for women with 
CHEK2 and ATM mutations, they recommend beginning annual mammography and breast MRI 
at age 40 instead of 30 (National Comprehensive Cancer Network, 2018b, pp. GENE-3-4).  
The Affordable Care Act (ACA) requires that all screening tests graded A or B by the 
U.S. Preventative Services Task Force (USPSTF) be covered without patient cost-sharing (i.e., 
without copays, coinsurance, and before any deductibles are met) (Johns & Bayer, 2016). 
However, there is no regulated limit on cost-sharing for diagnostic tests. According to the most 
recent update to the Grade A and B recommendations list, “The USPSTF recommends screening 
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mammography for women, with or without clinical breast examination, every 1 to 2 years for 
women age 40 years and older” (US Preventative Services Task Force, 2018).36 However, 
whether a test is considered and coded for billing purposes as screening or diagnostic depends on 
the circumstances in which it is offered. A test is deemed a screening or preventative service 
when it is performed in an asymptomatic individual; however, that same test would be 
considered a diagnostic test if it is performed in response to a symptom. Hence, mammograms 
are considered screening tests when they are performed as part of routine annual checkups in 
women ages 40 or older, but they are deemed diagnostic when they are performed in response to 
abnormal symptoms in women’s breasts, such as lumps, inflammation, swelling, discharge, or 
pain.  
Women who have not been affected by breast cancer but have genetic mutations that 
place them at higher risk for breast cancer are nearly always asymptomatic when they get their 
recommended annual mammograms or MRIs. If a person does not have breast cancer, they are 
not likely to have physical symptoms of the disease. Given that NCCN Guidelines clearly label 
mammography and breast MRI as “breast screening” and that mutation carriers are typically 
asymptomatic when they seek these tests, one would imagine that these procedures would be 
covered by insurance without cost-sharing. However, one of the findings I was most shocked by 
in this study is that breast cancer surveillance in women at genetic risk falls into what I refer to 
as the “diagnostic loophole”: mammograms for women who know they have pathogenic 
                                                             
36 The Department of Health and Human Services utilizes the 2002 USPSTF guidelines on breast 
screening rather than the revised 2016 final recommendation (US Preventative Services Task Force, 
2018). In the 2016 guidelines, the age range for the B grade was narrowed to women ages 50-74. 
Mammography was issued a C grade for women ages 40-49, and for women age 75 and over the USPSTF 
did not assign a grade because the evidence was insufficient to evaluate the balance of benefits and harms 
(US Preventative Services Task Force, 2016). 
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mutations are no longer deemed screening tests by providers or insurers. Instead, screening 
mammograms for women at genetic risk are always coded as diagnostic for insurance purposes. 
Moreover, MRIs are never considered screening tests, despite the fact that breast MRIs are 
recommended as screening procedures in the NCCN Guidelines. As a result, the women for 
whom breast screening is likely to confer the greatest benefit also face the greatest financial 
barriers in accessing those screenings.  
I first encountered the diagnostic loophole in my conversation with Marci, who was 
among the first women I interviewed. Marci had not yet made decisions about having 
preventative surgeries, and she was conveying her frustration with getting insurance to cover the 
screenings that had been recommended to her. 
The way it’s been explained to me is: anything that’s diagnostic is not covered, but 
preventative is covered. So as long as they bill it like my breast MRI is preventative, 
there’s the potential to get it covered, maybe. But all MRIs are generally considered 
diagnostic—they’re not considered preventative. In my mind, if you can consider a 
mammogram preventative, then you can consider a breast MRI preventative. You know, it 
would be the same theory. But [MRI] is a lot more expensive and the science, you know, 
like all the things now that are covered because they’re mandated to be covered, this level 
of specificity for people that are BRCA2, or BRCA1 even, the insurance companies 
aren’t there yet…. The woman I talked to at the insurance company, she was kind of like, 
“You can try it. They may cover one preventative MRI a year, but it’s a crapshoot. 
(Marci, Age 39, BRCA2) 
I initially thought that Marci’s challenge with getting her MRIs covered was an exception. 
Annual breast MRIs have been part of the recommended high-risk screening protocol since the 
early 2000s, and several studies have shown that breast MRI has, on average, nearly double the 
sensitivity of mammography in BRCA mutation carriers and other women with familial or 
genetic risk. The sensitivity of MRI ranges from 77% - 94%, while the sensitivity of 
mammography ranges from 33% - 59%; however, MRI has only slightly lower specificity than 
mammography, with ranges of 81% - 98% and 92% - 100%, respectively (Kriege et al., 2004; 
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Kuhl et al., 2005; Leach et al., 2005; Passaperuma et al., 2012; Riedl et al., 2007; Warner et al., 
2004). In a recent study evaluating the effectiveness of alternating MRI and mammography 
every six months, MRI detected breast cancers that mammography had missed just six months 
earlier (Le-Petross et al., 2011). Furthermore, the radiation exposure from mammography has 
been shown to increase breast cancer risk in younger women ages 25-29 (Pijpe et al., 2012). 
Hence, I expected most insurance companies’ policies to align with current science and cover the 
safer, more effective screening tool in high-risk women. 
 Marci’s story prompted me to begin researching policies on insurance coverage of breast 
cancer surveillance in high-risk women. Disappointingly, I learned that the fine print of the 
USPSTF breast screening guidelines explicitly specify that they do not apply to women who 
have known genetic mutations: 
These recommendations apply to asymptomatic women aged 40 years or older who do 
not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and 
who are not at high risk for breast cancer because of a known underlying genetic 
mutation (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer 
syndrome) or a history of chest radiation at a young age. (US Preventative Services Task 
Force, 2016) 
Hence, the diagnostic loophole was not a policy oversight; rather, it was designed. In an 
extension of the medicalization of carrying a high-risk mutation, asymptomatic BRCA carriers 
were grouped with women who had already had breast cancer and were purposefully excluded 
from the ACA’s cost-sharing protections for breast screening. Lisa, one of the genetic counselors 
I interviewed, acknowledged this inequity. She explained that clinics have gotten savvy at getting 
genetic testing covered with minimal or no patient out-of-pocket costs, but she noted that 
coverage for surveillance in mutation carriers is more difficult. “The problem lies in their 
management moving forward. We do hit insurance barriers there. A great example of that is MRI. 
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Even if it's covered by a patient's insurance, typically their deductible comes into play. So, they'll 
have to pay $1,500 or $2,000 for that MRI for their screening. So, we do hit insurance barriers 
for that future management.” 
Financial Incentives 
 After speaking with Marci, I began asking all of the women I interviewed about their 
insurance coverage for risk management, and I was stunned at what I uncovered. Only 20 of the 
75 women in this study had their recommended breast screenings covered by insurance without 
hassle and with annual out-of-pocket costs lower than $500. The other 55 women either 
encountered challenges getting their MRIs covered, incurred hundreds or thousands of dollars in 
out-of-pocket costs for MRIs, had sizable out-of-pocket costs for mammograms, or all of the 
above. For example, Diana, a young BRCA1 mutation carrier, told me that her breast screenings 
were not covered by her insurance and she had spent thousands of dollars on her care.  
So that’s been kind of a headache because the insurance company I’m with, they won’t 
cover the majority of it because it’s an individual risk versus a population risk. And 
unfortunately, we have a rather high deductible before it does start kicking in. They pay a 
small percentage of it…the MRI was probably around four grand is my guess, if I 
remember right. Meeting with the Onco-OB-GYN was probably over $100…the 
insurance wouldn’t cover the mammogram because it was labeled as diagnostic and not 
preventative, which is unfortunate. But that was probably a couple hundred dollars. I 
talked to both the insurance company and the clinic about changing the [billing] code, 
and neither one would budge and just said that’s how it has to be. So that was a bit 
frustrating. And then ultrasound was a couple hundred too. Whether it was $300 or $600 I 
don’t remember. But I know we’ve spent a couple thousand, I mean obviously with the 
mammogram, but I feel like everything together, we probably spent between $6,000 and 
$8,000. (Diana, Age 26, BRCA1) 
Similarly, Eleanor shared her surprise at receiving a bill for the MRI that had been recommended 
to her and relayed the conversation that ensued with her insurance company.  
We were told that it was indicated that with the elevated risk with the ATM gene I needed 
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to do an MRI once a year, a mammogram once a year, and that they needed to be spaced 
every six months. So, I went and had the MRI done. I got the bill, and I called the 
insurance company and explained the situation and said, “This is the recommended 
follow-up for this finding, why isn't the MRI covered?” She disappeared and came back 
and said, “Unfortunately it will never be covered because MRIs are something we don't 
categorize as required care.” I don't remember how she phrased it. It's something that's 
ordered as part of a diagnosis, and not part of prevention? So, she said they wouldn't 
cover the MRI. The bill on the MRI was like $10,000, and the insurance adjustment 
brought it down to like $1,800 which is much more manageable, but still that's a known 
cost that we'll have every year if we don't do a mastectomy. (Eleanor, Age 42, ATM) 
Stories like Diana’s and Eleanor’s kept emerging, with most women citing costs of at least $1000 
for their screenings in addition to their insurance premiums, which were also often high. Women 
like Eleanor who had “only” one to two thousand dollars in annual out-of-pocket costs often 
characterized their situations as “lucky” or said they felt “blessed” to have “good insurance.” 
They had heard stories from women like Diana and the 21 other women I interviewed who had 
exorbitant out-of-pocket costs ranging from $5,000 - $12,000. 
 Veronica, who was a leader of a local support group for women at BOC genetic risk, was 
furious about the diagnostic loophole. However, she was not angry because of her personal 
expenses; rather, she noted the injustice and potential for these charges to keep women with less 
privilege and fewer financial resources than her from seeking care.  
One thing that enraged me was that they charged me for mammograms—I had to pay co-
insurance, and it was like $150 or something. And you know, for us, that's not a problem 
to pay $150. But mammograms for screening purposes are under Obamacare supposed to 
be free. And because we're BRCA positive, this is considered a diagnostic mammogram, 
so it is not covered 100%. And so, I said to the person on the phone, "So what you're 
telling me is a woman who is at completely normal risk goes in for a mammogram and 
gets it for free. But we're at extremely high risk and these mammograms could save our 
lives and we, I have to pay $150?” And they're like, "Yes." And I'm like, "Do you see 
how that makes no sense?" And she was like, "Yes, but it's just how it is. We didn't write 
the law." I was like, "Okay. This is stupid and it's going to prevent people from getting 
screening, because there are women who are single mothers or who are, you know, who 
are not high income, and they will not be able to afford it and so they just won't get it 
done. And this is, I’m sorry, this is bullshit. (Veronica, Age 32, BRCA1) 
 
140 
Veronica’s concern that women might avoid recommended screenings or care because of these 
costs is likely accurate. Studies of health care use in the general population have shown that 
higher copays, deductibles, and out-of-pocket costs lead people to delay or avoid care (Ku, 
Deschamps, & Hilman, 2004; Taber, Leyva, & Persoskie, 2014). Likewise, several women in this 
study shared that they were considering skipping their recommended screenings because of the 
cost. For example, given how expensive Diana’s MRI was, she said, “I honestly don’t know if I 
would do it every year or if I would do every other year.” Similarly, Riki, a CHEK2 mutation 
carrier, said, “I think that if my first mammogram comes back clean as a whistle and my first 
MRI comes back clean as a whistle, I may do more due diligence to see if I want to do it every 
six months. You know what I mean? I don’t think that anything is set in stone. I understand that 
is their recommendation, but I also have to live my life and be aware of the costs associated.”  
 In addition to encouraging women to sometimes skip critical breast screenings because of 
their high annual out-of-pocket costs, the insurance loophole also generates financial incentives 
for women to have risk-reducing surgery. All of the 52 women in this study who had or were 
planning mastectomy had their breast surgeries covered or approved by insurance. While some 
of those surgeries also involved high out-of-pocket costs because of large deductibles, co-pays, 
or co-insurance, surgery is a one-time expense. In contrast, the diagnostic loophole leaves many 
women who choose surveillance with annually recurring uncovered expenses or extremely high 
out-of-pocket costs for their MRIs and mammograms. When compared to the repeated costs of 
MRIs and mammograms, surgery is often the more affordable option. Several women I 
interviewed noted that the recurring cost of screenings was one of the factors that shaped their 
decision to have surgery. For example, Scarlett, who has a CHEK2 mutation, shared her reaction 
to learning the risk management options from her doctor:  
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He said I could do MRIs once a year, mammogram once a year, and do one every six 
months. And they also wanted me to take Tamoxifen. I was not crazy about the 
Tamoxifen idea. And the MRI idea was kind of strong for me because of my $2,000 
deductible. Because I knew an MRI was probably $1,000 or more. So that was really kind 
of a, like, “Oh no! You know, I just don't know what should I do?” Anyway, my oldest 
daughter is a nurse practitioner and she was with me that day. And she said, "Momma, 
you're probably gonna meet your deductible with this MRI." She said, "You know, I just 
think that you ought to just do the prophylactic mastectomy. That way you won't have to 
take the Tamoxifen, too. And hopefully, you know, you'll be done with this." And I pretty 
much agreed with her. (Scarlett, Age 61, CHEK2) 
High out-of-pocket costs for MRIs were a concern for Scarlett, and coupled with her desire to 
avoid taking Tamoxifen, they contributed to her decision to have mastectomy. Her experience 
reveals that in addition to costing women thousands of dollars and encouraging them to skip 
needed screenings, another grave consequence of the diagnostic loophole is that it incentivizes 
risk-reducing surgery.  
Social Incentives 
Women’s and clinicians’ stories revealed not only financial incentives for women to have 
mastectomy, but also social incentives and encouragement. Media coverage of BOC genetic risk 
and cancer risk advocacy and support networks often praise women who have mastectomy, 
portraying the procedure as a brave and empowered choice. For example, Angelina Jolie stated in 
her Op-Ed: 
[T]here are many women who do not know that they might be living under the shadow of 
cancer. It is my hope that they, too, will be able to get gene tested, and that if they have a 
high risk they, too, will know that they have strong options. Life comes with many 
challenges. The ones that should not scare us are the ones we can take on and take control 
of. (Jolie, 2013) 
Nowhere in Jolie’s Op-Ed does she mention breast screening procedures such as MRIs and 
mammograms. Hence, the “strong options” that she refers to that enable women to “take control” 
of their genetic risk for breast and ovarian cancer are the surgical ones she chose: mastectomy 
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and reconstruction. Because of her celebrity, Jolie’s decisions about and perspectives on 
managing BOC genetic risk through prophylactic breast surgery were magnified by other media 
outlets and contributed to the positive framing of mastectomy and breast reconstruction as the 
brave and empowered choices for women.  
 Several of the health care providers I interviewed noted the impact of Jolie’s first op-ed 
on women’s interest in both genetic testing and prophylactic mastectomy. Alyssa, a genetic 
counselor, noticed a sharp increase in the number of patients seeking testing at her clinic 
immediately after the article was published. “[D]emand was extremely high, especially after 
Angelina Jolie published her Op-Ed in The New York Times. Our referral volume tripled that 
week. And I don't think it ever went back down.” Laura, a clinical geneticist, shared how Jolie’s 
2013 Op-Ed and other celebrity publicity of BRCA mutations had a positive impact on the field 
and public awareness of genetic risk for cancer.  
Angelina Jolie brought this, although others had before, Christina Applegate being 
another one. But I think some of the celebrities bringing this into the limelight actually 
help to increase awareness. People started thinking through this, trying to put themselves 
in the situation: “What would I do? Do I want this testing?” So, the learning curve, the 
health literacy or the genomic literacy for hereditary cancer testing, it's like the whole 
community took a leap up within that six months after Angelina Jolie wrote her Op-Ed 
piece. And I think that was good for the public. (Laura, Geneticist) 
Several studies have examined this potential “Angelina Jolie Effect” and have found that there 
were spikes in internet searches on genetic risk and requests for genetic testing and RRM 
following the publication of her Op-Ed (Bhatti & Redelmeier, 2015; Borzekowski et al., 2014; 
Desai & Jena, 2016; D. G. Evans et al., 2015; Noar et al., 2014). 
 However, while some clinicians and patients appreciated the awareness Jolie brought to 
BOC mutations and managing cancer genetic risk, others were concerned that it may have 
encouraged more women to have mastectomies and to perceive that decision as the best or right 
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choice. For example, Linda, who has been a cancer genetic counselor since the field’s inception 
in the 1990s, stated, “Sometimes people come in and think, especially with the Angelina Jolie, 
that if I have this [mutation], that means I'm having a mastectomy.” Steve, an oncologist who 
works with individuals at genetic risk for cancer, also mentioned Jolie and the impact of 
“celebrity culture” on uptake of mastectomy in the United States. But in addition, he discussed 
how celebrity influence is embedded in and predated by a broader set of “social network 
pressures” in the United States to have prophylactic breast surgery.  
The biggest social network pressures surround prophylactic mastectomy. I mean, I think 
that’s where it all comes from. And interestingly—I mean, social network pressures are 
different in different places. In Israel the social network pressures oppose prophylactic 
mastectomy, right? Like, “Why would you do that?” And not only from the religious 
authorities—I mean, certainly within the religious authorities, but also within the secular 
communities there, there is significant pressure. Whereas here, people blame Angelina 
Jolie, or point to Angelina Jolie, and I think she had something to do with it, kind of 
celebrity culture. But this was going on way before she came on the scene. And I think 
that what happens is—and I say this from conversations I have with women in my 
surveillance clinic—is that they go to certain support networks which are, dominated is 
too strong a word, but heavily populated by people who have already made a decision to 
have prophylactic surgery, and feel quite strongly that that was the right one. (Steve, 
Oncologist)  
 Steve importantly highlighted cross-national differences in attitudes toward mastectomy, 
clarifying how social encouragement to have prophylactic breast surgery is particularly strong in 
the United States. Yet I encountered few instances or stories of direct or explicit “pressure” on 
women to have RRM from other women with BOC mutations. Most women with mutations 
exhibited respect for the complex and deeply personal nature of other women’s surgical decisions 
and refrained from passing judgement on their choices. However, many participants shared 
positive feedback they had received from clinicians, family members, friends, and other 
previvors on their choice to have surgery. I came to understand this positive reinforcement of 
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mastectomy not as social pressure, but rather as a social incentive or encouragement to have 
surgery. Especially when coupled with the lack of support for the decision to continue with 
breast surveillance, which is an ongoing rather than acute stressful process, the affirmations 
surrounding mastectomy position it as the socially desirable option for breast cancer risk 
management.  
For example, several of the women I interviewed shared that they had clinicians, family 
members, and friends who described their decision to have surgery as courageous. Nina, who 
eventually opted for surveillance over mastectomy, recalled her interaction with her genetic 
counselor after learning about her BRCA1 mutation. “Originally when I met with the genetic 
counselor, I had said, ‘I’m gonna do a double mastectomy immediately, no questions about it.’ 
And then she was like, ‘You’re so brave! That’s so wonderful.’” Raina, who has a BRCA2 
mutation, explained that she received positive reactions from family and friends when she chose 
surgery. “I got a lot of encouragement of, ‘Good for you! You’re doing something proactive, and 
it takes courage.’ And I got a lot of pat-on-the-backs from family and friends that I was doing the 
right thing, which was nice at the time.” Veronica shared how a family member’s perspective that 
mastectomy was courageous shifted her own perception of her decision: 
My husband's aunt told me the other day when we were together, she said, "You know, I 
don't think I ever told you this but — when you got your surgery, but I think what you did 
was so brave." And she was like, "I don't know if I could have made the same decision." 
And it made me think, 'cause it didn't feel brave. I felt terrified. Like “Oh my gosh, I got 
this false positive [on a screening test], I don't want that to happen again. I'm doing this 
because I'm petrified.” But I started to think more and more, like, maybe she's right! And 
you know, now I kind of like to own that description. Like I, you know, I did something 
brave. I did something courageous. I did something empowering. And it feels good to 
know that sort of when the chips were down, I did something that was brave. (Veronica, 
Age 32, BRCA1) 
While Veronica was motivated to have surgery because of the anxiety she experienced after 
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receiving a false-positive breast-imaging result, her aunt viewing her decision to have surgery as 
brave helped her reframe her choices and instead view them as empowering. 
 The associations of mastectomy with bravery, strength, and empowerment are also 
underscored by the debate within Hereditary Breast and Ovarian Cancer (HBOC) communities 
over whether women can claim the identity of being a “previvor" if they have not completed 
their prophylactic surgeries. Joan, who learned about her BRCA2 mutation in her mid-twenties 
and has been active in online and in-person BRCA support communities for over a decade, 
explained:  
There's always a lot of discussion on there, because when people have a surgery, they're 
like, "Now I'm a previvor!" You know, and then people will be like, "Well... you can be a 
previvor and choose surveillance.” There's always kind of that back and forth about it…. 
I don't know that I identify myself as a previvor, but I do think about that word when I 
think about having the second surgery and kind of being done with that stuff. I do think 
about like, “Hey, will that make me a previvor?” (Joan, Age 34, BRCA2) 
Similarly, Veronica, who is also in her thirties and has a BRCA2 mutation, stated, “Some people 
feel like they don't wanna call themselves that until they have had prophylactic surgery and been 
cleared. So, I have my ovaries out. I had a mastectomy, and now I am a previvor, because now I 
have eliminated my risk to the extent possible. It's not like a hostile conflict, but it's something 
that people really wrestle over, and I think there's a layer of superstition, honestly, over calling 
yourself a previvor when you still have a risk for cancer.” Hence, while there is disagreement 
among women at genetic risk about what constitutes previvorship, for some women, becoming a 
previvor and fully belonging in previvor communities requires making the “strong” choice to 
have prophylactic surgery.  
 The widespread social validation of the decision to have mastectomy stands in sharp 
contrast to the lack of support resources for women choosing surveillance. As I highlighted 
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earlier in the chapter, women often experience stress and anxiety around their semi-annual breast 
screenings. Yet in over three years of fieldwork at patient advocacy conferences, there were only 
two sessions offered on the topic of “breast cancer surveillance” and none on managing 
scanxiety or other issues unique to the decision not to have prophylactic surgery. In contrast, 
these same conferences offered a total of 19 sessions, ranging from five to seven annually, on 
issues related to prophylactic mastectomy and/or breast reconstruction. These sessions on 
surgery covered both medical issues and the social and emotional dimensions of the procedures.  
 Lily explicitly mentioned the lack of social support for breast surveillance. She is a 
BRCA1 mutation carrier in her mid-twenties, and she was leaning toward having mastectomy in 
part because she felt that there was not adequate social support for the stress of ongoing 
screening. She expressed that her family, friends, and other women provided her with support 
and empathy when she first discovered her mutation, but not subsequently when she had her 
regular surveillance appointments. “There's, like, no support for that with the screening. There is 
support in the beginning, and then it’s, “Okay, well, now that you know you have this, you know 
what you really should do.” As I will illustrate later in the chapter, what women often felt they 
“should” do was have prophylactic surgery to reduce their risk.  
 Similarly, in online communities for women at BOC genetic risk, mastectomy and 
reconstruction are frequent topics, but there are far fewer discussions about choosing not to have 
surgery. In fact, Nina organized a separate group on social media for women choosing 
surveillance because she received very little support, and even some open criticism, when she 
shared her decision to continue with screenings but avoid RRM. The group Nina formed now has 
several hundred members, and it provides the women who find it some of that much needed 
social support for choosing breast screenings. However, the fact that she and other previvors felt 
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they needed a separate space to safely discuss choosing long-term surveillance, while 
information and support for prophylactic mastectomy are frequent topics in online HBOC 
communities, further illustrates how mastectomy is constructed as the socially normative and 
desirable choice. Hence, much like the diagnostic loophole creates financial incentives to have 
surgery, these stories from women and providers reveal that validation and praise for the decision 
to have mastectomy combined with the lack of support for surveillance generates social 
incentives to have surgery. Together, these financial and social incentives normalize and 
encourage RRM while constructing surveillance as the alternative choice over the long-term.  
Making the Wrong Choices? 
 Of course, one of the central goals of advocacy groups and social networks focused on 
BOC genetic risk is to provide a safe space in which women can share their personal 
experiences, whether those experiences are positive or negative. As I illustrated earlier in the 
chapter, most women felt relieved after their breast surgeries because the procedures reduced 
their anxiety about being at risk. In addition, some women described feeling even stronger and 
better than before they discovered their mutation. For example, Veronica described how having 
surgery helped her move from feeling powerless to powerful: 
When I first got diagnosed or tested positive, I felt like I had no control over my life. 
Like, this had been determined from conception. From the moment I was conceived, I 
was mutated. [LAUGH] Just, you know, I felt like I had no control. And now I feel like I 
have more control than ever, in that I feel like I in some ways have more control than 
people in the general population, because I took this step to reduce my risk, and now the 
risk is so low…. There’s always gonna be some kind of risk out there, but I am personally 
doing everything that I can, and it feels very empowering. (Veronica, Age 32, BRCA1) 
When women like Veronica share their positive feelings and successful outcomes with their 
“tribe,” they do so with the best of intentions. Much like Angelina Jolie expressed in her op-ed, 
they want other women with mutations to feel supported, to be aware of their options, and to 
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know that they can and will get through this experience. Tara, a BRCA2 mutation carrier who 
had served several times as a peer support person for other women at genetic risk, explained 
what she hoped to convey: “Just helping them understand that it's not a scary process and it can 
be really easy and it can be quick and it doesn't have to be painful. And you can live a normal life 
when you're done.”  
 However, the social discourses that frame mastectomy as the strong and empowered 
choice, which are rooted in positive intentions, can also contribute to the demands of genetic 
responsibility (Clarke et al., 2003; Lupton, 1995; Rose, 2007) and, in turn, the marginalization of 
women who choose not to have prophylactic breast surgery. For example, Lily felt that the 
support groups she participated in were hyper-focused on surgery and described an underlying 
sentiment that “you’re not brave if you don’t do it”: 
There is definitely pressure, almost peer pressure from the BRCA community that that's 
what you have to do or you're not brave…. Nobody has ever point blank been like, "I 
don't think you are brave." But even the magazines, you know, now it's sort of like a 
trendy subject to bring up every October. And so, they will have a spread. Glamour 
Magazine will say, "I was in my 20s and I had my breasts removed." That will be the 
byline. And I'm like, “Okay. But that's because that's more interesting than ‘I just go to 
the doctor every six months.’” So, there's no one actually being like, "You should do this 
now!” but just the general sense of “Are you finally gonna have the surgery?” I mean, 
people act as if themselves, they are not brave. And the groups that I went to, the few 
meetings, it was just like psyching themselves up to have a surgery. That was all, it felt 
like that was the goal. Like, "If I could just have the surgery, then all my problems will be 
solved.” (Lily, Age 27, BRCA1)  
Even in the absence of direct or explicit pressure to have RRM, Lily’s experiences highlight how 
the discourses that describe surgery as the interesting, brave, or strong decision can indirectly 
position surveillance as the boring, timid, or weak one.  
 The social norms and incentives surrounding mastectomy also made some women feel 
that if they did not do “everything possible” to reduce their risk that they would be to blame if 
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they eventually did develop cancer. For example, Nora discovered her BRCA2 mutation after her 
sister was diagnosed with breast cancer at age 35 and tested positive. She said, “Everyone in my 
family was like, ‘Do it, do it, do it!’” regarding surgery, and she explained that she would feel at 
fault if she chose not have RRM and then developed cancer.  
I would feel guilty. I would feel major, major guilt if I didn't have the surgery and I was 
diagnosed with breast cancer and I had to call my sister and say, "I didn't listen to you and 
now I have it." And I'm her little sister. We all protect each other—especially sisters, we 
protect them—and we're super, super close, and it would break her heart. And then to 
know that I have to tell my children, "Mommy has breast cancer," when I could have 
prevented it. (Nora, Age 32, BRCA2) 
Nora’s feelings are a salient example of feelings of genetic obligation (d'Agincourt-Canning, 
2001; Dagan & Goldblatt, 2009; Nina Hallowell, 1999; N. Hallowell et al., 2006; Hamilton et al., 
2009)—she felt she should have surgery to protect her sister and her children. Steve, the 
oncologist who works with people at genetic risk for cancer, discussed how messages that often 
circulate within women’s social networks were contributing to his patients’ feelings of obligation 
and guilt and, in turn, their decisions to have mastectomy.  
And so, it’s not exactly a shaming effect, but sometimes it is a shaming effect. Sometimes 
it’s a, “Don’t you want to be there for your children?” And then people come and tell me 
that they’ve heard that, both in support groups, Facebook groups, and from family 
members. So, I don’t mean necessarily social network just on Facebook, I mean it being 
social networks in the broadest context. And so, they feel this incredible sense of, 
sometimes, guilt. “Gee, of course I want to be there for my children, you know?” And 
those are not unreasonable points of view. I understand those points of view, I think they 
are legitimate points of view. I just think sometimes it is very, very difficult for people to 
push back against them when they are expressed that way. (Steve, Oncologist) 
Steve emphasized that he did not feel that choosing to have mastectomy to “be there for your 
kids” was “wrong.” Rather, he was concerned about how such social messages might leave 
women feeling like surgery was the only “right” choice among their options. 
 
150 
 Several women I interviewed who had chosen long-term surveillance did feel 
mastectomy was often presented as the “right” choice. This framing of RRM is relatively recent; 
in the initial years following the discovery of the BRCA genes, mastectomy was often labeled a 
“drastic” measure. Yet as BRCA-positive status has become increasingly medicalized in the new 
era of multi-gene panel testing, prophylactic breast surgery has become the normative choice. 
Overall, it was uncommon for women in this study to share experiences that reflected explicit 
judgement from others about their decisions. However, when women did discuss feeling judged, 
it was nearly always about pursuing surveillance rather than surgery. For example, Anna 
described how other women in Facebook groups criticized her when she shared her decision to 
do long-term screening with new group members:  
Whenever I tried to throw an alternate viewpoint out there for surveillance—people 
would ask, “Hey I just got diagnosed, what are you doing?” And I would answer, “Here’s 
what I’ve been doing, I’ve been doing it for six years.”—I would get attacked. “Why are 
you doing that? Why are you advising people to do that? That’s a ticking time bomb! Oh 
my god, why would you even put yourself through that?” And it got to the point where I 
just closed those loops. I don’t look at them anymore, I don’t comment, I don’t respond, 
anything like that. (Anna, Age 37, BRCA1) 
Nina, who like Anna has a BRCA1 mutation, also felt judged in online groups for her decision to 
avoid prophylactic breast surgery. In fact, she became an advocate for surveillance and started a 
surveillance-only Facebook group for women with BRCA mutations as a result of her 
experiences. She explained, “One day I was like, ‘Hey you know, I’m not doing any 
mastectomies, I’m doing surveillance,’ and the response I got was, ‘That’s your death sentence!’ 
and ‘Fuck, you’re stupid!’ And I got like, you know, people private messaging me hate mail. So, 
I left the group, and I was not going back.”  
 A few women in this study exhibited the type of criticism that Nina and Anna both 
experienced. These women had opted for surgery and felt bewildered by other women at genetic 
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risk who had chosen to avoid BPM or CPM. For example, Scarlett mentioned women in her 
CHEK2 support group who had been diagnosed with cancer and opted for breast conserving 
surgery. She referred to their decisions as “the craziest thing I've ever heard”:  
You've got the CHEK2 gene and you're going to have a lumpectomy and radiation? 
Knowing that your recurrence rate is probably high, why would you do that? Why 
wouldn't you just go on and have the prophylactic mastectomy and get as much breast 
tissue taken off and reduce your risk down to, you know, five percent? That kind of stuff 
just really blows my mind…To me I'm thinking they're just set up for disaster, you know? 
(Scarlett, Age 61, CHEK2) 
Similarly, Tara, whose sister died from breast cancer, was openly frustrated with women who 
chose not to have preventative surgery. “It's like, ‘You have a choice!’ My sister didn't have a 
choice. She just died. You know? I get angry about that. You have a choice to get new boobs and 
not have to think about this every six months 'cause you have to go in for an MRI or a 
mammogram. Why wouldn't you do that? I can't understand.” Hence, in contrast to the initial 
years following the discovery of the BRCA genes when women felt criticized for considering the 
“drastic” measure of mastectomy, Lily’s, Anna’s, Nina’s, Tara’s, and Scarlett’s experiences 
illustrate that when judgement occurs, it is now more often directed at the decision not to have 
surgery. As Marci clearly summarized, when surgery is constructed as the best and normative 
choice, “deciding not to do anything beyond just active monitoring is a challenge.”  
Framing Mastectomy as the Best Medical Choice 
 A central tenet of genetic counseling that has infused the broader field of genetic 
medicine is that providers should be non-directive with patients (Rapp, 2000; A. M. Stern, 2012). 
Counselors and clinicians with extensive training in genetics often see their roles as guides or 
“shepherds” (Rose, 2007) who provide patients with the best information available so that those 
patients can then make complex, personal decisions that are best for the unique context of their 
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lives. For example, when Steve discussed the pressures his patients experienced in their social 
networks to have mastectomy, particularly the emphasis on “being there for your kids,” he 
contrasted those messages with clinical approaches to discussing options for risk reduction. “In 
medicine we wouldn’t say that. I mean, it’s a little too directive, right? But social networks don’t 
have those historical constraints against directive counseling.” However, I found that while many 
clinicians avoided being explicitly directive, the discourses and practices of genetic medicine 
encourage mastectomy by framing it as the best medical choice. 
 All of the women in this study indicated that their health care providers had appropriately 
recommended enhanced breast surveillance options with them. Yet their stories revealed that 
MRIs and mammograms were often presented as “bridge” procedures—tools they could use to 
monitor their bodies until they were ready to have mastectomy. Women described implicit and 
explicit assumptions amongst both doctors and their peers that at some point they would have 
prophylactic breast surgery. As Marci, a BRCA2 mutation carrier who was still undecided about 
mastectomy, stated about the procedure. “I mean, the sense I get is that with breast it’s like 
eventually you’ll want to do it…. it’s the when you’re going to have it, not if you’re going to 
have it.”  
Right Choice for BRCA mutations 
Marci’s impression of people’s fatalistic attitudes toward prophylactic breast surgery 
mirrors the experiences of other women with BRCA mutations. Many of the BRCA-positive 
women in this study shared stories of doctors and genetic counselors who had indicated that 
mastectomy was the clear recommended option for medically managing their increased risk. For 
example, Veronica, who has a BRCA1 mutation, stated that her doctors had told her surgery was 
“the right thing to do” from a clinical standpoint. “They said, you know, ‘This is the right 
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decision medically.’ Not that it ends up being the right decision emotionally for every person, but 
medically, they were very clear: ‘This is where the road leads to.’” Anita, a young BRCA2 
mutation carrier with a newborn who was planning on having mastectomy once she was done 
having children, explained that her breast surgeon was not neutral when she reviewed risk-
management options with Anita. “I would almost say that maybe she was—it was kind of clear 
that her opinion was definitely very pro-PBM [prophylactic bilateral mastectomy].” While Anita 
was “of that opinion as well” and therefore did not personally find her doctor’s position 
problematic, other patients might desire a less directive consultation. Tara’s doctors conveyed 
that mastectomy was the best choice for managing her BRCA2 mutation by noting that they 
would recommend surgery to their family members. She recalled: “I remember asking the breast 
surgeon ‘If you were me, what would you do?’ And I think this is why I picked them. They were 
both like, ‘I would do exactly what you're doing.’ And the plastic surgeon said the same thing. 
He said, ‘If you were my wife…’” 
 Several of the women who had BRCA mutations but had elected not to have mastectomy 
described encounters with health care providers who initiated unprompted conversations about 
prophylactic mastectomy with them that were dismissive of their preferences to avoid surgery. 
For example, Marci recalled an interaction she had with her sister’s oncologist, who knew Marci 
was BRCA2-positive. “My sister’s cancer doctor turned to me during one of my sister’s visits 
and said, “When are you having your breasts removed?” or something to that effect. And I said, 
“Well, you know, I want to have kids. I want to breastfeed.” She was like, “Oh, you don’t need 
your breasts to have kids. You should just do it now.” Rather than respecting Marci’s expressed 
feelings about avoiding surgery until she was done breastfeeding, this oncologist told Marci what 
she “should” do without any request from Marci for that advice. 
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 Brenda and Dorothy also encountered doctors who advised or encouraged them to have 
mastectomy long after they had initially learned about their BRCA mutations and without them 
asking for new guidance or information. Brenda is a BRCA1 mutation carrier who was planning 
RRSO when we spoke but was not interested in RRM, in part because she only has a family 
history of ovarian cancer, not breast cancer. She described how she has had mixed responses 
from clinicians about her decision not to have prophylactic breast surgery.  
I did meet with people who were like, “You should get a preventative double mastectomy 
– why are you waiting?” I’ve also had providers who were like, “If you do get your 
ovaries removed, that will give you a protected factor for the breast cancer as well” …. It 
is varied. I haven’t found a doctor who has pushed it in a way where it seems like they 
are focusing on it too much. But I have had people who have been very blasé about, 
“Yeah, you should just get a double mastectomy preventatively” type of thing. I feel like I 
have had some odd experiences with providers recommending that without any other 
contextual information or discussion. (Brenda, Age 39, BRCA1) 
While Brenda did not feel explicitly pushed to have a mastectomy, she faced providers who 
communicated that it was what she “should” do without engaging in a discussion with her about 
what her preferences and desires were.  
 Similarly, Dorothy is a BRCA2 mutation carrier who had her ovaries removed but was 
also not interested in having mastectomy. She described a recent interaction with her new breast 
surgeon who was monitoring her semi-annual screenings: 
The doctor that sees me, after I have my MRI, after I have my mammogram, the doctor 
that does my physical breast exam, is a surgeon. And the new one that they have assigned 
to me is very nice, but she is young. Have you ever heard the old saying: Everything 
looks like a nail if you’re a hammer? She talked so quickly on our very first meeting 
about mastectomy. And this was last year in the spring, and it was the last thing on my 
mind. I continue to have good test results, and I was surprised by it. It’s not that she was 
recommending it. She was saying, “I want you to know that that is an option for you, and 
your insurance company must pay for it. And they also must pay for the reconstruction. 
We can be really strong in that if we want to.” It was just an odd conversation. I didn’t 
ask for information on mastectomy at that time. I was just getting my results, and so it 
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was a surprise. (Dorothy, Age 53, BRCA2) 
At the time of Dorothy’s interaction with her new doctor, she had already had an oophorectomy 
and five years of MRIs and mammograms showed no suspicious findings. So, this was neither an 
initial conversation in which a physician was laying out Dorothy’s options for her, nor was it in 
response to what her screenings showed. Instead, the surgeon brought up mastectomy without 
any prompting and without asking Dorothy about her preferences. 
Safest Choice for MRMs 
Clinician recommendations to have mastectomy were not limited to women with high-
risk BRCA mutations. As I noted earlier in the chapter, Dana was the only woman out of the 75 
patient-participants in this study who was never offered prophylactic breast surgery by a 
provider, and over half of the women I interviewed had either moderate risk mutations or VUSs. 
Dana was 72 when she discovered her CHEK2 mutation, and she had never had cancer but was 
tested after her brother discovered he was CHEK2-positive. She explained that her provider 
explicitly told her mastectomy was not recommended: “The woman who had done the initial 
testing on me, the first thing she said to me after she gave me the results, she said, ‘We do not 
recommend bilateral mastectomy.’ She said with my condition, ‘We do not recommend a 
prophylactic bilateral mastectomy for your case.’” Notably, Dana was one of only two women in 
the study above the age of 70; over two-thirds of the participants were younger than age 50. 
Given that after age 75, even the benefits of breast screenings are not supported by evidence, her 
age was likely a factor in her genetic counselor’s recommendation against surgery.  
 Like Dana, some women with MRMs or VUSs initially saw health care providers who 
informed them that mastectomy was not recommended. But Dana’s provider was unequivocal 
when she stated that RRM was not indicated in her case. Other women’s doctors noted that 
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mastectomy was not an evidence-based practice for their mutations, but also communicated to 
women that they ultimately could choose whether or not to have surgery. For example, Janet 
shared that her provider recommended avoiding mastectomy in her case but would not 
discourage her from choosing it, either.  
So, she was pretty honest in saying that she had not come across too many patients with 
CHEK2, and that the last patient she’d had decided to move forward with the 
mastectomy. There was guidance, but there was no strong recommendation to do a 
mastectomy. She and I had already talked, and she calls herself a "breast conservationist.” 
She's—if at all possible, she wants to conserve, you know, the breast….What I 
appreciated her saying in the process was that, you know, yes, there was limited 
information and that she wouldn't necessarily make any changes to her recommendations, 
but, if based on what I could find out or had found out, if I wanted to change my mind 
and move forward with the mastectomy or bilateral that she wouldn't necessarily 
discourage me from that. (Janet, Age 44, CHEK2) 
Similarly, Scarlett, who also has a CHEK2 mutation, met with a surgeon who emphasized that 
surgery was her choice and shared what his previous patients had decided. She recalled their 
conversation: “I said, ‘What about other women that have had this gene, what did they do?’ And 
he looked at his nurse and he said, ‘Well, I think I've had four in the last year, and all four of 
them had the prophylactic mastectomy.’ And I was like, ‘Wow! I'm not going to be the guinea 
pig!’” Mindy, a nurse who has a CHEK2 mutation, encountered wavering, unclear advice from 
her surgeon, a trusted colleague who conveyed that the decision was Mindy’s to make.  
It made it a very complex decision for any health care professional to give me good 
information. They could tell me I'm at increased risk for a second breast cancer, meaning 
not a reoccurrence of the current one, but a completely separate cancer. You're at risk for 
quite a large percentage. It's not as high as BRCA, but it's enough that insurance would 
absolutely cover prophylactic mastectomy on the other side and reconstruction. I guess it 
just made it really hard for me to know how much risk was I willing to live with? The 
surgeon that took care of me is somebody that I've worked with for many years, and he's 
a close work colleague and I really trust him. He could not tell me what the right thing to 
do was. He could tell me that if I never want to think about it again, the best way to go 
was prophylactic mastectomies. (Mindy, Age 59, CHEK2) 
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While Mindy noted that her surgeon did not explicitly tell her surgery was the “right” thing to 
do, he indicated that RRM would be most effective at alleviating worry and easing her mind. 
Hence, his guidance ultimately leaned in the direction of having prophylactic breast surgery.  
 Similar to Mindy, Deena had a provider who presented options to her under the guise of 
being non-directive while still communicating that surgery was, in his opinion, the best choice. 
Deena learned that she had a CHEK2 variant—one with conflicting interpretations—and a VUS 
on the MUTYH gene after being diagnosed with Stage 1 thyroid and colon cancer at age 42. 
Both the genetic counselor and the clinician she initially saw encouraged her to have additional 
breast screenings, but not breast surgery. Yet the genetic counselor also referred her to an 
oncologist who specialized in breast cancer, and the oncologist advised her to have mastectomy 
despite it not being a recommended practice.  
They recommended the MRIs and all that stuff. And then I went to another doctor and she 
kind of said, “Oh, I wouldn't go having anything removed, but let's send you to an 
oncologist. Let's see what he recommends” …. So, she directed me towards an 
oncologist and he basically, very nicely said, “I can't tell you what to do, but I'll be honest 
with you, if I were you, I'd just want them removed after already having two cancers. I 
know the recommendation is to watch, but I would rather have them removed, too.” And 
then he said, “You take one doctor off the plate.” Because they were suggesting MRIs 
and all that every six—what is it, like every six months? And then a mammogram every 
six months. Or I could go on, is it Tamoxifen? Tamoxifen or something like that, that they 
said I could go on for five years. But he said, “Then you're risking uterine cancer, and 
you're having me as a doctor.” He said, “If I were you, I'd have them removed and you 
would eliminate a doctor.” So, I went ahead and I had the double mastectomy. (Deena, 
Age 45, VUSs on CHEK2 and MUTYH) 
While Deena’s oncologist expressed that he could not “tell [her] what to do,” he then 
immediately followed that statement with a recommendation about what to do. Moreover, his 
guidance was a clear departure from medical guidelines. According to the NCCN Guidelines, 
VUSs should not affect medical management. Neither of Deena’s variants were firmly classified 
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as pathogenic—the MUTYH variant was considered a VUS by all labs, and there were 
conflicting interpretations of her CHEK2 variant. Hence, even recommending additional breast 
screenings for her was questionable, albeit understandable in the case of a woman who had 
already had two cancer diagnoses at a young age. However, neither Tamoxifen nor mastectomy 
are advised for pathogenic CHEK2 mutations, so even if her oncologist was cautiously 
interpreting the variant as likely pathogenic, those recommendations were not aligned with 
clinical guidelines.  
 Finally, there were several women in the study with MRMs who indicated that their 
providers had consistently and explicitly communicated that mastectomy was the “right choice” 
for managing their risk. Despite having quite different risk profiles, these women’s experiences 
were very similar to those of women with BRCA mutations. Their doctors had discussed 
surveillance options with them, but mammography and MRI were described as effective bridge 
procedures, not optimal long-term options. These women’s stories reveal messages from their 
providers that mastectomy was the “right” choice and that eventually they should undergo the 
procedure. For example, Summer is a 35 year old woman with an ATM mutation, and she said, 
“It was definitely every doctor that I have seen since finding out about my mutation, it is the first 
thing that they recommended to me.” Similarly, Naomi, who has a PALB2 mutation and was 
scheduled for an upcoming mastectomy, stated, “I went to [big city] and met with this breast 
specialist and she said, ‘Yes, I absolutely feel like you should have a double mastectomy and 
reconstruction…. When you are ready, I am here to talk about doing something a little more 
drastic for prevention.’” 
Reflecting and Reinforcing Medicalization 
 Most often, when women shared a story about a doctor who implied or explicitly stated 
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that breast surgery was the best medical choice, that doctor was a surgeon. In addition, several 
genetic counselors and clinicians I interviewed commented that the surgeons they worked with 
were inclined to recommend mastectomy and did not calibrate their recommendations according 
to the penetrance of women’s mutations. For example, Lisa, a genetic counselor, stated, “Our 
surgeons, they feel very strongly that risk-reducing mastectomy is the answer to everything…. 
Our oncologists are a little bit better about it, but definitely from our surgeons’ perspectives, a 
positive result equals a bilateral mastectomy.” Similarly, Steve explained that most of the 
clinicians he worked with as an oncologist tried to avoid being “too directive” about prophylactic 
mastectomy, but he noted that surgeons were an exception. “If you don’t have a prophylactic 
oophorectomy at some point—I mean the issue is timing—but if you don’t have one at some 
point, then you really are swimming against medical advice. Whereas for prophylactic 
mastectomy, it is a little bit more balanced in terms of the presentation, as long as it’s not a breast 
surgeon.” 
 Two of the women I interviewed who had elected not to have mastectomy found surgeons’ 
pushback on their decision to do long-term surveillance frustrating, but also understood that it 
was well-intentioned. For example, Becky shared the ongoing tension she experienced with her 
medical team regarding her decision to avoid surgery.  
Some doctors, I guess, are used to their patients with this mutation to just get the 
preventative surgery. So, when I go in every six months for a screening, a lot of them 
think that it’s a hassle, they’re like “why would you want to travel all this way to do a 
screening every six months when you could just do the surgery and then you wouldn’t 
have to worry about it?” So, that’s, I feel like a disagreement that we often have, because 
of my personal feelings and issues about surgery. So, to me this is highly more preferable 
than going through that and I don’t always feel like that’s a doctor’s perspective because 
they’re just about prevention and maybe doing what they think is more of a sure thing. 
(Becky, Age 31, BRCA1) 
As Becky noted, her doctors, including the surgeon who served as one of the primary doctors on 
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her team, wanted her to do the “sure thing” and to prevent cancer rather than treat it. Similarly, 
Marci, a BRCA2 carrier who is also a public health professional, commented on how breast 
surgeons’ perspectives are understandably shaped by the trauma they see in their cancer patients.  
Surgeons like to do surgery. And I don’t mean that negatively, but it’s just—that is what 
they know and do. And that’s what they have seen save people’s lives, and so that is what 
they are focused on. My sense was her perspective was, “I’ve seen a lot of women die of 
cancer, and so I am going to do everything I can so you don’t die of cancer.” Which is 
fine except for the fact that I don’t have cancer. And so, it’s a very weird conversation to 
have since it’s a gamble. (Marci, Age 39, BRCA2) 
 Marci’s and Becky’s comments are reminders that breast surgeons are people whose 
attitudes, beliefs, and practices are socially and culturally embedded. Just as women’s 
perceptions of cancer risk and desire for preventative surgery are shaped by their own mothers’ 
and close relatives’ illness experiences (Nina Hallowell, 2000; Hesse-Biber, 2014), surgeons’ 
feelings about cancer risk are affected by their personal experiences working closely and 
regularly with women who sometimes die from breast cancer. Of course, oncologists also 
regularly work with patients who die from breast cancer. However, the primary tools of 
oncology—chemotherapy, immunotherapy, and radiation therapy—are only capable of treating 
breast cancer; they cannot prevent breast cancer from developing. In contrast, mastectomy, the 
primary tool of a breast surgeon, can both prevent and treat breast cancer. Thus, when the option 
exists, surgeons may understandably be inclined to encourage women to choose surgical 
prevention over the potential for needing surgical treatment.  
 However, framing prophylactic breast surgery as the best medical choice for women at 
genetic risk raises the stakes of the “imperative of health” and the demands of genetic 
responsibility (Clarke et al., 2003; Gibbon, 2007; Lupton, 1995; Rose, 2007), much like the 
financial and social incentives that encourage women have surgery. The need many women felt 
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to “do everything possible” to prevent cancer, along with the guilt and self-blame they said they 
would experience if they did not have RRM and then were later diagnosed with cancer, was 
connected to the messages they had received about the “right” and “wrong” medical choices. For 
example, Marci, like Lily and Nora, felt that she would be at “fault” if she chose to continue with 
surveillance and then eventually developed breast cancer. She explained, “There’s no thing here 
that I need to be treated for, so just not making people feel—giving the information without it 
being like, “But if you make the wrong decision…” Because now it feels like if I was diagnosed 
with cancer, it’s like, ‘Well, it’s my fault.’” Marci’s comment underscores how mastectomy is 
often framed as the “right choice” and discussed as if it is the standard treatment protocol for a 
disease rather than as one option women can consider for managing their risk. 
 Moreover, while Marci understood that the recommendation from her sister’s surgeon 
that she have mastectomy was well-intentioned, Marci was also puzzled by the surgeon’s 
response because, as she noted, unlike her sister, she does not have cancer. Her repeated 
emphasis on this difference through comments such as “except I don’t have cancer” and “there’s 
no thing here I need to be treated for” illustrates the extent of the medicalization of risk for breast 
cancer. Marci had to explicitly note the distinction between her situation—being at risk of 
developing breast cancer—and that of her sister—having actual breast cancer—because the 
boundary between the two has blurred. As Chapter One illustrated, risk is now treated like a 
disease. In addition, Marci’s response provides another critical reminder that is simultaneously 
obvious and yet often invisible in the practices of genetic medicine: that the benefits of risk-
reducing surgery are a “gamble” because not all women who have BOC genetic mutations—even 
high-risk ones—will develop breast cancer. 
 Neither women who have RRM nor their doctors can ever be certain whether they would 
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have developed breast cancer if they had not had prophylactic surgery. There is no 
counterfactual. Breast surgeons objectively know, based on current risk estimates, that a sizable 
proportion of women with BOC mutations—and a majority of women with MRMs—will never 
develop cancer in their lifetimes. Yet their surgical recommendations and practices, well-
intentioned as they might be, often obscure that data and imply the opposite. By offering 
mastectomy to women with both high- and moderate-risk mutations out of a motivation to “save 
their lives” or a feeling that prevention is better than treatment, surgeons’ practices in US genetic 
medicine both reflect and reinforce fatalistic notions about developing cancer and further 
entrench the medicalization of breast cancer risk.  
 Taken together, the stories from women in this section illustrate that the practices of BOC 
genetic medicine often frame mastectomy as the best medical choice for women with both high- 
and moderate-risk mutations. While several women’s health care providers were cautious about 
being too directive regarding the decision to have mastectomy, the clinicians conveyed that it 
was the right choice and safest option for women in multiple ways: using “should” language 
about the procedure, not directly inquiring about women’s feelings about surgery, initiating 
unprompted or decontextualized conversations about RRM with women who opted for ongoing 
surveillance, and informing them of other women’s decisions to have the procedure. Health care 
providers sharing their thoughts with patients on the best course of action is not problematic; it 
is, in fact, an essential component of their work. However, when women’s choices to have 
mastectomy are lauded while their decisions to avoid surgery are questioned, interrogated, and 
doubted, it communicates to patients that having surgery is the right, safest, and best choice, 
while avoiding it is misguided. In turn, these discourses and practices encourage women, 
regardless of the penetrance of their mutations, to seek out surgery. 
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Co-Production of Genetic Testing and Mastectomy 
While women’s stories reveal that mastectomy is incentivized and framed as the "best" 
choice, they do not illuminate why and how the discourses and structures of US genetic medicine 
became, and continue to be, organized around surgery. In the final section of this chapter, I argue 
that the clinical value and social significance of the practices of genetic testing and risk-reducing 
mastectomy are co-constituted. BOC genetic testing produces the knowledge required to 
indisputably diagnose the "disease" of cancer risk, and positive results on genetic tests are now 
required to legitimize women’s access to insurance-covered prophylactic breast surgery. At the 
same time, the availability of prophylactic surgery validates the utility of BOC genetic testing by 
providing a pathway for treating the "disease" of risk and transforming the molecular knowledge 
generated by genetic tests into action and power. The two practices mutually define, justify, and 
sustain one another.  
Genetic Tests Legitimize Risk and Surgery 
 One of the consequences of the geneticization and medicalization of cancer risk is that 
genetic tests have become the primary arbiters of access to surgical interventions, such as 
mastectomy and RRSO, which are currently the only highly effective means of preventing breast 
and ovarian cancers.37 Risk-assessment tools and cancer pedigrees are still used to identify 
women at “elevated risk” who therefore qualify for genetic testing services and increased 
surveillance. But surgical eligibility is rarely based on family history alone or on the specific risk 
estimates or ranges of penetrance for particular mutations. Instead, clinicians and insurance 
companies now almost exclusively rely on the binary results of genetic tests (i.e., positive or 
                                                             
37 While, as noted earlier in the chapter, surveillance and mastectomy are similarly effective at reducing 
mortality, surveillance only detects cancer early; it does not prevent cancer from occurring. 
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negative) to determine women’s eligibility for risk-reducing surgeries. As Steve, an oncologist, 
stated, “The risk is continuous, and yet responses are dichotomous.” When BOC genetic tests are 
negative, women are typically considered ineligible for mastectomy even if they have an 
extensive family history of cancer. Conversely, if tests are positive for any BOC mutation, even 
if those mutations have low or moderate penetrance and the patient has no family history of 
breast cancer, RRM is allowed and covered by insurance. 
 Eleanor’s story provides an example of how genetic tests have molecularized risk and 
become the arbiter of whether women can “treat” their risk with surgery. When she was 
diagnosed with breast cancer at age 40, she initially opted to only test for BRCA mutations rather 
than to do a panel test. Because Eleanor had no known mutation when she was being treated for 
breast cancer, her providers and insurance company refused CPM. “They wouldn't take both 
[breasts]; they would only take one because I hadn't had the BRCA chain. The insurance 
company and oncologist wouldn't cover it, couldn't do a double because it was an elective 
surgery not indicated clinically.” However, approximately a year after her treatment, Eleanor’s 
gynecologist recommended a panel test because she was developing ovarian cysts, and through 
that test she discovered her ATM mutation. As soon as she had a positive result, mastectomy was 
presented as an insurance-covered option. She explained, “Now I have to decide if I'm going to 
have a second mastectomy because of the elevated risk of the ATM.”  
 Naomi’s experiences provide another example of how panel tests serve as the gatekeepers 
to surgery. Naomi had one of the most extensive family histories I encountered in my interviews. 
Her mother had two primary breast cancers, her maternal grandmother and one maternal aunt 
had breast cancer, and another maternal aunt had breast and ovarian cancer. Her paternal 
grandmother and one paternal aunt also had breast cancer, and her father passed away from 
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pancreatic cancer. Yet even in Naomi’s case—one in which both sides of her family suggested a 
hereditary risk of cancer—family history on its own was not considered enough by her providers 
to justify surgical intervention, which she found extremely frustrating.  
You see the writing on the wall over and over again. It is like, “This is your genetic 
legacy.” Then finding the genetic mutation was just almost a relief in that it was like, 
“Here is the evidence, or here is a different kind of evidence.” And maybe that was 
coming from my first experience where the oncologist was like, “You don’t have this 
[BRCA] mutation, so I don’t know what to tell you.” Use your knowledge of biology to 
understand genetics! … And that was, in part, frustrating because I was like, “How much 
cancer do I need to have in my family in order for you to step up my program or listen to 
me more or take seriously when I would say that I want to have this prophylactic 
mastectomy?” (Naomi, Age 47, PALB2) 
Like in Eleanor’s case, the reluctance among Naomi’s doctors to consider mastectomy was, in 
part, because she was tested in 2007 for BRCA mutations and those results were negative. As a 
result, she felt somewhat relieved when she eventually discovered her PALB2 mutation because 
she knew that would enable her to have surgery.  
 Naomi’s and Eleanor’s initial BRCA results are what genetics providers refer to as an 
“uninformative negative.” No one in their families had a known mutation at the time they were 
tested for BRCA mutations, so a negative result was not definitive and did not mean that they did 
not have significantly elevated risk.38 The recommendations for managing people with 
uninformative negatives are very similar to the official recommendations for managing people 
with MRMs—to triangulate those results with the patients’ family histories and information from 
risk estimation tools to determine their predicted degrees of lifetime risk and their eligibility for 
                                                             
38 In contrast, when there is a known mutation in a family and an individual tests negative, that is referred 
to as a “true negative.” When a woman receives a “true negative result,” her cancer risk is considered 
similar to the risk of women in the general population because she did not inherit the mutation linked to 
the cancers in her family. 
 
166 
increased surveillance, medications, or surgery. Yet women with MRMs are routinely offered 
prophylactic surgery, while women with uninformative negatives are rarely offered mastectomy 
even when, like Naomi, they have an extensive family history of the disease.  
 Once Naomi was retested with a panel test and discovered her PALB2 mutation, 
everyone was not only willing to consider surgery, but also recommended it. The genetic test 
results gave her the “evidence” she needed to access surgery.  
I felt like there was then an ‘“Okay!” moment that we could move forward. I do not 
know, if for [the doctors] that is because working with insurance companies—maybe it is 
an easier process when you have a mutation or something? I am not quite sure. But there 
was some hesitation, and once I had that report, they were like, “Okay, when are we 
going to schedule you?” (Naomi, Age 47, PALB2) 
Similar to Naomi’s clinicians, some women said that despite their family histories, they 
personally felt hesitant about having mastectomy until their risk was confirmed by a test. For 
example, Marianne explained: 
I mean, I sort of felt like a ticking time bomb with the history, but it felt kind of crazy 
almost to go ahead and have the prophylactic mastectomy without finding out the 
mutation. It just sounded a little extreme. I was very comfortable with the idea of having 
a mastectomy if a genetic mutation was found. Like I said, it was a bit of a relief to 
almost have something concrete to point to to make that decision. (Marianne, Age 59, 
CHEK2) 
Colette shared that her test results also made her risk feel more tangible and therefore actionable. 
“The genetic results made it absolutely more real because then it is on paper. There is a 
mathematical, quantifiable, thing that you can see on paper. Okay, here is the likelihood.” 
 Eleanor’s, Naomi’s, Marianne’s, and Colette’s experiences illustrate how, without the 
confirmatory power of the genetic testing result, the subjective knowledge of family history is 
almost never enough to justify surgical intervention. To use epidemiological terms, family 
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history is not sufficient39 for access to mastectomy. In fact, the only woman in this study who 
was advised to consider RRM prior to testing was Dana, who had her prophylactic mastectomy 
over a decade before the discovery of the BRCA genes in the early 1980s. Not one of the other 
74 women, the vast majority of whom had family histories of cancer, were advised to consider 
mastectomy until they knew they had positive testing results.  
 Interestingly, while familial risk, on its own, does not qualify women for surgical 
interventions, the NCCN Guidelines encourage clinicians to strategically mobilize the subjective 
knowledge of family history when counseling women with MRMs about mastectomy. They 
state, “Evidence insufficient, manage based on family history” (National Comprehensive Cancer 
Network, 2018b, pp. GENE2-GENE3). Thus, in a circular move, family history, which is often 
required to qualify women for genetic testing in the first place, gets redeployed in combination 
with the "factual" genetic test result to justify a surgical response to risk-management. The 
subjective knowledge of family history, which on its own is insufficient, is mobilized to extend 
the reach of genetic (dis)embodied knowledge in order to transform the uncertainty surrounding 
the management of MRMs into a clear course of action. Notably, the power to define disease and 
justify intervention is still rooted in the molecularized, (dis)embodied knowledge. While the 
subjective knowledge of family history can amplify the technoscientifically produced knowledge 
of genetic testing, family history is still, on its own, insufficient. 
Moreover, while the NCCN Guidelines formally require triangulation with family history 
to open the gates to prophylactic surgery for women with MRMs, a family history of breast 
                                                             
39 The “Sufficient-Component Cause Model” is a heuristic that is often used in epidemiology to illustrate 
causal inference and the multi-factorial nature of disease. A sufficient cause is one that on its own will 
lead to the outcome of interest. A necessary cause is one that must be present in every combination of 
factors leading to the outcome (Aschengrau & Seage, 2008). 
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cancer is not necessary; positive results on a genetic test, even without a family history, are 
generally deemed sufficient for access to prophylactic surgery. There were five women in this 
study whose mutations or variants are what genetics experts refer to as incidental or surprise 
findings (Table 5). Four of the women were tested with cancer panels because they were in their 
30s or 40s and had already had two cancer diagnoses. However, these women were suspected of 
having mutations on other genes associated with their types of cancer, and in the era of targeted 
testing, they would not have qualified for testing on BRCA2 or CHEK2, the genes of their 
mutations. Hannah’s situation was unique. She managed a fairly large genetic testing program in 
an OB/GYN’s office and tested herself to better understand the process and “see what [her] 
patients went through.” She was shocked when her results came back positive.  
 
Table 5: Women with Incidental or Surprise Findings 
 
None of the five women had a family history of breast cancer or a known first degree 
relative with a mutation associated with breast cancer. Yet, because of their CHEK2 and BRCA2 
mutations, all five women had been offered mastectomy—Deena, Hannah, and Penelope had 
already had the procedure, and Megan and Adele were both planning on breast surgery in the 
near future. Importantly, both Deena’s and Penelope’s CHEK2 variants are ones with discordant 
classifications; while consensus on both variants is converging and most labs now classify them 
as likely pathogenic, when Deena and Penelope were tested and had surgery there was less 
agreement on their pathogenicity. Hence, in the absence of a family history and even when the 
pathogenicity of variants was under question, positive results on genetic tests were sufficient for 
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women to gain access to prophylactic breast surgery. 
The recommendation in the NCCN Guidelines to triangulate knowledge between genetic 
testing results and family cancer pedigrees to determine medical management options for women 
with MRMs reflects good clinical practice. However, based on the experiences of women in this 
study, those recommendations are only formally followed in the presence of a family history in 
order to bolster support for the decision to perform mastectomy. When there is an absence of 
family history, like in the cases of surprise findings, triangulating data would suggest taking a 
cautious approach and avoiding RRM, yet that did not occur with the women I interviewed. 
What this suggests is that, in practice, the risk management guidelines for MRMs in the NCCN 
Guidelines are largely disregarded. A positive genetic test result, regardless of the penetrance of 
the mutation, is deemed both necessary and sufficient for access to prophylactic surgery, while a 
family history of breast cancer is neither. Hence, while women's family histories of cancer are 
still assessed, those data are now primarily used to determine their eligibility for high-risk breast 
screening and access to genetic testing. In turn, the (dis)embodied knowledge produced by 
genetic testing then determines whether women are eligible for risk-reducing surgery.  
Surgery Validates the Utility of Genetic Testing 
Given the complexity of gene-environment interactions and the knowledge that, by 
definition, a majority of women with MRMs will not develop cancer, why, in practice, is a 
mutation alone sufficient for surgery while a family history, on its own, is not? The answer to 
this question is embedded in another question posed by Steve, an oncologist. When he discussed 
the debate over BRCA population screening, he rhetorically stated, “The genetic community to 
some extent participates in this because if using genetics to stratify people for risk by 
intervention isn’t going to work, then what is our goal? What is our purpose, you know?” While 
 
170 
Steve was not directly addressing how genetic tests became the gatekeepers to surgery, his 
question implied that there would be little value to genetic testing if women’s risk could be 
managed based on family history alone. Hence, just as I illustrated in the previous section how 
genetic tests legitimize cancer risk and mastectomy, in this section I will reveal how prophylactic 
surgery validates the utility of genetic testing.  
Earlier in the chapter I highlighted that after receiving genetic test results that confirm 
their risk for breast cancer, many women desire mastectomy because it will reduce their anxiety. 
While most women at genetic risk were cognitively aware that they were not 100% certain to 
develop breast cancer, they felt like it was lurking around the corner waiting to pounce. For 
example, Josephine stated, “I always felt like it was coming for me,” and Naomi explained that 
genetic risk for cancer felt like a “predator that is stalking.” Marianne, Hannah, Nora, and 
Katarina all said that they felt like they had “ticking time bombs” in their breasts. Breast 
screenings cannot alter this sense among women that they are under imminent attack by breast 
cancer. Surveillance through mammography and MRI can closely monitor women’s bodies and 
hopefully detect cancer early if it develops. But screenings do not prevent breast cancer, nor do 
they remedy the anxiety of being at genetic risk. 
 Counterintuitively, treating the risk of breast cancer often involves a more invasive 
surgical procedure than treating actual breast cancer. Because nearly two-thirds of breast cancers 
are localized at diagnosis (National Cancer Institute, 2018d), breast cancer can often be treated 
by lumpectomy, which only removes the tumor and leaves the surrounding breast tissue intact. 
However, treating the risk of breast cancer requires removing both breasts in their entirety. Leah 
discovered her CHEK2 mutation after being diagnosed with high-grade ductal carcinoma in situ 
 
171 
(DCIS) (i.e., Stage 0 breast cancer),40 and her reasoning for choosing treatment mastectomy and 
CPM41 over lumpectomy highlights the distinction between treating cancer and treating the risk 
of cancer. “In talking with my husband and my adult kids we all decided—why not get rid of the 
risk for breast cancer entirely? Instead of always having to worry, ‘Is it coming back?’ We 
wanted to eliminate the worry.” Because Leah was already going to have some form of surgery, 
the factors that she weighed in her decision to have RRM were somewhat different from those of 
women with BOC mutations without breast cancer. However, like many of the women in this 
study who chose BPM, Leah chose CPM and treatment mastectomy over lumpectomy in order to 
“get rid of the risk” and “eliminate the worry” of developing breast cancer in the future.  
Women currently have one option for eliminating their worry and defusing the risk that 
feels like a “ticking time bomb” in their bodies: having their breasts removed. Steve, an 
oncologist, explained, “When they say, ‘Well we have preventative interventions,’ the truth is the 
only preventive intervention that has been proven to work is surgery. So yeah, we can talk about 
doing MRI screening, but the truth of the matter is, if you really want to make this a cost-
effective intervention, everybody has to have surgery.” While there are scientists and 
biotechnology companies researching and trying to develop highly-effective non-surgical 
approaches for preventing breast and ovarian cancer, those options do not yet exist. As one 
participant in a webinar about research into prevention of BRCA-related cancers poignantly 
                                                             
40 There is debate in clinical practice and the scientific literature about whether or not DCIS should be 
labeled “cancer” or “pre-cancer” (Carlson, 2015; Tarkan, 2004). Currently, it is most often discussed and 
treated as cancer, so that is how I will refer to it in this analysis. 
41 Just as RRM and reconstruction are two decisions, not one, so are mastectomy of a cancer-
affected breast and CPM. Mastectomy treats existing breast cancer, while CPM treats a future 
risk of breast cancer. However, the separateness of those decisions is often obscured, in part 
because the procedures are typically performed at the same time. 
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noted, “It’s amazing that in 2018 the only way we have to prevent breast cancer is to cut off our 
body parts.” But sadly, mastectomy is the only available “treatment” for the “disease” of cancer 
risk that is established through panel testing.  
 Throughout my fieldwork, the phrase “knowledge is power” was uttered by both patients 
and providers in reference to people doing genetic testing and learning about their genetic risk. 
However, as the literature on genetic testing for Huntington’s Disease reveals, when there is no 
possibility of changing the outcome of a disease, genetic knowledge can feel burdensome rather 
than liberating (Callon & Rabeharisoa, 2004; Lock, 2005; Novas & Rose, 2000). Many women 
in this study described feeling both frightened and relieved when their genetic tests came back 
positive. The indisputable confirmation of risk produced by genetic testing often initially 
heightened their anxiety and generated a feeling of being stalked by cancer. However, their 
positive test results also generated relief because those results were their tickets to mastectomy 
and the ability to take action to reduce their hereditary risk. Josephine explained:  
“It’s definitely brought with it a lot of anxiety, but also a kind of relief. It is like okay, we 
finally figured it out! We knew something was going on in our family but we just hadn’t 
discovered what it was yet or how to take any actions based on knowing that there was 
something there…. Now I have a little bit of knowledge that is going to give me a little 
bit of ability to take some actions and get insurance to cover some of those actions to try 
and prevent it.” (Josephine, Age 41, CHEK2) 
Similarly, Amber, who learned about her BRCA1 mutation at the young age of 23, stated, “I 
always knew that we had a high risk of breast cancer because my grandmother and aunt both had 
it. Knowing that there was a risk of breast cancer was not something new to me, but knowing 
that it was that high was kind of shocking. Knowing that I now can take preventative measures 
was a real relief.”  
 Amber’s and Josephine’s statements illustrate how the power of genetic testing is rooted 
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in the permission positive results grant women to “treat” their risk of cancer through prophylactic 
surgery. The (dis)embodied knowledge of women’s genetic risk legitimizes the subjective 
knowledge reflected in their family histories of cancer and gives them access to surgeries that 
can transform their hereditary and genetic knowledge into power. “Knowledge is power” because 
it bestows the ability to act. But uncoupled from that potential for action, BOC genetic 
knowledge would likely leave many women with heightened anxiety and no relief.  
 By providing a means for transforming the abstract, (dis)embodied knowledge produced 
by genetic testing into "action and power", the availability of RRM both validates the utility of, 
and drives demand for, genetic testing. For genetic testing to be a valuable clinical tool, it needs 
to lead to changes in medical management. However, as I noted in the previous section, a strong 
family history of breast cancer is often sufficient for women to gain access to earlier and more 
frequent breast imaging. Since a family history is often a pre-condition of genetic testing in the 
first place, most women who undergo testing already have access to more intensive screenings. 
Hence, one of the primary ways in which the knowledge produced by genetic testing is valuable 
to women is that it determines whether they are eligible for mastectomy. 
 Multiple providers discussed how their patients believed that the primary purpose of 
genetic testing was to determine whether or not they could and should have a mastectomy. For 
example, Lisa, a genetic counselor, shared how a majority of her clients come into the genetic 
testing process with an eye toward surgery.  
You know, I ask them, "Tell me a little bit about why you're here to see me. What has 
been explained to you about your reason for seeing me today?" And I'd say 95 percent of 
the time their answer is "Well, this is going to tell me if I have to have both my breasts 
removed." And my response to that is, "No. That is your choice. This can give us 
information that might help you make the decision. But you do not have to have a 
mastectomy unless you want a mastectomy." But they very much come into it being told, 




Steve noted the fused relationship between mastectomy and genetic testing in a discussion about 
the pros and cons of population testing for BRCA mutations. He said, “I see this world where all 
25 year old women go to their gynecologist to have their BRCA testing done to see whether or 
not they need to have a mastectomy, because that’s the way things are getting framed right now.” 
 Taken together, women’s and providers’ stories reveal how the practices of genetic testing 
and mastectomy are co-constituted and co-produced. The clinical utility and social significance 
of BOC genetic testing hinge on the availability of RRM; without prophylactic surgery, women 
could not seemingly transform their genetic knowledge into and “power,” and that knowledge 
would instead contribute to anxiety. At the same time, the clinical value and social meaning of 
RRM are inextricably linked to BOC genetic testing; without the legitimization of cancer risk 
produced by positive results on genetic tests, mastectomy would be considered drastic 
overtreatment rather than brave treatment. The practices of BOC genetic testing and prophylactic 
breast surgery mutually validate, grant meaning, and generate demand for one another.  
Conclusion: Which Choices? 
 This chapter explored how and why RRM has become a normative practice for women at 
genetic risk in the United States. As cancer risk was medicalized and transformed from a liminal 
state into a disease, prophylactic surgery emerged as the treatment for the disease of risk. For 
many women, as their stories illustrated, having prophylactic breast surgery brought them 
tremendous relief, as they no longer felt stalked by cancer. In addition, mastectomy has 
undoubtedly spared some of the women in this study grueling chemotherapy treatments by 
preventing breast cancer. However, this chapter also revealed that surgical practices in US 
genetic medicine are not in alignment with the internal, evidence-based standards established by 
 
175 
experts in the field. Despite clinical guidelines that indicate that prophylactic mastectomy is not 
supported by evidence of effectiveness in women with MRMs, there was little variation in risk-
management approaches between women with high- and moderate-risk mutations. Instead, 
women were typically lumped into two groups: positive for a mutation and therefore eligible for 
surgical interventions or negative/unknown for a mutation and therefore ineligible for them. 
Whereas a strong family history was once the primary determinant of whether a woman was 
considered at “high-risk” for breast cancer, family history is neither sufficient nor necessary for 
access to RRM. Instead, the power to define the “disease” of risk and therefore to grant or deny 
women access to the “treatment” of surgery is now almost exclusively located in positive genetic 
test results.  
 I further argued that the discourses and practices of genetic medicine continue to be 
organized around and to encourage women to have mastectomy because prophylactic breast 
surgery and genetic testing have a mutually constitutive relationship. The primary functional 
purpose of RRM is to treat the disease of cancer risk that is established and legitimized by panel 
genetic testing, and genetic tests have transformed mastectomy from a “drastic” action into a 
“powerful” and “brave” one. At the same time, the primary functional purpose of genetic testing 
is to determine eligibility for surgical management of breast cancer risk, and mastectomy 
transforms genetic knowledge, which on its own is anxiety-producing, into “action and power.” 
Thus, the social significance and clinical value of genetic testing and RRM are simultaneously 
bound to and reconfigure one another—genetic tests legitimize the need for prophylactic breast 
surgery, while surgery validates the utility of genetic testing. 
 Because over half of the women in this study had MRMs with lifetime breast cancer risks 
below 50%, it is almost certain that some of the women who had prophylactic surgery never 
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would have developed breast cancer. In noting that, my intention is not to critique or interrogate 
any individual woman’s choices; I respect the complex and deeply personal nature of women’s 
decisions about their bodies. However, it is important to bring visibility to and put analytic 
pressure on how structures and systems constrain and enable those choices. For example, the 
“diagnostic loophole” is a critical but fixable failure of policy that incentivizes mastectomy and 
discourages surveillance by burdening women with the highest risk for breast cancer with the 
highest out of pocket costs for breast screenings. In addition, the social and clinical discourses 
that frame mastectomy as the “best” choice and associate it with bravery, strength, and 
empowerment can both encourage women to have the procedure and contribute to the 
marginalization of women who choose not to have surgery. Thus, this chapter revealed how US 
genetic medicine magnifies and facilitates certain choices. In the following chapter, through an 
analysis of breast reconstruction practices, I will explore how the structures of genetic medicine 




Chapter 3: “This Is How A Woman Is Supposed to Look":  
Breast Reconstruction in US Genetic Medicine 
“There's more to it than the way they look. It's how they're going to feel. It's the risk they 
pose. You know? I'm trying to reduce the risk.” (Marlene, Age 35, CHEK2) 
“They’re willing to rebuild my breasts because that’s a sexual thing for men to look at. 
But I have no sensation in them. I need to be valued for who I am, not what I look like. 
None of the reconstruction is for me—it’s so I look good to somebody else. They’re 
giving me tits again.” (Nina, Age 35, BRCA1) 
“They are always either living in pain or in surgery—they can’t imagine an alternative. 
Because we live in a culture that doesn’t allow that to be visible. There aren’t images of 
being flat. Women aren’t given all their choices, so then how do you know you can 
choose something different?” (Eleanor, Age 42, ATM) 
Introduction 
The scientific literature on risk-reducing mastectomy (RRM), in both the biomedical and 
social sciences, tends to discuss and analyze mastectomy and reconstruction as a package deal 
that involves one choice rather than two. Despite mastectomy providing nearly all of the physical 
health benefits and reconstruction posing the vast majority of the risks, there is little research that 
disaggregates the procedures or examines the decision to not have reconstruction. Feminist 
breast cancer activists and advocacy groups have organized around some aspects of 
reconstructive surgeries, such as the invisibility of staying flat and the risks of specific types of 
breast implants. However, social scientists have not explored whether and how the structures of 
US genetic medicine normalize and encourage breast reconstruction.  
 This chapter examines how and why, in a medical field centered on minimizing and 
eliminating risks, the mainstream patient-pathways in breast and ovarian cancer (BOC) genetic 
medicine encourage women to undergo reconstructive surgeries that increase risks to their 
physical health. Drawing on fieldwork at cancer genetics conferences and interviews with 
women with BRCA1/2 mutations and moderate-risk mutations (MRMs), I explore women’s 
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experiences with breast reconstruction. Paying special attention to the social and structural 
factors that shape women’s decisions and outcomes, I illustrate how they are often un- or under-
prepared for the severity and duration of the side effects of reconstructive surgeries.  
 I highlight three structural elements of breast reconstruction practices within US genetic 
medicine. First, the structures, architecture, and discourses of genetic medicine typically funnel 
women toward reconstructive surgeries, despite the added risks of the procedures. Second, while 
women value and identify with their breasts in multiple ways—as visible markers of femininity, 
for their ability to feed babies, and as sources of intimacy and pleasure—breast reconstruction 
practices tend to prioritize form over function and feeling. Third, many women are un- or under-
prepared for the duration and severity of the side effects of their reconstructive surgeries. I argue 
that breast reconstruction practices in US genetic medicine both reflect and reconstitute 
normative, idealized constructions of desirable feminine bodies. Through a juxtaposition of the 
experiences of women who chose to stay flat against those of women who reconstructed, I 
identify pathways for disrupting and potentially reshaping these gendered expectations.  
Objectification and Fragmentation 
 Feminist theorists and gender and sexuality scholars have long argued that women are 
socialized to be sexual objects, not subjects. In her feminist theory classic, The Second Sex, 
Simone de Beauvoir argues that women have been constructed as the “other” and are expected to 
define and see themselves as objects for men (de Beauvoir, 1949). Philosopher Sandra Bartky, in 
a feminist critique and advancement of Marx’s theory of alienation, asserts that the 
objectification of women generates fragmentation between women’s bodies and selves. “The 
sexual objectification of women produces a duality in feminine consciousness. The gaze of the 
Other is internalized so that I myself become at once seer and seen, appraiser and the thing 
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appraised” (Bartky, 1982, p. 134). Bartky argues that this fragmentation alienates women from 
their bodies and sexuality, as they often view or judge their bodies through the perspective of 
others rather than through their own embodied experiences.  
 Despite second wave feminist activism challenging these alienated constructions of 
women’s bodies and roles, anthropologist Emily Martin argues that such “dismemberment is 
with us still” (Martin, 2001, p. 21). Through interviews with women about their experiences with 
menstruation, pregnancy, birth, and menopause, Martin illustrates how women consistently 
describe their reproductive bodies as separate from their selves, using language that suggests 
bodily fragmentation, alienation, and objectification. Similarly, in her interviews with adolescent 
girls, psychologist Deborah Tolman illustrates how the sexual alienation that Bartky described 
decades ago persists today and encourages girls to focus on being desirable to others rather than 
on understanding or exploring their own desire (Tolman, 2002). 
 This emphasis on women as objects, rather than their embodiment as agents and subjects, 
is both reflected and reified via the messages and practices surrounding prophylactic mastectomy 
and breast reconstruction. In her first op-ed in the New York Times, Angelina Jolie notes that the 
results of reconstruction can be "beautiful,” that her children "see nothing that makes them 
uncomfortable,” and that having a mastectomy and reconstruction has not made her “feel any 
less of a woman” or left her with a diminished sense of femininity (Jolie, 2013). Yet Jolie only 
describes how her breasts and body appear to others after her surgeries, not how they physically 
felt or looked to her. Similarly, as I will illustrate later in the chapter, my interviews with women 
reveal how the structures of genetic medicine place an emphasis on the appearance of women’s 
bodies and breasts rather than on their embodied experiences. The practices of breast 
reconstruction prioritize form over function and embodied sensations, which leaves many 
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women unprepared for the side effects that accompany their reconstructive surgeries.  
Reconstruction Options 
 Mastectomy is a major surgery, but not a complex one, as there are few, if any, choices for 
women to make about having their breasts removed. In contrast, there is a dizzying array of 
breast reconstruction techniques, and most of the surgeries are lengthy, complicated, and 
increase the physical health risks that women face. There are two main types of breast 
reconstruction: implant reconstruction and autologous tissue reconstruction (i.e., flap surgery). In 
implant reconstruction, surgeons rebuild women’s breasts by inserting pouches of synthetic 
material beneath the skin or muscle on women’s chests (Table 6). With flap reconstruction, 
surgeons use tissue taken from other areas of women’s own bodies to rebuild their breasts (Table 
6). In some cases, surgeons need to perform a hybrid procedure in which they use both implants 
and women’s own tissue to reconstruct their breasts (Nurudeen et al., 2017). For each type of 
reconstruction, there is a range of options to consider. For breast implants, there are decisions 
about the filling material (silicone or saline), shape (round or teardrop), and casing (textured or 
smooth). For flap surgeries, there are decisions about which part of the body the muscles and fat 
will come from (e.g., the abdomen, back, gluteals, or thighs) and how that tissue will be 
connected to a blood supply (Eisemann & Spiegel, 2018; Kulkarni et al., 2017; National Society 
of Genetic Counselors, 2017; M. M. Shah, Pederson, Djohan, Crowe, & Grobmyer, 2016). Table 





 Table 6: Breast Reconstruction Types and Options  
  
 For both implant and autologous tissue reconstruction, there are decisions about the timing 
of the surgery and whether and how to reconstruct nipples. Some women have immediate 
reconstruction that is performed directly after the mastectomy, while others need or choose to 
wait months between their surgeries. Implant reconstruction often requires the interim insertion 
of expanders to slowly stretch women’s tissue on their chest wall to make room for the implants. 
Regarding nipples, some women leave their reconstructed breasts bare, some have 3-D nipples or 
other decorative designs tattooed on their reconstructed breasts, while others have nipple-sparing 
mastectomy and reconstruction. In nipple-sparing procedures, the breast surgeon retains a 
woman’s nipples and areola from the tissue removed during the mastectomy, and then the plastic 
surgeon attempts to reconnect her nipples to the reconstructed breasts (Eisemann & Spiegel, 




 No matter the type of reconstruction or the options selected (including delayed 
reconstruction), adding reconstructive surgery is always riskier than having mastectomy alone. 
Risks unique to implants include a rare form of lymphoma; a variety of health complications that 
can arise if silicone implants rupture and silicone leaks into women’s body tissue; implant 
rejection; and the need for future surgeries (Grady, 2017a, 2017b; National Society of Genetic 
Counselors, 2017). Not only do expanders eventually have to be swapped for implants, but also 
implants have to be replaced approximately every 15 years because of their risk of leaking 
(National Society of Genetic Counselors, 2017; Nurudeen et al., 2017).  
 Flap surgeries are more complicated than implant surgeries. Flap procedures can take up to 
14 hours, and the extended length of time in surgery compounds women’s risks of infection, 
edema, and potential complications with anesthesia (National Society of Genetic Counselors, 
2017; Nurudeen et al., 2017). However, it is not just the duration of tissue surgeries that makes 
them riskier—they also add other risks when compared to those of mastectomy alone or implant 
procedures. These risks include infection, swelling, wound-healing issues, and scarring at 
another incision site on the body; necrosis, or dying skin tissue; tissue rejection; muscle 
weaknesses and/or scar tissue and chronic pain in the “donor” area of the woman’s body; and 
significantly extended healing time (Heidemann, Gunnarsson, Salzberg, Sorensen, & Thomsen, 
2018; Kulkarni et al., 2017; Nurudeen et al., 2017; M. M. Shah et al., 2016; Sue & Lee, 2018).  
 With nipple-sparing mastectomy and reconstruction, the reconstructed breasts may have a 
more “natural” appearance and retain some sensation. However, recent studies indicate that rates 
of necrosis in nipple-sparing surgeries are as high as 10%, and overall complication rates are as 
high as 20% (Heidemann et al., 2018; Muller, Baratte, Bruant-Rodier, Bodin, & Mathelin, 2017). 
In addition, current research is mixed as to whether preserving nipple tissue slightly elevates 
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women’s lifetime risk of developing breast cancer when compared to mastectomy without a 
nipple-sparing procedure (Galimberti et al., 2017; Jakub et al., 2018; Muller et al., 2017). Given 
that the goal with RRM is to reduce women’s risk as much as possible, there is an inherent 
tension in electing a cosmetic reconstruction procedure that may add to that absolute risk, even if 
the percentage remains small.  
 One benefit to flap surgeries is that, unlike implants, they do not require replacement, and 
therefore they eliminate the need for repeat surgeries over the long-term. However, additional 
surgeries in the first year after autologous tissue reconstruction are quite common, with one 
study finding that over 57% (n=102) of women had an unexpected procedure and nearly 22% 
(=39) had a complication that required additional surgery (Nurudeen et al., 2017). Often those 
additional procedures are to remove dying or infected tissue, and even when women’s bodies do 
not reject the transplanted tissue, they frequently have cosmetic revisions to remove “dog ears,” 
the flaps of loose skin that can hang along the ribcage, or to enhance the shape of their 
reconstructed breasts through fat or skin grafting (National Society of Genetic Counselors, 2017; 
Nurudeen et al., 2017; Sue & Lee, 2018). Each surgical procedure, whether it occurs 
immediately or decades later, requires time off of work and a recovery period that includes 
notable physical limitations. Unfortunately, given that women in the United States often lack 
paid sick leave and disproportionately serve as the primary caregivers for children, many women 
cannot afford to be out of commission for several weeks or months. 
A Swinging Pendulum 
 Risk-reducing mastectomy is a medical procedure that provides both mental and physical 
health benefits by greatly reducing women's risk of developing breast cancer. Reconstruction, 
however, is a cosmetic procedure that does not provide physical health benefits. However, 
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several studies have shown that breast reconstruction has social and psychological benefits and 
positively affects women’s mental and emotional well-being after having mastectomies 
(Fernandez-Delgado et al., 2008; Flitcroft et al., 2016; Matthews, Turner, Williamson, & Clyne, 
2018). In addition, prior studies have confirmed that the availability of reconstruction has been 
critical to many women’s decisions to undergo RRM (Nina Hallowell, 2000; Hesse-Biber, 2014; 
Sischo & Martin, 2014). For example, in her research on the surgical decisions of women in the 
United Kingdom (UK) at high-risk of breast cancer, health scholar Nina Hallowell found that 
women were hesitant about prophylactic mastectomy because they linked their feminine 
identities to a body with breasts. They viewed mastectomy as radical not because it was a surgery 
that would be performed on their healthy bodies, but rather because it would visibly remove a 
part of their bodies they viewed as inherently linked to their femininity. Hence, some women 
would only consider mastectomy in conjunction with breast reconstruction because they felt that 
without breasts they would no longer be ‘natural’ women (Nina Hallowell, 2000, pp. 166-167). 
 Women’s right to insurance-covered breast reconstruction is relatively recent success of 
women’s health activism. In the 1980s and 1990s, as breast cancer became a more visible 
disease, survivors shared stories about being denied insurance coverage for reconstruction 
procedures after mastectomy. In response, women’s health advocates fought for federal 
legislation that required insurance coverage of breast reconstruction after a medically indicated 
mastectomy. In October 1998, the Women’s Health and Cancer Rights Act (WHCRA) —
bipartisan legislation, co-sponsored by US Senators Alfonse D’Amato of New York, Dianne 
Feinstein of California, and 21 others—was signed into law (US House of Representatives, 
1998). WHCRA was a major women’s health victory. It requires both individual and group 
health plans, regardless of whether they are insured or self-funded, to include coverage for 
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reconstruction if they cover mastectomy. It also requires plans to cover an out-of-network second 
opinion for all cancer patients, which provides individuals, many of whom previously lacked 
access, with the ability to consult with experts in academic medical centers or major cancer 
centers (US Department of Labor, 2018). 
 Like the women Hallowell interviewed, several women in this study expressed that their 
identities and self-image were linked to having breasts and were grateful for the option to have 
reconstruction. Collette, a CHEK2 mutation carrier in her thirties, explained: “Your breasts are 
so much of your womanhood. They are very intimate. There is the aspect of your womanhood 
and sexuality.” Similarly, Bailey, another woman in her thirties with a CHEK2 mutation, stated, 
“You know, having your breasts, it defines part of who you are as a woman, it's part of your 
shape and it's part of how your clothes fit.” Knowing that their pre- and post-mastectomy bodies 
could look similar provided women with a sense of normalcy. For example, Jill, who has a 
BRCA2 mutation, conveyed that she was glad she made the decision to reconstruct. “I’m happy I 
did something. Definitely it makes you feel more normal.” Nora, who had recently discovered 
her BRCA2 mutation at age 32 and was waiting until she was older to have mastectomy and 
reconstruction, stated, “I want to look and feel as normal as I can when it’s all done.” Hence, 
reconstruction is important to many women, and because reconstructive surgeries are costly, 
mandating insurance coverage for reconstruction has, in practice, also enabled women to choose 
risk-reducing mastectomy. Without reconstruction as an accessible option, the decision to have 
risk-reducing breast surgery would be more difficult for some women.  
 However, some women in this study felt that the reconstruction pendulum has “gone too 
far to the other side.” For example, Ingrid, who decided not to reconstruct, expressed frustration 
with what she perceived as slanted information-sharing practices: 
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So, it's like, you know, if I hadn't done my homework, I would be on Tamoxifen right 
now. And I would be reconstructed. It's like, no. There was that time period when they 
wouldn't tell women what was available to them. And then the law came in that said that 
it's required to give you reconstruction, now they've gone totally the other way, that they 
don't even tell you about no reconstruction. You know, they do the opposite. And I don't 
think that that's right, either. I think that they need to give you all your options and help 
you decide, discern what's best for you as a person. (Ingrid, Age 62, PALB2) 
Ingrid's point is not that the pendulum should swing back to where it was before WHCRA. The 
fact that women who have mastectomies are now routinely provided information about 
reconstruction and have their surgeries covered by insurance has been a positive development in 
women's health policy and practice. Rather, what Ingrid noted was that women also deserve to be 
provided with information about not having reconstruction. As she stated, doctors should "give 
you all your options and help you decide."  
 Yet the stories from women that I will share in the following sections reveal how they are 
often encouraged, and in some cases even expected, to have breast reconstruction. Even though 
reconstructive surgeries are complicated and involve additional risks, the option to not 
reconstruct and “stay flat” remains relatively invisible. Instead, clinicians often assume that 
women will want both mastectomy and reconstruction and treat them as a package deal, despite 
them being separate choices with distinct benefits and risks.  
Funneling Women Toward Reconstruction 
Health Insurance Policies and Practices 
 Multiple components of the structures of genetic medicine propel women like Ingrid 
toward reconstruction and away from staying flat. For example, health insurance regulations and 
policies in the United States privilege reconstruction over staying flat by covering cosmetic 
revisions for reconstructive surgeries but not for mastectomy alone. Several women I 
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interviewed who chose not to reconstruct shared stories of other women they knew whose breast 
surgeons disregarded their wishes and did not leave them with the “clean, tidy, flat look” that 
they had requested. For example, Eleanor, who was diagnosed with DCIS at age 41 before she 
discovered her ATM mutation, had a mastectomy of her affected breast with no reconstruction. 
She shared her frustration with the disrespectful treatment experienced by some women in 
“Amazing Flatties”,42 a private social media group for women who choose not to reconstruct. 
“I’ve seen countless surgeries that are just botched, they’re horrible. And stories of women who 
said, ‘My surgeon told me it wasn’t a choice. I wanted to go flat but they said I would change my 
mind, they left me with all this extra skin.’” Naomi, who was awaiting her scheduled 
mastectomy and also did not plan to reconstruct, had seen and heard similar stories of doctors 
pressuring women to reconstruct and disregarding their wishes:  
The number one complaint is lack of counseling. Not lack of counseling in terms of 
support but in providing options or people saying that they were pressured into having 
reconstructive surgery. In some cases, I couldn’t believe that it wasn’t a lawsuit. Where 
they told them, straight up, “I want flat: nothing, nothing, nothing.” And they woke up 
with the skin flaps because the doctor said, ‘You will change your mind later.’ Multiple 
times. (Naomi, Age 47, PALB2) 
 Yet, while health insurance plans are required to cover “touch-up” surgeries and 
procedures for women who are unhappy with the appearance of their reconstructed breasts, most 
plans do not cover revisions for women who stay flat. Emily, who was 50 when she discovered 
her CHEK2 mutation, shared a recent conversation she had about this inequity with other women 
on “Amazing Flatties”:  
One of the things we were discussing was all the money that insurance companies put 
into multiple reconstructions, and even if everything goes right, after about ten years you 
                                                             
42 Like all names in this study, this is a pseudonym. 
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have to get it redone anyway. So, our thing was, “Well why won’t the insurance pay for 
us to get our torsos to match our deleted breasts?” Like a lot of us have puckering and 
dog-ears and all this other kind of stuff. Why won’t the insurance companies pay for that? 
And also, you know, we’re grown women so we had rounded bellies to match, and it’s 
normal. Once you take the breasts off and you actually take them down to the muscle, not 
only do you have dents in your chest and a pronounced sternum, even if you get clothes 
to fit, it looks bizarre, it looks strange. And you have this pronounced belly where before, 
it looked like a normal stomach. Why won’t the insurance companies pay to get those 
divots filled in? Now, you’re not trying to reconstruct breasts, you’re just trying to make 
a more normal appearance. Pay to get the, you know, what is it called? Fat transfer?43 Or 
whatever, just to fill in the divots, and also to remove the back fat or the stomach fat in 
order to give a more uniform torso. Because that would cost less than getting 
reconstruction. Why do women who choose not to get reconstruction and save the 
insurance companies all this money—why are they not given that option? (Emily, Age 51, 
CHEK2) 
Like women who choose to have reconstruction, Emily expressed a desire to have a “more 
normal appearance” after her mastectomy. For her and other women on “Amazing Flatties,” 
normal meant a smooth chest with minimal scarring and no indentations or loose, drooping skin 
along her chest and ribcage. Yet, as she notes, insurance companies rarely cover the costs of 
revisions and fat grafting for women who stay flat. Instead, they only cover these procedures 
when they help create a stereotypically feminine version of “normal”—a woman with breasts. 
 Emily voiced that some women who stayed flat desired surgery to remove belly fat that 
became much more visible once their breasts were removed. Marlene also discussed this issue. 
“Cause yeah, you don't have a chest, suddenly your belly seems bigger. That's the only complaint 
I've seen on Amazing Flatties, is their bellies are bigger than they thought. Take away your 
breasts, suddenly you're just staring at your belly.” This was point was striking because, as I will 
illustrate later in the chapter, women and surgeons I spoke with often displayed gendered 
assumptions that other women would want flatter stomachs and bigger breasts when they had 
                                                             




reconstruction. Several people touted the “benefit” of women getting a bonus “tummy tuck” 
along with their DIEP-flap reconstruction, which uses abdominal tissue to recreate breasts. 
Hence, Emily’s story illustrates how the “tummy tuck benefit” is paradoxically available only to 
women who choose an additional surgery—reconstruction—that already works to conceal their 
normal bellies, while it is unavailable to women whose procedure—mastectomy alone—makes 
those normal bellies appear more pronounced.  
 Insurance plans are also required to cover the cost of prostheses for women who choose not 
to reconstruct and bras that will accommodate the prosthetic breast(s), but they do not typically 
cover the cost of special bras or clothing for women who stay flat and do not wear prosthetics. 
Eleanor, who referred to herself as a “uni-flat,” was happy with her surgical results and body, but 
described difficulty finding a bra that would support her one breast and fit properly under 
clothing: 
The biggest frustration I had, really, was not being able to find a bra for the breast that's 
still here, that offers support but is also flat…. Bras are made for people who obviously, 
ideally, have two breasts. I hate sports bras and I’ve been stuck wearing sports bras since 
the surgery because that’s what will stay flat. I don’t have dog-ears to accommodate, I 
don’t have problems with scarring and tightness around my chest, but wearing a sports 
bra means I have an elastic band around my chest that drives me nuts. (Eleanor, 42, ATM) 
Eleanor’s story illustrates how even when insurance companies provide services to women who 
stay flat, these services are structured around covering up women’s flatness and giving them the 
appearance of breasts.  
Organizational and Referral Practices 
 The typical organizational and referral practices in genetic medicine also funnel women 
toward reconstruction by fusing mastectomy and reconstruction and treating them as a singular 
decision. For example, breast surgeons, who perform mastectomies, and plastic surgeons, who 
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perform reconstruction, frequently work in teams. As a result, choosing a breast surgeon for 
RRM often involves being referred to work or consult with that team’s plastic surgeon (or vice-
versa). One participant expressed frustration with having to switch her breast surgeon in order to 
work with a plastic surgeon who would perform the reconstruction she desired: 
They often work in teams and have hospital privileges in different places. My first 
opinion, I just liked her. But the plastic surgeons that she would be working with kept 
saying, “You are a candidate for a lumpectomy, so why don’t you go that route?” And 
they could only give me A cups,44 if that. Because I wanted a different plastic surgeon, I 
couldn’t then stay with that doctor. (Leah, Age 55, CHEK2) 
Most genetic counselors (or other clinicians who order women’s genetic tests) immediately refer 
women for consultations with one of these surgical teams after sharing their positive results with 
them. Alexandra, a genetic counselor in a regional hospital system, explained her process: “And 
then as far as prevention, I mention to them that I'm going to be referring them to a team of 
breast specialists and to a GYN-oncology surgeon.”   
 Because breast surgeons partner with plastic surgeons, the architecture of the system 
funnels women along the pathway of care that Ingrid described in which providers rarely discuss 
the option to stay flat. Understandably, genetic counselors and primary care doctors or 
OB/GYNs who order genetic tests want to ensure that women at high risk for breast cancer 
consult with a breast surgeon so that they are fully-informed about their risk-reducing options. 
But then that breast surgeon passes the patient along to the plastic surgeon on their team. Eleanor 
explained that the standard message is: “You have to have a mastectomy, and we’re going to do 
                                                             
44 Leah is referring to the breast cup size that the first plastic surgeon said they could provide her. The 
possible size of reconstructed breasts is dependent on a number of factors, such as the amount of skin and 
fat along women’s chests and, if they are having flap surgeries, from the “donor” area of their bodies. It is 
also dependent on the plastic surgeon’s skill and training, and therefore it is common for different 




 In fact, even women who expressed to their providers that they wanted to stay flat 
conveyed that they were still encouraged to see a plastic surgeon “just in case.” Sylvia, an ATM 
mutation carrier in her 50s, described a conversation with her doctor: “I told her that I didn’t 
want reconstruction. I just laid it down on the line. She encouraged me to still go see the plastic 
surgeon just to check that off of my list.” Similarly, Ingrid shared her frustration with how her 
breast surgeon continued to bring up the possibility of reconstruction. “They really push the 
reconstruction. So, even yesterday when I was at the [breast] surgeon, and I have told her how 
many times I'm not interested? She said, ‘And you can still have reconstruction if you decide.’ 
They continually tell you.” 
 The organization of breast and plastic surgeons into teams benefits women by ensuring 
clear communication and collaboration between their providers. Moreover, genetic counselors, 
oncologists, and breast surgeons who refer women to plastic surgeons usually do so with the 
intention of providing women with information about “all of their options” and empowering 
them to make informed choices. They encourage women to go talk to plastic surgeons so that 
they can find out what the reconstruction process entails. However, the women in this study were 
typically not provided with all of their options; while most were referred to both a breast and 
plastic surgeon, very few women’s providers discussed staying flat with them as an option.  
 For example, Naomi, who is in her late forties and has a PALB2 mutation, described how 
her breast surgeon assumed that she would want reconstruction and repeatedly referred her to a 
plastic surgeon. “He always followed it up with, ‘Okay, I can do the nipple sparing surgery and 
we will make a date with the plastic surgeon.’ Always, always. The assumption is that you are 
going to see a plastic surgeon. That was it. There was no discussion of ‘Here are all the 
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complications. Here are all the potential problems.’ Never, ever.” Naomi clarified that she 
deliberately avoided seeing a plastic surgeon because she did not want to feel pressured to 
reconstruct.  
[In the social media groups] it was a really common theme that women were saying a lot 
of pressure from plastic surgeons to get reconstruction. That worried me because I know 
that I am resolved, but I am also vulnerable. This is a vulnerable time and it is a hard 
thing to think about, and to look at pictures with women without their breasts because 
you are mentally trying to see your own body like that. I was like, “This is really hard.” 
Part of my wanting to avoid seeing a plastic surgeon was that I didn’t want to have to 
fight with the plastic surgeon about reconstruction. (Naomi, Age 47, PALB2) 
Naomi felt she needed to remove herself from the typical patient pathway through genetic 
medicine in order to maintain her “resolve” to stay flat, which sharply highlights how the 
architecture of genetic medicine exerts pressure on women to reconstruct. Taken together, the 
stories from women in this section illustrate how that architecture is linked to assumptions that 
women will want to have reconstruction and that mastectomy and reconstruction are a package 
decision rather than separate choices.  
Highlighting Benefits, Obscuring Risks 
 Naomi was frustrated that her breast surgeon did not discuss the risks of reconstruction 
with her before repeatedly referring her to a plastic surgeon because, like many women in this 
study, she wanted to weigh information on the risks and benefits of procedures as she was 
making her surgical decisions. She shared how she “began writing up a document” that helped 
her determine “the least sucky thing” she could do. Similarly, Maya conveyed, “You have to 
choose from unpleasant choices and decide which one you can live with,” and Eleanor and Fiona 
explicitly mentioned “weighing the pros and cons” of their options.  
 Naomi’s experience of having “no discussion” with her breast surgeon about the risks of 
reconstruction points to a communication pattern I repeatedly observed during fieldwork and 
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interviews in which the benefits of mastectomy were highlighted while the risks of 
reconstruction were obscured. As Chapter Two illustrated, there are both physical and mental 
health benefits of mastectomy for women with high-risk mutations that warrant being 
highlighted. The health benefits of RRM are available to women with or without reconstruction; 
however, patients and providers in genetic medicine often fused the benefits and risks of 
mastectomy and reconstruction and discussed them as if they were one procedure. That tendency 
skewed women’s lists of “pros and cons” or “positives and negatives,” making reconstruction 
appear less risky and more beneficial than it is in practice.  
 For example, when Marianne discussed the numbness and tingling she experiences in her 
reconstructed breasts, she said, “I guess it is a tradeoff that seems worth it, for me, to have less 
anxiety about ‘Am I going to get breast cancer?’” Marianne’s reduced anxiety about developing 
breast cancer is important to her quality of life, so it should not be disregarded. However, it is a 
result of her mastectomy, while the numbness and tingling she was experiencing were side 
effects of reconstruction; there is not an inherent tradeoff between the two. Similarly, Colette 
shared with me that she sometimes felt frightened by one of the social media groups for women 
having or considering RRM because other women posted pictures of what went wrong. 
However, what she described were pictures of complications with reconstructive surgeries, not 
pictures of complications with mastectomies. “There are a lot of women posting pictures of 
things that have gone wrong. It can tend to be kind of scary to think about with necrosis and 
extra fat grafting. That is just a place mentally that I am not wanting to go to yet.” 
 This tendency to map the benefits of mastectomy onto reconstruction was also evident in 
other social science literature on BOC genetic risk. For example, in her study of women with 
BRCA1/2 mutations, Sharlene Hesse-Biber argues that breast surgeries are empowering for most 
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women despite the fact that “some women experience very difficult surgeries and reconstruction 
that leaves them with negative feelings about their bodies…. Why? By and large, women who 
have surgery have an unwavering belief in the power of preventive surgery to eradicate their risk 
and take away their fear of getting cancer” (Hesse-Biber, 2014, p. 125). Hesse-Bieber asserts that 
women who have difficult reconstruction experiences frequently still feel empowered by their 
surgeries because those surgeries eradicated their risk. Yet that cannot be the case for 
reconstruction, which is a cosmetic procedure; only mastectomy is a medical procedure that 
reduces women’s risk of cancer.  
 While the benefits of mastectomy were often highlighted and mapped on to 
reconstruction, many women I interviewed conveyed that the converse was not true—their 
surgeons did not adequately convey the additional risks posed by reconstructive surgeries. For 
example, when Ingrid shared her experiences talking with plastic surgeons, she said, “They do 
not explain it to you. They just say whether you qualify and they'll do a nice job for you. But 
they do not tell you all of the negatives, no.” Brenda noted that her genetic counselor explicitly 
told her that surgeons would not explain the potential side effects of reconstructive surgeries. 
How much information are women being given? That is one thing that I feel like I have 
heard from a lot of different people. My genetic counselor said that you need to advocate 
for yourself around these certain things because this surgeon is not going to talk to you 
about this or that issue. There are a lot of women who have had double mastectomies and 
reconstruction but no one ever told them about certain aspects about the healing or that 
they wouldn’t have any feeling in their breast or nipples. Or that they didn’t have the 
choice for nipple sparing surgery when at a time that would have been a choice for them. 
(Brenda, Age 39, BRCA1) 
Emily explained how she initially considered flap surgery until she learned through her own 
research what the process actually entailed. 
And at first, the flap sounded like a reasonable thing, because it was using my own body 
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parts. But then when we really looked into what was going into the surgery—as far as 
cutting the rib bones, removing blood vessels from the groin…. And this stuff is not 
really discussed with women. They tell women, “Oh, we can make you whole again.” 
And it’s like, “No, they can’t.” And there’s lots of complications involved in that and they 
really need to be honest with women and I don’t think they’re being honest with them. 
(Emily, Age 51, CHEK2) 
Like Emily, Naomi also had to do her own research to learn the potential side effects, issues, and 
complications involved in reconstruction: 
I didn’t’ know with the implants that they had to be replaced frequently; I didn’t know 
that they recommend that every couple years you go in to have an MRI to make sure that 
they are not leaking. You know, there is all of this other stuff that is information that 
women are not provided with. It almost seems paternalistic in the fact that you just don’t 
know. “We know what is best for you so don’t worry yourself about it. We will take care 
of it.” (Naomi, Age 47, PALB2) 
The experiences of Brenda, Ingrid, Emily, and Naomi illustrate how practices in US genetic 
medicine tend to highlight the benefits of mastectomy but obscure the risks of reconstruction. To 
fully uncover those risks, women often had to do their own research and consult with resources 
and individuals beyond their medical providers.  
 Moreover, when the risks of reconstruction are acknowledged or discussed with women, 
they are often positioned against the benefits of mastectomy as a result of the tendency to fuse 
the procedures. Most people weighing ‘not dying from cancer’45 against ‘experiencing chronic 
pain, infection, or edema’ would understandably choose ‘not dying from cancer.’ However, if 
they could choose ‘not dying from cancer’ without those other additional side effects, they might 
prefer that pathway. Yet the structures of genetic medicine rarely disentangle mastectomy and 
reconstruction or explicitly highlight that the cancer risk-reducing benefits of RRM are available 
                                                             
45 I am using this framing of the benefit of mastectomy because it is one that women often conveyed to 
me. I do not mean to imply that RRM eliminates women’s risk of dying from breast cancer or that dying 
from cancer is an inevitable outcome without risk-reducing surgery. 
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to women without the additional risks and side effects that might be incurred from reconstructive 
surgeries.   
Finding Alternative Pathways 
 Some women did uncouple mastectomy and reconstruction and deviated from the typical 
path through genetic medicine, but it was usually only after actively seeking out that 
information; women rarely conveyed that their decision not to reconstruct was rooted in 
guidance from health care providers. Instead, most of the women I spoke with who chose to stay 
flat had to conduct their own research and relied heavily on information and support from other 
women in Facebook groups like “Amazing Flatties.” These are private groups devoted to women 
without breasts, either because they chose not to reconstruct or had implants removed (i.e., 
“explanted”) after being unhappy with their reconstruction.  
 Women formed and participated in these separate support groups because they felt the 
other breast cancer-related Facebook groups and support forums were dominated by the voices 
and issues of women undergoing reconstruction. One participant shared how what she had 
learned about staying flat in one of these groups empowered her to change surgeons:  
There are two choices. And they don't really make that clear to you. And that's another 
reason why I'm seeing this surgeon. I saw a male surgeon here too. I saw a female and a 
male. The male was like—I told him I was thinking about not getting it [reconstruction]. 
When I had seen the female, I didn't think I wouldn't do it. But by the time I saw the male 
I'm like, "You know, I don't think I'm going to do that." And he basically said, "You'll lose 
a part of yourself. You'll lose a part of being a woman.” And I thought, “Yeah, I don't 
want you as the surgeon.” You know what I mean? There's more to me than my breasts. 
(Marlene, Age 35, CHEK2) 
 Another woman who was awaiting her scheduled mastectomy conveyed the breadth and 
specificity of the information she learned from other women in “Amazing Flatties,” and how 
those women were a more valuable resource than her doctors: 
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They post pictures. They provide me with support in terms of “This is what your outcome 
can be. This is what we suggest that we talk to your doctor about—questions to ask them 
because you don’t want reconstruction—this is what your surgery will likely be like, 
what your recovery will be like. We suggest that you have these things in your home and 
organize your life in this particular way around this particular time.” They are actually 
providing me with more information and knowledge about what is coming up than I have 
been provided thus far by my health care providers. Which you might expect in some 
way, but in another way, it is like “Wow, this is shocking!” Shouldn’t my healthcare 
provider be providing this information? (Naomi, age 47, PALB2)  
These digital support and information communities that help to make flatness visible were 
critical to many women’s decisions to challenge normative ideas about their bodies and deviate 
from the mainstream pathway through genetic medicine.  
 Together, the stories shared by women in this chapter illustrate how the structures, 
architecture, and discourses of BOC genetic medicine in the United States guide patients along a 
standard path that moves from genetic counselor to breast surgeon to plastic surgeon and works 
to highlight the benefits and minimize the risks of the procedures. This pathway helps, in part, to 
explain why the United States has higher rates of RRM and reconstruction than our peer nations 
(Guth et al., 2012; Laitman et al., 2014; Mamtani & Morrow, 2017). Simply meeting with a 
surgeon and being placed along that pathway of care makes it more likely that women will 
choose both mastectomy and reconstruction. In combination with the tendency to fuse the 
benefits of mastectomy and reconstruction and provider silence around both staying flat and the 
risks of reconstructive surgeries, these practices normalize breast reconstruction and position 
staying flat as the unusual alternative.  
Prioritizing Form Over Function and Feeling 
Breasts, Womanhood, and Identity 
When women choose to reconstruct, no matter how they arrive at that decision, they often 
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encounter gendered attitudes about their bodies that prioritize how they look over how they 
feel. As noted earlier in the chapter, women in previous studies and participants in this project 
expressed the importance of breasts to their identity (Nina Hallowell, 2000; Hesse-Biber, 
2014; Sischo & Martin, 2014). For some women, this value was connected to the appearance 
of their breasts—to how their breasts and bodies looked, both in and out of clothes and to 
others and themselves. For example, Leah, a CHEK2 mutation carrier who had flap 
reconstruction but now regrets her decision because of the complications she has experienced, 
expressed that she initially was opposed to staying flat because she was very large-breasted. 
Having breasts had been a very important aspect of her identity.  
I was adamant that I did not. I did not want to stay flat. My girlfriend, my best friend, 
would tell me how she would choose to stay flat and she was upset that I was even 
thinking about lumpectomy at all. She said that I should just get rid of them. They are just 
breasts. I told her, “You’ve always had little ones, so it is probably not a big deal for you. 
But I have always had big honkers so it is kind of a big deal for me.” I would not even 
entertain the idea of staying flat. (Leah, Age 55, CHEK2) 
Similarly, Adele, a single woman with a BRCA2 mutation, said, “There’s never really been any 
question for me about getting reconstruction.” Having breasts was particularly important to 
Adele because she did not have a partner. “I’d like to have a sex life and I don’t feel like I would 
be very comfortable having one without breasts…. You know, I’m single, I don’t have a very 
active dating life, but I’d like to have the ability to date and I feel like that could really be a 
problem.” Lily, who discovered her BRCA1 mutation at age 25, expressed how her concerns 
about her appearance made her more comfortable with the idea of risk-reducing salpingo-
oophorectomy (RRSO) than mastectomy and reconstruction:  
I have thought about the surgeries, and I am like, “Well, at least an oophorectomy isn't 
how I look.” And that's terrible because, actually, that does a lot more to you hormonally 
and all that, internally. But I am like, “Well, but I am only 27.” Getting my breasts 
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removed feels so crazy right now still. And I want to do it in the next ten years, but I want 
to get married, I want to have a kid, and I just want to be a regular 30-something person 
and not do that yet. (Lily, Age 27, BRCA1) 
All of these women expressed that having the appearance of breasts was an important part of 
their identity and affected their considerations regarding risk-reducing surgeries. 
In addition to valuing their breasts as visible markers of their femininity, many women I 
spoke with conveyed other important ways in which they felt connected to their breasts. Some 
cited their biological function, noting how their breasts had been successful at producing milk 
and feeding their babies. Wendy, who discovered her CHEK2 mutation in her early 60s and 
chose not to reconstruct, conveyed, “My breasts did a great job. They breastfed two kids, they 
were very good tits, and now they are gone and its fine.” Other women cited lactation as one 
of the factors affecting either the timing of their mastectomy or their decision to not have risk-
reducing surgery. Bailey, who had recently discovered her CHEK2 mutation and was not 
planning on having mastectomy, said, “I’d love to be able to breastfeed my own children.” 
Anita was planning on having RRM, but wanted to wait until she was done with childbearing. 
“The thought of having children has made me delay because I wanted to breastfeed, and so I 
plan to have my family first and then to do that procedure afterwards.”  
Other women I spoke with appreciated their breasts as a source of intimacy and sexual 
pleasure and were concerned about losing that aspect of their sexuality. Eleanor, who opted for 
a single mastectomy with no reconstruction prior to learning about her ATM mutation, was 
considering removing her remaining breast prophylactically. “Making the decision about my 
other breast, that's tough, because there's an element of sexuality involved that would be lost if 
I don't have that breast there…. It gives you sexual pleasure so having it or not having it are 
two different things.” Margaret, who had had recently learned about her CHEK2 mutation and 
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had scheduled mastectomy and implant reconstruction, told me, “I think the biggest thing is 
the loss of feeling that I will have in my breasts. That is probably bothering me the most, still. 
And the fact that my nipples and chest will be numb or not have any feeling or very little. And, 
you know, that is a very active erogenous zone so I hate to give that up.” Ingrid, who had 
already had RRM for her PALB2 mutation, shared that losing sensation in her breasts was very 
difficult. “A big part of losing the breasts that was hard was losing the sensation. You know, I 
hadn't been in a relationship in ten years, and then I'm in this wonderful, loving, physical 
relationship, and then I lose my boobs.”  
How You Look, Not How You Feel 
Yet women rarely described other people understanding that the link between their 
breasts and identity was multifaceted and not simply about appearance. Multiple participants 
shared stories about how their plastic surgeons focused almost exclusively on how their 
reconstructed breasts looked (or would look) rather than on how they felt (or would feel) from an 
embodied perspective. For example, Liza, who was 29 when she discovered her BRCA1 
mutation and had implant reconstruction, was pleased with the appearance of her reconstructed 
breasts. “My boobs right now literally just look like boobs.” However, she also conveyed that her 
plastic surgeon did not warn her about lack of sensation or potential numbness in her breasts. 
“He did such a great job, so I trust him. But feeling-wise and what to expect, he didn’t go into 
any of that.”  
Luckily Liza had learned about issues with sensation and numbness from her sister and 
women in support groups, so she was prepared for those side effects even though her surgeon did 
not inform her of them. But other women expressed that they were unprepared for the complete 




I would say there were two things as I look back that I feel like I wasn’t told about. I 
don’t know if they would have completely changed my decisions, but I feel like I was 
completely unprepared. One was the complete lack of feeling in my breasts. They take 
out all the nerves, and the skin is cold. There’s nothing there. It looks nice in clothes, but 
really, it can’t move at all. (Beatrice, Age 64, BRCA1) 
Talia, a BRCA2 mutation carrier who had flap reconstruction, stated, “I don't remember anyone 
talking about like how the breasts would feel to me, you know?” Adele, who was planning on 
mastectomy and flap reconstruction in the future, expressed wanting nipple-sparing surgeries in 
order to preserve sensation in her breasts. “I would like to keep my nipples in particular because 
they are erogenous zones.” Unfortunately, Adele was unaware that the goal of nipple-sparing 
procedures is to produce a natural appearance, not to enhance sensitivity. Only a small 
proportion of women who have the procedure retain some sensation, and when they do, it tends 
to be limited (Eisemann & Spiegel, 2018; Galimberti et al., 2017).  
Other women noted how awkward and uncomfortable their reconstructed breasts felt 
internally, and this was especially true for women with breast implants. Tara, a BRCA2 mutation 
carrier who discovered her mutation at age 27 and later had implant reconstruction, talked about 
her feelings about her breasts before and after her surgeries. “Prior to having this done they were 
part of our sex life and I enjoyed when he touched them. But after my surgery, I did not. They're 
so weird. You don't want anybody to touch them. So, then they just become not a part of it 
anymore. It's like I rarely take my shirt off when we're messing around. They became a non.” 
Another woman I spoke with at a conference who had discovered her BRCA1 mutation in the 
late 1990s described how she used to avoid hugging her family members and friends because the 
pressure against her breast implants felt so awkward. When her implants needed to be replaced 
several years ago, that discomfort prompted her to have flap surgery rather than replacing the 
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implants. She was happy about that decision, as she felt much more comfortable with breasts that 
were reconstructed from her own body tissue.  
However, some women who had had flap surgeries also described awkwardness and 
discomfort with their reconstructed breasts. Leah told me, “I feel like they are just lumps on my 
body.” Similarly, Scarlett, who had flap surgery, noted how different her reconstructed breasts 
felt, both internally and externally. “If I touch 'em it's like it's pressing—it's just like having a ball 
against your chest and you press against it and you can feel that ball pressing against you. It's 
nothing at all like, no comparison to real breasts. No comparison whatsoever.”  
As I will discuss later in the chapter, several participants experienced complications as a 
result of their reconstructive surgeries. Some of these women had surgeons who dismissed their 
reports of pain or discomfort, and instead focused on how their breasts looked. For example, 
Talia, who struggled with abdominal weakness and back pain after her flap surgery, shared her 
surgeon’s response at their initial post-reconstruction visit: 
And I remember when I went to her office, and she saw the reconstruction for the first 
time, she said, "Cute! I did a good job." And I'm like, "I'm a 29-year-old woman, and I 
just had my breasts cut off. My body's cut up and sewn back together. It's not cute, and 
it's not about you doing a good job." It was so hurtful. I said to her afterwards that I didn't 
understand that this is what my abdomen would be like. And she just was really 
insensitive and defensive about it and told me I could go to the gym to firm up my abs if I 
wanted. (Talia, Age 38, BRCA2) 
Not only was Talia unprepared for how her surgery would reduce her abdominal strength, but 
also her surgeon was dismissive toward her concerns about how her body felt and functioned. 
Rather than using Talia’s experiences of pain and muscle weakness to evaluate the outcome of 
the surgery and assess her performance, the surgeon concluded she had done a “good” job 
because Talia’s breasts looked “cute” to her.   
 Leah’s experience provides the most startling example of a woman’s appearance being 
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prioritized over her embodied experiences. While she desired reconstruction, she had explicitly 
requested not to have expanders put in because she had learned from other women that they 
could be extremely painful and uncomfortable. Yet when she awoke from her surgery, she 
discovered that her breast surgeon had inserted them. “I did expect to come out of the surgery 
flat until I had the DIEP46 reconstruction done, so I was shocked when I had expanders in and 
had boobs. She didn’t want me to see myself flat, but she made that decision without even asking 
me.” This surgeon was so concerned with how Leah would feel seeing herself without any 
appearance of breasts that she disregarded Leah’s concerns about pain and discomfort and chose 
to insert expanders, in direct violation of Leah’s wishes.  
 The attitudes and behaviors of Leah’s and Talia’s surgeons are rooted in what sociologist 
Gayle Sulik calls an “aesthetic approach to coping” (Sulik, 2011, p. 35), which emphasizes 
restoring cosmetic femininity after treatment and concealing the emotional and physical impact 
of breast cancer. Initially promoted by the mainstream breast cancer movement in the 1980s and 
1990s, it involves campaigns such as the American Cancer Society’s Reach to Recovery, which 
supplied women with prostheses when they were not regularly covered by insurance, and Look 
Good, Feel Better, which provides women with hair and cosmetic products and services after 
chemotherapy. These campaigns that centered on improving women’s appearance post-
mastectomy highlight how “traditional feminine image and self-presentation became a 
touchstone for helping women to face breast cancer with greater confidence” (Sulik, 2011, p. 
39). Providing women with services that focus on making them “look good,” especially harmless 
ones such as wigs and makeup, is not problematic if those services actually help women “feel 
                                                             
46 DIEP is a type of flap surgery in which skin, fat, and blood vessels are taken from women’s lower 
abdomens to reconstruct their breasts. 
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better.” However, when surgeons’ aesthetics are prioritized over women’s embodied experiences, 
a focus on women’s appearance is problematic.  
The tension between surgeons’ aesthetic priorities and women’s embodied priorities 
reflects a similar tension that medical sociologist Nina Hallowell found between women 
considering mastectomy and reconstruction and women who had already had the procedures. The 
women who had not yet had mastectomy or reconstruction embraced the aesthetic approach to 
coping and felt that “the materiality of the body, whether it is composed of flesh or silicon, was 
less important than having a body that looks feminine” (Nina Hallowell, 2000, p. 175). However, 
for the women who had already had RRM and reconstruction, how their body looked mattered 
much less than how it felt. In fact, many of these women reported appearing more feminine after 
their reconstructive surgeries, yet feeling less feminine as a result of the considerably diminished 
sensation in and sensitivity of their breasts (Nina Hallowell, 2000).  
Collectively, women’s stories in this section illustrate how the model of breast cancer 
survivorship that has long emphasized restoring “normal” feminine presentation has been 
imported into the dominant models of “previvorship.” The practices of US genetic medicine 
often prioritize form over function or feeling and construct real breasts—breasts that produce 
milk and are women’s embodied sources of pleasure—as disposable. Instead, the field embraces 
an aesthetic approach to coping that constructs the appearance of breasts as valuable, even when 
the process of creating that appearance poses additional risks to women’s physical health. Hence, 
as Elianne Riska argues in her examination of gender and the processes of medicalization and 
biomedicalization, “the construction of the enhanced body recaptures normative, heterosexual 




Leaving Women Un- or Under-Prepared  
Severe or Extended Side Effects 
 The combination of the practices highlighted thus far in this chapter—funneling women 
toward reconstruction, mapping benefits and obscuring risks, and prioritizing form over function 
or feeling—results in many women being un- or under-prepared for the potential side effects of 
reconstructive surgeries. For some women, the duration of their side effects and recovery was 
much longer than they were initially told. Leah shared, “I knew that recovering from it was going 
to be at least two or three months long. That, I was prepared for. But you can never really prepare 
for it enough because it is a very difficult recovery. I thought that after two or three months all 
would be good. I did not think that it was going to be ongoing daily pain for the rest of my life.” 
 Other women were unprepared for the muscle weakness and pain in the “donation” site on 
their bodies that is common with flap surgeries. For example, Beatrice, one of the women who 
felt unprepared for the lack of sensation in her reconstructed breasts, was also unprepared for the 
back problems she experienced after her reconstruction.  
I would say there were two things as I look back that I feel like I wasn’t told about…. 
One was the complete lack of feeling in my breasts…. Second, because they removed a 
lot of muscle, I tend to have lots of upper back problems, which I am sure I make worse 
because I’m sitting around using an iPad all the time. But that is the main consequence of 
the surgery, is back problems. (Beatrice, Age 64, BRCA1) 
Talia—the woman whose surgeon dismissed her concerns about abdominal weakness and instead 
focused on the “cuteness” of her breasts—was also unprepared for the muscle weakness she 
experienced.  
I didn't understand how much it would impact my abdomen, like the shape of it, the 
strength of it, primarily. And it totally--it changed shape fairly dramatically. It stuck out, 
and it was really firm, and it just didn't feel like my body at all. And the whole reason I 
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had decided to have that type of reconstruction [flap surgery] was to keep my body as 
much like my body as I could…. So, I was thinking so much about my breasts, that I 
wasn't thinking about the abdomen. And I couldn't sit up. You know what I mean? I lost 
all strength in that part of my body. And you use the lower abdomen a lot, so it was like I 
just felt super-weak, and I thought I would never be able to be strong there again. I still 
feel really sensitive about that.  (Talia, Age 38, BRCA2) 
Talia’s comment that she was so concerned about her breasts that she did not consider the impact 
on the other parts of her body involved in the flap surgery highlights the importance of providers 
emphasizing those risks and issues. It is not surprising that women would be more focused on 
what is happening to their breasts given that those breasts are the locus of the cancer risks they 
are attempting to manage. But surgeons perform these procedures regularly, are not making 
stressful personal decisions, and are aware of the range of issues women might experience. 
Therefore, it is incumbent on providers to highlight risks like these that patients may not yet 
know enough to inquire or think about.  
 Scarlett, one of the women in Chapter Two who decided to have mastectomy and 
reconstruction in part because it was less financially onerous than ongoing surveillance, was 
unprepared both for the range of complications that she experienced and their duration. First, she 
experienced necrosis while she had her expanders in:  
I had places that had turned black, that didn't heal on both sides. And he kept watching it 
and he kept saying, "I hope this is going to heal, but we don't know if it will or not." So 
finally, when I went in on my third week checkup he said, "We're going to have to go in 
and we're going to have to work on these places that didn't heal. I'll have to cut them out." 
Anyway, so the next week, which was almost exactly a month to the day that I had my 
surgery, I had to go back in and have some more surgery where they actually went on 
both sides and they cut all that black off and they restitched it. (Scarlett, Age 61, CHEK2) 
After they removed all of the dying and infected tissue, Scarlett had wound healing issues, which 
limited her ability to do the physical therapy she needed to regain mobility in her arms:  
When they removed those stitches I immediately started bleeding in a few places. And 
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within two days I had one place that had opened up probably a half an inch. I was sick. I 
was sick about it because that was the worst—that was one of the worst things that I went 
through because it took that place forever to heal. A long time to heal. And it prevented 
me from getting my physical therapy when I was supposed to because of the stress that it 
would put on that spot…. So, I couldn't like raise my arms up over my head. My arms 
were pretty much T-Rex.  (Scarlett, Age 61, CHEK2) 
 Scarlett also developed surgical emphysema, which is air that gets trapped 
subcutaneously as a result of trauma to the tissue during a surgical procedure. “I noticed that my 
voice had changed. It sounded like I was talking out of my nose. I remember my grandkids were 
there. They were laughing at me because of the way I was talking. Anyway, then I noticed all this 
swelling that was taking place around my neck.” Despite these symptoms, her plastic surgeon 
was dismissive. “My plastic surgeon, I e-mailed him the next morning and told him about it. But 
they were like, ‘Oh well. You know, we've never seen that.’ I thought, ‘Oh well? Must not be that 
big a deal.’” Thankfully, Scarlett happened to hear from her breast surgeon soon after that, who 
conveyed to her, “This is not normal.” He had her immediately return to the clinic for imaging 
and followed up with her over the coming days to ensure her breathing was unaffected.  
Reconstruction Regret 
Some women I spoke with who had not yet had mastectomy explained how witnessing 
their friends or relatives endure severe, ongoing side effects like Scarlett’s had affected their 
feelings about having reconstruction in the future. They shared stories of women who—similar 
to Scarlett, Leah, and Talia—had unexpected, especially difficult, and/or extended side effects, 
and as a result experienced “reconstruction regret.” For example, Maya, who had a lumpectomy 
to treat her breast cancer, was clear that if she had a recurrence, she would have a double 
mastectomy because of her PALB2 mutation. But she was still undecided about reconstruction. 
“You’ve got decisions and choices, but none of them are great.” Maya’s feelings about 
reconstruction were affected by friends who regretted their decisions. “I know, personally, at 
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least three women who've had their implants removed because of pain difficulties and just being 
fed up with it.” Josephine, who is 41 years old and has a CHEK2 mutation, is currently 
undecided about whether or not she will have RRM. However, unlike Maya, Josephine is very 
clear that if she does decide to have her breasts removed, she will not do reconstruction because 
of the regrets she has heard from other women. “Almost everybody has some kind of regret 
about it. The couple people I have been DM-ing with on Twitter with were like, ‘Let me tell you 
about the DIEP’ or whatever one they did. ‘I wouldn’t do it again’ is what at least two people 
have told me.” 
 Leah’s story was the most striking firsthand account of reconstruction regret that I 
encountered in my research. As I illustrated earlier in the chapter, Leah never considered staying 
flat before she had her surgeries, and even rebuffed her best friend who recommended not 
reconstructing. Leah originally had size DD breasts, and having breasts was important to her 
identity and sense of self. But after dealing with daily pain and discomfort under her arms and 
across her abdomen for over a year, she wishes she had heeded her friend’s warning.  
Well, if I had to do it over again, I probably would have remained flat and not had the 
reconstruction done…. I have like a rope going across my abdomen because it’s like a lot 
of cording that my body formed and there is nothing I can do about it. Still, I feel like I 
might have lymphedema going on, but I have not had the time to see my physical 
therapist for it. And there is always some kind of pain involved with it. I just wish I 
would have stayed flat…. It is awful. (Leah, Age 55, CHEK2) 
Leah did not feel adequately prepared for the duration or severity of the side effects of her DIEP-
flap surgery, and therefore, despite originally feeling certain that she desired reconstruction, she 
now strongly regrets her decision.  
 The stories shared in this section from Leah, Beatrice, Talia, and Scarlett are a selection 
of many I heard from women about being un- or under-prepared for the risks and side effects of 
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their surgeries and/or regretting their decisions to reconstruct. What is especially striking about 
the lack of preparation for reconstruction is that, unlike mastectomy and RRSO, reconstruction is 
a cosmetic procedure, not a medical procedure. In highlighting that distinction, I am not implying 
that reconstruction lacks value or is a frivolous decision. As I illustrated earlier in the chapter, 
several women also shared stories about how important reconstruction was to their social and 
emotional well-being, and it is critical that women having medically indicated mastectomies 
continue to have access to insurance-covered reconstructive surgeries.  
 However, it is also critical for women to be fully and accurately informed about the 
physical health risks of reconstruction so that they can make truly informed choices. Yet, as I 
have illustrated, women often are not provided with the full range of risk and benefit 
information. Instead, the structures, architecture, and discourses of genetic medicine propel 
women toward reconstruction and emphasize form over function and feeling, leaving many 
women un- or under-prepared for side effects and living with reconstruction regret. Being 
adequately informed about the risks of reconstruction might not alter women’s decisions. For 
example, when discussing the two things she felt she was not told about, Beatrice said, “I don’t 
know if they would have completely changed my decisions, but I feel like I was completely 
unprepared.” But at minimum, additional information would likely make women feel more 
prepared—it could help them to calibrate their expectations and, as a result, cope better after 
their surgeries.  
 In addition, several women who had direct knowledge of the risks of reconstruction cited 
that awareness as a deterrent from having reconstructive surgery. For example, Tiffany opted to 
stay flat because she had witnessed her mother and sister both have severe complications with 
their reconstructive surgeries. 
 
210 
It kind of started with my mom's first surgery. Like I said, all she really had was nipples, 
so they put expanders in and all this crap. And she had problems. It knotted up in there, 
and she had to go in and they had to release the pockets, and move things around and all 
of that. And my sister, she had—it starts with a D47 now but it was called “tram flaps" 
back then—where they pull the stomach muscles and loop it and all that…. And my mom 
had to have hers redone now twice, and my sister still has an expander in from her second 
mastectomy. That hasn't been healthy enough to exchange it. (Tiffany, Age 54, CHEK2) 
Similarly, Holly, a CHEK2 mutation carrier who happened to work for a breast surgeon, cited her 
knowledge of the risks and side effects as a major reason she had chosen not to have mastectomy 
or reconstruction. “Working in a breast care center, I take phone calls from people that are like, 
‘It's red, it's infected, my nipple's turning black.’ Stuff like that that can happen, and I'm just like, 
‘I don't want that to be me.’” Hence, while there is no counterfactual, the perspectives of women 
who were more informed and understood the potential risks at a material level suggest that 
providing women with more precise knowledge of the risks and benefits of reconstruction might 
alter their decisions.   
Gendered Structures that Structure Gender 
 By highlighting how the structures of genetic medicine funnel women toward 
reconstruction, prioritize form over function, and leave them under-prepared for the side effects 
of surgeries, I am not asserting that surgeons and other health professionals intentionally 
encourage women to take on more risks, objectify their bodies, conceal information from them, 
or disregard their feelings and embodied experiences. Just as I noted in Chapter Two that most 
breast surgeons want to help women reduce their risk of developing breast cancer, most plastic 
surgeons want to help women “return to normal” and feel good about their bodies. However, 
                                                             
47 Tiffany is referring to DIEP-flap surgery. 
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intentionally or not, providers are participating in these macro-level processes, and drawing 
attention to them is important because they reveal how the practices that constitute genetic 
medicine are simultaneously gender-structured and work to structure gender.  
 Sociologist Raewyn Connell argues that gender is a process, or “linking concept,” that is 
constituted by practices and organizes social life (Connell, 1987, p. 140). That is, gender is 
simultaneously something we do and something that shapes what we do. Returning to Connell’s 
definition of structure as “the way practice (over time) constrains practice” (Connell, 1987, p. 
95), one can see how the structures of genetic medicine can simultaneously reflect the existing 
gender order and reproduce the individual, social, economic, and political practices that 
constitute that order. The gender order is, to some extent, always in flux because patterns of 
social divisions and power relations between men and women are not static. However, in the 
prevailing gender order in the United States, women are still frequently objectified, they are 
disproportionately judged by and valued for their appearance, and they continue to perform a 
significant majority of the physical, social, and emotional labor of childrearing. As a result, 
practices in genetic medicine emerge from those gendered social realities and sometimes 
reinforce them.  
 However, as Connell illustrates, social reproduction is one possible outcome of practices, 
but not an inevitable one. She argues that the effects practices have on practices can be either 
“divergent or cyclical”—they can lead to new and different practices or reproduce existing 
ones—and that cyclical practices are what institutionalize gender regimes and stabilize the 
gender order. “[G]ender is institutionalized to the extent that the network of links to the 
reproduction system is formed by cyclical practices. It is stabilized to the extent that the groups 
constituted in the network have interests in the conditions for cyclical rather than divergent 
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practice” (Connell, 1987, p. 141). Earlier in the chapter I illustrated how the architecture of 
genetic medicine, which is its “network of links,” funnels women toward reconstruction through 
regulatory, organizational, and referral practices. This is an example of cyclical practices 
institutionalizing gender. The pathways of care in genetic medicine emerge from gendered norms 
and assumptions about women’s bodies, and then being on those pathways through genetic 
medicine makes it more likely that women will, in fact, conform to those norms. Hence, one can 
see how the architecture of genetic medicine is both gender-structured and structures gender.  
 Similarly, the focus on how women look over how they feel after breast reconstruction is 
an example of cyclical practices stabilizing gender. The surgeons I spoke with at conferences 
genuinely wanted to empower women making the difficult choice to have and to help them 
recover and return to “normal.” However normalized bodies are gendered bodies. Moreover, 
plastic surgeons as a group have a strong professional interest in maintaining those norms and 
the high social value placed on women’s appearance because their “success” is defined by 
aesthetic outcomes. Hence, their practices, like the architecture of genetic medicine, are 
simultaneously gender-structured and structure gender. 
 Surgeons are only one of many groups operating in the Risk Management field of practices 
that responds to genetic risk. Genetic counselors, gynecologic oncologists, clinical geneticists, 
policymakers, insurance providers, advocacy groups, and people with genetic mutations are other 
critical actors in this field. As I have illustrated thus far through women’s decisions around 
reconstruction, many women with BOC genetic mutations engage in practices that reflect and 
reproduce the social value placed on women’s appearance. Other women engage in divergent 
practices, like staying flat, that disrupt and challenge gender norms. In the next section, I will 
examine circumstances in which women with genetic mutations participate in cyclical practices 
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that reflect and reinforce gendered norms and ideals for women’s bodies.  
Building Women's Bodies While "Cutting Them Down to Size" 
 Breast reconstruction does not just “structure gender” in a figurative or conceptual sense. It 
is a cosmetic surgical process that quite literally reshapes and constructs female bodies. Because 
breast reconstruction practices are also gender-structured and shaped by social and cultural 
gender norms, they are not neutral. Rather, they often help to build idealized feminine bodies that 
are thin, toned, and have large or perky breasts. For example, during a webinar for genetics 
professionals about reconstruction options, one plastic surgeon referred to DIEP-flap surgery as 
“a great way to get a free tummy tuck and a new breast.” This surgeon’s quip illustrates how 
breast reconstruction not only involves building new breasts, but also what advertising critic Jean 
Kilbourne refers to as “cutting women down to size”—encouraging them to occupy less physical 
space in the world and to make their bodies smaller and thinner (Kilbourne, 1999).  
 Brenda, a BRCA1 mutation carrier who was planning RRSO but not mastectomy, shared 
her concerns about how breast reconstruction practices contributed to these gendered norms:  
I have been noticing how a lot of the culture-dominant things are reinforced through these 
processes. Automatically assuming that women want to get breast augmentation. 
Automatically assuming that women want to get some kind of liposuction in order to 
reconstruct their breasts…. They are all bound up in this really dominant society, which is 
white Western capitalistic patriarchal culture, view that women’s bodies are this thing that 
need to appear a certain way to please other people, primarily men…  and that there is 
this one body type that women want to achieve that is wrapped up in being approved on 
by the public, in general, and society or anybody who wants to chime in on it.  (Brenda, 
Age 39, BRCA1)   
I initially met Brenda at a patient advocacy conference and later spoke with her in two in-depth 
interviews. During one of her interviews, she noted how grateful she was for the advocacy group 
sponsoring the conference because they help women access current, accurate information about 
their medical options and provide safe spaces for women to share their stories and experiences. 
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However, as a self-described “gender nerd,” Brenda was sensitive to how the discourses around 
reconstruction in previvor communities might reinforce stereotypically narrow 
conceptualizations of “ideal” feminine bodies.  
  Indeed, many women I spoke with participated in these discourses and felt positively 
about reconstruction precisely because it did or would help them achieve idealized feminine 
bodies. For example, at the patient advocacy conference where I met Brenda, there is an annual 
evening event, “Bare and Share,”48 in which women who have had mastectomy or reconstruction 
volunteer to semi-privately display their surgical “results” (i.e., their flat chests or reconstructed 
breasts) and discuss their experiences with women considering the procedures. Women gather at 
signs posted throughout the room that correspond to different types of reconstruction, some of 
them with their tops off and others fully-clothed.  
 At the Gluteal and Thigh Flap station, I met Isabella, Bryna, and Jane. Isabella and Bryna 
were both “models” at the station, and Isabella was especially friendly—she smiled throughout 
the event and encouraged other women to come over and talk with her. Jane had not yet had 
mastectomy or reconstruction, and she was surveying the room to consider her options. When 
she approached Isabella, Jane, who was quite thin, said, “See these thighs? Would they get rid of 
these?” Jane then asked Isabella if she would mind showing her scars. Isabella turned around, 
pulled down her shorts, showed Jane the incisions along the bottom of her gluteals, and noted 
that she had gone down two clothing sizes after the surgery. Jane responded, “Are you kidding?! 
From a what to a what?” Bryna, who had also had gluteal-flap surgery, said, “They gave me a 
complimentary tummy tuck, too, to even me out. I got rid of my baby pooch.” Jane turned 
sideways, pointed to her stomach, and said, “Oh, like this?” And when Bryna commented that 
                                                             
48 Like other proper names used in this study, this is a pseudonym. 
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Jane didn’t have a pooch, Jane replied, “Oh, that’s me sucking it in.”  
 Several women I interviewed also referred to these “side benefits” of their surgeries—the 
opportunity to have larger breasts and/or a “butt lift,” “thigh lift,” or “tummy tuck” that would 
make them appear thinner. For example, Liza who was only 30 when she had her mastectomy 
and reconstruction, said, “I knew that I wanted to try to get to my size and, if I could, get a little 
bit bigger. I figure since we have to go through it anyways.” Adele, who has a BRCA2 mutation 
and is planning on having DIEP-flap reconstruction, said, “I kind of almost look at it as the, you 
know icing on the evil, I guess. Because it’s not really cake. But that’s the one upside—that I can 
finally have big boobs.” Veronica, who has a BRCA1 mutation, also wanted her reconstructed 
breasts to be larger. “First of all, I asked the plastic surgeon to go up a size. I wanted bigger 
breasts. And I said, ‘I’m gonna get some benefit out of this, and so I want bigger breasts and I 
want that tummy tuck, we'll just keep digging.’ And, so I actually like my breasts better now than 
I did before, and I feel like, yeah, my stomach is flatter.” Marianne, who has a CHEK2 mutation 
and was in her late 50s when she had mastectomy and reconstruction, referred to her surgeries as 
a “win-win”: “I feel happy that I reduced my risk significantly. And I got some breasts that look 
better to me than they looked before.” Together, these stories illustrate how the gendered the 
focus on form and appearance in genetic medicine also reflects many women’s desires and 
priorities. Tiffany, a CHEK2 mutation carrier who chose not to reconstruct after her mastectomy, 
commented that “A lot of women are disillusioned into thinking ‘This is the fix-all, and I get new 
boobs in the process.’”  
 In fact, some women were so convinced that surgeries were a “fix-all” that they felt 
disappointed that they could not have procedures that would provide them with these “benefits.” 
For example, Colette, a CHEK2 mutation carrier who was in her mid-30s and had scheduled 
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implant reconstruction, shared how she initially had hoped for autologous tissue reconstruction. 
“So, at first, I thought that we could do the flap surgery, which means that they take fat from 
another part of your body. I thought, ‘Oh cool! It is a tummy tuck at the same time! So, if I have 
to do this maybe I’ll get the tummy tuck for what my son left me and get it off.’ But the plastic 
surgeon didn’t feel like I had enough.” Alexis shared how her sister, who tested negative for the 
BRCA2 mutation in their family, had wanted the reconstructive surgeries to “improve” her post-
baby body.  
My older sister, it’s been very interesting because she had shared with me that she wants 
breast reconstruction ‘cause she’s had three children, breastfed all three, and is not happy 
with her appearance. And she alluded to me that she was actually, I think, disappointed 
that she wasn’t [positive for a mutation]. (Alexis, Age 34, BRCA2) 
In contrast to Adele, who framed the possibility of having larger breasts as a “silver lining” in an 
otherwise bad situation, Alexis’s sister was only focused on the “benefits” of reconstruction. Her 
desire to improve the appearance of her body was so strong that she felt “disappointed” that she 
did not have a genetic mutation that confers risk for multiple cancers. As Alexis noted about her 
sister’s response, “I don’t think she’s fully absorbing what it would all mean.” Her sister’s 
narrow focus serves as a powerful illustration of the pressure on women to have their bodies 
conform to idealized social expectations.  
 The framing of reconstruction as a benefit or silver lining is linked to discourses that refer 
to the surgery as a “boob job,” which in turn can serve to obscure the risks of the surgeries. 
Amber, one of the two youngest participants in the study at age 23, was awaiting her scheduled 
mastectomy and flap reconstruction. She expressed how she framed reconstruction as a “boob 
job” in order to reassure herself about her decisions. “That is kind of how I look at it to make 
myself feel good about it. I just keep telling myself that it is a boob job. ‘It is just a boob job.’” 
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Naomi, who eventually opted not to reconstruct, explained how she also had initially viewed 
reconstruction this way before she fully understood the complexity and risks of the procedures. 
My assumption, like many people, previously, was that it was just like having a boob job. 
In my mind, that was exactly how I built it up. Okay, no big deal. I will just get implants 
or something. When I thought it wasn’t going to be so involved or complicated, I didn’t 
actually mind. I knew it didn’t meet my body expectations, but the reality is that it would 
probably be easier if the surgeries would be easier. That was before I really thought about 
what I was doing to my body afterwards. It was the fantasy of the breast reconstruction.  
(Naomi, Age 47, PALB2) 
Naomi’s story illustrates how a “boob job,” which entails augmenting existing breast tissue with 
implants, is a very different—and far less complicated—procedure than constructing entirely 
new breasts. The “fantasy” of reconstruction as a “boob job” simultaneously reflects how the 
risks of reconstruction are often obscured and serves to perpetuate the relative invisibility of 
those risks. In fact, Amber clarified that she intentionally used the fantasy as a coping 
mechanism to help her not think about the potential complications. When I asked her, “Is it just a 
‘boob job?’” She replied: 
No, it is a mastectomy. It is a lot different than a boob job because they have to 
completely take everything out and you won’t have sensation in your boobs anymore. I 
know that the scars are different. And I know it is different. I have really bad anxiety so if 
I think about having a major surgery like that it freaks me out and I won’t be able to 
sleep. I just keep telling myself that it is just a boob job to kind of get through it. I just try 
not to think about all the other details that go along with it. (Amber, Age 23, BRCA1) 
 
Gendered Pressure to Reconstruct 
 Brenda’s unease about the discourses and practices of reconstruction were rooted in a 
larger concern “that women don’t have the ultimate agency over their bodies.” She described her 
feelings during Bare and Share when she observed other women participating in conversations 
that constructed “ideal” women’s bodies as thin and/or large breasted:   
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It just makes me really conscious of how are other women in the room reacting to this? 
How are other people feeling? Do they have an eating disorder? Is this talk about, ‘Well 
of course there’s this side benefit of a tummy tuck!’ How is that making them feel? And 
how is that potentially going to impact their ability to get support from this group or get 
good treatment from their medical team? How much confidence did they feel to assert for 
what they wanted to happen for themselves, not only about their care, but their body 
overall? (Brenda, Age 39, BRCA1) 
Jessie, a CHEK2 mutation carrier, shared Brenda’s worry that some women’s decisions would be 
constrained by social, relational, or cultural factors. She said, “I hope they don’t get 
reconstruction just because they think they have to get reconstruction.” Both Brenda and Jessie 
understood that some women might choose reconstruction not because it felt like the best choice 
for them, but rather because, as Tiffany expressed, “Society says 'this is how a woman's 
supposed to look,’” or, as Eleanor conveyed, “the only socially acceptable decision is for you to 
have two breasts after surgery.” 
Unfortunately, several women in the study did convey that they or other women they 
knew felt social expectations and pressure to reconstruct. Emily, who discovered her CHEK2 
mutation after being diagnosed with DCIS, shared her experiences participating in an in-person 
support group for breast cancer survivors. “Almost everyone in my local breast cancer group has 
had reconstruction. But all they do is talk about how much pain they’re in, how much numbness 
they have, how it doesn’t look normal or natural, how they’re disappointed with the results. But 
yet, they felt like they had to get ‘em.” Unlike the women in Emily’s support group, Crystal, who 
was in her late 30s when she had implant reconstruction, expressed that staying flat sounded 
personally appealing. However, she also felt it was important to have the appearance of breasts 
given her relatively young age. 
And you know, staying flat sounded kind of nice, but I did feel like I was still young 
enough that I wanted breasts, the look of breasts, to balance me out. I thought to myself 
that if I were older then I probably would. You don’t have to worry about—after a few 
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years you have to get your implants redone. You don’t have to worry about that [if you 
stay flat]. And you don’t have to worry about bras, which I have always hated and much 
more now. It just seems a lot easier. It seems nice… But I guess for sanity reasons I got 
the reconstruction. (Crystal, Age 39, BRCA1) 
Even though Crystal expressed multiple ways she would have felt more physically comfortable 
flat, she still perceived having the appearance of breasts as the best way to protect her “sanity.”  
 Nina’s story provides the sharpest illustration of the social pressure some women feel to 
reconstruct. When I interviewed her, she was 35 years old, but she had learned about her BRCA1 
mutation nine years earlier, at age 26. At the time she chose to continue with surveillance rather 
than having RRM, and she formed an online support group for women at BOC genetic risk who 
chose surveillance because she felt there was little social visibility or support for that decision. At 
age 34, Nina was diagnosed with triple-negative breast cancer,49 and subsequently underwent 
chemotherapy, a bilateral mastectomy, and reconstruction. When I asked about her decision to 
reconstruct, she said, “I would have chose to go flat, I mean that would have been my preference, 
but I felt a lot of societal pressure to have breasts as a woman.” Nina chose implant 
reconstruction because she was concerned about the pain and extended recovery time involved in 
flap surgeries. Her expanders had been swapped with her implants only eight weeks before we 
spoke, so she was still experiencing discomfort and adjusting to life with her reconstructed 
breasts. “It hurts still. Things are sore and things are healing and things are itchy, and I can’t 
scratch them, and things are numb so I can’t relieve the pain, and there’s pressure.”  
 Nina later elaborated on social expectations she encountered about reconstruction. She 
                                                             
49 As explained in Chapter Two, when a breast cancer is “triple negative,” it lacks estrogen, progesterone, 
and HER2 receptors. Triple negative breast cancers are harder to treat than cancers with hormone 
receptors because they do not respond to hormone-blocking drugs. Women with BRCA1 mutations are 
disproportionately likely to develop triple negative breast cancer. While only 12-14% of breast cancers 
are triple negative, approximately 70% of BRCA1-associated cancers are (K. N. Maxwell, 2015). 
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remembered reading the critical comments people wrote about a Dove ad on Facebook in which 
shirtless breast cancer survivors were displaying their scars. “People are like, ‘Well, their 
insurance would have paid for reconstruction!’ And it was just so expected that they do that. 
There was so much negative comments.” In addition, Nina felt concerned about how negative 
perceptions of a flat body might intersect with the discrimination she already faced as a younger, 
tattooed Asian woman. 
I had just been promoted in my career, and so it just felt—I already have tattoos from 
when I was young and wild, and was gonna live a short life, right? So, I already feel that 
I’m treated as ‘less than’ because of that, and also being a woman of color. So, I wanted 
to try to assimilate as much as possible and avoid any sort of implicit bias. And I thought 
moving forward or advancing my career would be challenging if I looked sick. (Nina, 
Age 35, BRCA1) 
While Nina would have preferred to stay flat and understood reconstruction involved additional 
risks, she felt that a gender-non-conforming body might be perceived by others as looking 
“sick,” and that this could impact her professionally. She also conveyed that her surgical team 
encouraged her to reconstruct. “Both the surgeon and the plastic surgeon said it’s easier to do it 
now, and we’ll do—do somewhat skin sparing, do reconstruction. If you don’t like it and you 
don’t want to keep it, or it’s too challenging, we’ll take it out.”  
 Taken together, Nina’s experiences powerfully illustrate how gender circumscribes 
women’s choices in the risk management field of practices and how that field of practices works 
to reconstitute gender norms. Nina knew she would rather stay flat but felt she could not make 
that choice because of social expectations for how a feminine body should look and the gender 
and racial discrimination she faced in the workforce as an Asian woman. People and practices in 
genetic medicine are also shaped by those gendered expectations, leading Nina’s surgeons to 
view and frame reconstruction as the “easier” choice, despite it being riskier and more 
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complicated than not reconstructing. In turn, by propelling many women toward reconstruction, 
these genetic risk management practices reify social expectations for “normal” feminine bodies, 
thus reconstituting the gendered norms from which they emerge. 
Resisting Gendered Structures 
 Not all women who had or were planning reconstruction agreed with the discourses and 
practices that encouraged them to conform their bodies to gendered expectations. For example, 
Judy, who was in her mid-forties and had an ATM mutation, described how her surgeon had 
discussed DIEP-flap surgery with her. “Well, the plastic surgeon was like, ‘You can kind of get a 
tummy tuck with it.’ And I was like, ‘I am already losing one thing, why would I want to tummy 
tuck too?’” She eventually chose to have implant reconstruction instead. Leah shared how 
removing that abdominal tissue for her DIEP-flap surgery had an unexpected psychosocial and 
emotional impact on her: 
Having the DIEP and going through it and thinking you are going to be skinnier because 
they are taking your abdominal fat from your kids that you have accumulated. This is 
going to sound weird, but having that taken off of me was a weird feeling. It was like I 
never carried babies in my body. That pouch was always there because I had birthed three 
kids. So, having that removed, it was nice because now I am going to fit into some things 
better, but not nice because, wow, all evidence of having been pregnant and birthing kids 
is gone. (Leah, Age 55, CHEK2) 
Leah felt ambivalent about having a flatter stomach after her reconstruction. She welcomed it 
because she fit into smaller clothes, but mourned it because the extra weight on her abdomen was 
an embodied reminder of the physicality and materiality of motherhood. By noting that it was 
“going to sound weird” that she missed that weight, she simultaneously acknowledged and 
challenged the assumption that women should want to be thinner and have flatter stomachs.   
 Other women resisted the notion that larger breasts are always better. Hannah, a BRCA2 
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mutation carrier who, along with Amber, was one of the two youngest women in the study at age 
23, shared how her experiences trying to “go bigger” with her implants left her dissatisfied. 
I tried going bigger for a bit with the expanders, but I hated it. So, I had her make me 
small when she did the reconstruction. It wasn’t me. It really wasn’t me. Everyone was 
like, “Go bigger you’re getting your boobs done, you’ll love it!” I tried it and I didn’t like 
how my clothes looked. I didn’t like how I looked. I was like, “I have been flat chested 
my whole life. It is one of my favorite traits about me.” (Hannah, Age 23, BRCA2) 
Colette also did not want to be bigger, and in fact was looking forward to reducing the size of her 
breasts. “I am going to have a reduction so I will be smaller than I am now, which is something 
that I wanted.” Colette’s experiences also highlight how women do not uniformly conform to or 
resist gendered expectations, as she was one of the women who felt disappointed about not being 
able to “benefit” from the “free tummy tuck” provided DIEP-flap surgery.  
Empowerment or Constrained Agency?  
 In her study of women with BRCA mutations, Sharlene Hesse-Biber argues that women 
who have support for and feel “in control” of their risk management decisions are empowered by 
them, while women who are pressured to have preventive and reconstructive surgeries are more 
likely to experience regret. She asserts, “What have we learned? In the end, a woman can be 
empowered regardless of her treatment choice as long as she takes control of the decision-
making process”(Hesse-Biber, 2014, p. 124). To illustrate this point, Hesse-Biber shares the 
experiences of Caroline and Liz. Caroline always knew “there was no question” she would have 
risk-reducing surgeries if she was BRCA-positive. Hesse-Biber claims, “Most important in 
making Caroline’s experience an empowering one is her own confidence in preventive surgery 
being her own decision, and the right one” (Hesse-Biber, 2014, p. 120). In contrast, Liz initially 
opted for surveillance but eventually decided to have a mastectomy and a hysterectomy after one 
of her doctors told her that screening was “not enough.” Hesse-Biber asserts, “Liz’s experience is 
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disempowering, not only because of the circumstances leading up to the surgeries but also 
because she is uncertain about her decision when she reflects on it” (Hesse-Biber, 2014, p. 123).  
 However, as I have illustrated in this and the previous chapter, there are multiple ways in 
which the structures and architecture of BOC genetic medicine propel women toward RRM and 
reconstruction. That encouragement is rarely overt and explicit. Rather, the Risk Management 
field of practices funnels women toward reconstruction and encourages them to prioritize their 
appearance over their embodied experiences whether individual clinicians embrace and employ a 
rhetoric of choice (as many genetics professionals do) or are more directive and explicitly tell 
women to have surgery.  
 As individuals, we have agency and make choices, but our decisions are always filtered 
through and constrained and enabled by our social worlds. I have illustrated in both this chapter 
and the previous chapter that the structures and architecture of BOC genetic medicine in the 
United States funnel women toward RRM and reconstruction, making those choices appear 
natural and normal. Hence, when Caroline stated that she always knew she would have risk-
reducing surgeries and reconstruction, her knowledge and decisions were not formed outside of 
the practices or influence of genetic medicine. We are never outside of structure or culture. 
However, it is often only when our decisions run counter to structures or culture, as Liz’s 
decisions initially did, that the pressure they exert becomes visible. The practices in genetic 
medicine that funnel women toward RRM and reconstruction are like an ocean current: if you 
swim against the current, you feel its force, but if you float or swim with it, it is barely, if at all, 
noticeable. Hence, a key difference between Caroline’s and Liz’s surgical experiences was not 
whether those experiences were influenced by external factors or pressures; both women were 
swimming in the current. Because Caroline was swimming with the current, it was invisible to 
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both her and Hesse-Biber. Conversely, in trying to swim against the current, Liz rendered it 
visible. 
Side Effects Matter 
 The fact that Caroline experienced no unexpected complications or extended side effects is 
also integral to the very feeling of being “in control” that Hesse-Biber argues is essential to 
women’s “empowerment.” Hesse-Biber conveys that Caroline described her surgeries as 
“‘literally a breeze,’” and that she expressed bewilderment about why other women sometimes 
felt unhappy with their choices. “‘I don’t know why people have such bad experiences. I don’t 
know if that’s because they weren’t ready, if their doctors maybe weren’t right for them, I’m not 
sure. I knew what I was going to do was going to be good for me in the end’” (Hesse-Biber, 
2014, p. 120). However, there is no way for any woman to know, in advance, that her decisions 
are “going to be good for [her]” because women do not have control over the physical outcomes 
of their surgeries.  
 Several women in this study—for example, Leah, Talia, and Scarlett—initially felt certain 
about and “in control” of their decisions to have RRM and reconstruction. However, they later 
expressed varying degrees of regret about those decisions because they felt out of control when 
they experienced severe or extended side effects that were not in line with their expectations. 
Hence, much like women’s decisions are always in some way shaped by the structural systems 
that encourage them to reconstruct, women’s subsequent feelings about their surgeries are always 
filtered through and influenced by their knowledge about the potential side effects of the 
surgeries and their actual surgical outcomes. When those outcomes are positive or align with 
women’s expectations, the impact of side effects tends to be invisible, leaving women like 
Caroline happy and befuddled by other women’s dissatisfaction. Conversely, negative or 
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unexpected outcomes like Leah’s chronic pain and abdominal roping are often hard to ignore 
given the impact of those side effects on women’s daily well-being and quality of life.   
 Understanding that negative side effects and a misalignment between expectations and 
outcomes are major factors in women’s post-surgical satisfaction helps to explain why many 
women in this study who had reconstruction expressed regret about their decisions, but none of 
the women who stayed flat did. The range of potential side effects and complications for 
mastectomy alone is considerably narrower than the range for mastectomy with reconstruction. 
Hence, women who choose not to reconstruct may be more likely to be satisfied with their 
decisions because there is a reduced statistical likelihood that they will have a complication or 
side effect or experience misalignment between their expected and actual outcomes. 
Staying Flat, No Regrets 
 Most of the women I spoke with who stayed flat vociferously conveyed their satisfaction 
with their choices. For example, Tiffany stated, “I have no regrets going flat. I wear stuff now I 
would have never worn before. I was raised very modest. My dad was a minister, and now I can 
wear tank tops and all kinds of stuff with no bra, no tan lines, no cleavage, no breast showing, 
and I actually really feel free. Free! That's the only way I can explain it. It’s like, ‘Finally!’” 
Wendy described feeling strong and empowered by her decision to stay flat, in part because she 
was actively resisting gendered norms. “It is like a warrior. I look in the mirror at my scars, and 
I’m delighted. Society tells you have to look a certain way, and it’s sad.” Jessie also expressed 
her happiness with her decision not to reconstruct, noting that if she felt differently in the future, 
she could still have it done.  
[I’m] incredibly grateful that I didn’t do reconstruction…. My best friend from high 
school had reconstruction, she looks like she’s been stabbed. She’s had nothing but 
problems. So, I’m very, very happy and comfortable with my decision. Every day I am 
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very happy and comfortable with my decision. That’s not saying that sometimes breast 
cancer doesn’t stare me back in the mirror like a vengeance, but at the end of the day I’m 
very, very happy with my decision. Or I’d have reconstruction tomorrow, and that’s why I 
don’t is, I’m very happy with my choice. (Jessie, Age 48, CHEK2) 
 In fact, the only woman who stayed flat who expressed any dissatisfaction was Ingrid, 
and she was not unhappy with her decision. Rather, the surgeon who performed her mastectomy 
was a general surgeon, and she left extra skin behind. Ingrid disliked how the loose skin on her 
chest looked, but more importantly she felt concerned that the skin contained breast tissue or 
cells that would elevate her risk: 
I'm fine with not having breasts, I really am. However, because of this genetic mutation 
and because I keep on getting the cancers, I needed to have all my breast tissue removed, 
and she did not do that completely. So. I just saw her yesterday, I just had a five-month 
follow-up with her yesterday. She left a lot of skin. I don't know if you've seen pictures of 
this, but she left a lot of skin on the prophylactic breast. So, I will need to go for a follow-
up surgery…. If I didn't have the genetic component, I probably would be ok with the 
breasts the way that they are… but in the end, the bottom line is I want to do everything I 
can to not get the cancer again. (Ingrid, Age 62, PALB2) 
 Like Ingrid, other women who stayed flat expressed that they, in part, made the choice 
because they felt it conferred their best chances of survival. For example, Marlene referred to the 
iatrogenesis inherent in reconstructive surgeries when she posed the rhetorical question, “Why 
would I want to create another risk by reducing a risk?” Similarly, Wendy conveyed that her 
decision was affected by the recent finding that certain types of breast implants were associated 
with the development of a rare form of lymphoma. She explained, “I don’t care if it’s 1 in 5 
million. I want to give myself the best chance of survival.” For Wendy, any additional risk posed 
by a cosmetic surgery was too high for her to consider it a viable option. Emily was also 
concerned about added risks posed by reconstructive surgeries because, as a diabetic, she was 
disproportionately likely to have difficulties with wound healing. “Knowing that again, being 
diabetic, I was at high risk anyway, I thought to myself, ‘Why do I want to chase after perfection, 
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when no matter how talented a plastic surgeon is, it can never give me back what I lost?’” 
Restructuring Gender 
 Emily’s concerns about risk intersected with her disinterest in “chasing after” an idealized 
feminine body—she saw staying flat as the best way to minimize risks to her physical health and 
as a means of resisting gendered norms. However, whether or not women explicitly conveyed a 
desire to do so, staying flat inherently involves challenging gendered expectations for women’s 
bodies. One of the most striking examples of how linked breasts are to womanhood was 
illustrated by a thread Eleanor shared from “Amazing Flatties.” I spoke with her after HB2 had 
passed in North Carolina. This anti-transgender state bill restricted people to using the bathroom 
for their sex assigned at birth. Eleanor conveyed that other people had attempted to stop several 
women in the group who lived in North Carolina from using a women’s restroom because they 
were assumed to be transgender. The transphobia described in these stories was disturbing. In 
addition, these incidents revealed how breasts are such a powerful visible marker of womanhood 
that other people assumed that women without breasts must “really” be men. Hence, just by 
moving through the world in their flat bodies, women who choose not to reconstruct disrupt 
social and cultural constructions of idealized femininity.  
 Given the strong link between breasts and womanhood, it is not surprising that several of 
the women who chose to stay flat did explicitly challenge these normative, idealized 
constructions of women’s bodies. Naomi, who is a biology professor, researched the peer-
reviewed literature on her options before choosing not to reconstruct. She explained: 
I do know that breasts are not my body, they are not me, and they do not define me. All of 
the surgeries involved and all of the complications that I have learned about—not through 
my doctors, which really bothers me. In all the research that I had to do on my own, I 
started writing up a document that I could share with people at some point of these 
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studies. Okay, what are the complication rates after the first year of surgery? There are 
meta-analysis studies. What are the complications after a couple years? What are the 
satisfaction rates of reconstruction and without reconstruction? Is there that much of a 
significant difference? I started reading all of these studies and looking at pictures of 
women with different reconstruction. I started reading “Amazing Flatties” and those 
different kinds of websites. I decided, look, none of these decisions are great for me. It all 
sucks. What for me is the least sucky thing that I can do? That is having the mastectomy 
and then stopping there in terms of continuing surgeries. I just do not want all of that to 
meet some kind of conception of what my body should look like in front of other people. 
I know that for a lot of women, that would help them, but I think for me it would not. It 
would feel like I am doing this thing to meet societal expectations and that is continuing 
to injure my body. That was why I made that decision. (Naomi, Age 47, PALB2) 
Naomi’s decision to stay flat was partially rooted in the knowledge she gained through her 
research on the literature on reconstruction and through connecting with other women who had 
faced decisions about breast surgeries. But her decision was also linked to her sense that 
reconstruction was about meeting “societal expectations” for women’s bodies and appearing 
feminine to others. Because perpetuating those gendered expectations involved taking on 
additional physical health risks, she perceived it as “injury” to her body. Reconstruction would 
have left Naomi feeling less whole, not more.  
 Eleanor’s decision to stay flat was also strongly shaped by her identity as a feminist and 
her dissatisfaction with social and cultural constructions of gender that value women and their 
bodies for how they look and as objects of desire. 
I have issues with cultural constructions of gender that matter on appearances. I felt like 
signing up for reconstruction surgery was only going to perpetuate that…. I don't feel like 
I need to hide behind some fake breasts to make other people feel more comfortable…. 
I’m sure you’ve figured it out, but I’m a feminist, and I’ve been a feminist for as long as I 
can remember. And I feel we should not be defined by our outward appearance, we 
shouldn’t be defined by whether we conform to the cosmetic and beauty industry’s 
definition, or the porn industry’s definition of what a woman should look like. (Eleanor, 
Age 42, ATM) 
Like Naomi, Eleanor felt that reconstruction was mostly about making “other people feel more 
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comfortable” and “conforming” to external, idealized standards of feminine beauty. She felt that 
choosing reconstruction would serve to “perpetuate” the gender order, and so instead she actively 
challenged and attempted to disrupt the reconstitution of that order by staying flat.  
 Women who stay flat actively challenge the gendered structures of genetic medicine and 
the ways risk management practices reinforce gendered expectations for women’s bodies. Hence, 
they exhibit a high degree of agency, and may, in turn, also be more likely to feel and express 
satisfaction with their choices. On the surface, this might appear to support Hesse-Biber’s 
argument that women with BRCA mutations are “empowered” by their surgical decisions when 
they feel in control of them. However, Hesse-Biber’s argument is tautological—empowerment 
is, in part, defined by being in control. She conflates empowerment with satisfaction, and women 
being empowered in their surgical decisions is not the same as them being satisfied with those 
decisions. As this chapter has illustrated, when women are only or mostly given information on 
one set of options (reconstruction), and both the risks of that option and the alternative (staying 
flat) are obscured, they are neither empowered nor in control.  
 In addition, focusing on whether women are “empowered” by their surgical decisions 
perpetuates two common practices in research on BOC genetic medicine. First, it focuses 
attention on the individual or relational dimensions of women’s decisions rather than on how 
structures constrain and enable those decisions. Second, examining whether women are 
“empowered” in their surgical decisions obscures the impact of surgical outcomes on women’s 
lives. The absence of physical complications among women in this study who stayed flat was 
striking, particularly when compared to the severity and duration of side effects reported by 
women who had reconstruction. Focusing on women’s decision-making diverts attention away 
from how the structures of genetic medicine frequently leave women ill-equipped to make those 
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decisions in the first place and un- or under-prepared for the outcomes of those decisions.  
Conclusion: Which Risks? 
 This chapter shed light on the mutually constitutive relationships between gender and 
breast reconstruction practices in the United States. Drawing on the experiences of women with 
BRCA and moderate-risk BOC mutations, I illustrated three structural elements of breast 
reconstruction practices within US genetic medicine. First, women are propelled toward 
reconstruction through silence among providers about the option to stay flat, health insurance 
policies that privilege reconstruction, organizational and referral practices that fuse mastectomy 
with reconstruction, and practices that emphasize the benefits of mastectomy but minimize the 
risks of reconstruction. Second, reconstruction practices prioritize how women’s breasts and 
bodies look over how they feel from an embodied perspective. Third, practices in BOC genetic 
medicine obscure and minimize the potential risks posed by reconstruction, leaving many 
women under-prepared for the side effects of the surgeries. 
 I argued that these practices reveal how BOC genetic medicine is both structured by the 
prevailing gender order in the United States and works to structure and reconstitute that order. 
That is, the field of practices that responds to BOC genetic risk simultaneously reflects and 
reifies constructions of "ideal" feminine bodies: bodies that appear thin and toned and have large 
or perky breasts. By encouraging RRM, the practices of BOC genetic medicine treat real 
breasts—ones with sensation or that feed babies—as disposable because of their risk of 
developing cancer. Yet, as this chapter has shown, the appearance of having breasts is 
constructed as essential, even when creating that appearance through reconstruction poses 
additional risks to women’s health.  
 This chapter highlighted a tension in the Risk Management field of practices—it is 
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centered on reducing women’s risks, but which risks? Current practices in genetic medicine serve 
to magnify certain risks while minimizing others. In the previous chapter, I highlighted how 
women's risk of developing breast cancer is emphasized and targeted for reduction through 
mastectomy. In this chapter, I illustrated how the psychosocial risks generated by mastectomy are 
emphasized and targeted for reduction via reconstruction, while the risks that are iatrogenically 
added through reconstruction, such as scarring, chronic pain, muscle weakness, necrosis, and 
infection, are often minimized or overlooked. Thus, the cosmetic procedure that makes risk-
reducing mastectomy more socially acceptable also makes it more medically dangerous. 
 There is no question that the risk of developing, and potentially dying from, breast cancer 
is more severe than the risks of side effects and complications from reconstructive surgeries. But 
mastectomy, not reconstruction, is what reduces women’s breast cancer risk. Hence, risk-
reducing mastectomy is a medical procedure that increases women’s social and cosmetic risks. In 
contrast, breast reconstruction is a social and cosmetic procedure that increases women’s medical 
risks. Given that there is not parity in either the risks or benefits of the procedures, uncoupling 
mastectomy from reconstruction and making their unique risks and benefits visible seems critical 
in a field focused on risk-reduction and empowering women through knowledge. However, as I 
illustrated in this chapter, current practices in BOC genetic medicine in the United States tend to 
do the opposite. As a result, many women are un- or under-prepared for the risks and side effects 
of their reconstructive surgeries.   
 Women’s lack of preparation for reconstruction is striking because it is a cosmetic 
procedure with numerous potential risks and limited benefits to women’s physical health. 
However, women being unprepared for surgical side effects was not limited to breast 
reconstruction. In the next chapter, I will examine risk-reducing salpingo-oophorectomy (RRSO) 
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practices in the United States. In contrast to both mastectomy and breast reconstruction, RRSO 
has robustly-established, statistically-significant medical and physical health benefits for women 
at high risk of ovarian cancer. However, similar to the stories women shared about the side 
effects of breast reconstruction, women were also often un- or under-prepared for the impact of 
medically-induced menopause, which affects their cognitive, emotional, sexual, and physical 




Chapter 4: "The Doctor Didn't Tell Me That":  
Under-Preparation for Medically-Induced Menopause 
“I’m on a roller coaster ride that’s going so fast since my oophorectomy.” (Dorothy, Age 
53, BRCA2) 
“You’re 40 and going into menopause. No sort of acknowledgment of what that means, 
the sexual repercussions. All the things that come with menopause were just not 
acknowledged at all.” (Marci, Age 39, BRCA2) 
“As much as I complain about the implants and the fake breasts, the ovaries have 
definitely been more of an impact on my body overall, getting those removed. And again, 
I didn’t really anticipate how much they were going to change me.” (Raina, Age 43, 
BRCA2) 
Introduction 
 Several epidemiological and clinical studies have illustrated that risk-reducing salpingo-
oophorectomy (RRSO) between the ages of 35 and 4550 is the single most effective intervention 
for improving survival rates for women with BRCA mutations (S. M. Domchek et al., 2010; A. 
P. Finch et al., 2014; Ingham et al., 2013; A. W. Kurian et al., 2010; Parker et al., 2013). Yet, 
despite these findings, there is far less social science research on women’s risk reducing 
salpingo-oophorectomy (RRSO) experiences than on their experiences with risk-reducing 
mastectomy (RRM) and/or reconstruction. Moreover, like with most mastectomy and 
reconstruction research, the limited social science research on RRSO tends to examine 
individual- or familial-level factors that shape women’s decisions about and responses to 
prophylactic surgery (Borreani et al., 2014; Nina Hallowell, Mackay, Richards, Gore, & Jacobs, 
2004; Mai et al., 2017).   
 Drawing on fieldwork at cancer genetics conferences and interviews with 33 women with 
                                                             
50 The recommended age range for RRSO for women with BRCA1 mutations is ages 35 - 40. Onset of 
ovarian cancer tends to be later among BRCA2 mutation carriers, so they can usually safely delay RRSO 
until ages 40 - 45 (A. P. Finch et al., 2014; National Comprehensive Cancer Network, 2018b). 
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BRCA mutations,51 this chapter examines how and why younger women who have RRSO are 
often under-prepared for the severity and duration of the side effects of medically-induced 
menopause. The first section of the chapter illustrates how tensions between patients' and 
providers' risk management priorities and contemporary social and medical discourses 
surrounding ovarian cancer, RRSO, and hormone replacement therapy (HRT) work together to 
encourage women to rush into RRSO without full knowledge of the surgery's side effects. I then 
explore biomedical discourses and broader social and cultural contexts that influence women’s 
under-preparation and under-treatment for medically-induced menopause. The chapter reveals 
how RRSO practices prioritize protecting the reproductive functions and potential of women’s 
ovaries over their non-reproductive functions and women’s daily well-being and comfort. I argue 
that these practices emerge from and reflect gendered, racialized, and classed constructs of 
women's bodies and roles.  
Rushed in Blind and Undertreated 
Reducing Cancer Incidence vs. Reducing Mortality 
  Early in my fieldwork, I observed a tension between the priorities of providers and 
patients in cancer risk management: most health professionals prioritize reducing ovarian cancer 
risk, while most patients and the media are focused on reducing breast cancer risk. It is 
understandable that women are concerned about breast cancer given that it is the most common 
                                                             
51 Because none of the moderate-risk mutations (MRMs) are associated with a statistically significant 
increased risk of ovarian cancer, I draw mostly on interviews with women with BRCA1/2 mutations in 
this chapter. However, some women with MRMs had salpingo-oophorectomies or hysterectomies because 
they were concerned about ovarian cancer. Therefore, when their experiences are relevant, I also draw on 
their stories. In addition, as I explain in Appendix B, all of the women with BRCA mutations who 
participated in the study learned about their mutations prior to natural menopause. 
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cancer in the United States, with 3,418,124 women living with the disease in 2015 (National 
Cancer Institute, 2018d; Noone et al., 2018). In comparison, ovarian cancer is relatively rare—in 
2015, there were 224,940 women living with ovarian cancer, and it is the 17th most common 
cancer in the United States (National Cancer Institute, 2018e; Noone et al., 2018).  
 However, despite breast cancer’s high prevalence, as one clinician said to me at a 
conference, “Ovarian cancer is what kills you.” Current five year survival rates for ovarian 
cancer are only 47%, in part because there are no effective ovarian cancer screening tools 
(National Cancer Institute, 2018e; Noone et al., 2018). While many women at genetic risk for 
ovarian cancer continue to get annual pelvic ultrasounds and/or blood tests for CA-125,52 these 
practices are not evidence-based or recommended (National Comprehensive Cancer Network, 
2018b; U.S. Preventive Services Task Force et al., 2018). Neither of these tests are sensitive or 
specific53 enough to be used for screening in either general or high-risk populations. In addition, 
randomized studies have shown no significant reduction in ovarian mortality among women who 
had pelvic ultrasounds and CA-125 tests (Jacobs et al., 2016; Pinsky et al., 2016). As a result of 
the lack of effective screening options, in nearly 60% of cases ovarian cancer is only caught after 
it has metastasized,54 and the five-year survival rate for these women is an abysmal 29% 
(National Cancer Institute, 2018e; Noone et al., 2018).  
                                                             
52 The test for Cancer Antigen 125 (CA-125) is FDA approved for monitoring the effectiveness of ovarian 
cancer treatment. However, it is not recommended for screening because it has a high rate of false-
positives and only detects approximately 50% of early stage ovarian cancers (U.S. Preventive Services 
Task Force et al., 2018). 
53 A test’s sensitivity refers to its effectiveness at identifying positive cases; a high sensitivity results in 
few false-negatives or missed cases. A test’s specificity refers to its effectiveness at identifying positive 
cases only; a high specificity results in few false-positives, or incorrectly identified cases. 
54 The epidemiological literature identifies three stages of cancer at diagnosis: localized (confined to the 
primary site), regional (spread to the regional lymph nodes), and distant (metastasized to other organs or 
parts of the body). 
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 In contrast, there are excellent breast cancer surveillance tools, such as mammography, 
magnetic resonance imaging (MRI), and ultrasound, all of which are supported by decades of 
evidence of clinical effectiveness.55 As a result, only 6% of breast cancer cases are identified 
after they have metastasized, while nearly two-thirds are found while the cancers are still 
localized (National Cancer Institute, 2018d; Noone et al., 2018). In turn, five-year survival rates 
for breast cancer are high: 90% overall, and 99% for the two-thirds of cases that are localized 
(National Cancer Institute, 2018d; Noone et al., 2018).  
 The effective early-detection tools and favorable survival rates for breast cancer help to 
explain why RRM is less commonly practiced in countries with national health systems. These 
tools and rates also illustrate why current clinical guidelines in the United States indicate that 
health professionals should discuss, not recommend, mastectomy for women at genetic risk 
(National Comprehensive Cancer Network, 2018b). RRM is a primary prevention tool, albeit a 
crude one. Because a majority of breast cancers are caught early, the vast majority of women 
diagnosed with breast cancer will survive, and most cases of breast cancer will not require 
chemotherapy. Hence, at the population-level, preventing breast cancer provides only marginal 
benefit over treating it. However, for ovarian cancer the opposite is true. A majority of ovarian 
cancers are discovered after they have metastasized, and a majority of women diagnosed with 
ovarian cancer will not survive. Therefore, preventing ovarian cancer provides significant benefit 
over treating it. 
 
                                                             
55 The overall effectiveness of mammography at detecting breast cancers that are not palpable is well 
established. However, the age at which scientific evidence supports using mammography as a screening 
tool in the general population (not among high-risk women) has been debated by experts in recent years. 
These debates center on the age ranges in which the benefits of mammography outweigh its risks (Bleyer 




 Because there are no effective surveillance tools for ovarian cancer and the prognosis for 
most patients is poor, health professionals working in cancer genetics, along with the clinical 
guidelines that inform their practices, place a high priority on managing ovarian cancer risk 
through RRSO. Linda, a genetic counselor, discussed how she introduces medical management 
options with her BRCA positive clients. “We talk about which ones are not really negotiable, 
meaning you really don't want to keep your ovaries. It's dangerous. We don't have a reliable way 
to detect that when it's curable.” Similarly, Steve, an oncologist, explained how RRSO is 
different.  
Oophorectomy for BRCA has become so robustly established that, if you don’t have a 
prophylactic oophorectomy at some point—I mean the issue is timing—but if you don’t 
have one at some point, then you really are swimming against medical advice. Whereas 
for prophylactic mastectomy, it is a little bit more balanced in terms of the presentation, 
as long as it’s not a breast surgeon.  
Both Steve and Linda are experienced BOC genetics health professionals, and they illustrate how 
genetics providers place a high priority on reducing ovarian cancer risk through RRSO. In 
contrast to this approach, patients and the media often focus more heavily on managing breast 
cancer risk through mastectomy. These different emphases in BOC risk management practices 
are produced through what I refer to as socio-clinical tension: a tension between the concerns 
and issues magnified in social contexts and those amplified in clinical contexts.  
 Medical providers are trained to make recommendations based on standards of care and 
current evidence from scientific, clinical, and epidemiological research. However, laypeople are 
not generic rational actors who make personal decisions about their health based solely on 
statistics and population-level data. Even models of individual health behaviors that are rooted in 
rational choice theory, such as the Health Belief Model, account for how people’s decisions and 
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actions are based on their perceptions of risks, benefits, and barriers, not the numeric estimates 
of their risks (Glanz, Rimer, & Viswanath, 2008). In addition, people’s perceptions are not 
formed in a vacuum—they are filtered through their emotional, relational, social, and cultural 
contexts. As more complex interpersonal and community-based theories of health behavior 
illustrate, individuals are influenced by the stories they see in the media, the issues they 
encounter in their communities and workplaces, their own life experiences, and those of their 
colleagues, friends, and family members.  
 Given breast cancer’s high prevalence, nearly everyone knows someone who has been 
affected by the disease. Moreover, even though five-year survival rates for breast cancer are 
nearly double those for ovarian cancer, because over 3 million women are affected by breast 
cancer, the absolute number of deaths from breast cancer is almost three times greater than the 
number for ovarian cancer. In 2018, the estimated number of female breast cancer deaths is 
40,920, while the estimated number of ovarian cancer deaths is 14,070 (Noone et al., 2018). 
Hence, somewhat counterintuitively, even though ovarian cancer is proportionally far deadlier, 
people are more likely to know someone who died of breast cancer.  
 Breast cancer also dominates media coverage, and as a result, the social imagination. As 
sociologist Gayle Sulik illustrates, “[B]reast cancer has become one of the most mass-mediated 
illnesses of our time” (Sulik, 2011, p. 113). Features on breast cancer are regularly printed in 
newspapers and women’s magazines and aired on local TV news and national morning programs 
like The Today Show and Good Morning America. One study that tracked coverage of cancer in 
major newspapers over a two-year period found that breast cancer was mentioned at least four 
times as frequently as any other cancer in headlines and at least twice as frequently in article text 
(Saywell, Henderson, & Beattie, 2000). Pink ribbons have become so ubiquitous that it would be 
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difficult to not know that they are the symbol for breast cancer. From Band-Aid, to the NFL, to 
Boeing, countless companies have commercially branded products that they sell or display in 
October during Breast Cancer Awareness Month (S. King, 2006; Sulik, 2011).56 There are also 
numerous breast cancer advocacy organizations that are household names and sponsor huge 
events in cities across the country, such as Susan G. Komen’s Race for the Cure and the Avon 
Foundation for Women’s Walk to End Breast Cancer (S. King, 2006).  
 Yet there is no comparable movement for ovarian cancer. As Sulik states, “October is 
now so closely identified with the cause of breast cancer that it is commonly referred to as 
‘Pinktober’” (Sulik, 2011, p. 48). However, outside of individuals in families affected by ovarian 
cancer, most people could likely not report that September is Ovarian Cancer Awareness Month 
or that its ribbon color is teal. While there are a handful of ovarian cancer advocacy 
organizations who sponsor local fundraising events, such as The Ovarian Cancer Research Fund 
Alliance and The National Ovarian Cancer Coalition, these groups—in visibility, size, 
participation, funding, and donations—are shadowed by those for breast cancer. The differential 
impact of Angelina Jolie's two Op-Eds also highlights how public and media attention on ovarian 
cancer is scant when compared to the focus on breast cancer. While Jolie's initial Op-Ed was 
extensively covered by media outlets, I only observed her Op-Ed on RRSO discussed in social 
media groups for BOC mutation carriers.  
 The tremendous visibility of breast cancer activism in the media combined with breast 
cancer’s high prevalence magnifies its risks and is reflected in women’s priorities around risk-
reducing surgeries. Over two-thirds of the 33 women with BRCA mutations who participated in 
                                                             
56 Several feminist advocacy organizations and social scientists have critically examined these practices 
of “pinkwashing” and the neoliberal consumer culture of breast cancer activism (Breast Cancer Action, 
2018; S. King, 2006; Klawiter, 2008; Sulik, 2011). 
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this study either had or were planning to have both RRSO and mastectomy. At the outset of this 
study, given my knowledge about clinical guidelines, ovarian cancer mortality rates, and the 
effectiveness of breast cancer surveillance tools, I expected many women with BRCA mutations 
to have had or be planning on RRSO but not mastectomy. Yet only three women in this study had 
(or intended to have) RRSO but were not planning on having a mastectomy. However, an even 
more surprising finding was that three other women in the study had undergone mastectomy but 
were “swimming against medical advice” and were not planning on having RRSO.  
 As Angelina Jolie illustrates, even when a woman’s family history involves ovarian 
cancer, she might still prioritize managing her breast cancer risk. Her mother died from ovarian 
cancer, not breast cancer, yet Jolie chose to undergo mastectomy first. In “My Medical Choice,” 
she invoked her “risk” as an explanation for this decision: “I started with the breasts, as my risk 
of breast cancer is higher than my risk of ovarian cancer, and the surgery is more complex” 
(Jolie, 2013). However, the standard medical recommendation to a 37-year-old woman with a 
BRCA1 mutation whose mother had died of ovarian cancer would be to have RRSO as soon as 
possible, not mastectomy. Hence, while Jolie’s statement is technically accurate, it depends on 
which risks you focus on. While Jolie’s lifetime risk of developing breast cancer was greater than 
her risk of developing ovarian cancer, her risk of dying from ovarian cancer was greater. In 
addition, removing women’s ovaries may also reduce their risk of developing and/or dying from 
breast cancer(Jacobson & Narod, 2018),57 but removing their breasts has absolutely no effect on 
their ovarian cancer risk or odds of overall survival. Yet like Angelina Jolie, despite these clinical 
                                                             
57 Recent research suggests the reduction in breast cancer risk may only be significant among BRCA2 
mutation carriers (Heemskerk-Gerritsen et al., 2015; Kotsopoulos et al., 2017), but the reduction in breast 
cancer mortality may only be significant among BRCA1 mutation carriers (Huzarski et al., 2013; K. 
Metcalfe et al., 2015). These differences in findings highlight the importance of disentangling cancer 
incidence and mortality outcomes in research. 
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guidelines and/or their personal family histories, many women in this study conveyed that they 
were initially more concerned about the prospect of breast cancer and the effects of mastectomy 
than the possibility of ovarian cancer or effects of RRSO. 
RRSO Is Quick and Easy 
 One of the reasons women tended to be more concerned with mastectomy and 
reconstruction than RRSO is that, as Jolie stated, with RRSO “the surgery is less complex” 
(Jolie, 2013). RRSO is almost always performed laparoscopically, and as a result is a relatively 
short and minimally-risky surgery. It is frequently performed as an outpatient procedure, on 
average lasts under two hours, and typically involves a brief recovery period of one or two weeks 
(Dawood, 1999; De Felice et al., 2017; Kenkhuis et al., 2010; Piszczek, Ma, Gould, & Tseng, 
2017; Shushan, Mohamed, & Magos, 1999). Most women in this study reported that their 
gynecologic oncologists (GYN/ONCs) or OB/GYNs appropriately informed them that RRSO 
was, as surgeries go, a short procedure that rarely involved complications.  
 Providers’ emphasis on the safety and simplicity of the surgery itself and recovery from 
the surgery led many women to believe that the overall impact of RRSO on their bodies would 
also be easy and manageable. Several women conveyed that prior to their surgeries they were 
much more concerned about the effects of their mastectomies and reconstruction than they were 
about the effects of their salpingo-oophorectomies. For example, Raina, who had RRSO and 
mastectomy in her early 40s, told me about RRSO, “It just didn’t seem as big of a deal to me as 
getting the breasts taken off.” Similarly, Alicia also had RRSO in her early 40s, and she told me 
that she didn’t think she “approached it with the right amount of respect.” One of the factors that 
shaped her initial attitudes toward RRSO was her understanding that the procedure itself was 
simple. “I was probably a little cavalier about that surgery. I kind of was so worried about the 
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mastectomy because it seemed like such a big surgery that, you know, ‘[RRSO] is gonna be a 
walk in the park!’ You just go in, it’s going to be laparoscopic, da-da-da-da…. I think I was 
looking at it from the physical standpoint of the surgery, how it was an outpatient surgery.”  
 Even women who were not at increased ovarian cancer risk thought RRSO would be “a 
walk in the park” compared to mastectomy. Maya, who has a PALB2 mutation and therefore was 
at increased risk for breast cancer but not ovarian cancer, was not interested in mastectomy. But 
she conveyed that she would have considered RRSO because it seemed like an easier surgery. 
“Now, if it were something like an increased risk for ovarian cancer. I’d probably very happily 
have my ovaries removed. That's a pretty minor change and surgery compared to a bilateral 
mastectomy.”  
 The examples from Raina, Alicia, and Maya illustrate how the discourses and practices in 
BOC genetic medicine correctly convey that RRSO is a less complicated procedure than 
mastectomy or reconstruction and involves a shorter recovery period than either type of breast 
surgery. Yet this factual information about RRSO compounds the effects of socio-clinical tension 
in BOC risk management practices and leaves many women un- or under-prepared for the 
enduring and sometimes severe effects of medically-induced menopause. As I illustrated earlier, 
most women are disproportionately worried about breast cancer and RRM, while most clinicians 
in BOC genetic medicine are more concerned about ovarian cancer and RRSO. When women 
hear from their providers that RRSO is a relatively quick and easy procedure but mastectomy 
and reconstruction are complicated, they understandably focus even more intensely on learning 
about and planning mastectomy and reconstruction. 
 Conversely, because most providers know RRSO is a comparatively simple and safe 
procedure that confers a significant survival benefit, some doctors encourage women to have the 
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procedure as soon as possible. For example, Veronica, who had two adopted daughters and was 
not planning on having biological children, shared her doctor’s RRSO recommendations: 
It was a more minor surgery. You know, it was outpatient, laparoscopic. And I was kind 
of nervous about it, because it puts you into menopause. But the doctor, my oncologist, 
he said, “If you're not having biological children and you were my wife, I would tell you, 
'Get them out now,' because ovarian cancer is so bad and if you get the surgery, your risk 
will be, like, you know, lower than the general population, you know, which is already 
pretty low.” So, I said, “Fine, let's do it.” (Veronica, Age 32, BRCA1) 
Hearing that her oncologist would recommend to his wife to “get them out now” encouraged 
Veronica to jump in and have RRSO right away. Marci explicitly stated that she felt pressured by 
her clinicians to have surgery as soon as possible, despite the fact that she had not yet completed 
her desired childbearing.  
What I heard was, “Cut off your breasts and cut out your ovaries,” was what I heard. 
That’s not exactly what she said. She did say that they recommended an oophorectomy, 
and—this was the part I laughed about—that research suggests that women who have the 
oophorectomy closer to 36 end up faring better. And at the time I was already 38, so I was 
just like, “Well, shit, you know, guess I’m screwed!” You know, it was just one of 
those—it made it feel like, “You should really do this as soon as possible, like people 
closer to 35 have better results.” But then I also recognize that they don’t know and it’s 
individual. And so, it was this sort of—things were couched in certain ways. But I 
definitely felt the pressure to have these surgeries quickly. (Marci, Age 39, BRCA2) 
 Importantly, both Veronica and Marci were below the recommended age ranges for 
RRSO, which are ages 35 - 40 for BRCA1 mutation carriers but can be safely delayed to ages 40 
- 45 for women with BRCA2 mutations (A. P. Finch et al., 2014; National Comprehensive 
Cancer Network, 2018b). Hence, while Marci noted that the pressure she experienced was 
“couched” in data on RRSO outcomes, the data her clinician cited was relevant to BRCA1 
mutation carriers, but not to Marci, who has a BRCA2 mutation. At age 38, she did not need to 
immediately rush into surgery to protect her health. The same was true for Veronica—at age 32, 
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she was several years younger than even the lower end of the clinically recommended age range 
for BRCA1 mutation carriers. 
 Having RRSO earlier than the recommended age ranges is not necessarily better for 
women’s health, and may in fact be worse because of the potentially severe health risks and 
effects of medically-induced menopause. Linda, who has been a cancer genetic counselor for 
over 25 years, explained, “So right now the guidelines say you need to do [RRSO] ideally by 35 
or 40. But it's also important for people to know it's not a healthier thing to do it at 25. Right? 
You're not getting a bunch more protection by putting yourself in menopause in your 20s.” While 
neither Veronica nor Marci were in their twenties, they were still encouraged to have RRSO 
earlier than necessary without fully being presented with how the surgery might have an ongoing 
impact on their bodies. And as the stories in the following section illustrate, while RRSO may be 
a relatively short and easy surgery, the effects of the procedure on women’s health and lives are 
far from simple.  
Menopause Is Enduring and Difficult 
 Medically-induced menopause is associated with a wide range of risks, some of which 
are also life-threatening. These effects include an increased risk of cardiovascular disease, 
Parkinson’s disease, osteoporosis, fractures, vaginal dryness, hot flashes, diminished sexual 
response, cognitive impairment, and mood and sleep disturbances (Faubion, Kuhle, Shuster, & 
Rocca, 2015; A. Finch & Narod, 2011; C. Garcia, Lyon, Conell, Littell, & Powell, 2015; W. A. 
Rocca et al., 2016; Shuster, Gostout, Grossardt, & Rocca, 2008; Tucker et al., 2016). Despite 
these risks, the overall clinical benefit of RRSO among BRCA mutation carriers has been 
robustly established. While research has shown that among women in the general population, 
salpingo-oophorectomy prior to the age of 45 significantly increases all-cause mortality (E. C. 
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Evans et al., 2016; Parker et al., 2013; Walter A. Rocca, Grossardt, de Andrade, Malkasian, & 
Melton, 2006), several recent studies have demonstrated that among women who are BRCA-
positive, salpingo-oophorectomy prior to age 45 significantly reduces all-cause mortality (S. M. 
Domchek et al., 2010; A. P. Finch et al., 2014; Ingham et al., 2013; A. W. Kurian et al., 2010).  
 As I argued in Chapter Three, the practices surrounding breast reconstruction—a 
cosmetic procedure that contributes additional physical health risks—can be in tension with one 
of the central goals in BOC genetic medicine: reducing women’s risks. In contrast, RRSO is 
medically-indicated among women with BRCA mutations and confers the health benefit that 
most people looking to reduce their risk of cancer ultimately desire—to increase their overall 
chances of survival. Thus, unlike with reconstruction, RRSO practices do not funnel women 
toward a relatively risky procedure with limited health benefits that they might later regret. 
Rather, with RRSO, BOC genetic medicine practices propel women toward a surgery that has 
some physical health risks, but also very significant benefits that, on balance, usually outweigh 
those risks.  
 The favorable risk-benefit profile for RRSO was reflected in women’s feelings about the 
surgery. Many women expressed certainty and relief about having RRSO even if they struggled 
with, or felt unprepared for, medically-induced menopause. For example, Alicia, the woman who 
didn’t feel she treated RRSO “with the right amount of respect,” conveyed, “I had a harder time, 
I think, emotionally with that surgery just because of the hormone levels and everything going 
out of whack. But that was, for me, just a no-brainer for that surgery, just knowing how 
unreliable the surveillance is for ovarian cancer.” Beatrice used similar language to describe her 
certainty about having RRSO. “It was a no-brainer. I don't know what the numbers in terms of 
risk would have had to have been for me to say 'we should wait and think about this.' It was 
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presented as an extremely high risk.” In fact, Dorothy was the only woman who expressed some 
regret about her decision to have RRSO. She was still experiencing severe menopausal side 
effects five years after her surgery, but even she felt that it was the “right” choice. “I had a friend 
who had ovarian cancer and it was horrible, and she died. And I learned that it is really hard to 
test for that. By the time you know you have it, you’re half dead. So, for that reason, it felt like 
the right thing to do.”  
 However, even though most women who had RRSO expressed that they felt they made 
the “right” decision, many of them were notably un- or under-prepared for the side effects of the 
surgery and struggled with quality of life issues. Some women were surprised by the severity of 
their menopausal symptoms. For example, Alicia shared, “I just, I was a little cavalier about how 
that surgical menopause was going to hit me…. And I pretty much went insane. I lost the ability 
to cope. The hot flashes were just crazy. I was having heart palpitations—it was just insane.” 
Dorothy, who had RRSO in her late 40s, was similarly unprepared for the severity of the 
menopausal side effects she experienced. Her doctors had told her she would “go into 
menopause,” but they not describe the specific side effects that might occur, nor did they explain 
how the abruptness of medically-induced menopause was different than natural menopause. 
Because she was fairly close to menopausal age and her mother had managed natural menopause 
smoothly, she expected to have a similar experience and was shocked when she did not. “I was 
catapulted into menopause, and it was such a surprise…. the hot flashes were so frequent I 
couldn’t believe it…. it’s been harder than I ever expected it would be.” The duration and 
severity of Dorothy’s menopausal side effects is what led her to feel some regret about her 
decision to have surgery. 
There’s some days when I would say, ‘Oh my gosh, I would take this back, just give me 
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my ovaries again’…. I think that the effect of that oophorectomy has been more defining 
in my life than my breast cancer risk. It is a thing that I deal with every single day. I feel 
well taken care of with my [breast cancer] screening, and so I don’t really have anything 
to complain about in terms of my risk. What I have to complain about is menopause.” 
(Dorothy, Age 53, BRCA2) 
 Like Dorothy, many women who had RRSO reported that they were cursorily warned 
that the surgery would cause them to “go into menopause,” but their clinicians provided them 
very little detail on the severity or duration of menopausal symptoms or the ongoing impact 
RRSO could have on their quality of life. Talia explained, “I think the conversations were like, 
were really rushed and sort of just factual, like, ‘You may experience some vaginal dryness. You 
may experience hot flashes.’ You know, like that kind of thing. And then, it wasn't like, ‘Let's 
really delve into this topic, you know?” However, some women’s providers did not mention any 
of the consequences of RRSO in conversations with them. Marci, who was in her late 30s, was 
still undecided about both RRSO and mastectomy. As I illustrated earlier, she felt very pressured 
to have RRSO by an oncologist and was frustrated that neither that doctor nor her other providers 
had conveyed the health risks associated with the procedure. “Actually, there’s been zero 
mention by any of the doctors that if I get my ovaries removed it’s going to put me straight into 
menopause, which has risks of heart disease and emotional stuff and all these other things. Zero 
mention.”  
 The experiences of Alicia, Talia, Dorothy, and Marci illustrate how the practices of BOC 
genetic medicine encourage women to rush into RRSO without fully informing them about the 
severity and duration of the menopausal symptoms they might experience. It is understandable 
that providers would want to encourage BRCA-positive women to have RRSO as soon as 
possible. Not only does RRSO reduce all-cause mortality in BRCA mutation carriers, but also 
several studies have shown that unsuspected ovarian cancers are discovered in 4% - 8% of 
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women with BRCA mutations who have RRSO (Conner et al., 2014; Powell, 2014; Zakhour et 
al., 2016). Yet, even for a procedure that, on balance, may have stronger benefits than drawbacks, 
it is still critical that providers give women a comprehensive picture of the risks and side effects 
they may face. One of the axioms I heard throughout my fieldwork was “knowledge is power.” 
And while women were almost universally glad to know about their mutation and to have the 
opportunity to manage their risk, few women in this study felt adequately prepared with 
knowledge about how RRSO and medically-induced menopause might negatively impact their 
quality of life. Instead, women often rushed into the procedure unknowingly blind, and as a 
result, several of them struggled to manage and cope with their menopausal symptoms. 
HRT or No HRT? 
 Another important finding in this study is that women were not only uninformed about or 
under-prepared for their menopausal symptoms—they also were often untreated for those 
symptoms. Studies have shown that for women who have RRSO, supplementing with short term 
hormone replacement therapy (HRT) that does not extend beyond the average age of natural 
menopause reduces many of the risks and side effects of medically-induced menopause. 
Premenopausal HRT use among women who do not have ovaries reverses their increased risk of 
all-cause mortality, protects against bone loss and heart disease, and reduces hot flashes and 
sexual side effects, all without significantly increasing BOC risk (De Felice et al., 2017; Faubion 
et al., 2015; Amy Finch, Evans, & Narod, 2012; Johansen et al., 2016; Kenkhuis et al., 2010; 
Rebbeck et al., 2005; W. A. Rocca et al., 2016; Vermeulen et al., 2017). Given the demonstrated 
health benefits of HRT in premenopausal women who have salpingo-oophorectomy, offering 
HRT to BRCA-positive women who have RRSO and have not had breast cancer has become 
standard practice at the top cancer-genetics clinics in the United States. Yet, provision of HRT to 
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women at BOC genetic risk remains uneven because many women do not receive care at the 
nation's top academic medical centers.  
 There were eleven women in this study who had their ovaries removed premenopausally 
(through salpingo-oophorectomy or total hysterectomy), had not had cancer of any kind, and had 
no other contraindications (e.g., a history of blood clots) to taking hormones. All eleven of these 
women should have been eligible for HRT, yet six of them were not taking hormones. Three of 
the women who were not on hormones had doctors who had erroneously told them that their 
BRCA mutations made them ineligible for HRT because it might increase their breast cancer 
risk. For example, when Dorothy complained about the severity of her hot flashes and 
menopausal symptoms, her doctor said to her, “Oh, gosh, you know, it’s bad, I know. A lot of 
women go through it. Because of your mutation, we don’t recommend hormone replacement 
therapy. We’re trying to reduce the estrogen in your body.” Dorothy was the only woman who 
expressed some regret about having RRSO, and those feelings were connected to the severity of 
her symptoms. She noted that, unlike her risk for cancer, menopause is something she deals with 
“every single day,” so she, in particular, could have benefited from taking the HRT that she 
should have been offered. In addition, four of the six women not taking hormones had already 
had mastectomy, and of the other two, one was planning her breast surgery in the near future. 
Hence, even if those women’s doctors were not aware of studies showing that HRT has 
protective effects for premenopausal women without ovaries, concerns about an increase in 
breast cancer risk among women whose breast tissue had already been removed (or soon would 
be) should have been minimal.  
 The other three women who were not on hormones had been prescribed HRT by their 
doctors, but they either never started taking the drugs or went off them because they were 
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personally concerned about them increasing their breast cancer risk. While these women were at 
least offered HRT, they were not appropriately counseled about the protective health effects of 
hormone use, and this was also true for several women in the study who were taking HRT. 
Instead, women’s doctors often suggested that taking hormones was either neutral or still posed 
some risk, but that it was “their choice” or “up to them” because HRT could improve their 
quality of life. For example, Jill, one of the women who elected not to take hormones, explained 
what her doctor told her about HRT: 
He said that it didn’t show that it really hurt you and you know it was really a choice. I 
wasn’t willing to do it, because I felt like if I’m doing this surgery to get rid of all of these 
hormones and take everything out and decrease my risk for everything. And I also 
thought, “Well, it’ll just prolong the whole menopausal thing.” Might as well just rip the 
band aid off and just be done with it. (Jill, Age 45, BRCA2) 
Brooke, who has a BRCA1 mutation, was another woman who stopped taking hormones because 
of concerns about the cancer risks. “I just went off them myself. I knew that the estrogen would 
feed the potential to feed the cancer if there was one that was going to develop, and I just said, ‘I 
don't need these.’” After Brooke went off HRT, she had a very hard time with her menopausal 
symptoms, and she approached her doctor about going back on hormones. She reported that her 
doctor said, “It's up to you. You know the risk. If you want to go back on and improve your 
quality of life and take the estrogen, let's take it.” When patients are being asked to weigh risks 
and benefits and make a choice about their health, they need accurate information, yet this is not 
what women reported receiving. There is a notable difference between hearing from a doctor that 
hormones “don’t hurt you” or “you know the risk” and hearing that taking HRT prior to the 
natural age of menopause reduces all-cause mortality and protects your cardiovascular and bone 
health.  
 Hence, women with BRCA mutations are often denied or not given accurate information 
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about HRT, a treatment that could mitigate many of the side effects of medically-induced 
menopause and increase their quality of life without significantly increasing their risks of 
developing breast cancer. Withholding HRT from BRCA-positive women who have RRSO is 
especially problematic in light of research showing that medically-induced menopause often 
produces more severe side effects than natural menopause. A recent study in the Netherlands of 
women with BRCA1/2 mutations who underwent RRSO prior to menopause found that the 
severity and duration of menopausal symptoms was significantly greater for women who had 
RRSO than for women who experienced menopause naturally (Stuursma, van Driel, Wessels, de 
Bock, & Mourits, 2018). Over two-thirds of the women in the study experienced moderate to 
severe menopausal symptoms, and for a majority of women, those symptoms persisted for 10 or 
more years after the surgery. Notably, unlike in the United States, premenopausal Dutch women 
who have RRSO are routinely prescribed HRT to reduce menopausal symptoms. Given the 
unevenness of the provision and use of HRT among women in the United States who have 
RRSO, the severity and duration of medically-induced menopausal symptoms in US women may 
be, on average, even greater. 
Ovaries: Egg Factories or Endocrine Glands? 
Obscuring Non-Reproductive Functions 
 A majority of the doctors and genetic counselors I interviewed and met during my 
fieldwork were concerned about the side effects of RRSO and recommended HRT to previvors. 
However, the health professionals with whom I spoke were are all cancer genetics specialists 
who either work at nationally renowned cancer genetics clinics or regularly attend cancer 
genetics conferences. It is not surprising that the health care providers who are most 
knowledgeable about current research and best practices in the field are also more likely to 
 
252 
comprehensively inform their patients about the wide range of risks of RRSO and to 
appropriately manage those risks. But unfortunately, as I noted in Chapter Two, most women are 
not seeing those clinicians.  
 Regardless of their training or where they practice, GYN/ONCs and OB/GYNs do not 
intentionally withhold information from their patients or actively attempt to obscure the lived 
realities of medically-induced menopause. As I argued in Chapter Three in relation to breast and 
plastic surgeons, most clinicians want to help their patients. But because many GYN/ONCs and 
OB/GYNs have witnessed the gravity of ovarian cancer with previous patients, they are also 
likely to want to spare their current patients from that experience. Given the robustness of the 
research on RRSO, GYN/ONCs and OB/GYNs are likely to know that the procedure 
dramatically reduces ovarian cancer risk, significantly reduces all-cause mortality, and is a fairly 
safe and simple procedure. Hence, for most clinicians, RRSO is, like Alicia and Beatrice said, a 
“no-brainer.” From doctors’ perspectives, the benefits of RRSO heavily outweigh the potential 
side effects, so it is understandable that they might quickly run through a list of potential side 
effects without delving into them in depth, as Talia described earlier.  
 However, the under-preparation for medically-induced menopause that many women in 
this study experienced is not solely rooted in the injurious benevolence of some doctors. RRSO 
practices in the United States both reflect and reinforce other social, cultural, and medical 
discourses about women’s bodies. There is an established history in US biomedicine of ignoring 
the non-reproductive functions of steroid hormones and treating ovaries as if they are egg 
factories that are only important for making babies (Fausto-Sterling, 2000; Oudshoorn, 1994; C. 
Roberts, 2007). In common discourse, ovaries make eggs and "sex hormones", and those "sex 
hormones" affect mood, desire, and reproduction. Yet in reality, ovaries are important endocrine 
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glands that store, grow, and release eggs and make steroid hormones, which regulate numerous 
critical functions in the body beyond reproduction and the development of secondary sex 
characteristics. As feminist biologist Anne Fausto-Sterling has written, hormones are “multi-site 
chemical growth regulators” (Fausto-Sterling, 2000) that affect bone mass, blood clotting, blood 
lipids, vasoconstriction and vasodilation, body temperature, immunoregulation, metabolism, fat 
deposition, muscle mass, and sexual response, (Manolagas & Kousteni, 2001; Muñoz-Cruz, 
Togno-Pierce, & Morales-Montor, 2011; S. I. A. Shah, 2018; Sloane, 2002, pp. 77-81). 
 Science studies scholar Nelly Oudshoorn argues that "sex hormones" are not preexisting 
natural substances that scientists discovered, but rather have been constructed through 
biomedical discourses and practices. Oudshoorn describes how in the early twentieth century, 
laboratory scientists and gynecologists measured and defined hormones in a variety of ways. In 
1932, they convened the Conference on the Standardization of Sex Hormones, where they settled 
on the vaginal smear test as the standard test for “female sex hormones,” thereafter labeled 
“oestrus-producing hormones” (Oudshoorn, 1994, pp. 46-47). The vaginal smear test measured 
changes in the vaginal cells of rodents characteristic of estrus. In 1935, at the Second Conference 
on the Standardization of Sex Hormones, scientists and clinicians accepted the comb test, which 
measured comb growth in castrated roosters, as the standard test for “male sex hormones” 
(Oudshoorn, 1994, p. 49). Oudshoorn highlights how these standardized measures were not 
preordained, but rather were decisions with consequences: 
[I]n this process of sorting out the specific tests for sex hormones, all functions and 
processes that were unrelated to sexual characteristics and reproduction were dropped. 
The testing methods that became accepted as standard tests for sex hormones were based 
not on muscular activity or body weight, but on internal sexual organs (vagina and 
seminal vesicles) and on a so-called secondary sexual characteristic (the comb of the 
rooster). In this way, scientists attributed to the substances they had just isolated, and 
which they had named sex hormones, the properties predicted by the biological paradigm 
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in which sex hormones were defined as the chemical messengers of masculinity and 
femininity. (Oudshoorn, 1994, p. 53) 
Oudshoorn argues that these active choices by scientists illustrate how medical and scientific 
“facts” and discourses about bodies are not neutral or natural, but rather reflect and reconstitute 
the social and cultural contexts from which they emerge. 
 Building on Oudshoorn’s argument, Fausto-Sterling argues that these standardized tests 
and measures for hormones transformed steroid hormones—substances that have systemic 
effects in bodies and regulate multiple functions and processes—into “sex hormones.”  
From the moment the process of measuring male or female hormones was standardized, a 
set of molecules of a known chemical composition and structure officially became sex 
hormones. From that time on, any physiological activity those hormones had were, by 
definition, sexual, even though the “male” or “female” hormones affected tissues such as 
bones, nerves, blood, liver, kidneys, and heart (all of which was known at the time). 
(Fausto-Sterling, 2000, p. 187) 
By settling on standardized tests and definitions for hormones that were linked to sexual and 
reproductive systems, clinicians and scientists “shaped the sexing of the sex hormones” (Fausto-
Sterling, 2000, p. 187). They focused attention almost exclusively on how hormones regulate sex 
and reproduction, thus obscuring the numerous other physiological functions that are regulated 
by hormones.  
 Contemporary RRSO practices emerge from, and then further contribute to, this history 
of rendering the non-reproductive functions of hormones invisible. Clinicians in BOC genetic 
medicine are sensitive to the reproductive impact of oophorectomy. The NCCN guidelines 
specify that “RRSO should only be considered upon the completion of childbearing” (National 
Comprehensive Cancer Network, 2018b, pp. MS-27), and as I will illustrate in the next section, 
clinicians almost always talk to women about completing childbearing prior to the surgery. 
However, many women’s doctors failed to address the non-reproductive risks and side effects of 
 
255 
RRSO, even for some of the most well-known effects. For example, Jessie is one of the women I 
discussed in Chapter Two who has a CHEK2 mutation and had a hysterectomy due to her 
concerns about potential links between ovarian cancer and CHEK2. Jessie conveyed that her 
doctors did not address the risk of bone loss from medically-induced menopause. “And the 
biggest thing that I wish there would be more talk about is the osteoporosis side. I know from 
what I have read on the osteoporosis side, but nothing has been talked about.” Marci’s doctor did 
not discuss the cardiovascular effects of RRSO with her despite her strong family history. “As I 
mentioned, heart disease is really rampant in my family. So, if going into menopause early 
increases an already-increased risk, nobody has asked me about that…. There was just no 
mention of osteoporosis or heart disease.” Bone loss and cardiovascular risks have long been 
established as harmful side effects of medically-induced menopause, but Jessie’s and Marci’s 
doctors did not discuss these risks with them.  
 Other women reported getting little to no information about the potential effects of 
medically-induced menopause on sleep, weight, and cognition, all of which are dimensions of 
health that can have a major impact on quality of life. Raina shared, “Actually one of the biggest 
side effects of not having my ovaries, which I had no idea it was even a side effect, was 
disturbing my sleep.” Dorothy explained that she had other side effects in addition to her severe, 
unrelenting hot flashes. “Like weight gain, that whole middle. I’m exercising, I was always very 
thin. And so now I have really had to reduce my food intake and exercise a lot more. And yet I’m 
still kind of getting that middle…. And my memory, and I don’t know how much of this is just 
aging, but my memory, my short-term memory especially, is just noticeably worse. And that 
bothers me a lot.” Dorothy stressed that being unprepared for all of these symptoms made it 
harder to cope with them. She wished that her providers had taken more time to prepare her for 
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the range of possibilities. “The surgeon that removed my ovaries, she said, ‘Now, you probably 
will go through menopause.’ But she didn’t talk to me anymore. You know, her job was surgical, 
I guess. The genetic counselors didn’t either. I wish that I’d had a chance to talk that through. 
Not that I would have made a different decision, but my expectations might have been 
managed.” 
Silence about Sexuality 
 Several women also noted that their providers were silent about the impact of RRSO on 
sexual response. For example, Liza explained that she had to learn about the sexuality-related 
effects of preventative surgeries from her sister and a family friend who had had the procedures. 
The doctors would talk about everything except for sex. It was so weird to both of us 
[Liza and her sister] how bright red and shut down they all get when it came to that. It is 
such a huge part of it. I don’t know. I think it is silly that people aren’t willing to talk 
about it and help out patients with regaining a part of their sex life. It is a big part of 
everybody’s life. (Liza, Age 30, BRCA1) 
Similar to Liza, Raina shared that she only learned about the sexual side effects of RRSO from 
other women in online support groups. Her doctors had not given her any information about risks 
of decreased libido or vaginal dryness, and as she noted, “I mean, that’s not really something I 
would talk about with my mom, and I don’t really have any friends who had it done.” Without 
other people to inform her in the way Liza’s sister did, Raina was unprepared for the sexual side 
effects she experienced. 
 Brenda’s genetic counselor explicitly told her to ask her surgeons about the impact of 
RRSO on quality of life issues like libido and sexual response because they would not bring 
those topics up on their own. Brenda said her counselor stated, “Here are some questions to ask 
around that. And know that you should ask questions but that is not something that surgeons are 
going to want to talk to you about, so you have to find your own information about it.” Jackie, a 
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genetic counselor who ran the cancer genetics program at a regional hospital, mentioned her own 
reluctance to discuss the sexual side effects of medically induced menopause. “Even I don’t talk 
about it that much. I often mention heart health, bone health, but not libido.” 
 In addition to providers’ silence around the sexual side effects of RRSO, some women 
were not told by clinicians that having a total hysterectomy instead of RRSO could compound 
the impact on their sexual response. Involuntary uterine contractions are involved in orgasm, and 
for some women, removing their uterus leads to decreased sexual response and pleasure (Sloane, 
2002, pp. 172-177). For example, Elaine, the nurse with a BRCA2 mutation who had to fight 
with her doctors to get HRT, was not informed of the potential sexual side effects of total 
hysterectomy and regretted choosing the procedure over partial hysterectomy or RRSO. She said, 
“If I had to do it over again, I would keep my cervix because of sexual orgasm.” The first 
GYN/ONC Brenda spoke with—the same man who discouraged HRT—also urged her to have a 
full hysterectomy. 
He was very focused on small percentages of remaining risks, and the most risk-reducing 
thing I could do was a full hysterectomy. He said that the bonus is that if you don’t have a 
cervix, you don’t ever have to get another pap smear…. he was assuming that I would be 
so glad to jettison my cervix. Yeah, he was very surgically minded. (Brenda, Age 39, 
BRCA1) 
While Brenda’s doctor highlighted the “benefit” of not needing pap smears when you don’t have 
a uterus, he did not inform her that one potential drawback of “jettisoning” her cervix might also 
be less pleasurable sex. Luckily Brenda’s genetic counselor had encouraged her to educate 
herself about the relationship between gynecologic surgeries and sexuality, so Brenda knew that 
she wanted to keep her uterus going into that meeting with the gynecologic surgeon.  
 The silence in US genetic medicine about how medically-induced menopause affects a 
wide range of bodily systems and functions, including sexual response, is both rooted in and 
 
258 
reconstitutes broader social and cultural discourses that portray women’s ovaries and uteruses as 
primarily valuable through their work in reproduction. As I argued in Chapter Three, breast 
reconstruction practices that prioritize women's attractiveness over their internal sensations and 
pleasure reflect a higher regard for women as sexual objects than as sexual subjects. Similarly, 
RRSO practices prioritize women's procreative capacities over their daily well-being and 
comfort, which reflects a higher regard for women as reproducers than as embodied agents. In 
the following sections, I will highlight how these practices are filtered through and reflect not 
only gendered constructs of women's bodies and roles, but also racialized and classed ones. A 
majority of BOC genetic medicine patients are white, middle-class women (Armstrong et al., 
2015; Cragun et al., 2017; McCarthy et al., 2016; Underhill, Jones, & Habin, 2016), individuals 
whose reproductive futures are most valued in the prevailing social order in the United States 
(Bridges, 2011; D. Roberts, 1997; Silliman, Fried, Ross, & Gutiérrez, 2004; Vandenberg-Daves, 
2014). It is perhaps not surprising, then, that while the structures of US genetic medicine often 
gloss over the effects of RRSO on women’s sexual response and other critical bodily functions, 
they frequently emphasize the impact of the procedure on women’s reproductive capacity. 
Hurry Up and Have Kids 
 Women in this study were well-informed that if they desired biological children, they 
would need to have those children or freeze their eggs prior to having RRSO. In fact, nearly all 
of the women who had or were planning on having their ovaries removed conveyed that their 
doctors had discussed, often in detail, the reproductive impact of the surgery with them. But 
many women also reported that when their clinicians talked to them about RRSO and 
childbearing, the conversation frequently included encouragement to have kids soon or at a 
younger age than the women might have otherwise planned. Several women conveyed hearing 
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from their doctors what Lily heard from other women with mutations in her in-person support 
group: “I gotta get married and have a kid, so I can have the surgery.” For example, Alicia 
expressed that one factor that had shaped both her mother’s and her decision to get genetic 
testing was that her mother’s oncologist had said, “Well, you really need to get tested. If you 
have the mutation, then your daughter needs to hurry up and have kids.” One of Talia’s doctors 
communicated a similar message about having kids without first asking her about her 
childbearing preferences or if she was partnered. “He didn't ask me anything. I felt scared. And 
that was part of the thing, that he was so surgeon-like. He was just totally detached and basically 
was like, ‘If you're going to do it, do it now.’ And I was thinking like, ‘I’m not even with 
somebody.’ You know what I mean?” Even though Talia was only 30 at the time, which is well 
before the recommended window for RRSO for BRCA2 mutation carriers, her doctor 
encouraged her to have children right away.  
 Becky described hearing constant reminders from her providers about having children, 
despite being fairly young. She was only 27 when she discovered her BRCA1 mutation and 31 
years old when I interviewed her. She conveyed, “Most of my gynecological appointments are 
talking to me about the age of which I should be thinking about having children…. that it’s the 
sooner the better, and that I’m not getting any younger.” Becky had a particularly difficult time 
dealing with the pressure surrounding reproductive decision-making; she teared up as we 
discussed childbearing. She felt ambivalent about having children, both in general and with her 
current partner, and the constant reminders added to her stress: 
I don’t have any children, but every doctor reminds me that I should think about that. So, 
it’s definitely forced me to do that planning a lot earlier. I still don’t have immediate plans 
to have kids, but it’s definitely something on the back of my mind as I need to make that 
decision pretty quickly. So, it’s affected my relationship in that sense, my relationship 
with my partner, just deciding if that’s something that I want to do and it should happen 
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as soon as possible. (Becky, Age 31, BRCA1) 
 Becky’s doctors likely had good intentions in checking in with her regularly about 
childbearing. Many clinicians in BOC genetic medicine have also had patients like Marci, who 
wants to be a mother and discovered her BRCA2 mutation as a single woman without children in 
her late 30s. Marci grappled with difficult decisions about if and when to have preventative 
surgery and using reproductive technologies. Hence, it is understandable that providers would 
want to help other patients who learn about their mutations at younger ages avoid choosing 
between having biological children or delaying RRSO and increasing their risk of developing 
cancer.  
 Indeed, some women I spoke with experienced reminders from or discussions with their 
health care providers about the reproductive impact of being BRCA-positive as opportunities to 
make different choices. For example, Audra conveyed, “Definitely at a younger age, it’s like the 
pressure is on to have kids. But in my mind, it’s like it’s better to know that. Because I would 
really hate to not know these results and, not knowing my risks, waiting and waiting and waiting 
for the right time to have kids, and waiting too long to the point where I can’t.” Audra, who was 
28 years old and had very recently discovered her BRCA2 mutation, preferred being encouraged 
by providers to have children sooner over waiting and later being unable to have them. There 
examples illustrate that initiating discussions with BRCA-positive patients about reproduction 
can be helpful, especially given that women are increasingly delaying childbearing and there is a 
significant medical benefit to having RRSO in those later childbearing years. Thus, the 
problematic aspect of the communications between Becky and her doctors was not that they 
repeatedly addressed childbearing; rather, it was that in those conversations, her doctors made 
assumptions and did not inquire about her personal fertility desires or life context. 
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 The assumption that women would want to be or should be mothers was also illustrated 
by Alexis’s experiences. Alexis was in her mid-thirties, and unlike the other women in her age 
range with BRCA mutations, her doctors did not explicitly discuss childbearing plans with her. 
Instead, Alexis said they would not talk to her in detail about RRSO, which was highly unusual. 
She felt that their reluctance to discuss RRSO with her was because she was single and childless: 
Because I was single and I don’t have kids, they didn’t want to do much talking about, 
like, surgery or egg freezing. They’re like, “You have plenty of time. You have until 
you’re 40. Just keep doing screenings.” So, I didn’t feel like they were being flippant, but 
they just didn’t seem—I obviously did, well, I did and I do have a lot of anxiety about it, 
and I don’t think that they like took that into account. And they definitely were like, 
“We’re not doing surgery. You still need to have kids if you want them.” But for me, I’m 
like, “Well, I don’t know if that’s going to happen.” And I, I am really nervous about this. 
So, I think they had an idea in their minds of like what I should do. And I don’t feel like I 
got all of the options…. I feel like I need to have a child. Then they’ll discuss stuff with 
me.” (Alexis, Age 34, BRCA2) 
As a BRCA2 mutation carrier, Alexis had up to age 45 to have RRSO within the recommended 
age range, so her providers were accurate that she had “plenty of time” to make decisions. But 
making decisions requires information about “all of the options,” which Alexis did not feel she 
received. Alexis’s doctors could have asked her about her personal priorities or how she felt 
about the tradeoff between RRSO at an earlier age and having biological children. Such a 
conversation would have enabled her to make her own informed decisions. Instead, similar to 
Becky’s doctors, they “had an idea in their minds” about what would or should be most 
important to Alexis, which they thought was preserving her ability to have a naturally-conceived 
child.   
HRT vs. PGD 
For women who have not yet had their desired number of biological children but are 
approaching or within the recommended age-range for RRSO, egg or embryo freezing allows 
 
262 
them to preserve the possibility of having a biological child while still doing RRSO within the 
recommended timeframe. Later, when they are ready to have children, women can undergo in-
vitro fertilization (IVF) cycles using their frozen eggs or embryos. Preimplantation genetic 
diagnosis (PGD) is another fertility procedure available to women with genetic mutations that 
allows them to avoid passing their mutation on to their children. Whether women are doing 
immediate IVF or using frozen eggs or embryos, if they choose to add PGD to the process, all of 
their embryos are tested for their genetic mutation, and only embryos without the mutation are 
implanted (Derks-Smeets et al., 2014; H. J. Stern, 2014).  
Many of the women in this study mentioned egg freezing and/or PGD in our 
conversations and, unlike Alexis, said their genetic medicine providers had either discussed 
reproductive technologies with them or had referred them to fertility specialists. For example, 
Liza, the woman who noted that doctors were reluctant to discuss sexuality, told me, “My 
ovarian doctor already mentioned freezing eggs and how they can test for BRCA-positive and 
negative even down to that level to make sure that they fertilize BRCA-negative babies. She has 
talked to me about all of that.” Hannah’s clinicians informed her that some women with BRCA 
mutations have diminished fertility and mentioned egg freezing in that context. “I have to have 
my AMH58 tested every six months to make sure my egg reserves are still okay. If they ever do 
start to decrease they talked about my need to freeze my eggs to make sure that when I do want 
to have kids I will be able to.” Alexandra, one of the genetic counselors I interviewed, shared that 
she makes referrals to reproductive specialists for women of childbearing age. “When you talk 
about younger women, fertility preservation is something else that comes up. So, I talk about 
                                                             
58 Anti-Mullerian Hormone (AMH) is secreted by cells in ovarian follicles and is sometimes used to 
measure women’s ovarian reserve. 
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finding reproductive endocrinologists that will work with them, partly because they may be 
interested in having an oophorectomy, and partly because they may be interested in some 
reproductive technology to avoid having an affected child.”  
Making referrals to reproductive specialists and informing women with BOC mutations 
about their fertility options are important practices that expand women’s knowledge and respect 
their reproductive desires and autonomy. For example, Marci, who was 37 when she discovered 
her BRCA2 mutation, benefited from being referred to a fertility specialist. She chose to freeze 
her eggs because she wanted children but was not partnered and did not want to rush into 
becoming a parent. “And then she referred me to—I don’t know if it was a reproductive 
endocrinologist or a reproductive cancer doctor. I don’t know which was my next visit. I had two 
different things that I was looking at. One was to explore egg freezing, so I started that process of 
looking and ended up doing that.” Because Marci was informed about egg freezing and able to 
afford and access the procedure, her desire to have biological children is not a barrier to her 
having RRSO. Joan, who discovered her BRCA2 mutation at age 24, also had benefited from 
referrals to reproductive specialists. She and her husband had embryos frozen soon after they got 
married, both because of fertility issues that she was told were related to her BRCA mutation and 
in order to give her flexibility in her risk management decision-making. When I interviewed her, 
they had two healthy children as a result of those fertility procedures.  
Several women expressed anxiety about the possibility of passing on their mutation, and 
they were reassured by the availability of PGD, even if they were not certain they would use the 
procedure. For example, Anna explained that she and her husband, who were exploring adoption, 
had never considered having biological children prior to the availability of PGD. “We started just 
recently talking about biologically having kids, before that wasn’t even really on the table. 
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Especially now with the introduction of tests being able to test the embryos for specific genes, 
that got him really interested. And that was the only reason why we’re now introducing the 
actual genetic kids, biological kids, into the discussion.” Nora wished that she had known about 
her BRCA2 mutation and had had the option to consider PGD prior to having children. Worrying 
about her daughters having inherited her mutation made Nora feel “sick to [her] stomach.”  
I think about it a lot. The guilt. And I think about my girls, that they're going to have this 
fear, and I think about when is the right time to tell them? Because when I found out, 
automatically I was just convinced in my head that I had cancer. I was a ticking time 
bomb. So, when do you tell these young girls? At 18, when they could get tested and be 
proactive? I don't want them at 18 years old thinking that they're going to get cancer and 
going through what I went through. I wish I would have—it probably wouldn't have 
stopped me from having kids, but I wish I would have known. I don't feel that it's a life or 
death sentence, but I maybe would have chosen different avenues to have children had I 
known. Maybe had my eggs tested. (Nora, Age 32, BRCA2) 
Nora expressed that she could not say, with certainty, that she would have gone through the PGD 
process, but she was very clear that she wished she had had the option.   
Egg and embryo freezing, PGD, and IVF are all procedures that require women to use 
hormones that stimulate ovarian follicle growth and, in turn, estrogen production (Brinton, 
Sahasrabuddhe, & Scoccia, 2012; Lederman, 2017; H. J. Stern, 2014). Recent studies and meta-
analyses indicate that, in the general population, fertility treatments do not significantly increase 
women’s risk of developing ovarian cancer (Brinton et al., 2012; Diergaarde & Kurta, 2014; 
Rizzuto, Behrens, & Smith, 2013; Siristatidis et al., 2013). Research also suggests that fertility 
drugs are not associated with a significantly increased risk of breast cancer, but findings on that 
relationship are not as strong (Brinton et al., 2012; Derks-Smeets et al., 2014; Kotsopoulos et al., 
2008; Lederman, 2017). However, studies have been mixed on whether fertility treatments 
increase women’s risk of endometrial cancer (Brinton et al., 2012; Lederman, 2017; Reigstad et 
al., 2017). In addition, research on the cancer risks of fertility treatments in BRCA mutation 
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carriers has been limited, in terms of both the size and number of studies. However, the studies 
that have been done suggest that it is relatively safe for women with BRCA mutations to use 
fertility treatments, particularly given that women with mutations are often pursuing egg/embryo 
freezing because they are planning on having risk-reducing surgeries (Gronwald et al., 2016; 
Kotsopoulos et al., 2008; Lederman, 2017; Perri et al., 2015; Rodriguez-Wallberg & Oktay, 
2012). Hence, fertility drugs and HRT share a number of similarities. Both treatments expose 
women to hormones, have the potential to improve women’s quality of life, and appear to be safe 
for previvors with BRCA mutations. Yet, interestingly, people’s perceptions of the safety of HRT 
and fertility drugs differed. 
In contrast to several women’s concerns about the potential for HRT to increase their risk 
of breast cancer, only two women expressed worries about the potential risks of hormone 
exposure from fertility treatments. One of those women was Joan, the BRCA2 carrier who had 
two healthy children through embryo freezing and IVF. Joan explained that she stopped doing 
additional IVF cycles due to her concerns about the effects of continued hormonal stimulation. 
“[C]hoosing not to just keep going through IVF cycles, was also, you know, kind of because of 
the BRCA diagnosis. I didn't want to keep exposing myself to a bunch of estrogen 
and progesterone.” Similarly, Veronica and her husband were “on a break” from doing fertility 
treatments when she unexpectedly learned about her BRCA mutation from a direct-to-consumer 
ancestry test. She explained how concerns about additional hormone exposure made them decide 
not to continue and to pursue adoption instead. “I didn't want to keep stimulating my ovaries. I 
mean, I don't ovulate on my own, so I didn't wanna keep stimulating my ovaries with the 
hormones, because I was at risk for ovarian cancer.”  
Women with BOC mutations who are considering RRSO often learn that one of the ways 
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RRSO is believed to reduce women’s breast cancer risk is because it reduces women’s 
circulating estrogen and progesterone. Hence, it makes sense that, without additional information 
on safety, Veronica and Joan might feel concerned about taking drugs that could increase their 
hormone exposure. In fact, I was somewhat surprised that only these two women expressed 
concerns about the risks of fertility drugs. As I illustrated earlier, several women remained 
worried about using HRT to treat their menopausal symptoms despite studies showing that the 
drugs improve survival and outcomes for premenopausal previvors. Given that the safety data on 
HRT use by BRCA mutation carriers is more robust than the safety data on their use of fertility 
treatments, I expected more women to be concerned about the latter, not fewer.  
Even more surprisingly, none of the women in the study reported that their health care 
providers had mentioned concerns about potential cancer risks associated with fertility 
procedures. As I noted earlier in the chapter, even some of the providers who prescribed HRT to 
women had indicated to their patients that they would incur some risk by using HRT to manage 
their menopausal symptoms. However, those doctors told women that the decision to take HRT 
was “up to them” because the slight increase in breast cancer risk could feel worth the tradeoff in 
quality of life improvements. Given that there is robust data on the safety of HRT use by 
premenopausal women with BRCA mutations who have RRSO but very little data on the safety 
of fertility treatments among BRCA mutation carriers, I expected more women to share stories of 
primary care providers’ misconceptions about fertility drugs and cancer risks. Yet none did.   
What can explain this contrast between perceptions of the risks of HRT and those of the 
hormones used in association with IVF, egg freezing, and/or PGD? One possible explanation is 
that clinicians who are not cancer genetics experts are not aware of current data on HRT safety 
for premenopausal women who have RRSO, and as a result their patients are not aware either. In 
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my fieldwork and interviews, I frequently heard stories about primary care and other medical 
generalists who had misconceptions about BOC genetic testing and/or risk management. Many 
women and most doctors would likely have heard that HRT use is associated with an increased 
risk of breast cancer, which is accurate for postmenopausal women in the general population. 
The link between HRT and breast cancer has been widely publicized since July 2002, when the 
combined estrogen and progestin trial in the Women’s Health Initiative (WHI) was halted mid-
study due to a significantly increased risk of breast cancer in the treatment arm (Fred Hutchinson 
Cancer Research Center, 2018). Lacking current data on outcomes in premenopausal women 
and/or in BRCA carriers, women and their doctors might assume HRT use is unsafe for women 
of any age who are at high risk for breast cancer.  
Differences between the duration of women’s hormone exposure with HRT and fertility 
drugs may also affect people’s perceptions of the safety and risk of the drugs. When women take 
HRT, they usually do so daily over several months or even years, whereas the hormones in 
fertility treatments are most commonly used intermittently for a few months. Hence, it is possible 
that because women and their doctors understand that fertility drugs will be used for less time, 
they feel less concerned about them, regardless of what the scientific literature indicates in 
relation to health risks and benefits.  
Another interpretation of why patients and providers are wary of HRT use but open to 
fertility treatments is that these attitudes reflect the gendered tendency in BOC genetic medicine 
to overlook sexuality and quality of life issues and focus on reproduction. As women’s stories in 
this chapter have illustrated, genetic medicine practices often encourage women to rush into 
RRSO and leave them un- or under-prepared for the effects of medically-induced menopause. 
Not offering women HRT or framing the drugs as potentially risky emerges from and reinforces 
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larger practices that de-prioritize women’s sexuality, embodied experiences, and quality of life. 
At the same time, the practices of genetic medicine encourage women to hurry up and have kids 
and emphasize how RRSO will affect reproduction. Informing women about the availability of 
fertility treatments and referring them to reproductive endocrinologists while refraining from 
raising concerns about their use of fertility drugs are practices that further reflect and reproduce 
the high value placed on childbearing and motherhood. Of course, women should receive 
medically accurate information about their options and appropriate referrals to specialists. But 
the high priority placed on reproduction in BOC genetic medicine illuminates the relative low 
priority placed on non-reproductive issues that affect women’s quality of life. Thus, the problem 
is not that motherhood and childbearing are valued, but rather that women’s sexuality and daily 
embodied experiences are not.  
Valuing Reproductive Bodies 
Ovaries Are Disposable 
 The contrast between attitudes toward fertility drugs and HRT illustrates how practices in 
BOC genetic medicine signal both what is and what is not valued about women’s bodies. 
Encouraging women to “hurry up” and have children so that they can have their ovaries removed 
conveys that ovaries are important until women have completed childbearing, but afterward are 
expendable. Veronica’s oncologist who encouraged her to have an oophorectomy before the 
recommended age range is a prime example of these practices. He explicitly told Veronica that if 
she wasn’t “having biological children,” that she should “get them out now.” Discourses that 
construct ovaries as disposable after childbearing both reflect and reinforce the invisibility of the 
non-reproductive functions of hormones. 
 Several women I interviewed had internalized these discourses and the belief that ovaries 
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were only important for reproduction. They made references to how they no longer “needed” 
their ovaries or uteruses anymore because they were done having children. For example, Rose is 
a CHEK2 mutation carrier who was relieved that there was not a confirmed link between 
CHEK2 mutations and ovarian cancer. She said, “With the CHEK2 gene they give you a list of 
other things you can have—brain cancer, thyroid cancer. But not ovarian!” When I asked Rose 
how she felt about ovarian cancer not being on that “list,” she conveyed that she was glad not to 
need another surgery. “Because I would have just had a hysterectomy. I don’t need my ovaries 
anymore, so I would have just taken it all out.” Similarly, Adele talked about her mother’s 
experiences managing her BRCA2 mutation, and noted, “They did a full hysterectomy with her 
as well because she’s not having any more kids either.”  
 Talia’s story sharply illustrates how women’s bodies are valued for their reproductive 
capacity and how, in turn, their internal organs are treated as disposable when they are no longer 
“needed” for reproduction. Unlike with breasts, very few women explicitly connected their 
femininity, identity, or womanhood to their ovaries or their uterus. However, Talia was an 
exception. She shared how she grieved the loss of her ovaries because she had always envisioned 
being a mother. Giving up the ability to conceive and bear children felt like losing a major part of 
her womanhood. “It was much more emotional for me to have the ovaries removed. I felt like I 
was not a woman…. I think the recovery from the mastectomy and reconstruction was much 
more about the physical, and the recovery from the ovarian was more emotional for me.”  
 Talia was one of three lesbian women I interviewed, and she was also the only woman 
who shared a story about a doctor openly dismissing her grief or concerns about giving up the 
ability to conceive and bear children through RRSO. Talia described a conversation with the first 
gynecologic oncologist she saw: 
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I was really crushed about not having a baby, and I said that to her. And she was like, 
"Well, you're lucky you're with a woman. She can carry the baby." And that's just like, 
that's not how it works, you know? We're not all interchangeable. Women are not like—
we don't all want to carry a baby, and it's my experience, not her experience, you know? 
It's my body. She can't be my body for me. (Talia, BRCA2, Age 38) 
This GYN/ONC did not ask Talia about her fertility desires, listen to her grief, provide her with 
resources on egg freezing, or discuss delaying RRSO with her, despite the fact that Talia was 
only in her early 30s at the time. Instead, the doctor dismissed Talia’s emotional and embodied 
experiences, and treated her ovaries as disposable even before she began childbearing. Whereas 
most clinicians only constructed women’s ovaries as disposable after they had babies, Talia’s 
doctor saw her ovaries as immediately expendable because there was another woman in Talia’s 
partnership who had eggs and ovaries that could be used for babymaking. As Talia said, this 
clinician treated women’s bodies as “interchangeable” rather than addressing Talia as an 
individual embodied agent.  
 Moreover, constructing ovaries as expendable organs that lack usefulness after women 
have completed childbearing contributes to women’s under-preparation for medically-induced 
menopause. For example, Raina conveyed how she initially thought RRSO would be “no big 
deal” because she was done having children, and then was surprised by how her body was 
affected once they were gone. “It just didn’t seem as big of a deal to me as getting the breasts 
taken off. Like, ‘Oh they’re just my ovaries. I’ve already had my kids, no big deal, you don’t 
need them anyway’ kind of thing. I don’t think anybody really prepared me for how different I 
would feel without them.” Raina’s account illustrates how discourses that frame ovaries as only 
relevant for making babies can lead to shock when women experience other side effects after 
their oophorectomies. 
 Perhaps if women had better understandings of the significant systemic effects of steroid 
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hormones and how they impact heart and bone health, cognition, mood, sleep, and sexuality, 
some women at genetic risk might be more cautious about “jettisoning” their ovaries. That is not 
to say that they would not have them removed—the data on RRSO reducing all-cause mortality 
among BRCA mutation carriers are strong. However, if ovaries were regarded as important and 
functional at all life stages and people better understood how ovarian function changes over the 
lifespan, women would be better prepared for the range of risks they might face with RRSO and 
could advocate more effectively for their menopausal side effects to be treated. 
The Pancreas Is Essential 
 Examining the practices in BOC genetic medicine for managing women's increased risk 
of pancreatic cancer, which is the third most common cancer associated with BRCA mutations, 
sheds further light on how ovaries are constructed as disposable. The pancreas and ovaries are 
both endocrine glands, and there are several similarities between pancreatic cancer and ovarian 
cancer. The prevalence of the two cancers in women is nearly identical, with 11.2 out of every 
100,000 women per year being diagnosed with pancreatic cancer, and 11.6 out of every 100,000 
women per year being diagnosed with ovarian cancer (National Cancer Institute, 2018e, 2018f; 
Noone et al., 2018). Both cancers lack effective screening tools and therefore are extremely 
difficult to detect. Similar to ovarian cancer, at diagnosis over 80% of pancreatic cancers have 
spread regionally or to distant organs, with 52% having metastasized and only 10% being 
localized (National Cancer Institute, 2018f; Noone et al., 2018).  
 Recent risk estimates indicate that BRCA mutation carriers’ lifetime risk of developing 
pancreatic cancer is, on average, 5%, but ranges from 2-10 times the risk in the general 
population (Iqbal et al., 2012; Mersch et al., 2015). These estimates are lower than current 
estimates of BRCA carriers’ lifetime risk of developing ovarian cancer, which are approximately 
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17% for women with BRCA2 mutations and 44% for women with BRCA1 mutations 
(Kuchenbaecker et al., 2017). Hence, among BRCA mutation carriers, women’s overall risk of 
developing pancreatic cancer is lower than their risk of developing ovarian cancer.  
 However, five-year survival rates for pancreatic cancer are less than 9%, by far the worst 
of any cancer (National Cancer Institute, 2018f; Noone et al., 2018). With 44,330 people 
estimated to die of pancreatic cancer in 2018, it is the third leading cause of cancer death in the 
United States, trailing only lung cancer and colorectal cancer, both of which are far more 
prevalent (National Cancer Institute, 2018f; Noone et al., 2018). Moreover, while both pancreatic 
and ovarian cancer tend to be caught after they have spread, even in the 10% of cases when 
pancreatic cancer is localized at diagnosis, the five-year survival rate is only 34% (National 
Cancer Institute, 2018f; Noone et al., 2018). In contrast, in the 15% of ovarian cancers that are 
localized at diagnosis, the five-year survival rate is 92%(National Cancer Institute, 2018e; Noone 
et al., 2018). Because of its terrible prognosis, more women in the United States die each year 
from pancreatic cancer than ovarian cancer. From 2011-2015, the annual death rate per 100,000 
women from pancreatic cancer was 9.5, whereas for ovarian cancer it was 7.2 (National Cancer 
Institute, 2018e, 2018f; Noone et al., 2018).  
 Given the extremely low survival rates from pancreatic cancer, any significantly elevated 
risk is of concern. One might think that concerns about pancreatic cancer risk would be 
particularly high for women with BRCA2 mutations, who, compared to BRCA1 mutation 
carriers, have almost twice the lifetime risk of developing pancreatic cancer but less than half the 
risk of developing ovarian cancer (Cavanagh & Rogers, 2015; Kuchenbaecker et al., 2017; A. W. 
Kurian et al., 2010; Salo-Mullen et al., 2015). In fact, for a woman with a BRCA2 mutation who 
has no family history of ovarian cancer but two or more relatives who have had pancreatic 
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cancer, estimates of her lifetime risk of developing both cancers might be close to 10%. Yet risk-
reducing pancreatectomy (RRP) is never considered in the absence of clinical symptoms of 
pancreatitis, even for BRCA2 mutation carriers who have strong family histories of pancreatic 
cancer. RRP is only considered in individuals who have pre-cancerous lesions or chronic 
pancreatitis, and even then, it is rarely performed (Canto et al., 2013; Del Chiaro, Segersvärd, 
Lohr, & Verbeke, 2014; Lucas, 2014). At the ten multi-day scientific meetings and two dozen 
webinars on cancer genetics that I attended between 2013 and 2017, I never once heard anyone 
even mention RRP in a session or discussion.  
 In highlighting patients’ and providers’ reluctance to consider or speak about RRP, I am 
not suggesting that BOC genetic medicine should move toward the procedure as a mass practice. 
When people have their pancreas removed, they instantly develop insulin-dependent, or Type 1, 
diabetes, which is associated with an increased risk of heart disease, stroke, kidney disease, 
blindness, and nerve damage (Imperatore, Mayer-Davis, Orchard, & Zhong, 2016). Given the 
low prevalence of pancreatic cancer, every death averted by RRP might also result in many more 
individuals experiencing harms, even when accounting for pancreatic cancer’s extremely high 
mortality rate. But because of that high mortality rate, in targeted populations at very high risk of 
pancreatic cancer, all-cause mortality might go down with RRP, similar to outcomes of RRSO in 
populations at high risk for ovarian cancer. Yet scientists cannot test either hypothesis because 
the data on RRP are too thin—providers only consider and offer the procedure in extreme 
circumstances.  
 One might suspect that RRP is an almost unthinkable practice because data are lacking 
on the morbidity and mortality associated with the procedure. Being launched into insulin-
dependent diabetes in mid-adulthood might result in different health outcomes than becoming a 
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Type 1 diabetic in childhood or young adulthood, when the disease typically develops 
(Imperatore et al., 2016; Menke et al., 2013). But RRSO was recommended to BRCA mutation 
carriers long before 2010, when the first studies were published showing that RRSO reduced all-
cause mortality (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010). Prior to that, there were 
only data on oophorectomy in the general population, and those findings suggested that 
premenopausal salpingo-oophorectomy in BRCA carriers might increase all-cause mortality. The 
hesitation to even discuss RRP is also not because people are unable to live without their 
pancreas or endogenous insulin. Type 1 diabetes is a serious disorder, but with access to quality 
medical care, it is also a treatable and livable one; current estimates indicate that over one 
million children and adults in the United States currently live with the disease (Imperatore et al., 
2016; Menke et al., 2013). Hence, we know that with careful medical management, people can, 
and do, live otherwise healthy lives with a non-functional pancreas by taking injectable insulin. 
Living without a pancreas or with one that does not produce insulin is by no means optimal, but 
it is manageable. So why is RRP viewed as unfathomable, even in individuals with a high risk of 
pancreatic cancer, but RRSO is regarded as an “easy” procedure that women at high risk of 
ovarian cancer should hurry up and get?  
 The discrepancies in the discursive and clinical practices surrounding pancreatic cancer 
risk and ovarian cancer risk are, in part, linked to differences in how ovaries, the pancreas, and 
the hormones they produce are constructed. The pancreas is an endocrine organ that produces a 
hormone, insulin, that is widely presented and understood as critical to healthy bodily 
functioning. But, as I have illustrated through women’s stories in this chapter, ovaries are 
endocrine organs that are commonly constructed as disposable after childbearing, and the 
systemic, non-reproductive effects of the steroid hormones they produce are largely rendered 
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invisible. In other words, the different ways in which we view and talk about parts of our bodies 
have material effects and consequences. When body parts are framed as essential, like the 
pancreas is, doctors are cautious and reluctant to even discuss the possibility of removing them. 
But when bodies are fragmented and organs are constructed as disposable, like ovaries are, 
individuals are more likely to be willing to remove them or to be rushed into surgery under-
prepared. Perhaps if the systemic effects of hormones were more widely understood and ovaries 
were regarded as valuable organs throughout women’s lives, clinicians would more consistently 
inform BRCA mutation carriers about the sometimes severe side effects of RRSO and manage 
those effects with HRT. As I have emphasized, there are solid data on the health benefits of 
RRSO in high-risk women. But some of those benefits are offset by the casual practices 
surrounding the surgery, and the seriousness with which medical professionals regard RRP 
brings the “cavalier” discourses and practices surrounding RRSO into sharp focus.  
Intersectional Bodies 
 The discursive and clinical practices in BOC genetic medicine that construct women’s 
ovaries and uteruses as disposable after childbearing are highly gendered. Jackie, the genetic 
counselor who shared that she often does not address with her clients how RRSO might affect 
their sexuality, noted about that practice, “I think it’s an incredibly sexist thing that we don’t talk 
about it more. If this were men, we wouldn’t be telling them to take their reproductive organs out 
at the same rate.” Indeed, there are no stages in the life course or circumstances in which men’s 
sexual and reproductive organs are portrayed as unimportant or disposable. Instead, it is widely 
assumed that men will want to retain their testes and prostate throughout their lives and not have 
their organs removed after they have had their desired number of children. Prostate cancer is the 
most prevalent cancer among men in the United States and is the second leading cause of male 
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cancer deaths (National Cancer Institute, 2018g). Yet prophylactic prostatectomy is not a 
phenomenon, even among BRCA2 mutation carriers and other men at high genetic risk (National 
Cancer Institute, 2018g; PDQ® Cancer Genetics Editorial Board, 2018; Pesmen, 2015). 
 Even more than the prostate, testicles are constructed as essential to maleness. 
Approximately 50% of testicular cancers are genetically linked, which is a much higher 
proportion than the 10% - 15% of breast and ovarian cancers that are heritable (Litchfield et al., 
2015; Wang et al., 2017). However, no one suggests that men consider prophylactically having 
their testes removed if they have mutations or clusters of genetic markers associated with high 
testicular cancer risk. It is also nearly impossible to imagine a man who is done having children 
saying, like many women did about their ovaries, “I don’t need my testicles anymore.” In fact, 
when a nationally-regarded gynecologic oncologist referred to RRSO as “castration” in a plenary 
talk at a cancer genetics meeting, there were visible looks of shock on the faces of several 
audience members, and one of the genetic counselors sitting near me uttered “Wow.” 
 The GYN/ONC’s usage of the word castration was medically accurate, as the scientific 
definition of the verb “castrate” means to remove the testes or ovaries. But that instance was the 
only time in my three years of research on this topic that I ever encountered a person referring to 
oophorectomy as castration, either in speech or writing. In common parlance, “castration” is 
understood as the process of cutting off a man’s testicles, and it is perceived as a severe 
intervention that has negative associations; “castrate” also means “to render impotent or deprive 
of vitality” (Merriam-Webster, 2018). By referring to oophorectomy as castration, the 
GYN/ONC drew attention to the severity of the procedure, which elicited surprise among some 
members of the audience. Those reactions, in turn, highlighted the gendered discursive and 
clinical practices in genetic medicine. Removing a woman’s ovaries is often constructed as 
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routine and easy, but invoking the parallel procedure in men made it seem shocking and extreme.  
  Moreover, the discourses and practices in BOC genetic medicine that embrace 
reproductive technologies and frame women’s ovaries and uteruses as disposable after 
childbearing are not just gendered—they are intersectionally gendered, racialized, and classed. 
Gender, race, and class—as constructs, social structures, and axes of identity—are interactive; 
they do not operate separately or additively, nor can they be neatly disentangled. This is reflected 
in reproduction, which is stratified, both in the United States and globally (Colen, 1995; 
Ginsburg & Rapp, 1995). That is, the ways in which reproduction is and is not socially valued is 
markedly uneven by race and class. Anthropologist and science studies scholar Rayna Rapp 
explains, “Reproductive futures are embedded inside other forms of hierarchy: Access to 
respectful, competent prenatal care, eugenic attitudes toward ‘excessive’ or ‘wasteful' 
pregnancies, and financial and social resources for differently abled children are socially 
stratified in familiar patterns” (Rapp, 2000, p. 311). In the United States, motherhood among 
middle- and upper-class white women has mostly been valued, while, comparatively, 
motherhood has often been devalued among poor women, immigrant women, and women of 
color (Bridges, 2011; D. Roberts, 1997; Silliman et al., 2004; Vandenberg-Daves, 2014). 
Moreover, economically advantaged white women’s reproductive concerns have often been 
prioritized within major women’s health advocacy organizations, whether those priorities have 
been to not have children through access to contraception and abortion services or to have 
genetic or biological children through access to reproductive technologies (Gordon, 2002; 
McFarlane, 2001; D. Roberts, 1997; Silliman et al., 2004; Staggenborg, 1991).  
 The patient population in BOC genetic medicine in the United States is disproportionately 
female, white, highly-educated, and middle-class (Armstrong et al., 2015; Cragun et al., 2017; 
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McCarthy et al., 2016; Underhill et al., 2016), and thus it reflects the groups of women among 
whom reproduction and motherhood tend to be more valued. Science studies scholars have 
illustrated how the skewed demographics of patients in genetic medicine are, in part, a reflection 
of the field's early engagement with Ashkenazi Jewish and other European populations 
(Mozersky & Joseph, 2010; Wailoo & Pemberton, 2006). Scientists created databases of genetic 
samples from these populations that were used for early genetic research, which concentrated 
knowledge on variants more commonly seen among Ashkenazi Jews and other people of 
European ancestry. In turn, greater knowledge about cancer genetic risk in those populations has 
sedimented racialized ideas, among both lay people and health professionals, about who is and is 
not at risk and therefore who tends to use genetic testing services (Montoya, 2011; Mozersky & 
Joseph, 2010; Wailoo & Pemberton, 2006). The demographic distribution of the women who 
participated in this study is similar to the typical patient population in BOC genetic medicine--
they were overwhelmingly white and over 80% of them had at least a college degree.59  
 The effort made by clinicians in genetic medicine to inform women about, and provide 
them with referrals to, reproductive technologies is an example of how practices in the field are 
not only gendered, but also racialized and classed. Like BOC genetic medicine, reproductive 
technology services, such as egg/embryo freezing, PGD, and IVF, are disproportionately used by 
white women (Dieke, Zhang, Kissin, Barfield, & Boulet, 2017; Ethics Committee of the 
American Society for Reproductive, 2015; Smith et al., 2011). In addition, these services also are 
extremely expensive and are rarely covered by insurance. Prices for reproductive technologies 
are variable, but estimates for the average cost of medications and treatment for one cycle of egg 
                                                             




freezing range from $10,000 - $15,000, and then storing those eggs costs approximately $500 
annually. When women are ready to use their frozen eggs, the average cost of IVF (which is 
always required with egg/embryo freezing) and PGD (which is optional) are an additional $5,000 
and $3,500 per cycle, respectively (Advanced Fertility Center of Chicago, 2018a, 2018b; 
Beltsos, 2018; Neighmond, 2014; Shady Grove Fertility, 2017). As Marci, who froze her eggs, 
stated, “Egg freezing is a car. It’s its own thing. There is nothing cheap about that process at all.” 
Given the high costs of using reproductive technologies, they are likely to be difficult to access 
for many women. For example, Lily was exploring the possibility of PGD, but she was doubtful 
she could afford it. “I am interested about the genetic testing—like, the pre-genetic testing with 
the children. I have looked at that, and it's very expensive, as you may know. It's really expensive 
and I'm just like—I don't know if that's really an option for me.”  
 As I have illustrated throughout these chapters, scientific and medical practices are filtered 
through larger historical, social, and cultural contexts. Thus, women's experiences shared in this 
chapter, such as referrals to reproductive technologies, should be understood within a broader 
landscape of contemporary gender politics that disproportionately values motherhood among 
middle-class, white women. The lens of distributed reproduction focuses attention on how RRSO 
practices that prioritize and emphasize women's reproductive capacities are not reflective of how 
all women’s bodies in the United States are valued. Rather, these practices in genetic medicine 
align with social and cultural values about women's bodies and roles that are specific to the 
intersectional racial and class locations of the women who tend to access BOC genetic medicine. 
Conclusion: How Much Knowledge? 
This chapter examined the discursive and clinical practices involved in constructing and 
managing genetic risk for ovarian cancer in the United States. Drawing on fieldwork at cancer 
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genetics conferences and interviews with clinicians and BRCA mutation carriers, I illustrated 
multiple axes of competing priorities in BOC genetic medicine. First, there is a foundational 
socio-clinical tension in the field: concerns about breast cancer risk and pressure to have 
mastectomy are magnified in social contexts, while concerns about ovarian cancer risk and 
encouragement to have RRSO are amplified in clinical contexts. Second, there is a disparity 
between how RRSO is framed, which is as a quick and easy surgery, and women’s embodied 
experiences after the procedure, which are enduring and difficult. Third, the structures of genetic 
medicine reflect longstanding biomedical practices that emphasize the reproductive functions of 
ovaries and steroid hormones while obscuring their systemic non-reproductive effects. I argued 
that there are material, embodied consequences of the social, clinical, and discursive practices 
that prioritize the reproductive capacities and functions of women's ovaries and uteruses over 
their non-reproductive functions. These discourses and practices often result in women rushing 
into RRSO without having without adequate information about the severe and enduring side 
effects of medically-induced menopause.  
When viewed in isolation, several of the RRSO practices highlighted in this chapter are 
positive, and even optimal. Most clinicians are accurately conveying the health and survival 
benefits of RRSO to BRCA carriers, which helps women make informed decisions. In addition, 
the structures and architecture of BOC genetic medicine in the United States largely respect 
women’s reproductive autonomy. The field tends to provide appropriate information about the 
impact of RRSO on fertility and often issues referrals to reproductive medicine specialists when 
women are nearing the recommended age ranges for RRSO and want more children. Hence, the 
tension evident in RRSO practices is most often not around the information women do receive, 
but rather around the information they do not. 
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BOC genetic medicine patients need to be better informed about the systemic impact of 
steroid hormones on multiple systems in the body, the full range of potential health risks and side 
effects of medically-induced menopause, and current research on the health benefits of HRT use 
for premenopausal previvors. While most women stated that with this information they still 
would have chosen RRSO, not having that knowledge prior to their surgeries caused them added 
stress and, in the case of information about HRT, led to their symptoms being under-managed. I 
cannot count the number of times I heard women in this study repeat the phrase “Knowledge is 
power.” BOC genetic medicine is centered on helping women “take control” of their lives and 
make “strong choices.” But the stories in this chapter illustrate that when women are not 
provided with accurate, current risk and benefit information—when they only have a slice of the 
knowledge they need rather than the full picture—their choices are circumscribed, and it can lead 
to their experiences feeling out of control.  
Women’s under-preparation for medically-induced menopause is also especially striking 
because participants in this study, like most patients in BOC genetic medicine, were 
disproportionately privileged. Almost 95% of the women I interviewed were white, 43% had a 
graduate degree, another 40% had graduated from a four-year college, and 100% of them had 
health insurance. In addition, the vast majority of the women were active in a patient advocacy 
group, whether that was an in-person support group, a local chapter of a national organization, or 
a virtual group on Facebook. In other words, these are the very women whom one would expect 
to have the best access to resources, information, and services, and yet even their care and 
knowledge were falling short. How can we improve the quality and evenness of the information 
and clinical care women receive in BOC genetic medicine? I will address this question and other 
policy and practice recommendations in the final chapter that follows.   
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Conclusion: "A Higher Level of Communication, a Basic Standard of Care":  
Policy and Practice Recommendations for the Panel Testing Era 
“I think if there was some sort of generalized plan for people with mutations. I don't 
know if that could happen, it's so relatively new. But if there could be a plan...” (Marlene, 
Age 35, CHEK2)  
“We really do have to update the way that we think about delivering our services if we 
want to accomplish our mission of making sure people have the genetic information that 
they need.” (Alyssa, Genetic Counselor)  
“We also have to have some sense of what the right answer is. And it can’t just be, 
‘We’re going to do all of this testing so people can make up their own minds about what 
the heck it is that they should be doing.’” (Steve, Oncologist)  
  
 This project examined practices in breast and ovarian cancer (BOC) genetic medicine in 
the United States in the new era of multi-gene panel testing. Departing from frameworks in 
clinical research on BOC genetic risk, I explored the active construction of risk, and I extended 
social science scholarship on cancer genetics by studying the recently emerged groups of women 
identified as having "moderate" or "uncertain" BOC risk via panel testing. Going beyond an 
individual- or familial-level analysis of women’s risk management decisions, the study explored 
how social and structural aspects of BOC genetic medicine limit or expand women’s options and 
actions.  
 Over a three-year period, I collected data at cancer genetics conferences, analyzed reports 
and documents from genetic testing laboratories, and conducted interviews with women with 
BOC mutations and health care providers working in BOC genetic medicine. I examined the 
technologies, practices, tools, and documents used to interpret and classify cancer genetic risk, 
generate risk estimates, and explain BOC genetic risk information. I then explored women’s risk 
management experiences—the guidance they received, their insurance coverage for testing and 
surveillance, the surgical and medical management options they were provided, and 
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their participation in support groups and health activism. 
 One major finding of this study is that the shift to panel genetic testing has contributed to 
the blurring boundary between risk and disease. Women with high-risk BOC mutations like 
those on the BRCA1/2 genes are now rarely viewed or treated, by health professionals or 
themselves, as occupying a liminal state between health and illness. Rather, women with BRCA 
mutations are now typically viewed and counseled as if they have a disease that should be 
managed according to clearly defined protocols. Instead, it is women with variants of uncertain 
significance (VUSs) or moderate-risk mutations (MRMs), such as those on the CHEK2, PALB2, 
or ATM genes, who now face confusion and uncertainty in their medical management.  
 This study also finds that the organization and practices of US genetic medicine point 
women with BOC mutations toward risk-reducing mastectomy (RRM) and breast reconstruction 
and encourage choosing those surgical responses over breast surveillance or staying flat. The 
experiences of women in this study revealed how mastectomy is both viewed and used in 
practice as the “treatment” that cures the “disease” of genetic risk for breast cancer, regardless of 
whether women’s mutations are high- or moderate-risk. Even though mastectomy is a medical 
procedure that reduces women’s risk of developing breast cancer and reconstruction is a 
cosmetic procedure that confers additional risks to women’s physical health, the two surgeries 
are often presented to women as a package deal. I argue that the practices in genetic medicine 
that structurally encourage breast reconstruction both reflect and reinforce gendered norms and 
expectations for women’s bodies.  
 Beyond this encouragement to undergo mastectomy and reconstruction, this project 
illustrates that women—particularly those with moderate risk mutations—experience tremendous 
unevenness in the care they are provided. Broadly, the US healthcare landscape is marred by 
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variability in providers’ knowledge and training and the cost and coverage of health care 
services. However, genetic medicine, in particular, lacks uniform protocols for interpreting and 
reporting variants and managing women’s risk through surgeries. These inconsistencies in 
provider knowledge and practices left many of the women in this study un- or under-prepared for 
the risks and consequences of breast reconstruction and risk-reducing salpingo-oophorectomy 
(RRSO). 
 This project also revealed that the high social value placed on conventional femininity 
implicitly and explicitly encourages women to take on additional risks in order to have breasts 
that lack sensation or biological function. I illustrated how having the visible appearance of 
breasts is framed as essential, while real breasts are treated as disposable. However, while breasts 
are marked by their visibility, ovaries are both literally and figuratively marked by their 
invisibility. Because they are internal organs, you can cannot physically see their presence or 
absence, and at the same time social and medical discourses obscure the systemic bodily effects 
of the steroid hormones produced by ovaries. Hence, ovaries, which are endocrine organs with 
critical biological functions beyond reproduction, are constructed as disposable, while breasts are 
considered so indispensable that women are encouraged to replace them despite the additional 
risks to their health reconstructive surgeries pose. Together, breast reconstruction and RRSO 
practices reflect and reinforce gendered, racialized, and classed social and cultural values that 
prioritize women's appearance and their reproductive capacity over their embodied experiences 
and daily quality of life.  
 Women’s stories illustrated that their involvement in cancer genetics communities and 
advocacy networks sometimes improved their knowledge and helped them to more effectively 
navigate the complex maze of genetic medicine. As institutions, social and support networks for 
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women at BOC genetic risk have become valuable education and advocacy blocs that help to 
buffer the unevenness of the US healthcare system. However, while these groups make efforts to 
collectively reshape clinical care, in the fragmented, private insurance-based US system, those 
opportunities are limited and stymied. Hence, the knowledge shared through advocacy and 
support groups may result in individual-level improvements for the women who find them, but 
the information-sharing in these groups is a patchwork stopgap that leaves the larger structures of 
genetic medicine unchanged.  
 One of the themes explored throughout this study is how the practices of genetic 
medicine are framed by rhetorics of “choice” and “empowerment” but are often marked by 
constraint and inequality. Focusing on women’s testing and surgical choices instead of the 
structures that circumscribe and facilitate those choices puts the onus on women to be informed 
and manage their care rather than asking the system to better serve their needs. But women at 
BOC genetic risk should not have to bootstrap themselves into quality, informed care. As Steve, 
an oncologist, said, “I’m all in favor of shared decision making, I think it’s important. But we 
also have to have some sense of what the right answer is. And it can’t just be, ‘We’re going to do 
all of this testing so people can make up their own minds about what the heck it is that they 
should be doing.’” Indeed, several women in this study indicated that they wished they had 
clearer guidance, information, and recommendations so that they could make truly informed 
choices. What follows in this final chapter are suggestions for system- and structural-level 
changes to the policies and practices of BOC genetic medicine that could improve women’s 
experiences and options. 
Develop a Uniform Risk Classification System 
Susan Domchek, the director of the Basser Center, one of only two BRCA research 
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centers in the United States, succinctly summarized the conundrum at the heart of breast cancer 
risk management for women with BOC mutations: “Although the risk of breast cancer is high 
among women with BRCA1 and BRCA2 mutations, it is not absolute; some women will not 
develop cancer; thus, mastectomy would have been unnecessary. Conversely, despite screening 
and early detection, not all breast cancers will be curable but may have been prevented with risk-
reducing mastectomy” (S. M. Domchek, 2019, p. 27). Several women who participated in this 
study understandably felt that developing an incurable cancer that might have been preventable 
was a worse fate than having a mastectomy that was unnecessary, and therefore they chose to 
have RRM. However, women’s stories also illustrated that many of them were not accurately 
informed about the ranges of penetrance for their mutations or the consequences of 
reconstruction and RRSO, all of which are critical to women’s personal risk/benefit calculations 
about surgeries.  
Moreover, the probabilities of having unnecessary RRM or opting to wait and 
subsequently developing an incurable cancer are not equal to one another or evenly distributed 
across women. Rather, both probabilities are modified by the type and location of women’s 
particular mutations, their family histories, and their personal lifestyle factors (such as whether 
they smoke or drink). Women with higher-risk mutations that tend to develop aggressive cancer 
subtypes, such as BRCA1 mutations, are more likely than women with mutations on moderate-
penetrance genes like CHEK2 to develop an incurable cancer if they avoid mastectomy. 
Conversely, RRM is more likely to be unnecessary among women with CHEK2 mutations than 
among women with BRCA1 mutations given that the highest lifetime risk estimates for CHEK2 
mutation carriers are approximately half those of BRCA1 mutation carriers (Couch et al., 2017; 
Kuchenbaecker et al., 2017; Tung et al., 2016). Yet current approaches to reporting genetic test 
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results group these two very different mutations together as “positive” results, which frames 
them as similarly risky.  
The current approaches to communicating BOC genetic risk derive from the targeted-
gene testing era, when women who had genetic testing were typically screened for mutations on 
only the BRCA1 and BRCA2 genes. The lifetime risk estimates and risk profiles of mutations on 
these two genes, while different, are similar enough that they were initially grouped together. In 
addition, standardized reporting practices were not essential in this era, given the general 
consensus on the risk profiles of the BRCA genes and the limited volume of genetic information 
being communicated to patients and other providers. However, now that panels screen for 
variants on dozens of genes that confer a much wider range of risks, the volume and complexity 
of information provided by genetic testing has dramatically increased, but reporting and 
counseling practices have not kept pace with these changes. In combination with the fact that 
BOC genetic risk is increasingly viewed and managed like a “disease,” the binary division of 
genetic testing results into “positive” and “negative” is no longer sufficient and, I have argued, 
contributes to the over-management of risk. 
Chapter One highlighted that while clinicians and scientists have devoted resources to 
assessing and improving VUS knowledge and management, there is practically no discussion in 
genetic medicine about the over-management of MRMs. Most genetics experts understand that 
prophylactic surgeries are only recommended for high-risk and not moderate-risk mutations, but 
those distinctions are not clearly communicated to patients or providers without expertise in 
genetics. Rather, the current unstandardized reporting system is both highly variable and overly 
simplistic, as labs provide patients with different risk information but then classify all variants 
deemed likely pathogenic or pathogenic as “positive,” regardless of whether the variant poses a 
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25% or 75% lifetime risk of developing cancer. This binary positive/negative approach to 
reporting genetic testing results encourages patients to view and manage all BOC mutations as 
similarly risky when they are not.  
  Genetic medicine would benefit from a simple, uniform system for classifying and 
reporting on mutations that 1) groups them according to their varying ranges of risk, and 2) 
indicates the appropriate interventions for managing each range of risk. Such tiered classification 
systems, like the ones currently used in oncology for staging and grading tumors, clearly 
communicate complex information about tumor biology and disease progression to patients and 
their other providers. If, for example, genetic experts developed a similar scale for classifying 
mutations into four risk groups (e.g., Risk Levels 1 - 4) and laboratories uniformly used that 
system, then patients and their primary care providers or surgeons who do not have training in 
genetics might more clearly understand the spectrum of risk and calibrate their responses 
accordingly. Most cancer patients understand that while all cancers are bad, Stage III tumors are 
worse than Stage I tumors and require more intensive and invasive treatments. Thus, it follows 
that if women and providers were given the appropriate conceptual frameworks and tools, they 
could grasp similar distinctions about risk for cancer and would understand that having a “Level 
4 Risk” might warrant RRM but a “Level 1 Risk” would not. Such an approach would also help 
to distinguish between the risks of having BRCA1 and BRCA2 mutations, which Domchek 
emphasizes are “related but distinct cancer susceptibility syndromes” (S. M. Domchek, 2019) 
that require different responses.  
Of course, even with a uniform risk classification system, there will always be individual 
cases that are difficult to categorize, and multiple factors would have to be considered to 
determine patients’ risk classifications. Just as breast tumors are classified as Stage II when 
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either there is lymph node involvement or tumors exceed two centimeters in size, individual 
women with CHEK2 mutations might be upgraded in their risk level if they also had multiple 
relatives with breast cancer. But similarly, the criteria for each risk level and the interventions 
considered appropriate at each level would not vary across genetics laboratories or clinics, just as 
hospitals and pathology labs do not each develop their own tumor grading and staging criteria. A 
standardized risk classification system for BOC genetic medicine would make notable strides in 
improving clarity and consensus about the health and clinical implications of different BOC 
mutations, something many of the women with MRMs in this study said they desired.  
Provide Patient-Centered Reports that Minimize VUSs 
Genetic testing results reports are enduring documents that communicate risk 
information. While many of the women in this study who met with genetics experts before or 
after being tested remembered their interactions during these pre- and post-test counseling 
sessions, for some women, their recollections of the detailed specifics of those conversations, 
such as numeric risk estimates they were provided, had faded over time. However, their test 
reports were firm sources of information that they could (and did) refer back to to remind 
themselves of their risks and locate additional resources. Hence, the organization, content, and 
framing of panel test reports is critical, and modifying those factors could alter patients’ 
understandings of, and responses to, being at risk.  
Chapter One highlighted the tremendous variability in the reports of the five major cancer 
genetics laboratories in the United States. The labs differed in how they conveyed information 
about VUSs, who their target audience was, the different associations they identified between 
specific genes and cancers, and the types of risk estimates they provided. The variability in the 
information provided in panel test reports contributed to women's confusion about what cancers 
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they were at risk for, how serious those risks were, and the most effective ways to manage those 
risks. Developing a uniform risk classification system would help to rectify some of the 
inconsistencies and variability in information that women encountered. In addition, modifying 
genetic test results reports so that they are directed to patients rather than providers could 
improve women’s experiences navigating BOC genetic medicine. Color’s current reporting 
practices can serve as a model for other laboratories. As was illustrated in Chapter One, Color’s 
reports are patient-oriented in their language and presentation, minimize VUS results, and list 
only robustly established cancer associations. 
In the debates within genetic medicine over whether and how to report VUSs, advocates 
for providing information on uncertain variants typically argue that VUS findings are owed to 
patients, both because it is their genetic data and because variants might be upgraded and later 
reclassified as harmful. However, as Chapter One illustrated, all variant classifications are active 
interpretations by genetic scientists, and therefore all variant classifications can change. Yet 
laboratories do not currently report on benign or likely benign variants that they identify during 
sequencing, despite that information also being patients’ personal genetic data and the possibility 
of those variants being upgraded in the future. Moreover, recent studies have shown that even 
after 10 - 20 years, at most only 25% of VUSs are reclassified, and over 90% of the VUSs that 
are reclassified are downgraded to benign or likely benign (Macklin, Durand, Atwal, & Hines, 
2018; Mersch et al., 2018; M. L. Murray et al., 2011; T. P. Slavin et al., 2018). Hence, only 
approximately 3% of the people given VUS results are likely to eventually have a reclassification 
to pathogenic or likely pathogenic that would warrant additional medical management. Yet, 
according to studies on responses to receiving VUS information, as many as 10% - 20% of 
individuals who were told they had a VUS had prophylactic surgeries (Miller-Samuel et al., 
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2011; M. L. Murray et al., 2011; Vos et al., 2008). These results suggest that the current 
approach to reporting taken by most laboratories, which is to prominently identify all VUS 
results from BOC panel tests, is associated with a greater proportion of women being overtreated 
with surgery than the proportion of women who would be under-screened if those VUSs were 
never reported. If more laboratories utilized Color’s approach of noting that a VUS was found 
but not highlighting that information or indicating the location of the variant unless the patient or 
provider requested additional information, it is likely that fewer women with VUSs would end 
up having mastectomy or RRSO.  
Either in addition or as an alternative to adopting Color’s reporting practices, laboratories 
also could follow the recommendations from scientists and clinicians at the Transforming 
Genetic Medicine Initiative (TGMI). In a 2017 blog post, TGMI proposed that only the specific 
VUSs that scientists were suspicious might be harmful, which they referred to as “variants under 
surveillance/suspicion,” be reported as VUSs.60 They stated: 
The variants the current system doesn’t handle well are the tiny group of VUS that we are 
already suspicious are pathogenic. They don’t quite meet the formal evidence 
requirements to be called likely pathogenic, but we would willingly stake a decent wager 
that they will. Much of the over-management of VUS occurs because people think all 
VUS are variants we are suspicious are pathogenic. But these suspicious VUS form a tiny 
minority of the variants we include within the VUS category…. A simple fix might be to 
change VUS to be the Variants Under Suspicion or Variants Under Surveillance. We 
have ample evidence that people assume this is what a VUS is. If we put the variants that 
are appropriate to be considered in this way into that category we will have less of a 
mismatch between what we mean and what others think we mean. (Nazneen Rahman, 
2017)  
                                                             
60 Both Color’s approach to reporting and TGMI’s re-definition of VUSs would benefit women who are 
in active cancer treatment. As noted earlier in the study, genetic findings are increasingly being used to 
determine eligibility for certain drugs and clinical trials. Therefore, access to information about the 
specific location of VUSs and knowing whether they are under suspicion of being pathogenic can be even 
more important for cancer patients than for unaffected individuals. 
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Rather than asking patients to understand the nuances of geneticists’ complicated terminology 
and classifications, the TGMI team argues that genetic scientists and clinicians should alter their 
language and definitions of VUSs to align with the mass public’s understandings of the term.  
Eliminate the Diagnostic Loophole 
Eliminating the diagnostic loophole, which is a failure of women’s health policy and 
practice, is another system-level change that could greatly improve women’s experiences 
navigating US genetic medicine. Annual mammograms and breast MRIs spaced six months apart 
are the routine screening procedures that are recommended for women with BOC mutations. 
Thus, like annual mammograms for women 40 and older in the general population, annual 
mammograms and breast MRIs should be coded and treated as screening services and covered by 
insurance with no cost-sharing. Instead, mammograms and MRIs are currently coded as 
diagnostic for asymptomatic women with BOC mutations in the United States, which erects 
sizable financial barriers to breast screening services only for women with higher-than-average 
risk. As the stories from women in this study revealed, the diagnostic loophole discourages the 
women who most need breast screening services from seeking them, and, in some cases, 
encourages them to seek surgery instead. Hence, coding these important breast screening 
services as diagnostic is both fiscally nonsensical and threatens women’s health. But, in addition, 
the diagnostic loophole discursively contributes to the conflation of genetic risk with disease and 
the sense among women with BOC mutations that developing breast cancer is inevitable. A 
symptom is a physical manifestation of illness. Thus, if women’s BOC mutations are considered 
“symptoms” that warrant their screening services to be coded as diagnostic, then either their 
“disease” is risk or their mutation is being treated as a sign of an impending cancer. 
Recent activism around the US Preventative Services Task Force (USPSTF) breast 
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screening guidelines for women at average risk not only highlights that it is possible to eliminate 
the diagnostic loophole, but also brings its injustice into sharp focus. The Affordable Care Act 
requires that insurance companies cover the costs of screening services graded B or better by the 
USPSTF with no patient cost-sharing (111th Congress, 2010; Johns & Bayer, 2016). In 2016, the 
USPSTF finalized revisions to their breast screening guidelines that included changing the 
recommended frequency of mammography screening from annual to biannual and downgrading 
mammography from a B to a C among women ages 40 - 49 (US Preventative Services Task 
Force, 2016). The breast screening recommendations were revised after a thorough, multi-year 
review of the scientific evidence illustrated that, among women at average risk, the optimal 
screening interval was biannual and prior to age 50 the risks of breast surveillance outweighed 
the benefits (Gotzsche & Jorgensen, 2013). However, there was swift backlash among women, 
health care providers, and advocates who expressed concerns about how the revised guidelines 
would reduce women’s insurance-covered access to mammography, which many women had 
become accustomed to and perceived as “lifesaving” (Pitman et al., 2017; Squiers et al., 2011; 
Witten & Parker, 2018). In response, Congress mandated that the Department of Health and 
Human Services (HHS) continue to use the USPSTF’s 2002 breast screening guidelines, which 
issued a B grade to annual mammography for women 40 and older (US Preventative Services 
Task Force, 2018). This new legislation that required HHS to rely on the 2002 guidelines rather 
than the more recent 2016 guidelines ensured that women at average risk could continue to 
affordably access breast screening services.  
The public and legislative response to the USPSTF guidelines suggests that widespread 
support would exist for eliminating the diagnostic loophole if it were brought to light. In contrast 
to women in the general population, there is robust scientific evidence of the benefits of annual 
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mammography screenings and breast MRIs in women at higher-than-average risk of breast 
cancer. Yet current medical coding practices that wrongly classify these critical screening 
services as diagnostic exempt insurance companies from covering them without cost-sharing. In 
turn, women with BOC mutations who have high co-pays, co-insurances, or deductibles have to 
pay hundreds or thousands of dollars every year to receive their necessary routine screenings, 
leading some of them to skip those services or choose surgery instead.  
Throughout this analysis, I have highlighted the fact that while RRM dramatically 
reduces women’s risk of developing breast cancer, it has not been shown to significantly reduce 
mortality when compared to the high-risk breast screening protocol. But mastectomy 
unquestionably confers a survival benefit to women with BOC mutations when it is compared to 
doing nothing (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010), which is precisely what 
women might receive in the current context that financially penalizes them for seeking their 
recommended screenings. As the USPSTF guidelines saga illustrates, legislators mandated 
adherence to old breast screening guidelines not supported by current medical evidence in 
response to public outcry over mammograms becoming costlier for women at average risk. 
Hence, surely advocates could spur Congress to issue legislation requiring similar coverage of 
mammograms and breast MRIs for the women most at risk and for whom screenings provide 
significant medical benefits. Given the considerable resources devoted to breast cancer advocacy 
in the United States and bipartisan support for breast cancer research and funding, eliminating 
the diagnostic loophole is both a worthy and feasible goal.  
Provide Risk and Benefit Information on All Choices 
 The current structures and architecture of BOC genetic medicine are geared toward 
supporting women through their “choice” to have mastectomy and reconstruction. But this 
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project has highlighted the importance of also supporting women who choose not to reconstruct 
and those who choose surveillance. We need to make sure that the full spectrum of women’s 
options are being supported and that women truly have choices, not just veneers of choice. If 
women were provided with a full spectrum of options, those options would not only include 
having insurance-covered access to surgeries, but also choosing not to have surgery and still 
receiving full insurance coverage for their necessary screenings and tests. Similarly, there should 
be education and social support provided to help guide women through both surveillance and 
surgery. Eliminating the diagnostic loophole is a critical component of making breast 
surveillance services more patient-friendly. But in addition, providing online information and 
sessions at patient advocacy conferences on managing scanxiety and creating support groups or 
buddy systems at breast imaging centers for high-risk women could also help women navigate 
the stresses of screening.  
In addition, clearly separating mastectomy from reconstruction in initial discussions 
about RRM, and presenting the risks and benefits of each procedure separately, would be a small 
discursive shift that could make large strides in providing women with more patient-centered 
information and care. As I highlighted in Chapter Three, mastectomy is a risk-reducing 
procedure while reconstruction is a cosmetic procedure, and the two surgeries have very different 
profiles in terms of what risks the procedures, themselves, pose. Disentangling the risks and 
benefits of mastectomy and reconstruction and providing women with honest, comprehensive 
information about each procedure separately is critical. 
Separating mastectomy from reconstruction is one component of a much broader shift 
that is needed in BOC genetic medicine in the United States: ensuring that comprehensive risk 
and benefit information about the full range of risk-management options is provided to women. 
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Providing women with honest, comprehensive information and patient-centered care requires 
neither dismissing their social and emotional needs nor deferring to their desires or choices. For 
example, clinicians should discuss the potential mental health benefits of mastectomy with 
women at high genetic risk of breast cancer. Eliminating the constant daily stress of “waiting for 
cancer to come” and the intense episodic anxiety generated by yearly MRIs and mammograms 
could improve women’s daily quality of life. At the same time, women also deserve to know that 
mastectomy has not been shown to significantly reduce mortality, and women with MRMs 
should be clearly informed that the physical health risks of breast surgeries likely outweigh their 
benefits. Clinicians and counselors have an obligation to provide women with current, evidence-
based information about all of their care options; anything short of that means women are not 
making fully informed choices.  
Health care professionals also should critically examine what “informing and educating” 
patients looks like in practice. For example, it is not enough to say to women about RRSO, “You 
will go through menopause,” because that does not convey the daily impact the procedure could 
have on their lives. Instead, women should be informed about the specific consequences of 
medically-induced menopause—which can include sudden and intense hot flashes, vaginal 
dryness, disruptions in sleep, decreased libido, challenges with cognition, and bone loss— and 
told how they can mitigate some of those side effects. Similarly, women considering 
reconstruction deserve to know the high rates of complications and revisions associated with 
those surgeries and what those complications include, such as necrosis, scar tissue, muscle 
weakness, numbness, and pain at incision sites. If women were fully informed about the risks 
and benefits of surgeries prior to their procedures, perhaps they could avoid being blindsided and 
overwhelmed by the side effects.  
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Linda, one of the genetic counselors who also ran a support group for women with BOC 
mutations, shared how she discussed mastectomy with her patients, and what she described was a 
more patient-centered approach that did not funnel women toward RRM but instead encouraged 
them to weigh risks and benefits. She explained: 
And so, we talk about some benefits and some limitations. And the other thing that I'd 
like people to know up front is having a positive result opens up the conversation and it 
doesn't mean a person has to make immediate decisions, you know? The positive result is 
not an emergency, it's showing us which direction to go. Because sometimes people come 
in and think, especially with the Angelina Jolie, “If I have this that means I'm having a 
mastectomy.” And I try and make sure people understand, “No, that's not true. What it 
means is we get a breast MRI and then we start thinking about, ‘Is that something I want 
to explore, is that something I want to learn more about?’ It puts it on the table as a 
conversation piece. It makes it fair game for doctors to talk to you about it or you to talk 
to your doctors about. (Linda, Genetic Counselor)  
Marci also shared a story about an oncologist who provided her with comprehensive information 
and had a sensitive, patient-centered approach. This doctor did not make assumptions about 
Marci’s preferences, and instead listened to her and asked her questions. However, Marci only 
found this supportive clinician after first seeing a “very pressuring” oncologist who had 
encouraged her to hurry up and have RRSO without inquiring about her personal reproductive 
desires or broader life context. Marci contrasted her new oncologist's approach to the first doctor 
she had seen: “[The new oncologist] was a lot more open. She started with an, ‘Ok, where are 
you in your life? What do you want? Do you want children? How do you feel?’” If more 
providers considered the social and emotional context of women’s lives and provided them with 
accurate risk information, women would be making fully informed choices, whether those 
choices were to have or avoid surgery.  
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Reckoning with the Risks of Risk 
The findings from this study can also inform the current debate in genetic medicine over 
whether there should be population screening for BOC mutations. While some experts have 
expressed caution about adopting population-wide testing (Leib, Olopade, Pal, Rebbeck, & 
Vadaparampil, 2015; Yurgelun, Hiller, & Garber, 2015), several prominent clinicians and 
scientists have recently advocated for population genetic screening for BRCA mutations (M. C. 
King et al., 2014; Leib et al., 2015; Manchanda et al., 2018; Manickam et al., 2018; M. F. 
Murray, 2018). For example, Mary Clare King, one of the scientists who discovered the BRCA1 
gene, has been a vocal advocate for population testing for BRCA mutations in light of robust 
evidence that demonstrates their risks and the survival benefit conferred by RRSO (M. C. King 
et al., 2014). More recently, researchers studying whole exome61 or whole genome sequencing 
have argued that population screening would be beneficial because such testing catches 
mutations in people who do not meet current testing guidelines (Manickam et al., 2018; M. F. 
Murray, 2018).  
Clinicians and scientists who support population screening assume that identifying more 
people at risk is better, but this study suggests that is not always the case. The net effect on 
women’s health might be negative if, as was the case for many women who participated in this 
project, the effects of medically-induced menopause are systematically under-treated and 
moderate genetic risk for breast cancer is over-managed with mastectomy and followed with 
reconstruction. Moreover, there is, in fact, a greater likelihood that the net health effect of genetic 
risk knowledge would be harmful among people currently deemed at “average” risk. The lifetime 
                                                             
61 The exome is the coding-portion of the genome. 
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risk estimates of developing cancer among carriers of BOC mutations are subject to 
ascertainment bias, as these percentages have largely been derived from studies that included 
women at the highest end of the risk spectrum, such as women who had already developed breast 
cancer or those from “cluster” families with extensive cancer histories. Hence, the lifetime risk 
estimates of BRCA mutation carriers in the general population are likely to be notably lower. 
Given that it is unclear whether RRM confers a survival advantage even among BRCA1 and 
BRCA2 mutation carriers in the highest-risk populations, mastectomy is unlikely to reduce 
mortality among a broader population of women with overall lower risk. In addition, learning 
they have a mutation might trigger anxiety in women in the general population who previously 
had no reason to constantly be “waiting for cancer to come.” Hence, both the physical and 
mental health benefits of genetic risk knowledge and risk-management interventions are likely to 
be lower among women who do not meet current genetic testing criteria.  
The millions of dollars annually that population BRCA testing would require could 
instead be devoted to research aimed at developing effective screening tests for ovarian and 
pancreatic cancers and non-surgical approaches to preventing breast and ovarian cancers. As 
Susan Domchek, the medical oncologist who directs the Basser Center, recently stated in an 
article on RRM in the Journal of the American Medical Association (JAMA), “Women deserve 
better choices” (S. M. Domchek, 2019, p. E2). Indeed, they do, and significant financial and 
scientific resources should be devoted to developing those choices. But until those better, non-
surgical "treatment" options exist, offering BOC genetic testing to all women over 30 would 
expose vast numbers of women to the potential harms of mastectomy, reconstruction, and RRSO. 
Steve, an oncologist, addressed that potential for harm when he discussed his hesitance about 
population screening:  
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[I]f you really want to make this a cost-effective intervention, everybody has to have 
surgery. And that’s a weird world. I don’t think that’s what people meant when they 
started thinking about genetics. And if that model gets built in for that, where does that 
stop? CHEK2? ATM? And so, we need to come to some agreement about what the 
downstream consequences are going to be. (Steve, Oncologist)  
I spoke with Steve early in this study, before I interviewed women with MRMs and 
learned that we are, in fact, not stopping at CHEK2 and ATM. But his concerns are even more 
salient now that whole genome sequencing is making its way into clinical care (Manickam et al., 
2018; M. F. Murray, 2018). Cancer genetics is the subspecialty within US genetic medicine that 
is supported by the greatest volume of data and research. Yet, as this project has highlighted, the 
expansion of BOC genetic testing from sequencing two genes to sequencing 30 has generated 
notable uncertainty, confusion, and mismanagement among patients. As we look toward a future 
in which people’s entire genomes might be sequenced and genetic risk is explored in areas of 
health with a weaker knowledge base than cancer, the downstream consequences Steve 
mentioned years ago will be exponentially magnified. This study has illustrated that producing 
and managing genetic risk for cancer generates new health risks and consequences. Hence, as the 
scope of genetic screening tools continues to expand, the primary challenge for BOC genetic 
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Appendix A: Acronym Glossary 
Acronym Referent 
ACMG American College of Medical Genetics and Genomics 
AMP Association for Molecular Pathology 
ATM Moderate-risk gene 
BARD1 Moderate-risk gene 
BOC Breast and ovarian cancer 
BPM Bilateral prophylactic mastectomy 
BRCA1 High-risk gene 
BRCA2 High-risk gene 
CA-125 Blood test used in ovarian cancer management and screening 
CDH1 High-risk gene 
CHEK2 Moderate-risk gene 
CPM Contralateral prophylactic mastectomy 
DNA Deoxyribonucleic acid  
EUS Endoscopic ultrasound 
GYN/ONC Gynecologic Oncologist 
HRT Hormone replacement therapy 
IVF In vitro fertilization 
MRI Magnetic resonance imaging 
MRM Moderate-risk mutation 
MUYTH Low-risk gene 
NCCN National Comprehensive Cancer Network 
NGS Next generation sequencing 
OB/GYN Obstetrician/Gynecologist 
PALB2 Moderate-risk gene 
PGD Preimplantation genetic diagnosis 
RRM Risk-reducing mastectomy 
RRP Risk-reducing pancreatectomy 
RRSO Risk-reducing salpingo-oophorectomy 
SDHA Low-risk gene 
STS Science and technology studies 
USPSTF US Preventative Services Task Force 




Appendix B: Research Methods and Approach 
 
This research project, originally envisioned as a study of young, healthy carriers of 
BRCA mutations, began in the spring of 2012, approximately one year before Jolie’s op-ed, the 
AMP v. Myriad decision, and the shift to panel testing. However, during preliminary fieldwork at 
scientific cancer genetics meetings in 2013, and through conversations with key informants I met 
at those conferences, it became clear that BOC genetic science and medicine were undergoing 
major transformations, and I turned my gaze toward exploring the consequences of those 
important shifts. Between the fall of 2013 and spring of 2017, I conducted over three years of 
qualitative research that included participant observation at both professional and patient-
centered cancer genetics conferences; in-depth interviews with health professionals working in 
US BOC genetic medicine and women with BOC variants and mutations; and document analysis 
of laboratory reports, industry and advocacy group educational and promotional materials, and 
scientific and clinical guidelines. The data I collected through participant observation, document 
analysis, and interviews informed one another; combining methods enabled me to test and refine 
my working hypotheses on how BOC genetic risk is produced and managed in the United States 
in the era of panel testing. Because qualitative research is both iterative and dialectical, data 
collection and analysis were conducted concurrently, with interviews and field notes being 
transcribed and coded soon after they were completed and preliminary findings informing 
subsequent data collection. 
Participant Observation 
Between the fall of 2013 and spring of 2017, I engaged in participant observation at over 
40 different professional and patient-centered events. These included seven national scientific 
conferences for genetics professionals, four regional or national advocacy conferences for people 
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with BOC mutations, 21 webinars for scientists and providers working in cancer genetics, and 
nine webinars or symposia on cancer genetic risk aimed at the lay public. I also regularly 
attended monthly research seminars focused on cancer genetics at a major academic medical 
center between 2014 and 2016. My preliminary fieldwork began in the fall of 2013, just months 
after the Myriad Genetics v. AMP ruling and as multi-gene panels were being adopted 
throughout US BOC genetic medicine. This timing provided unique insights into the social, 
scientific, and practice concerns about panel tests and variant classification at a key moment of 
transition in cancer and clinical genetics. The first national professional meeting I attended in the 
fall of 2013 included a full-day pre-conference session focused on panel tests, and in subsequent 
years there were both breakout and plenary sessions at scientific conferences that centered on the 
issue. These sessions highlighted ongoing debates and disagreements among experts about the 
benefits and limitations of multi-gene panel tests and variant classification and reporting.  
Initially, data from fieldwork helped me to develop my research questions and working 
lists of themes to explore and to design semi-structured guides for in-depth interviews. In 
addition, at conferences and events, I built relationships with key staff at cancer genetics clinics 
and in advocacy groups, and I had numerous conversations and interactions with women with 
mutations. These connections were helpful in recruiting women with mutations or variants for 
interviews and meeting other relevant experts. Once I began conducting semi-structured 
interviews, participant observation data were used to triangulate and refine the findings that were 
emerging in the interviews. During conference sessions, webinars, and meetings, I took 
photographs and detailed field notes on the content of the presentations and the tools and 
language experts used to communicate genetic risk information. In the exhibit areas and other 
less structured public spaces, I observed interactions among attendees, which I recorded in 
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ethnographic “jottings” (Emerson, Fretz, & Shaw, 1995) and expanded into detailed field notes 
within 24 hours. I also gathered brochures and informational materials for document analysis 
from genetics laboratories and patient advocacy groups that exhibited at meetings. Throughout 
my fieldwork, I paid special attention to how risk was enacted and made visible, questions that 
were asked and the answers provided, issues or concerns that arose in discussions, tensions 
between patients’ and professionals’ priorities, how women with mutations and health care 
providers were responding to new developments in the field, and the processes of active problem 
solving that occurred in interactions.  
Observing, firsthand, the actual interactions among and between scientists, health 
professionals, and women with mutations at conferences provided insight into the social and 
structural contexts of genetic medicine, the ways in which information was communicated (as 
opposed to how individuals recalled it being communicated), the immediate feelings and 
concerns of mutation carriers, and any competing logics and disputes between patients and 
providers. The events for scientists and health professionals shed light on how experts 
communicated with one another about BOC genetic risk, clinical and scientific developments in 
the field, and the topics and issues of importance to genetics professionals. The patient-centered 
and public seminars and conferences were rich sources of data on the issues of importance to 
women with mutations, whether and how mutation carriers were forming biosocial identities and 
communities, and the ways in which experts communicate and translate complex genetic risk 
information to people with mutations and lay publics.  
Document Analysis 
Genetics laboratories and scientists are integral to the production and visibility of BOC 
genetic risk. They devote significant resources to researching links between genetic mutations 
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and cancer, develop the classification criteria for genetic variants, design computer models for 
evaluating individuals’ cancer risks, produce informational materials for both patients and 
providers, and generate reports for genetic counselors and clinicians that identify and summarize 
patients’ risks. During fieldwork, I gathered and systematically analyzed publications, brochures, 
webpages, and reports produced by the five major US laboratories that perform most BOC 
genetic testing in the United States: Ambry Genetics, Color Genomics, GeneDx, Invitae, and 
Myriad Genetics. Similarly, cancer advocacy groups, genetics professional organizations, and 
government agencies such as the Centers for Disease Control and Prevention (CDC) and the 
National Cancer Institute (NCI) create risk assessment tools and produce educational materials 
for the public. In addition, the positions and guidelines issued by these groups influence health 
policy, allocation of research funds, research priorities, and the attitudes and actions of providers 
and women with mutations. Hence, I also examined materials published by key advocacy groups 
for BOC mutation carriers, professional societies involved in BOC genetic medicine, and federal 
institutes or agencies that provide funding, resources, information, and data on cancer or 
genetics. For all documents and materials, I explored what information they highlighted, what 
they omitted, the images and language they used to convey risk, the audiences they targeted, the 
references they drew on, and any tensions in their narratives in order to uncover their encoded 
themes and values. I then triangulated those findings with data collected in interviews and 
participant observation.  
Interviews 
Concurrent with fieldwork and document analysis, I conducted a total of 85 in-depth, 
semi-structured interviews: 75 with women with BOC mutations or variants and 10 with health 
professionals working in cancer genetics. One-on-one interviews are especially useful for 
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uncovering the meaning and significance of events or situations for participants, providing data 
not only on what happened, but also on how people make sense of their experiences (Creswell, 
2007; Kvale & Brinkman, 2009; Rubin & Rubin, 2005; Warren & Karner, 2010). Thus, these 
lengthy conversations with women with BOC mutations or variants provided opportunities to 
elicit rich, detailed narratives from them about their experiences navigating US BOC genetic 
medicine; their beliefs, understandings, and feelings about BOC genetic risk; and their risk 
management decisions. Throughout the interviews with women, I paid careful attention to the 
language, logics, and evidence that they used to explain their experiences and choices and to 
similarities and differences between women with high- and moderate-risk mutations. The 
interviews with genetic counselors and clinicians both provided important insights into the 
processes involved in producing genetic risk and making it visible and facilitated an analysis of 
agreements and disjunctures between professionals’ and patients’ descriptions of the practices of 
US BOC genetic medicine. 
Typical interviews lasted approximately one hour and 15 minutes, but they ranged from 
as short as 35 minutes to as long as two hours and 15 minutes. All interviews were conducted via 
telephone or computer video-chat applications (e.g., Skype, FaceTime, or Google Hangout) and 
were digitally audiorecorded in order to capture participants’ exact responses. I also made 
ethnographic jottings (Emerson et al., 1995) during interviews about occurrences or visual details 
not captured on audio, including body language and nonverbal exchanges, and then expanded 
those into detailed field notes and memos immediately after the interviews concluded. In 
accordance with the procedures approved by Columbia University’s Institutional Review Board 
(IRB), participants were emailed a combined study information sheet and HIPAA form in 
advance of their interview, and then verbal consent to both participate in the interview and to 
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audio record the discussion were obtained at the beginning of each conversation. I continued 
conducting interviews with genetics health professionals and women with BOC mutations or 
variants until my findings reached saturation in each group (J. A. Maxwell, 2005; Warren & 
Karner, 2010). 
Utilizing a modified, constructivist approach to grounded theory (Charmaz, 2006; Corbin 
& Strauss, 2008), I developed semi-structured guides for the interviews that drew on topics and 
themes I had identified through preliminary fieldwork and existing literature on BOC genetic 
medicine and risk. For women with mutations or variants, these broad topics included their 
experiences with genetic testing, understandings of genetic risk, feelings about being at risk, 
decisions about risk management, interactions with providers and the health care system, and 
involvement with advocacy and support groups. I also incorporated questions about if and how 
being at BOC genetic risk affected their identities, feelings about their bodies, and their social 
and familial relationships. For experts, the initial topics and themes I explored in interviews 
included the tools they used to identify risk and explain risk estimates and classifications; how 
they communicated about VUSs; the risk management guidance they provided to women with 
high- and moderate-penetrance mutations; their feelings about and responses to recent 
developments in the field, including the use of multi-gene panels; their interactions with other 
genetics and medical professionals; and their perspectives on future directions or challenges for 
the field. As is common practice in qualitative research, I used the data I gathered in initial 
interviews to refine and modify the questions on the interview guides so that they focused on the 
themes and associations that were most strongly emerging in the data (Kvale & Brinkman, 2009; 
Rubin & Rubin, 2005; Warren & Karner, 2010). For example, I modified the guides for women 
with mutations to include additional questions on insurance coverage and the costs of care, the 
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decision to have breast reconstruction or stay flat and not reconstruct, and preparation for and 
knowledge about the side effects of oophorectomy because these topics surfaced as important 
themes in early interviews.  
Recruitment and Sampling 
The ten health professionals with whom I conducted in-depth interviews—eight genetic 
counselors and two physicians—were recruited during fieldwork at scientific and professional 
meetings and through relationships I built at those meetings with key informants. The primary 
way women with mutations or VUSs were recruited into the study was through cancer genetic 
counselors. The genetic counselors I partnered with were located throughout the United States, 
as I met them either at national conferences or in the online cancer special interest group (SIG) 
of one of the national professional associations for genetic counselors.62 I joined the cancer SIG 
based on the recommendation of one of the genetic counselors I met early in fieldwork who 
became a key informant. She suggested that I share information about the study in their SIG’s 
online listserv when recruitment of women with moderate-risk mutations (MRMs) and VUSs 
was slow. Genetic counselors who were interested in the project secured permission from their 
institutions to share the study’s IRB-approved recruitment flyers in the patient information 
packets they distributed to their clients. These flyers provided brief information about the 
purpose of the study, the eligibility criteria, and my contact information where interested patients 
could follow up.  
In addition, I recruited women through a modified snowball approach to sampling. At the 
                                                             
62 This organization has a membership category for professionals who are not genetic counselors but do 
work related to genetic counseling. In all communications in this group, I was transparent about being a 




end of each interview, I asked women who had participated if they would be willing to share 
information about the study with other women they knew with BOC mutations or VUSs. I then 
shared the IRB-approved flyers with those who agreed. Many women I interviewed belonged to 
private online social media groups for individuals with similar mutations or for women making 
breast or ovarian surgical decisions, and some offered to share the study flyers in those groups. 
Thus, the snowball approach was particularly effective in finding eligible women in subgroups 
that were less prevalent within the population of women at BOC genetic risk but had formed 
online support groups, such as women with MRMs or VUSs, women who chose to stay flat after 
risk-reducing surgery, and women who opted for surveillance.  
Finally, I recruited patient participants through national education and advocacy groups 
that serve people with BOC mutations. One group maintains an online database of active 
research projects that people with mutations can access to find studies in which they would like 
to participate. That group added this study to their database, posted the IRB-approved flyers for 
the project on social media, and added a link to the study flyer in their monthly email update. 
Another advocacy group allowed me to put recruitment flyers on information tables at their 
annual national meetings. That same group maintains online message boards for individuals at 
genetic risk for cancers and their allies, and I obtained permission from them to post links to the 
study flyers in appropriate threads, including one for research projects, one for people with 
MRMs, one for younger women with mutations, and one for individuals with VUSs. Summary 
characteristics for the 75 women who participated in the study are provided in Tables 7 and 8: 
Table 7 summarizes their genetic information and surgical decisions, while Table 8 provides 










Table 8: Participants’ Summary Demographic Characteristics and Cancer Information 
 
The initial recruitment plan was designed using systematic ethnographic sampling 
(Hirsch et al., 2009), which is a purposive approach that is guided by variables previous research 
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has found to be relevant to the experiences being studied. Like all purposive or theoretical 
sampling approaches for qualitative research, systematic ethnographic sampling is not intended 
to ensure statistical representativeness or to capture the experiences of individuals in any one 
particular cell in the sampling distribution (M. N. Marshall, 1996). Rather, this approach helps 
researchers explore similarities and differences along broad social axes of interest. The initial 
sampling frame for the study was structured along three key axes of interest: race/ethnicity, 
socioeconomic status/education, and genetic variant classification (i.e., high risk, moderate risk, 
or of uncertain significance). I also planned to limit participation among women to those who 
were age 45 or younger and unaffected by cancer. Younger women with BOC mutations face 
unique challenges because the risk-reducing surgeries that are recommended for women at 
increased risk of ovarian cancer limit reproductive functioning and cause medically-induced 
menopause (Hamilton et al., 2009; Werner-Lin, Hoskins, Doyle, & Greene, 2012). Similarly, the 
risk-benefit ratios of surgical risk management options for women diagnosed with cancer, who 
usually already require some type of surgery, are different from those for healthy individuals 
(Dagan & Goldblatt, 2009). 
There are several groups of individuals who have been underrepresented in BOC 
research: men, women of color, younger women, unaffected women, and economically 
disadvantaged women. Their underrepresentation is, in part, linked to the uneven demographic 
distribution of clinical genetic testing clients in the United States, who have been 
disproportionately white, female, highly-educated, post-menopausal, and afflicted with cancer 
(Armstrong et al., 2015; Suther & Kiros, 2009; Underhill et al., 2016). However, science studies 
scholars have illustrated how the skewed demographics of patients in genetic medicine are, 
themselves a reflection of the field's early engagement with Ashkenazi Jewish and other 
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European populations (Mozersky & Joseph, 2010; Wailoo & Pemberton, 2006). Scientists 
created databases of genetic samples from these populations that were used for early genetic 
research, which concentrated knowledge on variants more commonly seen among Ashkenazi 
Jews and other people of European ancestry. Greater knowledge about cancer genetic risk in 
those populations has sedimented racialized ideas about who is and is not at risk and, in turn, 
influences who tends to use genetic testing services (Montoya, 2011; Mozersky & Joseph, 2010; 
Wailoo & Pemberton, 2006). One of the outcomes of this history is that the population of women 
who gets tested for BOC mutations is much whiter than the population of women who develops 
breast cancer (Armstrong et al., 2015; National Cancer Institute, 2018d; Suther & Kiros, 2009; 
Underhill et al., 2016). 
I originally intended to target recruitment among women in some of these 
underrepresented groups. I was particularly interested in interviewing women of color because 
both VUSs and certain BOC mutations have a higher prevalence among US women of color than 
among non-Hispanic white women (A. W. Kurian, 2010; Pal et al., 2014) and because several 
studies have shown that race and ethnicity affect perceptions and practices related to managing 
risk (Callon & Rabeharisoa, 2004; Cragun et al., 2017; A. W. Kurian, 2010; Shaw, 2011). 
However, this dissertation is focused on women who had already had BOC genetic testing and 
either received a positive or uncertain result. Prior to initiating the project, I had not fully 
appreciated how choosing that population as my sampling frame meant that it had already passed 
through multiple filters of racialization and would limit my ability to recruit women of color. 
Early in the project, I actively attempted to bolster recruitment among women of color by 
partnering with genetic counselors and local chapters of advocacy groups based in urban areas 
with greater patient or member racial/ethnic diversity and reaching out to cancer support or 
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advocacy groups that specifically serve women of color. In the future, to avoid producing 
additional research on genetic risk among white women, I would consider recruiting from among 
cancer patients at baseline because black women develop breast cancer at similar rates to white 
women (National Cancer Institute, 2018d).  
The rapid and widespread adoption of panel tests, which have been identifying more 
women with VUSs and MRMs, coincided with my preliminary research, and it quickly became 
apparent that the most important axis of difference in the sample was the penetrance 
classification of people’s genetic variants. Multi-gene panels were not only placing more people 
into a category of unknown risk, but also were generating new tiers of risk among individuals 
who tested positive for mutations, and these shifts in the zones of risk were transforming 
practices in the field. Yet because MRMs have lower population prevalence than BRCA 
mutations (Couch et al., 2015; PDQ® Cancer Genetics Editorial Board, 2019) and because, as I 
will highlight in Chapter One, genetics experts actively attempt to de-medicalize VUSs, 
recruiting women in these categories also proved challenging.  
The restrictions among women by age and cancer status compounded the difficulties of 
recruiting women with MRMs and VUSs; however, I later discovered that these eligibility 
criteria were less relevant than I initially theorized, particularly in these populations. According 
to current research and clinical guidelines, women with MRMs and VUSs do not meet evidence-
based eligibility criteria for surgical approaches to ovarian cancer risk management, such as risk-
reducing hysterectomy (RRH) or risk-reducing salpingo-oophorectomy (RRSO). I had limited 
participation in the study to women age 45 or younger because of the clinical impact of those 
surgeries, but that restriction was not relevant among women with BOC MRMs or VUSs. 
Furthermore, a majority of breast cancers are diagnosed in Stage 0 or Stage 1, when typically, 
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patients are candidates for lumpectomy. Thus, while there are still differences in the decision-
making processes for women who are already affected by breast cancer and women who are not, 
women in both groups who opt for double mastectomies are electing to undergo several 
additional surgical procedures that, based on current evidence, do not significantly improve their 
chances of survival (S. M. Domchek et al., 2010; A. W. Kurian et al., 2010; Li et al., 2016; 
Portschy, Kuntz, & Tuttle, 2014). Moreover, no matter whether women’s RRM procedures were 
BPM or CPM, once they had breast surgery, they faced the same decisions about breast 
reconstruction and endured the same complications and side effects from reconstruction 
procedures, which also emerged early in the study as important themes. Thankfully, with the 
partnership of cancer genetic counselors from the Cancer SIG and after modifying the eligibility 
criteria to allow women with MRMs and VUSs to participate regardless of age or cancer status, 
my efforts at targeted recruitment in these groups were successful.  
Data Analysis 
Because qualitative research is both iterative and dialectical, I conducted ethnographic 
data collection and data analysis concurrently in this study so that I could I could reformulate 
study and interview questions and modify the samples and approaches in response to emerging 
themes (Charmaz, 2006; J. A. Maxwell, 2005; Warren & Karner, 2010; Wolcott, 2009). 
Interviews were transcribed as soon as possible after completion, and those transcripts and my 
field notes were coded on an ongoing basis throughout the project. I primarily drew on a 
constructivist grounded theory approach to coding (Charmaz, 2006; Corbin & Strauss, 2008). In 
the initial phases of analysis, I developed a priori codes based on the existing cancer genetics 
literature, my preliminary fieldwork, and the study’s main research questions (Miles & 
Huberman, 1994). I then allowed patterns and hypotheses to emerge inductively from the data 
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and checked them against new data and findings.  
In looking for themes and patterns, I primarily used the constant-comparative method, 
which involves triangulating and exploring the similarities and differences between data from the 
interviews, participant observation, and document analyses (Charmaz, 2006). In combination 
with the a priori codes I had established, I began with open coding, which requires going through 
the data line by line, labeling the actions and processes that are apparent, and looking for 
emergent themes. I searched for data that confirmed and challenged my working hypotheses, 
paying particular attention to any strong language, repetitions, transitions, gaps, and unusual or 
extreme cases (Miles & Huberman, 1994). I then moved to focused coding, in which I organized, 
refined, and further developed the initial codes by comparing them with new data. I searched for 
relationships between codes, paying particular attention to similarities or variations along 
theoretical and conceptual axes of interest. Throughout data analysis, I wrote memos in which I 
defined codes, explored themes and conceptual relationships, and reflected on the research 
process (Emerson et al., 1995). I used MaxQDA 18.1, robust qualitative data management 
software, to transcribe interviews, organize and store documents and memos, assign codes to text 
segments, trace associations between codes and themes, and explore similarities and differences 
in the data.  
IRB, HIPAA, and Privacy 
This research project followed the human subjects guidelines of Columbia University’s 
Morningside Institutional Review Board (IRB), including all procedures for obtaining informed 
consent, protecting the anonymity of study participants, securing data, and compliance with 
HIPAA. Careful measures were taken to ensure that the privacy and confidentiality of 
participants were protected and that all data remained confidential. Any handwritten field notes 
 
346 
were scanned and then shredded, and all audio recordings, interview transcripts, and field notes 
were stored on my encrypted and password-protected laptop in password-protected folders. Once 
the audio-recordings were transcribed, they were moved to a password protected and encrypted 
external hard drive. All identifying information was removed from transcripts, field notes, and 
memos, and any data used in publications and presentations has also been de-identified. Each 
participant was assigned a unique ID code and pseudonym, and only those were used to label 
audio-files and transcripts. A master list matching these codes and pseudonyms to participant 
names and contact information were stored in a password protected file on a password protected 
and encrypted external drive to which only I had access. I altered any quotations or descriptions 
used in the preceding chapters that contained potential identifying information, such as unique 
elements of their life stories, to protect the confidentiality and privacy of participants. 
 
